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Chapter 1: Introduction 
Bacterial Infection and Antibiotics 
 Bacterial infection is a ubiquitous aspect of the human condition, representing one of the 
most significant sources of human mortality from antiquity to the present day.  It is estimated 
that over 16 million people succumbed to communicable diseases in 2008,
1
 despite over 100 
years of biomedical research into controlling infection. Though the knowledge that outside 
agents could be used to control infection has been employed for millennia, modern academic 
inquiry into anti-infective agents can be thought of as beginning in 1871, when Dr. Joseph Lister 
noted the antibacterial effect Penicillium mold had on urine samples and infected wounds.
2
  
Although the Penicillium family of molds was studied sporadically for the next 50 years, 
Alexander Fleming’s 1928 isolation of an organic residue exuded by Penicillium notatum 
capable of destroying Staphylococcus aureus cultures
3
 caused a rush of interest.  Twelve years 
later, Chain, Florey, et al. demonstrated that a partially purified and stabilized concentrate of this 
substance, dubbed “penicillin,” could reliably treat infection in human patients.4 The 1930s and 
1940s saw the ushering in of the “antibiotic age,” characterized by an explosion in the 
development of several classes of antibiotics, including the sulfonamides,
5
 aminoglycosides,
6
 
and tetracyclines.
7
  The ready availability of antibiotic agents was one of the most transformative 
advances of the 20
th
 century, leading to unprecedented decreases in mortality from infectious 
disease.
8,9,10
  The effectiveness of antibiotics led several prominent infectious disease experts to 
conclude as recently as 1978 that bacterial infection would soon be eradicated,
11,12
  but evidence 
to the contrary had already been mounting for years.  Fleming himself noted the possibility of 
bacteria developing resistance to antibiotics via exposure to sub-lethal doses in his Nobel lecture 
in 1945.
13
 
 In less than 70 years since the widespread availability of antibiotic drugs, bacterial 
resistance to antibiotics has become a worldwide health crisis. Several multiply-resistant strains 
of both Gram-positive and Gram-negative bacteria are now commonplace in the human 
population, especially in the hospital setting.
14,15
  Antibiotic resistance generally arises when an 
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individual bacterium acquires mechanisms to deactivate or evade the action of a given drug, 
either through random mutation, lateral gene transfer from a resistant individual, or phage-
acquired genetic material.
16
  Bacterial populations with a few resistant members will have the 
vast majority of susceptible bacteria wiped out by the antibiotic treatment, allowing the resistant 
population to quickly become dominant within the host.  In spite of the ever-increasing threat of 
widespread bacterial resistance, the number of new drugs in clinical trials for combating bacterial 
infection has been on a steady decline for decades, due mostly to the difficulty of  their 
development and the reality that any new antibiotic will be used as an agent of last resort and is 
thus unlikely to recoup research costs through revenue.
17
  The tandem threat of increasing 
resistance and diminished research into traditional antibiotics prompts the need for focused 
scientific inquiry into novel antibacterial development. 
Anti-Virulence Antibiotics 
 One promising novel approach to the problem of bacterial resistance is the development 
of virulence inhibitors.  Invasive bacteria produce a number of proteins or secondary metabolites 
known as virulence factors in order to enhance infectivity and ensure colony survival in a host 
organism. If the action or the production of these factors can be inhibited, the bacterial colony is 
rendered into a more vulnerable state and is potentially more easily controlled by the host 
immune response.  More importantly, the specific inhibition of virulence factors with small 
molecules that do not affect bacterial growth should lower the selective pressure to acquire 
resistance.
18
 Traditional antibiotics, on the other hand, by directly inducing bacterial cell death or 
preventing bacterial reproduction, exert rapid evolutionary pressure by enriching bacterial 
populations capable of resisting treatment.  Anti-virulence antibiotics have garnered the interest 
of several research groups over the last fifteen years, targeting a variety of virulence factors, 
including bacterial toxins,
19
 adhesion factors,
20
 quorum-sensing systems,
21,22
 and virulence-
inducing signaling pathways.
23
  Though no anti-virulence drugs have yet progressed to use in the 
clinic, inhibitors of anthrax toxin cell permeability,
24
 N-acyl homoserine lactone-mediated 
quorum sensing,
25
 and QseC histidine sensor kinase activation
23
 have demonstrated efficacy in 
murine models of infection. 
Group A Streptococcus 
Streptococcus pyogenes, or Group A Streptococcus (GAS), represents one example of the 
global threat of bacterial infection.  This Gram-positive, hemolytic species of bacteria is a 
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ubiquitous human pathogen responsible for up to 700 million infections per year worldwide.
26
  
GAS is most commonly associated with relatively benign clinical presentations, including upper 
respiratory infection (“strep throat”) and superficial skin infections. However, particularly 
virulent strains can induce far more serious systemic infections.  Cases of systemic GAS 
infection are thought to approach 500,000 annually, with a mortality rate of 15-35%.
27,28
 Some of 
the most dangerous systemic GAS infections include streptococcal toxic shock syndrome 
(STSS), which induces hyperinflammatory responses, hypotension, and organ failure;
29
 acute 
rheumatic fever induced by cross-reactivity of anti-GAS immunoglobulins with heart tissue;
30
 
and acute necrotizing fasciitis, characterized by massive invasion of the connective tissue 
surrounding internal organs.
31
 
A considerable body of research to characterize GAS virulence factors has evolved over 
the last half-century, revealing that its virulence is complex and multifaceted.
32
  The most well-
studied GAS virulence factors are the M-family of proteins and hyaluronic acid, both of which 
are responsible for resistance to phagocytosis by leukocytes.  M-protein is a dimeric coiled-coil 
α-helical protein that extends from the cell membrane through the peptidoglycan wall.33  The 
environment-exposed end of this protein binds to several circulating factors, most importantly 
C4 binding protein (C4BP), inhibiting the recruitment of opsonization factors C3b and C4 to the 
microbial surface.
34
 In the absence of M-protein, GAS cells are readily opsonized (marked for 
phagocytosis) and destroyed.
35
  Hyaluronic acid is an aminopolysaccharide polymer secreted by 
GAS in order to encapsulate its cells, conferring up to 100-fold higher resistance to phagocytosis 
when compared to unencapsulated strains.
36
  GAS also produces a host of adhesin molecules, 
such as fibronectin binding protein and lipoteichoic acid, which promote association with various 
host epithelial tissue features. Adhesin presentation on the bacterial protein coat allows GAS to 
anchor itself to solid tissue and initiate biofilm formation, a process strongly associated with 
enhanced virulence.
37
 The mechanics and clinical importance of biofilm formation in systemic 
infection is further discussed in Chapter 4.  Finally, GAS secretes a number of exotoxins 
including hemolytic enzyme streptolysin O,
38
 cysteine protease SpeB,
39
 and the fibrinolysis 
promoter streptokinase (SK).
40
 These exotoxins allow GAS to destroy aspects of host systems 
that are intended to neutralize infections (e.g. leukocytes, lysosomes, and fibrin clots). 
Our collaborators in the Hongmin Sun group at the University of Missouri – Columbia 
are particularly focused on the contribution of SK to GAS virulence.
40
 SK essentially functions 
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as a chaperone-like protein capable of binding to human plasminogen (Plg) and inducing a 
conformational change.  Plg is the catalytically inactive zymogen of plasmin, a serine protease 
responsible for the cleavage of fibrin.
41
  Fibrin cleavage leads to the dissolution of blood clots, 
and plasmin is normally activated in response to excessive clotting or in the removal of blood 
clots that are no longer needed.  Plg is normally held in the inactive state until a specific cleavage 
between Arg561 and Val562, endogenously catalyzed by fibrin-associated protein tissue plasmin 
activator (tPA) or urokinase plasmin activator (uPA).
42,43
 Tight regulation of this cascade gives 
the body fine control over the equilibrium between excessive and insufficient clotting.  However, 
when Plg associates with SK, a conformational shift is induced that confers catalytic activity 
without proteolytic cleavage.  This activated SK-Plg complex is then capable of efficiently 
cleaving other molecules of Plg to plasmin, activating its fibrinolytic capability.
44
  By increasing 
local concentrations of plasmin, GAS colonies can evade the host immune response of clotting 
around foci of infection, thereby maintaining its ability to achieve systemic distribution.  Sun et 
al. were instrumental in determining that the specificity of the SK-human Plg interaction is the 
major biochemical determinant of GAS’s exclusive virulence in humans.40 
Identifying GAS-SK Modulators 
  Armed with the knowledge of SK’s ability to mediate potentially fatal systemic GAS 
infection, Sun and coworkers initiated a high-throughput screen (HTS) for chemical agents that 
could attenuate GAS-SK.
45
  The direct inhibition of protein-protein interactions with small 
molecules is very difficult, owing to the typically large amount of surface area of each protein 
involved in the association.  Therefore, the decision was made to identify compounds that inhibit 
SK production at the transcriptional level, presumably by the disruption of transcription factors 
or upstream signaling cascades that induce its production.  The HTS assay parameters required 
the combination of datasets from two separate screens (Figure 1.1). In the first screen, GAS 
colonies transfected with a plasmid coding for a kanamycin (Kan) resistance gene downstream 
from the ska gene promoter region (“SKKanGAS”) were incubated with screening library 
compounds in media containing kanamycin.  Therefore, if a small molecule exerted an effect that 
reduced transcription at the ska promoter, the test colony was sensitized to kanamycin and cell 
death was induced.  The second screen employed a separate strain of GAS (UMAA2641) with 
constitutive kanamycin resistance conferred by the knock-in of the ΩKm-2 viral gene 
interposon.
46
  This second screen was intended to identify any compounds that had innately 
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bacteriotoxic effects.  In keeping with the goal of identifying compounds with strictly anti-
virulent effects, we were interested in compounds that had potent effects at the ska promoter 
(>50% inhibition of SKKanGAS strain) while having minimal effects on normal bacterial growth 
(<10% inhibition of UMAA2641) to avoid inducing selective pressure for resistance. 
 
Figure 1.1. Design of tandem HTS screen for identifying compounds that inhibit GAS-SK 
transcription. 
 
Top pane: HTS design. A: Transfection of plasmid containing Kan resistance gene fused to 
upstream ska promoter. B: SKKanGAS strain (ska-dependent Kan resistance) and UMAA2641 
(constitutive Kan resistance) incubated in the presence of compounds in Kan+ media. 
Compounds that sensitize SKKanGAS to Kan >50% affect UMAA2641 growth <10% are 
considered hits. C: Initial hits are triaged by dose-response confirmation, activity assay with 
fresh powders, and elimination of hits with structural liabilities. Bottom pane: Structures of lead 
compound 1 and related commercial analog 2. 
 
The screen was performed using the 55,000-compound Center for Chemical Genomics 
screening collection at the University of Michigan at test concentrations of 5 to 10 µM.  After 
screening both GAS strains and comparing datasets, 95 compounds were identified that satisfied 
the previously stated activity and selectivity criteria.  Dose-response curves were generated for 
these 95 initial hits, revealing 20 that possessed IC50 values of 30 µM or less for SKKanGAS 
inhibition and at least tenfold higher IC50s against UMAA2641.  Of these 20 confirmed hits, 8 
were commercially available as fresh powders. 4 of the 8 compounds, when prepared from fresh 
stock, indicated significant (>30%) inhibition of UMAA2641 at 50 µM, and were dropped from 
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consideration.  Considerations of HTS hit rate, potential for off-target reactivity, and conformity 
to Lipinski’s “Rule of 5”47 led to the selection of CCG-2979 (1) as the lead compound.  Follow-
up functional assays confirmed that 1 decreased SK activity in wild-type GAS, enhanced GAS 
susceptibility to phagocytosis in mouse blood, and closely related analog 2 downregulated the 
expression of SK and several other virulence factors as measured by RNA microarray analysis 
(Figure 1.2).
45
   
Figure 1.2. Summary of GAS RNA levels after incubation with 2 for several important 
genes, relative to colonies treated with DMSO only.  
 
Figure adapted from Sun et al., PNAS 2012, 109 (9), 3469-74. 
 
 The encouraging cell-based data collected to this point led Sun et al. to characterize the 
utility of 1 to control GAS infection in vivo (Figure 1.3).  As previously discussed, human 
plasminogen is required for systemic GAS infection. Therefore, mice were sensitized to GAS 
infection via the transfection of the human plasminogen gene into the mouse genome.  When the 
transgenic mice were dosed with 5 or 40 µg of 1 every 24 hours via intraperitoneal injection for 
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4-5 days after infection with GAS, significant protective effects were observed over the course of 
the 10-day study.
45
 Interestingly, closely related commercial analog CCG-102487 (2) did not 
exert the same protective effect, despite similar activity in cell-based activity assays.  A possible 
explanation for this phenomenon may be related to significant differences in metabolic stability 
observed between these two compounds, an issue discussed more thoroughly in Chapter 2. 
Figure 1.3. Survival curves for mouse populations treated with test compound (dashed 
lines) or DMSO only (solid lines).  
 
Graph A: Mice treated i.p. with 12.7 nmol 1 every 24 hours for 5 days post-infection with 2.8-
8.3 x 10
5 
CFU GAS. n = 27 for test and control population. Graph B: Mice treated i.p. with 101 
nmol 1 every 24 hours for 4 days post-infection with 1.2-4.2 x 10
6 
CFU GAS. n = 19 for test and 
22 for control population. Graph C: Pooled data from Graphs A and B. Graph D: Mice treated 
i.p. with 93 nmol 2 every 24 hours for 4 days post-infection with 4.2 x 10
6 
CFU GAS. n = 10 for 
test population. Pooled data from Graph C added for reference. Figure adapted from Sun et al., 
PNAS 2012, 109 (9), 3469-74. 
  The completion of several assays suggesting the SK-attenuative properties of 1, 
combined with favorable in vivo proof-of-concept study data (a relatively rare occurrence for 
unmodified HTS lead compounds), suggested it was a good starting point for initiating a 
structure-activity relationship (SAR) study.  The SAR study was conceived with the intent of 
increasing the modest potency (% of plasmin activity at 50 μM = 48 ± 28%) of the lead, and 
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improving the predicted pharmacokinetic properties of the scaffold.  In particular, we were 
concerned about its high lipophilicity (cLogP = 7.1), which can be associated with poor 
solubility and metabolic stability.
48
  Our efforts toward improving the attenuation of GAS-SK 
with a compound series based on 1 are discussed at length in Chapter 2. 
The results of these pilot studies on 1 also raised the prospects of other studies of 
academic interest.  Cell-based HTS assays are ideal for identifying innately cell-permeable 
compounds that induce a desired phenotype, but give no insight into the macromolecular target 
of the lead compound.  The identification of the macromolecular target of this compound series 
could offer great advantages to the SAR effort by supplementing cell-based assays with more 
direct activity/affinity profiling using the purified target.  More broadly, target identification 
would also help to elucidate potentially novel bacterial mechanisms of virulence control in GAS; 
any significant findings could have implications for other human bacterial pathogens, depending 
on the presence of homologous proteins in other species.  Our design of chemical probes for the 
purpose of target identification and the associated preliminary biological data is discussed in 
Chapter 3. Finally, the mRNA microarray data (Figure 1.2) suggests that this class of compounds 
exerts activity on other virulence factors, including several genes associated with biofilm 
formation.  The ability for bacteria to form biofilms confers greatly increased colony survival in 
host organisms, and is thus a very attractive target for anti-virulence antibiotic development.  Our 
efforts toward optimizing this scaffold for biofilm inhibition are detailed in Chapter 4. 
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Chapter 2: GAS-SK SAR Study 
SAR Logic 
 Lead compound 1, while showing acceptable activity in the HTS assay and in early in 
vivo trials, exhibited a number of shortcomings that had to be addressed in the structure-activity 
relationship (SAR) campaign.  Though efficacy was indeed observed in mice,
45
 the IC50 reported 
by our cell-based assay of SK activity was found to be greater than 50 µM.  In addition to its 
fairly low potency, 1 is also quite lipophilic (cLogP = 7.1), which is indicative of low aqueous 
solubility and a greater propensity for oxidation by P450 oxidase enzymes, which could lead to 
instability in vivo.
48
  
With these observations in mind, we proposed several modifications to the scaffold with 
the intent of maximizing potency and aqueous solubility while minimizing the number of 
metabolically labile sites (Figure 2.1).   We sought to modify the n-butyl sulfide appendage by 
replacement of the sulfur with smaller heteroatoms (O, N) and incorporation of polar groups to 
assist in increasing solubility and stability. Smaller alkyl substitutions to replace the 
spirocyclohexyl substituent of the central ring were intended to serve the same purpose.  We 
were also particularly interested in introducing substitutions around the phenyl ring.  With the 
entire polar functionality of 1 confined to one small region of the molecule, there are likely very 
few strong intermolecular contacts (e.g. dipole interactions, H-bonds) made with the protein, 
implying that 1 must rely on relatively weak hydrophobic effects for binding affinity.  We 
reasoned that a more even distribution of polar contacts around the scaffold could lead to 
significant increases in potency, provided they were sterically allowed by the binding site.   
10 
 
Figure 2.1. Lead compound 1 and proposed alterations to its scaffold for SAR study. 
 
GAS-SK Assay 
 All new compounds were evaluated by the Sun group at University of Missouri - 
Columbia for their ability to suppress SK expression using a chromogenic assay of plasmin 
activity.
45
  Briefly, two identical cultures of GAS were grown in the presence of the desired 
concentration of test compound or DMSO and allowed to grow to OD600 ≈ 1.0.  After 
centrifugation, an aliquot of supernatant was combined with human plasma and synthetic 
plasmin substrate S-2403.  Decreased expression of SK induced by the test compound lowers the 
amount of activated plasmin, in turn reducing the rate of cleavage of S-2403 to colored product 
p-nitroaniline. The concentration of p-nitroaniline was measured by absorbance at 405 nm (A405) 
and compared to the DMSO control. Activity data is reported as the ratio of A405(test) divided by 
A405(control) (T/C).  To provide an approximate readout of potency, the assay was run initially at 
both 5 and 50 μM of test compound.  An optical density reading at 600 nm (OD600) gave an 
estimate of cell density and thus overall bacterial growth inhibition; this data is also reported for 
the higher concentration of compound (50 μM) as a ratio of the OD600 of the test culture divided 
by the OD600 of the DMSO control culture.  Selected compounds that inhibited SK activity by 
more than 50% at 50 μM and inhibited growth by less than 25% at 50 µM were subjected to full 
dose-response titrations to determine approximate IC50 values using the same assay. 
During the course of evaluating the new analogs, it was observed that there was a 
relatively high level of inter-assay variability in the activity assay.  There are a number of likely 
contributing factors, most notably the variability inherent to working in a live bacterial system.  
For example, it has been noted that minimum inhibitory concentration (MIC) values for 
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determining bacteriotoxicity tend to vary by up to three-fold from assay to assay.
49
  Furthermore, 
the currently unknown macromolecular target of these compounds likely affects a pathway 
including a transcription factor, which are known to be low-abundance proteins
50
 that exhibit 
significant temporal expression changes, potentially contributing to the variability.  It was noted 
early in the SAR effort that 17 was both moderately active and particularly consistent from assay 
to assay.  In an effort to reduce the number of anomalous data points, 17 was included in each 
assay as a positive control.  Assays in which 17 exhibited activity deviating from the mean 
activity at 5 and 50 μM by more than one standard deviation (calculated from a total of 35 
assays) were discarded.   
Synthesis 
Spirocyclohexyl tetracyclic analogs 
Initial synthetic SAR development was accomplished by Jenny Ryu in the Larsen group 
using a known 5-step synthetic pathway to access intermediate 6 beginning from cyclohexanone 
(Scheme 2.1).  A Knoevenagel condensation with ethyl cyanoacetate generated Michael acceptor 
4, which was subjected to nucleophilic attack by benzylmagnesium chloride and subsequently 
cyclized to the tricyclic aminoester 5 in the presence of concentrated sulfuric acid.
51
  Addition of 
the amine to allyl isothiocyanate followed by hydroxide-promoted cyclization provided 6 on 
multigram scale.
52
 From this intermediate a variety of S-alkylated analogs (7-13) could be 
accessed under basic alkylating conditions. Other heteroatomic substitution at the 2-position of 
the pyrimidinone ring was achieved via nucleophilic substitution of thiomethyl for the ethyl ether 
via the action of sodium ethoxide (12, Meghan Breen), or through replacement of the methyl 
sulfone with ethylamine under basic conditions (13).
53
 Synthetic procedures and spectral 
characterization of compounds made by other chemists are fully disclosed in our publication on 
the topic.
54
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Scheme 2.1. Preparation of spirocyclohexyl analogs of 1.
a
 
 
a
Reagents and conditions: a) ethyl cyanoacetate, AcOH, NH4OAc, toluene, 150°C, 5h, 89%; b) 
BnMgCl, Et2O, RT, 72h; c) H2SO4, 0°C-RT, 7h 68% over 2 steps; d) allyl isothiocyanate, EtOH, 
reflux, 10h; e) KOH, EtOH:H2O (1:1), reflux, 10h, 30% over 2 steps; f) R-X, base, EtOH or 
MEK, 0-70°C, 10min-16h, 72-95%; g) NaOEt, EtOH, 40°C, 48h, 73%; h) (i) mCPBA, DCM, 
RT, 16h, (ii) EtNH2, K2CO3, THF:DMF (1:1), RT, 5h, 53% over 2 steps.   
†
Compound originally 
synthesized by Jenny Ryu. 
‡
Compound originally synthesized by Meghan Breen. 
 
Gem-dimethyl tricycles 
Given the relative ease with which the original spirocyclohexyl-substituted analogs were 
synthesized, we were surprised to find that the generation of gem-dimethyl analogs (e.g. 17-22, 
Scheme 2.2) using the chemistry outlined in Scheme 2.1 was extremely unreliable and low 
yielding.  While Michael addition of benzylmagnesium chloride into ethyl 2-cyano-3-methylbut-
2-enoate proceeded as desired, the acid-catalyzed cyclization to β-aminoester analogous to 5 
proceeded in a yield too low to generate more than a few S-alkylated final compounds (Meghan 
Breen).  Likewise, the stepwise addition and cyclization reaction with allyl isothiocyanate shown 
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in Scheme 2.1 did not proceed in greater than a 25% yield, severely limiting the utility of this 
synthetic route. 
Scheme 2.2. Synthesis of gem-dimethyl substituted analogs 17-24.
a
 
 
a
Reagents and conditions: a) LDA, diglyme, -78°C, 1h; then ethyl 3,3-dimethyl acrylate, ZnI2,    
-78°C-RT, 2h, 41%; b) allyl-NCS, AcOH, EtOH, 70°C, 16h, 24%;  c) R
1
-X, Cs2CO3, MEK or 
DMF, 70°C, 16h 71-96%; d) NaOEt, EtOH, 40°C, 48h, 69%; e) (i) mCPBA, DCM, 0°C-RT, 
16h; (ii) EtNH2, K2CO3, THF:DMF (1:1), RT, 5h, 41% over 2 steps. 
†
Compound originally 
synthesized by Meghan Breen. 
 
Through extensive optimization, it was determined that the β-aminoester 15 could be 
accessed in one step beginning from commercially available o-tolunitrile 14 (Scheme 2.2). In the 
presence of LDA, smooth addition of the benzyl anion of 14 to the β-position of ethyl 3,3-
dimethyl acrylate afforded an enol ester intermediate that readily cyclized in the presence of 
ZnI2, providing amino ester 15.
55
  In contrast to the basic conditions used to generate 6, acid-
catalyzed conditions for condensation with alkyl isothiocyanates were found to more efficiently 
furnish the 2-thioxo-dihydropyrimidinone intermediate 16.  Subsequent alkylation at sulfur 
ultimately allowed the synthesis of gem-dimethyl analogs 17-22 in a total of 3 steps.  Further 
derivatization of thiomethyl analog 22 to generate ether and amino derivatives 23 and 24 was 
achieved in the same manner as for 12 and 13, respectively.   
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Aryl ethers and phenols  
 Modification of the synthetic scheme to generate aryl ethers and phenols (29-39) was 
fairly straightforward (Scheme 2.3).  The requisite tolunitriles were either purchased from 
commercial sources (26c) or were synthesized via nickel (II) bromide-promoted SNAr addition of 
cyanide ion to the corresponding o-chlorotoluene aryl methyl ethers 25a,b.
56
  The addition of 
methyl iodide in toluene to the crude reaction isolate allowed for the facile removal of tetraalkyl 
phosphonium salts and drastically simplified purification of 26a and 26b. Elaboration to the S-
alkylated analogs 29-33 proceeded as previously described.  Though we had hoped that the aryl 
methyl ether of 29 could be cleaved to the free phenol in a regioselective manner, we found that 
BBr3-mediated demethylation resulted in a mixture of aryl and alkyl ether removal.  When the 
sulfur appendage was changed to ethyl (i.e. 31-33), BBr3 demethylation proceeded smoothly to 
furnish phenols 34-36.  From these three intermediates, a variety of alkylating agents could be 
used to generate a library of aryl ether analogs.  Our primary concern with these analogs was at 
first to identify the optimal positioning of a PEG appendage on the molecule for the target 
identification effort (Chapter 3).  Therefore, PEG-like compounds 37-39 were synthesized using 
2-methoxyethyl tosylate as the alkylating agent.  A full complement of diverse aryl ethers at the 
8-position was synthesized by chemist Roderick Sorenson, and a thorough discussion of these 
analogs can be found in our SAR publication.
54
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Scheme 2.3. Synthesis of aryl ethers 29-39.
a 
 
a
Reagents and conditions: a) (i)NiBr2, Zn (dust), PPh3, KCN, THF, 50-60°C, 24h; then (ii) MeI, 
toluene, 0°C, 2h, 68-90%. b) LDA, -78°C, 1h, then ethyl 3,3 dimethyl acrylate, ZnI2, -78°C-RT, 
2h 33-59%; c) allyl-NCS, AcOH, EtOH, 75°C, 16h, 21-59%; d) R
1
-X, Cs2CO3, MEK or DMF, 
70°C, 16h, 69-88%; e) BBr3, DCM, 0°C-RT, 16h, 43-62%; f) CH3OCH2CH2OTs, Cs2CO3, DMF, 
70°C, 16h, 65-71%. 
†
Compound synthesized by Roderick Sorenson. 
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Scheme 2.4. Analogs with varied pyrimidinone N-substitution.
a 
 
a
Reagents and conditions: a) R
2
-NCS, AcOH, EtOH, 75°C, 16h, 27-31%; b) R
3
-X, Cs2CO3, 
MEK or DMF, 70°C, 16h, 55-71%. 
 
Analogs with varied substitution at the N- and O- positions of the pyrimidinone ring 
amide were accessed through two synthetic paths (Schemes 2.4 and 2.5).   Beginning from 
aminoesters 15 and 27a, treatment with other alkyl isothiocyanates (methyl, ethyl, 2-
methoxyethyl) yielded the corresponding pyrimidinones 40a-c, which could be further 
elaborated into analogs 41-43 (Scheme 2.4).  The synthesis of O-alkylated analogs first required 
the assembly of the unsubstituted thioxo-dihydropyrimidinone ring (Scheme 2.5). Treatment of 
15 or 27a with benzoyl isothiocyanate, followed by ring closure and hydrolysis of the resulting 
N-benzoyl group with aqueous KOH generated intermediates 44a,b (Scheme 2.5).
57
 
Chemoselective alkylation of the sulfur was achieved under neutral conditions, while subsequent 
base-catalyzed alkylation of the amide generally gave some mixture of N-alkylated (46, 47) and 
O-alkylated (48-50) analogs.  
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Scheme 2.5. Generation of N- and O-alkylated substitution pairs 46-50.
a 
 
a
Reagents and conditions: a) benzoyl isothiocyanate,  EtOH, 75°C, 5h; b) KOH, EtOH:H2O (2:1) 
70°C, 2h, 62% over 2 steps; c) R
2
-X, NaHCO3, DMF, RT-70°C, 30min-16h, 71%; d) R
3
-X, base, 
EtOH or DMF, 70-80°C, 16-24h, 13-36% yield. 
†
Compound originally synthesized by W.G. 
Rajeswaran.  
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Scheme 2.6. Generation of compounds with lower propensity for metabolic oxidation.
a 
 
a
Reagents and conditions: a) CH3CH2I, Cs2CO3, DMF, 70°C, 16h; b) CF3CH2I, Cs2CO3, DMF, 
50°C, 24h, 24%; c) mCPBA, DCM, 0°C-RT, 12h, 62%; d) 1.1 equiv Oxone, THF/H2O (1:1), 
0°C to RT, 16h, 62%. 
Metabolic Liability Reduction 
As part of an effort to generate analogs of 32 with reduced susceptibility to P450 
oxidation, three additional analogs were built beginning from intermediate 28a (Scheme 2.6).  
Simple alkylation with 2,2,2-trifluoro-1-iodoethane generated analog 51.  Analog 32, generated 
as in Scheme 2.3, could be used as the starting material to prepare sulfone (52) and sulfoxide 
(53) derivatives by treatment with mCPBA or controlled quantities of Oxone
®
,
58
 respectively.  
No alkene epoxidation or other off-target oxidation events were observed using either set of 
conditions.  
 
Template modifications: Scaffold distortion and central ring substitution changes 
In addition to the more library-based synthesis of the compounds related above, a variety 
of prototype compounds were produced to probe significant changes to the central ring.  This 
ring is the least amenable to structural diversity generation in our general scheme, and therefore 
each analog required significant synthetic departures. 
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The generation of compound 58 with a 5-membered central ring (Scheme 2.7) proceeded 
from commercially available 3,3-dimethylindan-1-one 54 once it was determined that β-
aminoester 56 could not be generated under acid-catalyzed Friedel-Crafts conditions (see 5, 
Scheme 2.1, step c).  The indanone was functionalized at the α-keto position via Claisen 
condensation to yield ketoester 55,
59
 followed by conversion of the ketone to the conjugated 
enamine via ammonium acetate.
60
  With aminoester 56 in hand, it was discovered that our 
standard set of conditions for generating the thioxopyrimidine ring did not yield any product. 
After screening a variety of methods, it was eventually found that combining 56, allyl 
isothiocyanate, and pyridine in a pressure vessel and heating to reflux was the only set of 
conditions that furnished 57 in adequate yields.
61
 Thioalkyl pyrimidinone 58 was finally 
synthesized after the alkylation of sulfur under basic conditions. 
Scheme 2.7. Synthesis of ring-contracted analog 58.
a
 
 
a
Reagents and conditions: a) NaH, dimethyl carbonate; then 54, THF, 80°C, 4h, 97%; b) 
NH4OAc, MeOH, reflux, 23h, 55%; c) allyl-NCS, pyridine, reflux, 17h, 23%; d) 
CH3OCH2CH2OTs, Cs2CO3, MEK, 80°C, 16h, 62%. 
 
A racemic mixture of 6-methylated derivative 63 was synthesized with particular 
attention focused on using methods that would eventually allow its production in 
enantiomerically pure form (Scheme 2.8).  Beginning from 2-phenylpropan-1-ol, modified 
Mitsunobu conditions to form a new C-C bond afforded intermediate 60.
62
  Unlike similar 
substrates in this SAR campaign, it was found that the cyanoester could be effectively cyclized to 
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61 in the presence of triflic acid in excellent yield.
63
  Installation of the pyrimidinone and S-
alkylation proceeded as normal to furnish 63.  The relatively weak activity of this analog in 
GAS-SK activity assays led us to abandon synthesis of the corresponding enantiomerically pure 
analogs. 
Scheme 2.8. Synthesis of racemic methylbenzyl analog 63.
a
 
 
a
Reagents and conditions: a) DIAD, PPh3, -20°C, THF, then 59, ethyl cyanoacetate, THF, -20-
0°C, 24h, 82%; b) TfOH, DCM, RT, 24h, 92%; c) allyl-NCS, AcOH, EtOH, 75°C, 16h, 35%; d) 
CH3OCH2CH2OTs, Cs2CO3, MEK, 75°C, 16h, 75%. 
 
Two other attempts were made to introduce chiral substitution on the central ring, 
resulting in compounds 67 and 75.  Compound 67 was synthesized in order to assess whether the 
LDA/ZnI2 reaction conditions could be used to diastereoselectively synthesize β-aminoester 65 
and possibly other structurally similar intermediates (Scheme 2.9).  To this end, 2-
ethylbenzonitrile and ethyl crotonate were used as the starting materials in the LDA/ZnI2 
cyclization.  The reaction proved to proceed more rapidly than normal, likely owing to the 
reduced steric bulk around the β-position of the Michael acceptor.  It was found that the standard 
ZnI2-promoted conditions led to an inseparable mixture of diastereomers in a 1:3 ratio.  
Omission of the ZnI2 or addition before the Michael addition step led to 1:1 ratios, albeit in 
greatly reduced yields.  The isothiocyanate cyclization and sulfur alkylation steps followed the 
standard procedures, eventually furnishing final compound 67.  Unfortunately, the 
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diastereomeric mixtures were found to be totally inseparable at every stage in the synthetic 
scheme, leading to the submission of 67 as a 1:3 mixture of diastereomers.  It was noted that the 
final compounds appear to be separable by HPLC (TR = 6.44 and 6.89 min, HPLC Method B, see 
Chapter 6), potentially allowing for separation via prep-scale HPLC, but this option was not 
explored given the relatively low level of activity observed for this compound. 
Scheme 2.9. Synthesis of diasteromeric compound 67.
a
 
 
a
Reagents and conditions: a) LDA, diglyme -78°C, 1h, then ethyl crotonate, ZnI2, -78°C-RT, 2h, 
36%; b) allyl-NCS, AcOH, EtOH, 75°C, 16h, 30%; c) CH3OCH2CH2OTs, Cs2CO3, MEK, 75°C, 
16h, 67%. 
 
Analog 75 was built as part of a campaign to introduce an additional heteroatomic 
“handle” for diversity generation at the benzyl position of the central ring (Scheme 2.10).  
Finding substitution amenable to surviving the LDA/ZnI2 cyclization conditions proved to be 
quite challenging.  A variety of masked oxygen (TBS ethers, acetyl groups) and nitrogen 
(diphenyl imine, phthalate) substitutions at the benzyl position were found to be incompatible 
with these rather harsh conditions. Ultimately, only 2-(methoxymethyl)benzonitrile 72 was 
successfully transformed to its corresponding β-aminoester.  This intermediate was synthesized 
from commercially available phenyl bromide 68 via nucleophilic substitution of sodium acetate 
at the benzyl position, followed by saponification
64
 and methylation to yield intermediate 71.  
SNAr with cuprous cyanide was found to efficiently produce benzonitrile intermediate 72.
65
  
After cyclization to 73, the rest of the synthetic scheme proceeded as usual to generate racemate 
75.  Attempts to demethylate 75 to reveal an alcohol amenable to functionalization (76) instead 
led to the immediate aromatization of the central ring via 1,2 methyl shift (77), effectively ruling 
out this strategy for significant diversity generation. 
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Scheme 2.10. Synthesis of methoxybenzyl substituted analog 75.
a
 
 
Reagents and conditions: a) NaOAc, DMF, 70°C, 16h, 93%; b) K2CO3, MeOH, RT, 60 min, 
96%; c) MeI, KOH, DMSO, RT, 90min, 96%; d) CuCN, DMF, 120°C, 16h, 81%; e) LDA, 
diglyme -78°C, 1h, then ethyl 3,3-dimethyl acrylate, -78°C-RT, 2h, 54%; f) allyl-NCS, AcOH, 
EtOH, 75°C, 16h, then NaOEt, RT, 30 min, 53%; g) EtI, Cs2CO3, DMF, 75°C, 16h, 55%; h) 
BBr3, DCM, 0°C-RT, 16h. 
SAR Discussion 
We first examined the spirocycloalkyl substituted compounds with varied substitution 
patterns at the 2-position of the pyrimidinone ring system (Table 2.1).  Aromatic substitution at 
R
1
 (2, 7, 8) did not appreciably increase potency over 1, but methyl substitution (11) conferred a 
modest increase in activity (IC50 = 19 μM vs. >50 μM).  Interestingly, polar groups were 
tolerated as part of smaller alkyl groups at the 2-position (e.g. 9, 12).  The replacement of sulfur 
with nitrogen (13) led to an unacceptable decrease in growth.  Similarly, basic amine 
functionality appended to sulfur (10) led to growth inhibition in some trials.  We defined 
acceptable growth inhibition to be no greater than 15% at 50 µM of test compound.  The 
favorable potency of commercially available spirocyclopentyl analog 78 relative to closely 
related spirocyclohexyl analog 2 led us to hypothesize that the size of the geminal substitution on 
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the central ring could be reduced, allowing reduction of both the lipophilicity and the molecular 
weight of future analogs. 
Table 2.1.  Inhibition of SK activity by spirocycloalkyl analogs. 
# Structure 
5 µM SK 
T/C 
a 
50 µM SK 
T/C 
a 
50 µM 
Growth T/C
b
 
IC50 
(µM) 
MLM t1/2 
(min)
c 
Aq. Sol. 
(μM)
d 
1† 
 
0.84 ± 0.14 0.48 ± 0.28 0.95 ± 0.08 >50 37.2 9 ± 2 
2† 
 
0.74 ± 0.16 0.57 ± 0.21 0.96 ± 0.06 >50 0.6 9 ± 2 
7† 
 
1.00 ± 0.33 0.82 ± 0.44 1.05 ± 0.06    
8† 
 
0.96 ± 0.46 0.74 ± 0.28 0.96 ± 0.14    
9† 
 
0.47 ± 0.28 0.29 ± 0.15 0.99 ± 0.10  6.4 9 ± 2 
10† 
 
0.72 ± 0.12 0.52 ± 0.37 0.88 ± 0.20    
11‡ 
 
0.60 ± 0.19 0.42 ± 0.03 0.98 ± 0.03 19 ± 6.0 13.5 22 ± 5 
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# Structure 
5 µM SK 
T/C 
a 
50 µM SK 
T/C 
a 
50 µM 
Growth T/C
b
 
IC50 
(µM) 
MLM t1/2 
(min)
c 
Aq. Sol. 
(μM)
d 
12‡ 
 
0.53 ± 0.23 0.14 ± 0.05 1.02 ± 0.09   14.5 ± 3 
13 
 
0.78 ± 0.47 0.56 ± 0.70 0.32 ± 0.18   9 ± 2 
78 
 
0.44 ± 0.06 0.23 ± 0.16 1.07 ± 0.04    
a 
Ratio of A405 of SK-cleaved substrate in GAS culture treated with the indicated concentration of 
test compound divided by A405 of DMSO control (see Chapter 6: Experimental Section).  Values 
are the mean of at least three experiments ± standard deviation.  
b
Ratio of OD (600 nm) for 
growth of GAS in the presence of test compound divided by DMSO control. Values are the mean 
of at least three experiments ± standard deviation. 
c
Half-life of parent compound during 
incubation with mouse liver microsomes. 
d
Kinetic solubility of compound in aqueous Todd 
Hewitt bacterial media. †Synthesized originally by Jenny Ryu. ‡Synthesized originally by 
Meghan Breen. 
 
Exploration of analogs with gem-dimethyl substitution of the central ring (Table 2.2) 
began with the assessment of commercially available analogs 79-81, all of which showed an 
increase in potency in comparison to 1. Polar substitution at the 2-position was generally well-
tolerated (19, 21, 17, 81) except for primary amide 18. Introducing an alcohol on the sidechain 
(20) to improve solubility led to unacceptable bacteriotoxicity. This toxicity was also observed 
with heteroatomic analogs 23 and 24 versus sulfur analog 80, leading us to conclude that 
retention of the sulfur was necessary to avoid inhibition of bacterial growth.  Altering the 
substitution of the N-position of the pyrimidinone was found to lead to bacterial toxicity (41) or 
attenuation of activity (46) compared to N-allyl (17).  Overall, the S-Et and S-CH2CH2OMe 
analogs 80 and 17 were found to be the optimum compounds from this series. 
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Table 2.2.  Inhibition of SK activity by gem-dimethyl analogs. 
# Structure 
5 µM SK 
T/C 
a 
50 µM SK 
T/C 
a 
50 µM 
Growth T/C
b
 
IC50 (μM) 
MLM t1/2 
(min)
c 
Aq. Sol. 
(μM)
d 
79 
 
0.65 ± 0.25 0.35 ± 0.14 1.03 ± 0.03 10.8 ± 3.0  9 ± 2 
80 
 
0.24 ± 0.07 0.17 ± 0.08 0.89 ± 0.05 2.0 ± 0.5   
81 
 
0.54 ± 0.10 0.27 ± 0.12 1.01 ± 0.02    
17‡ 
 
0.35 ± 0.11 0.13 ± 0.07 0.86 ± 0.10 3.2 ± 0.6 1.7 22.5 ± 4.5 
18‡ 
 
0.79 ± 0.17 0.64 ± 0.16 1.00 ± 0.02  <2  
19‡ 
 
0.40 ± 0.09 0.13 ± 0.07 1.05 ± 0.02    
20‡ 
 
0.48 ± 0.17 - 0.06 ± 0.03    
21 
 
0.37 ± 0.17 0.23 ± 0.06 1.00 ± 0.03  20.6 34.5 ± 7.5 
23 
 
0.34 ± 0.08 0.23 ± 0.10 0.50 ± 0.23  0.9  
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# Structure 
5 µM SK 
T/C 
a 
50 µM SK 
T/C 
a 
50 µM 
Growth T/C
b
 
IC50 (μM) 
MLM t1/2 
(min)
c 
Aq. Sol. 
(μM)
d 
24 
 
0.48 ± 0.19 - 0.06 ± 0.03  1.1  
41 
 
0.41 ± 0.23 - 0.39 ± 0.15  0.8  
42 
 
0.20 ± 0.12 0.15 ± 0.20 0.64 ± 0.38    
46¥ 
 
0.71 ± 0.40 0.61 ± 0.32 0.97 ± 0.07  9.4  
a 
Ratio of A405 of SK-cleaved substrate in GAS culture treated with the indicated concentration of 
test compound divided by A405 of DMSO control (see Chapter 6: Experimental Section). Values 
are the mean of at least three experiments ± standard deviation.  
b
Ratio of OD (600 nm) for 
growth of GAS in the presence of test compound divided by DMSO control. Values are the mean 
of at least three experiments ± standard deviation. 
c
Half-life of parent compound during 
incubation with mouse liver microsomes. 
d
Kinetic solubility of compound in aqueous Todd 
Hewitt bacterial media. 
‡
Originally synthesized by Meghan Breen. 
¥
Originally synthesized by 
W.G. Rajeswaran. 
Our attention then turned to exploring substitution of the aromatic ring (Table 2.3) at 3 
different positions.  Assessment of methyl ether analogs 31-33 revealed that substitution at the 8- 
and 9- positions conferred a moderate increase in potency over 80, while substitution of the 7-
position did not.  Interestingly, S-ethoxymethyl compound 29 was observed to be less potent than 
S-ethyl compound 31, in contrast to similar compounds 17 and 79 which were essentially 
equipotent.  The installation of methoxyethyl ethers (37-39) generally led to the attenuation of 
the potency gains seen with 31-33.  Though unfortunate, this data was valuable for guiding our 
synthetic strategy for the target ID probes (Chapter 3).  Phenol compounds 34-36 (Scheme 2.3) 
induced acute toxicity in preliminary activity assays and were thus not followed up on.  This 
occurrence was not unexpected, as it is known that many phenols have bacteriotoxic effects.
66
 
The generation of a larger library of aryl ethers was undertaken by chemist Roderick Sorenson, 
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but generally displayed low activity, consistent with the trend of increased steric bulk decreasing 
activity as previously observed with 31-33 vs. 37-39.  Compound 30, also synthesized by 
Roderick Sorenson, had moderate activity and low metabolic stability, but was important to the 
preliminary biofilm effort (Chapter 4).  A number of aryl carboxylic acid derivatives (ester, 
amide; synthesized by Michael Wilson) also proved to be almost completely inactive (data not 
shown).  Ultimately, 9-methoxy analog 32 was found to be the optimal compound from this 
series, exhibiting a 90% reduction in streptokinase activity at 5 μM and an IC50 of 1.3 μM, 
representing a greater than 35-fold improvement in potency over 1, although some modest 
inhibition of bacterial growth at high concentrations was introduced.  
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Table 2.3.  Inhibition of SK activity by analogs with 7-, 8-, and 9-position substitution. 
# Structure 
5 µM SK 
T/C 
a 
50 µM SK 
T/C 
a 
50 µM 
Growth T/C
b
 
IC50 (µM) 
MLM t1/2 
(min)
c 
Aq. Sol.  
(μM)
d 
29 
 
0.47  ± 0.25 0.25  ± 0.18 0.89  ± 0.16    
30† 
 
0.33  ± 0.15 0.28  ± 0.16 0.92  ± 0.16 6.9 ± 0.3 0.6 14.5 ± 3.5 
31 
 
0.18  ± 0.09 0.07  ± 0.01 0.87 ± 0.19 3.1   ± 0.7 0.8 14.5 ± 3.5 
32 
 
0.10  ± 0.06 0.07  ± 0.02 0.73  ± 0.07 1.3  ± 0.6 2.3 9 ± 2 
33 
 
0.26  ± 0.07 0.29  ± 0.18 0.28  ± 0.26    
37 
 
0.58  ± 0.24 0.43  ± 0.15 1.02  ± 0.10    
38 
 
0.84  ± 0.23 0.40  ± 0.21 0.94  ± 0.08    
39 
 
0.46  ± 0.35 0.36  ± 0.41 0.85  ± 0.22    
a 
Ratio of A405 of SK-cleaved substrate in GAS culture treated with the indicated concentration of 
test compound divided by A405 of DMSO control (see Chapter 6: Experimental Section). Values 
are the mean of at least three experiments ± standard deviation.  
b
Ratio of OD (600 nm) for 
growth of GAS in the presence of test compound divided by DMSO control. Values are the mean 
of at least three experiments ± standard deviation. 
c
Half-life of parent compound during 
incubation with mouse liver microsomes. 
d
Kinetic solubility of compound in aqueous Todd 
Hewitt bacterial media. 
†
Compound synthesized by Roderick Sorenson. 
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Activity data for N- and O-alkylated compound pairs is summarized in Table 2.4.  No 
general efficacy advantage for N- or O- alkylation was observed; O-alkylated 48 was somewhat 
more potent than 46, while 32 remained much more potent than its O-alkylated counterpart 50.  
Compounds 47 and 49 displayed similarly weak activity. 
Table 2.4. Effect of N-vs. O-alkylation on GAS-SK inhibition and metabolic stability.  
# Structure 
5 μM SK 
T/C
a 
50 µM SK 
T/C
a 
50 µM 
Growth T/C
b
 
IC50 
(µM) 
MLM t1/2 
(min)
c 
46¥ 
 
0.71 ± 0.40 0.61 ± 0.32 0.97 ± 0.07  9.4 
48¥ 
 
0.46 ± 0.37 0.24 ± 0.15 1.00 ± 0.09 5.5 ± 0.7 45.1 
47 
 
0.78 ± 0.36 0.49 ± 0.17 1.01 ± 0.04  3.0 
49 
 
0.51 ± 0.20 0.38 ± 0.23 0.89 ± 0.02  45.5 
32 
 
0.10  ± 0.06 0.07  ± 0.02 0.73  ± 0.07 1.3  ± 0.6 2.3 
50 
 
0.89 ± 0.33 0.68 ± 0.39 0.96 ± 0.02  8.3 
a 
Ratio of A405 of SK-cleaved substrate in GAS culture treated with the indicated concentration of 
test compound divided by A405 of DMSO control (see Chapter 6: Experimental Section). Values 
are the mean of at least three experiments ± standard deviation.  
b
Ratio of OD (600 nm) for 
growth of GAS in the presence of test compound divided by DMSO control. Values are the mean 
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of at least three experiments ± standard deviation. 
c
Half-life of parent compound during 
incubation with mouse liver microsomes. 
¥
Originally synthesized by W.G. Rajeswaran. 
 
Activity data for the template-modified compounds described in Schemes 2.7-2.10 are 
summarized in Table 2.5. Although compounds 67 and 75 show reasonable activity, all four of 
these compounds were found to be quite toxic at 50 µM, suggesting that even small changes to 
the central ring of the scaffold are not tolerated.  The activity data for these four compounds led 
us to stop exploring the central ring as a point of diversity in the SAR study. 
Table 2.5. GAS-SK activity data for compounds with modified central rings. 
# Structure 5 µM SK T/C
a 
50 µM SK T/C
a 
50 µM Growth T/C
b 
58 
 
0.61 ± 0.20 - 0.60 ± 0.31 
63 
 
0.74 ± 0.19 - 0.46 ± 0.25 
67 
 
0.40
c 
0.09
c 
0.30
c 
75 
 
0.38
c 
0.10
c 
0.39
c 
a 
Ratio of A405 of SK-cleaved substrate in GAS culture treated with the indicated concentration of 
test compound divided by A405 of DMSO control (see Chapter 6: Experimental Section). Values 
are the mean of at least three experiments ± standard deviation.  
b
Ratio of OD (600 nm) for 
growth of GAS in the presence of test compound divided by DMSO control. 
c
Value derived from 
only one experiment. Values are the mean of at least two experiments ± standard deviation 
unless indicated. 
Microsomal Stability and Metabolite Identification 
In our previous publication identifying 1 and 2 as inhibitors of SK expression, it was 
determined that 1 displayed efficacy in mouse models of GAS infection while 2 did not, despite 
having similar activity in bacterial assays.
45
  We hypothesized that a difference in susceptibility 
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to oxidative metabolism might be playing a role in the activity differential between 1 and 2 in 
mammalian systems.  We submitted each of these compounds for stability testing in mouse liver 
microsomal (MLM) extract (performed by the Duxin Sun group at University of Michigan). The 
metabolic half-life data from these assays supported our hypothesis, with 1 displaying more than 
60-fold higher stability to oxidation than 2 (t1/2 = 37.2 min vs. 0.6 min, respectively).  A survey 
of several more compounds in the series (Tables 2.1-2.6) revealed that most were highly unstable 
(t1/2 < 5 minutes), despite several structural modifications that would potentially reduce their 
propensity to oxidation, including lowered lipophilicity, fewer unsubstituted aliphatic, olefinic, 
or aryl carbons, and replacement of sulfur with oxygen or nitrogen.  Interestingly, we also noted 
that the spirocyclohexyl compounds were generally more stable than the corresponding gem-
dimethyl analogs (e.g. 9, t1/2 = 6.4 min vs. 17, t1/2 = 1.7 min), despite their greater degrees of 
lipophilicity.   
In collaboration with the Duxin Sun group, a metabolite ID study was performed using 
compound 9 to elucidate the most metabolically labile sites on the scaffold.  Possible metabolites 
were identified by LC-MS analysis, then fragmented via collision-induced dissociation (CID). 
Further MS analysis of the resulting metabolite fragments allowed us to deduce the structure of 
each metabolite.  This study indicated that the most metabolically labile portions of the molecule 
were the substitutions on the pyrimidinone ring (Figure 2.2).  No oxidation was indicated on the 
spirocyclohexane ring or any of the four unsubstituted aromatic carbons.  Based on the findings 
of the metabolite ID study, we prepared five analogs of our optimum compound 32 that 
deactivated this portion of the scaffold to oxidation (Table 2.6); however, these were also found 
to be quickly metabolized.   Interestingly, metabolic assessment of the O-alkylated compounds 
48-50 (Table 2.4) showed that they were consistently more stable (4-15 fold) than their N-
alkylated counterparts.  This observation, paired with the generally greater stability of the 
hindered spirocyclohexyl analogs vs. the corresponding gem-dimethyl analogs, suggests that 
hydrolysis of the pyrimidinone amide may play a key role in the metabolic breakdown of these 
compounds.  Compound 48, despite being four-fold less potent than 32 (IC50 = 5.5 μM vs. 1.3 
μM), demonstrates the potential viability of O-alkylated analogs as more metabolically stable 
alternatives to the N-alkylated compounds. 
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Table 2.6. Analogs of 32 with potentially reduced metabolic liability. 
# Structure 
5 µM SK 
T/C
a 
50 µM SK 
T/C SD 
a 
50 µM 
Growth T/C
b
 
MLM t1/2 
(min)
c 
32 
 
0.10  ± 0.06 0.07  ± 0.02 0.73  ± 0.07 2.3 
43 
 
0.66 ± 0.20 0.20 ± 0.14 0.83 ± 0.15 1.7 
47 
 
0.78 ± 0.36 0.49 ± 0.17 1.01 ± 0.04 3.0 
51 
 
0.45  ± 0.19 0.22 ± 0.08 0.86 ± 0.07 4.8 
52 
 
0.83 ± 0.31 0.70 ± 0.13 1.03 ± 0.03 3.8 
53 
 
1.00 ± 0.13 0.51 ± 0.31 1.01 ± 0.05 2.8 
a 
Ratio of A405 of SK-cleaved substrate in GAS culture treated with the indicated concentration of 
test compound divided by A405 of DMSO control (see Chapter 6: Experimental Section). Values 
are the mean of at least three experiments ± standard deviation.  
b
Ratio of OD (600 nm) for 
growth of GAS in the presence of test compound divided by DMSO control. Values are the mean 
of at least three experiments ± standard deviation. 
c
Half-life of parent compound during 
incubation with mouse liver microsomes. 
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Figure 2.2. Potential routes of metabolism identified by MLM incubation and MS analysis.  
No oxidation of the left-hand side of the molecule was observed. 
 
Aqueous Solubility 
In addition to microsomal stability, the aqueous solubility of small molecules has been 
shown to be a critical physicochemical property for predicting the efficacy of compounds in 
living systems.  Lipinski suggests that to achieve oral bioavailability at a dose of 1 mg/kg, a 
compound needs to achieve a minimum aqueous solubility of 52 μg/mL,67 corresponding to a 
concentration of ~150 μM for small analogs similar in size to 32. Therefore, several key 
compounds from the SAR library were assessed for kinetic solubility in Todd Hewitt (THY) 
bacterial media.  Taking inspiration from Lipinski’s turbidimetric assay of compound solubility 
and a high-throughput method of solubility determination employed by GlaxoSmithKline,
68
 we 
developed a 96-well plate-based solubility assay that kept DMSO concentrations low (1%) and 
constant over the range of test compound concentrations.   
The solubility of all compounds tested (Tables 2.1-2.3) was equal to or less than 25 μM, 
with the exception of nitrile 21 (aq. sol. = 34.5 ± 7.5 μM). It was found that the solubility of 
these compounds was considerably lower in phosphate-buffered saline (PBS) than in THY media 
(eg. 2 ± 1 vs. 9 ± 2 μM [PBS:THY]  for 1, 3 ± 1 vs. 34.5 ± 7.5 μM [PBS:THY] for 21), 
suggesting that the protein and lipid content of THY media may increase the effective aqueous 
solubility of this compound class.  Preliminary activity studies indicated that the activity of 1 
(but not 21) was reduced when human serum albumin (HSA) was added to the bacterial media, 
reinforcing the hypothesis that some compounds in this series may bind to protein. The measured 
solubility has a weak negative correlation to the cLogP (R
2
 = 0.533), and the most soluble 
compound 21 does indeed have the lowest cLogP (3.55).    Further decreases in cLogP should 
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logically result in greater aqueous solubility; however, nearly all efforts to significantly decrease 
lipophilicity, including replacement of the fused phenyl ring with pyridyl and replacement of the 
central ring with lactones or lactams (Scheme 2.11), have thus far led to the reduction or loss of 
activity (data not shown).   
Mammalian Cytotoxicity 
A representative subset of compounds (1, 32, 31, 17, 46, 48, 79) was assessed by the 
Hongmin Sun group for toxic effect in HeLa cells using a standard tetrazolium-formazan assay 
of cell viability (see Chapter 6: Experimental Section).  It was found that none of the compounds 
inhibited growth by more than 35% up to 100 μM, the highest concentration tested. 
Scaffold Alteration 
A number of alternative scaffolds based on the core structure of 1 were pursued by other 
chemists in the group.  The basic structures of these compounds are delineated in Scheme 2.11.  
A particular emphasis was placed on decreasing lipophilicity by breaking up the planarity of the 
ring system (82, 83) or by simply introducing more polar functionality (84-87). Though a 
significant number of compounds were synthesized from these scaffolds (~50 in total), none of 
them displayed activity comparable to the best compounds identified from the rest of the SAR 
study, and were not followed up on.  Interestingly, the spiropiperidine analogs (entry 86), 
although only modestly active in the GAS-SK study, were found to be more metabolically stable 
and possess another easily functionalized site for diversity generation, which had significant 
implications for the anti-biofilm study (Chapter 4). 
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Scheme 2.11. Scaffold modifications explored by other VMCC chemists.
a
 
 
a
82-85 developed by Roderick J. Sorenson. 86 developed by W.G. Rajeswaran. 87 developed by 
Michael Wilson. 
Follow-up HTS and Commercial SAR Campaign 
Given the high attrition rate inherent to drug development campaigns, our research group 
and collaborators recognized the importance of evaluating several hit compounds to maximize 
the probability of developing a potent and pharmacokinetically competent lead.  The original 
screen performed at the Center for Chemical Genomics at the University of Michigan was 
performed on the modestly sized in-house library of 55,000 compounds, which returned CCG-
2979 (1) as the only workable lead compound due to issues of reactivity, availability, and 
reproducibility of the other hits.
45
   To find additional hit compounds, the original HTS protocols 
were used in a second screen, this time employing the 303,000 compound library at the Broad 
Institute of MIT and Harvard.  The second screen returned 7 additional hits from 6 distinct 
chemical classes (Scheme 2.12).  As with the CCG-2979 series, a short round of commercial 
SAR was initiated to assist in deciding which scaffolds to evaluate further. 
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Scheme 2.12. Hit compounds identified from follow-up HTS at the Broad Institute. 
 
A total of 73 commercially available compounds across the 6 scaffolds were tested for 
activity in GAS (10-15 compounds per scaffold), sampling a breadth of substitution patterns 
around the basic skeleton of each hit.  The thienopyrimidine (based on 89 and 93) and quinoline 
(based on 94) series showed very little SAR between analogs and were generally low in potency, 
leading to their removal from consideration.  Of the remaining four scaffolds, chromenone-based 
similar in structure to 88 exhibited the widest range of activity in the GAS-SK assay (Table 2.7), 
with a few (103, 104) showing exceptional activity on par with potent compound 17. 
Furthermore, the aqueous solubility of these compounds, although not tested, is likely enhanced 
due to the reduced overall planarity of the compound and the presence of a basic amine.  Lead 
compound 88 was not commercially available in sufficient quantities to be included in the 
commercial SAR study, but several close analogs (99, 101, 102) were obtained.  Although the 
GAS-SK activity data was encouraging, incubation of representative compound 102 with liver 
microsomes revealed a severe propensity for rapid oxidation (MLM t1/2 = 0.6 min). Given our 
long-standing issues with metabolic stability in the CCG-2979 series, it was decided the 
chromenone scaffold would not be pursued as an alternate template.  The growing interest in the 
biofilm arm of the study led us to decide that none of the other 3 potent scaffolds would be 
assessed further in the GAS study, but the purchased compounds were retained for screening for 
anti-biofilm activity (Chapter 4). 
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Table 2.7. GAS-SK Activity data for chromenone-based compounds 95-104. 
# Structure 
5 µM SK 
T/C
a 
50 µM SK 
T/C
a 
50 µM 
Growth T/C
b 
95 
 
1.48 ± 0.15 1.16 ± 0.01 0.87 ± 0.01 
96 
 
1.28 ± 0.14 0.81 ± 0.01 1.04 ± 0.00 
97 
 
1.27 ± 0.04 0.82 ± 0.07 1.06 ± 0.02 
98 
 
1.25 ± 0.01 1.00 ± 0.04 1.06 ± 0.00 
99 
 
1.19 ± 0.07 0.83 ± 0.01 1.01 ± 0.01 
100 
 
0.75 ± 0.21 0.68 ± 0.04 1.05 ± 0.00 
101 
 
0.73 ± 0.03 0.49 ± 0.02 1.05 ± 0.00 
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# Structure 
5 µM SK 
T/C
a 
50 µM SK 
T/C
a 
50 µM 
Growth T/C
b 
102 
 
0.69 ± 0.05 0.36 ± 0.07 0.84 ± 0.01 
103 
 
0.58 ± 0.11 0.09 ± 0.04 0.90 ± 0.02 
104 
 
0.34 ± 0.05 0.17 ± 0.01 1.13 ± 0.02 
17 
 
0.44 ± 0.02 0.06 ± 0.04 0.93 ± 0.01 
a 
Ratio of A405 of SK-cleaved substrate in GAS culture treated with the indicated concentration of 
test compound divided by A405 of DMSO control (see Chapter 6: Experimental Section). Values 
are the mean of at least three experiments ± standard deviation.  
b
Ratio of OD (600 nm) for 
growth of GAS in the presence of test compound divided by DMSO control. Values are the mean 
of three replicates within one assay, ± standard deviation. 
4. Conclusions 
The GAS-SK SAR study ultimately resulted in the synthesis of 123 analogs of 1 
developed by myself and five other chemists. Over the course of the study, we discovered 
several more potent compounds, with 32 identified as the best analog of the series (IC50 = 1.3 
μM).  Despite gains in potency, the overall efficacy of these compounds is no doubt hampered by 
issues of low metabolic stability and aqueous solubility across nearly all analogs. Careful 
structure-metabolism relationship analysis identified that alkylating the O- position of the 
pyrimidinone amide (e.g. compounds 48-50) conferred significant (4-15 fold) increases in 
metabolic stability in comparison to identical N-substitution. Unfortunately, compound 50, the 
O-alkylated isomer of 32, was much less potent, and is still rather unstable despite a 4-fold 
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longer MLM half-life (t1/2 = 8.3 min vs. 2.3 min for 32).  The aqueous solubility of these 
compounds remains quite low, and most attempts to increase solubility via the installation of 
polar functionality were met with severe drops in activity.  Ultimately, three factors led to the 
indefinite suspension of the GAS-SK study: (1) the inability to identify compounds retaining 
potent activity while enhancing solubility and stability; (2) the overall variable, poorly 
reproducible, and time-intensive nature of the activity assay; and (3) the discovery of anti-
biofilm activity in S. aureus with this compound series. While the GAS-SK portion of the study 
has concluded, the compounds and physicochemical data gleaned from this study are still highly 
valuable to the ongoing biofilm inhibition effort (Chapter 4).  
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Chapter 3: Target Identification 
Phenotypic Screening and Target Identification 
Screening campaigns employing phenotypic assays, like the one used to identify 1, have 
the benefit of identifying hit compounds possessing physicochemical properties sufficient for 
cell permeability and access to intracellular targets. In contrast to target-based screening, 
phenotypic screening does not rely on a priori knowledge of the affected biological pathway to 
identify hit compounds, making it a useful tool for discovering novel biochemical mechanisms of 
action.
69
 These advantages, taken together with the limited number of successful drug 
development studies derived from target-based screening of bacterial proteins,
70
 demonstrate the 
potential utility of phenotypic screening for identifying novel antibacterial agents.  The benefits 
of phenotypic screens come at the cost of offering no insight into the macromolecular target of 
hit compounds. Therefore, the use of some method of target identification is necessary to gain a 
fuller biochemical understanding of the affected systems. In the context of our project, 
identifying the target of lead compound 1 would be important for (a) helping to establish a 
biochemical assay with which to improve the potency and specificity of the compound series, 
and (b) identifying potentially novel pathways in virulence gene expression.  
 The potent activity of our compounds against SK expression, combined with RNA 
microarray data indicating the down-regulation of other important GAS virulence factors (M 
protein, streptolysins, fibronectin and collagen-like binding proteins, Figure 1.2), suggests that 
their macromolecular target(s) are involved in the upstream regulation of GAS virulence 
mechanisms. The control systems governing GAS virulence have been the subject of a 
considerable body of research that has elucidated the roles of several transcriptional 
modulators.
71
  Various aspects of GAS virulence are controlled by the growth-phase dependent 
activation of the response regulator (RR) proteins Mga,
72
 RALP (also known as RofA),
73
 and 
Rgg.
74,75
 In addition, a number of two-component systems (TCSs) have been characterized that 
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regulate gene expression based on environmental stimuli detected by membrane-embedded 
sensor proteins.  Three TCSs with a role in GAS virulence control have been well-studied: the 
Ihk/Irr system (leukocyte evasion),
76,77
 FasBCAX (RNA-mediated streptokinase induction),
78,79
 
and CovR/CovS (down-regulation of several virulence factors during stationary phase).
80
  More 
recent studies have identified several other systems that influence GAS virulence, including TCS 
system Streptococcus pyogenes Ser/Thr phosphatase (SP-STP),
81
 putative RNase CvfA,
82
 and 
GAPDH, a glycolytic surface-expressed enzyme.
83
 It is possible that one of these systems may 
contain the target of our compound series, but the highly complex nature of GAS virulence and 
virulence control mechanisms makes this somewhat unlikely. Furthermore, genomic sequencing 
of multiple virulent GAS serotypes has revealed several well-conserved putative RRs and at least 
10 TCSs that have yet to be characterized.
84
 The identification of a previously uncharacterized 
protein would represent an excellent opportunity to expand the current understanding of GAS 
virulence. 
42 
 
Figure 3.1. A survey of possible methods of chemical probe-based target identification.
 
A: An “affinity matrix” column consisting of agarose beads functionalized with probe compound 
for the selective enrichment of target proteins. B: Noncovalent association of probe with target 
proteins to be enriched via avidin affinity column. C: Use of alkyne-modified bifunctional small 
molecule photoprobes employed to first selectively bind to target proteins, then covalently bond 
to the binding site under UV irradiation, and finally be modified with a biotin group via click 
chemistry to facilitate avidin column enrichment. 
Chemical probes are commonly employed in target identification studies, and several 
strategies have evolved for successfully identifying targets (Figure 3.1).
85,86,87,88
 Affinity 
chromatography is a popular method that involves the use of agarose beads conjugated with a 
small molecule, either directly or through a biotin/streptavidin association, to “pull-down” 
proteins that interact with the probe compound (Figure 3.1A, 3.1B).  Control experiments that 
add a soluble competitor compound abolishes specific probe-protein interactions, enabling the 
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differentiation of specific and nonspecific binding events (Figure 3.2).  Biotinylated probes most 
often incorporate a linker region (commonly alkyl amide or polyethylene glycol-derived) of 
variable length between the biotin and ligand portion of the molecules to avoid steric clashing of 
the target and streptavidin.  Drawing upon previous studies with similar goals, we first decided to 
pursue the synthesis of biotinylated versions of our more potent GAS-SK compounds. 
 
First Generation Probes: Biotinylated Ligands 
Before biotinylated probes could be synthesized, we first determined the optimal 
attachment point for a biotin linker on the scaffold.  To do so, we incorporated a methoxyethyl 
group as a model of the poly(ethylene glycol) spacer at 5 different attachment points on the 
molecule: three positions on the aryl ring, and one each at the sulfur and amide nitrogen of the 
pyrimidinone ring. The synthesis of each of these compounds is described in Chapter 2.  A 
comparison of their relative activity in the GAS-SK assay (Table 3.1) indicated that attachment 
to the aryl ring (37-39) led to lower or erratic activity. Compound 42 was found to be essentially 
equipotent to 17, but induced bacteriotoxicity in several trials.  Therefore, the pyrimidinone 
sulfur was chosen as the attachment point for the first generation of target identification probes.   
Figure 3.2. Schematic of Western blot 
indicating a successful target ID using 
biotinylated probes. Lane A: Proteins 
that interact nonspecifically with column 
components are visualized. Lane B: In the 
presence of probe, proteins are now a 
mixture of nonspecific protein-column 
and protein-ligand interactions, as well as 
possible specific protein-ligand 
interactions. Lane C: Inclusion of a 
soluble competitor reduces specific probe-
ligand interaction, indicating possible 
target. 
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Table 3.1. Comparison of 2-methoxyethyl substitution at 5 attachment points. 
# Structure 
5 µM SK 
T/C
a 
50 µM SK 
T/C
a 
50 µM 
Growth T/C
b 
17‡ 
 
0.35 ± 0.11 0.13 ± 0.07 0.86 ± 0.10 
37 
 
0.58  ± 0.24 0.43  ± 0.15 1.02  ± 0.10 
38 
 
0.84  ± 0.23 0.40  ± 0.21 0.94  ± 0.08 
39 
 
0.46  ± 0.35 0.36  ± 0.41 0.85  ± 0.22 
42 
 
0.20 ± 0.12 0.15 ± 0.20 0.64 ± 0.38 
a 
Ratio of A405 of SK-cleaved substrate in GAS culture treated with the indicated concentration of 
test compound divided by A405 of DMSO control (see Chapter 6: Experimental Section). Values 
are the mean of at least three experiments ± standard deviation.  
b
Ratio of OD (600 nm) for 
growth of GAS in the presence of test compound divided by DMSO control. Values are the mean 
of at least three experiments ± standard deviation. 
‡
Originally synthesized by Meghan Breen. 
Biotinylated Probe Synthesis 
Synthesis of the first generation affinity probe was fairly straightforward.  We 
incorporated a polyethylene glycol-based spacer region derived from hexaethylene glycol (PEG-
6) to ensure an adequate distance between the target and the solid-supported streptavidin. 
Elaboration of PEG-6 to its corresponding monoamine 108 was completed via a known 
procedure.
89
  The monomesylation of the glycol in the presence of silver oxide as a chloride ion 
sink proceeded in low, but useful yields to furnish 106. The displacement of the mesylate group 
with sodium azide followed by Staudinger reduction generated amine 108, which could then be 
N-protected with a Boc group and mesylated to generate the bifunctional spacer precursor 110. 
Treatment of the 2-thioxopyrimidinone intermediate 16 with 110 under standard alkylating 
conditions furnished ligand-spacer adduct 111.  Acid-catalyzed removal of the Boc group 
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revealed free amine 112 that was subsequently coupled to the carboxylic acid moiety of biotin to 
furnish PEG6-biotin probe 113. 
Scheme 3.1. Synthesis of noncovalent biotinylated probe 113.
a
 
a
Reagents and conditions: a) MsCl, Ag2O, DCM, RT, 48h, 26%; b) NaN3, DMF, 80°C, 6h, 67%; 
c) PPh3, THF, 0°C-RT, 12h, then H2O, RT, 12h, 94%; d) Boc2O, DIPEA, DMF, 0°C-RT, 16h, 
83%; e) MsCl, DIPEA, DCM, RT, 16h, 69%; f) 16, Cs2CO3, DMF, 70°C, 16h, 62%; g) 
TFA:DCM (1:2), RT, 2h, 81%; h) Biotin-OSu, DIPEA, DMF, RT, 16h, 51%. 
With 113 in hand, collaborator Colin Kretz in the Ginsburg group first attempted 
pulldown assays in whole GAS cells, which indicated the induction of bacteriotoxicity (data not 
shown).  This finding was not entirely unexpected given the significantly increased size and 
TPSA of these compounds. We hypothesized that these two factors likely drastically reduced or 
abolished the ability of these compounds to permeate the cell membrane, leading subsequent 
trials to be performed using GAS lysates.  Unfortunately, while proteins were indeed pulled 
down via biotin/avidin affinity column, none of them were likely target compounds, and no 
selective protein band reduction was evident in competition assays with 17.  It could be that 
appending the spacer and biotin moieties led to a loss of activity as well as permeability. It was 
decided the next generation of biotinylated probes would be designed to incorporate photolabile 
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groups to allow the covalent attachment of probes to the target before enrichment, circumventing 
potential issues associated with low target-ligand binding affinity. 
Second Generation Probes: Photolabile Biotinylated Probes 
Biotinylated chemical probes can overcome the issue of low target affinity by 
incorporating groups that covalently bond to the target, such as amino acrylates,
90
 vinyl 
sulfones,
91
 or UV-promoted crosslinking groups.
92
  We decided to pursue the incorporation of 
UV-active photolabile groups over other covalent strategies as they offer control over the 
initiation of the crosslinking reaction, and are generally irreversible.  A number of different 
photolabile groups are commonly employed in target ID studies, including benzophenones, 
diazirines, and aryl azides (Scheme 3.4).
92
 Upon irradiation with long-wavelength UV light 
(~365 nm), each of these moieties breaks down into a highly reactive intermediate species 
conducive to rapid reaction with associated proteins.  A synthetic scheme was devised to allow 
for the production of a basic ligand-spacer-biotin scaffold with an attachment point for 
photolabile groups built into the spacer.  DL-lysine with orthogonally protected amine groups 
allowed for the late-stage introduction of photolabile groups using a straightforward synthetic 
route. 
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Scheme 3.2. Synthesis of photolabile biotin probes 122 and 123.
a
 
a
Reagents and conditions: a)MsCl, DIPEA, DCM, RT, 16h, 72%; b) 16, Cs2CO3, DMF, 75°C, 
16h; c) TFA:DCM (1:2), RT, 2h; d) Boc-Fmoc-DL-Lysine, HOBt, EDC, DIPEA, DCM, RT, 
24h, 58% over 3 steps; e) piperidine, DMF, RT, 60 min, 75%; f) Biotin-OSu, DIPEA, DCM, RT, 
16h, 79%; g) TFA-DCM (1:2), RT, 2h, 99%; h) 4-benzoyl benzoic acid, EDC, HOBt, DIPEA, 
DCM, RT, 16h, 41%; i) 131 (Scheme 3.3), DIPEA, DCM, RT, 48h, 36%. 
 Beginning from NHBoc-PEG3 (obtained from Mike Wilson), mesylation followed by 
alkylation with intermediate 16 and Boc deprotection revealed primary amine 117 ready for 
further elaboration.  Installation of the Boc-Fmoc-Lysine proceeded under standard amide 
coupling conditions to yield 118.  In an effort to introduce the photolabile groups as late as 
possible in the synthesis, the Fmoc group was removed first with 20% w/v piperidine in DCM, 
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and the resulting amine was treated with biotin succinimide to furnish biotinylated intermediate 
120.  After deprotection under acidic conditions, the resulting common intermediate 121 could 
be coupled to the desired photolabile group via EDC promoted conditions to yield benzophenone 
probe 122 or direct addition of the amine to the tetrafluorophenyl azide NHS ester
93
 to generate 
probe 123. 
After the successful synthesis of 122 and 123, our collaborators performed UV-
crosslinking followed by immunoblotting to visualize biotinylated proteins. Briefly, GAS cell 
lysates were pre-cleared of biotinylated proteins by incubating with avidin-coated beads, then 
treated with the selected probe.  Crosslinking was induced via 365nm UV radiation for 5-90 
minutes, then the resulting probe-protein adducts were purified by avidin column.  Proteins were 
separated via SDS-PAGE, transferred to a polyvinylidene difluoride (PVDF) membrane, and 
treated with horseradish peroxidase (HRP)-avidin fusion protein. Peroxide staining allowed the 
visualization of proteins conjugated to HRP-avidin.  
Crosslinking trials with benzophenone 122 yielded very faint protein bands after 60 
minutes of UV exposure, indicating the relatively low UV-induced reactivity of this probe. The 
inclusion of 17 as a soluble competitor did not lead to the attenuation of any protein bands, 
which is likely due to a high incidence of nonspecific binding. In addition, the long UV exposure 
time required for crosslinking (60 minutes) probably allowed the equilibration of binding 
between 17 and 122, diminishing the effects of competition-based decreases in specific labeling.   
Increasing the exposure time to UV radiation from 60 to 90 minutes in an effort to enhance 
labeling instead resulted in extensive protein aggregation and breakdown. Our inability to find 
optimal crosslinking conditions led to the dropping of 122 from future trials.  Tetrafluorophenyl 
azide probe 123 on the other hand was extremely reactive, labeling a myriad of proteins after 
only 5 minutes. The high level of binding observed made the discernment of specific labeling 
events in competition studies with 17 virtually impossible. Based on this result, we theorized that 
generating a “dummy probe” (129, Scheme 3.3) might enable us to deduce which of the proteins 
pulled down, if any, were due to specific interactions.  This probe retained the photolabile group, 
spacer, and biotin portions of the molecule, but replaced the ligand portion with a small 
lipophilic group. The deletion of the ligand portion was intended to abolish interaction at the 
specific target of 122 and 123, but retain most of the nonspecific binding capacity of the rest of 
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the molecule. The dummy probe was synthesized in a manner similar to 123, using O-benzyl 
ethanolamine 124 as the starting material instead of intermediate 117.   
Scheme 3.3. Synthesis of “dummy probe” 129.a 
a
Reagents and conditions: a) Boc-Fmoc-DL-Lysine, HATU, DIPEA, DMF, RT, 90 min, 100%; 
b) piperidine, DMF, RT, 60 min, 100%; c) Biotin-OSu, DIPEA, DCM, RT, 16h, 76%; d) 
TFA:DCM (1:2), RT, 2h; e) 131, DIPEA, DMF, RT, 24h, 36% over 2 steps; f) N-hydroxy 
succinimide, EDC, DCM, 35°C, 16h, 78%. 
 Studies that employed the active and dummy aryl azide probes in tandem did not meet 
with much success.  When used alone, 123 did indeed pull down a large number of proteins as 
evidenced by HRP-avidin immunoblot.  Unfortunately, when the same conditions were repeated 
with 129, the desired diminishment of any protein bands relative to treatment with 123 was not 
observed. While disappointing, these results do not conclusively rule out the occurrence of 
specific reactions. The interaction may have been too weak (low potency) or too sporadic (low 
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target abundance) to be detected in the presence of the noise generated by nonspecific binding 
events. 
Tag-free Photoprobes 
The failure of the traditional biotinylated probe study left us searching for alternative methods of 
target identification. Recently, other groups have demonstrated the utility of combining the 
advantages of photolabile biotinylated probes with the more biologically suitable properties of 
conventional small molecule inhibitors by replacing bulky appendages with small “handles” 
amenable to bioorthogonal click chemistry (Figure 3.1C).
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,95
 These probes incorporate a 
photoreactive group and a terminal alkyne into the scaffold of a potent compound. This probe is 
then covalently crosslinked to protein in the intact cellular milieu with UV light. An azide-
modified fluorescent or biotin-derived moiety can then be appended to the alkyne-functionalized 
protein(s) via copper(I)-mediated click chemistry after cell lysis, resulting in target proteins with 
covalently attached tags for visualization or selective purification respectively. The lower 
molecular weight and TPSA of these “tag-free” probes increases their likelihood of being cell-
permeable, allowing them to be used in whole-cell systems rather than lysates. Cell-permeable 
affinity probes are advantageous in that they enable the confirmation of their activity in 
phenotypic assays before beginning target identification studies. The probes also have the added 
benefit of access to all proteins in their native cellular conformations.  
To identify the unknown molecular target of our series of GAS anti-virulence 
compounds, we envisioned the synthesis of several tag-free photoprobes based on structural 
insights gained from our SAR studies on this scaffold. Although the maintenance of a high level 
of potency was a primary concern in the synthesis of the probe molecules, the nature and 
positioning of the UV-active and terminal alkyne groups were equally important to us as they are 
crucial for ensuring a compatible orientation for labeling.
96,97
 A number of different photolabile 
groups have been employed to positive effect in the literature, varying in their stability, 
reactivity, and preference for C-C or C-heteroatom bond formation.
92
  The presently unknown 
features of the binding site ultimately determine the features necessary for a functional probe, so 
we set out to synthesize a diverse series of compounds with one of three photolabile groups 
(benzophenone, diazirine, aryl azide, Scheme 3.4) at different points on the scaffold to maximize 
our chances of identifying the target. 
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Scheme 3.4. Long-wave UV-induced reactivity of benzophenones, diazirines, and aryl azides in 
the context of molecular target capture. Ketyl radicals (top pane) preferentially form new C-C 
bonds, while carbenes and nitrenes (middle, bottom pane) more commonly insert into hydrogen-
heteroatom bonds. 
 
Synthesis 
The chemistry to install benzophenone, diazirine, and aryl azide functionality onto the 
core scaffold of this class of compounds required three distinct synthetic routes. Synthesis of the 
benzophenone-based probes (Scheme 3.5)  began with the LDA-promoted Michael addition of 4-
bromo-2-methylbenzonitrile (132) to ethyl 3,3-dimethyl acrylate and subsequent ZnI2-mediated 
cyclization to afford β-aminoester 133.55 Stannylation via halogen-metal exchange98 followed by 
carbonylative Stille coupling
99
 successfully delivered benzophenone 134. Acid-catalyzed 
addition of the amine to allyl isothiocyanate followed by cyclization generated 2-
thioxopyrimidinone intermediate 135 that underwent sulfur alkylation with propargyl bromide or 
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139 (generated by tosylating commercially available propynol ethoxylate, 138) under mildly 
basic conditions to generate probes 136 and 137.  
Scheme 3.5. Synthesis of benzophenone-functionalized tag-free probes 136 and 137.
a
 
 
a
Reagents and conditions. a) LDA, then ethyl 3,3-dimethyl acrylate, ZnI2, diglyme, -78°C – RT, 
50%; b) (Bu3Sn)2, Pd(PPh3)4, toluene, reflux, 37%; c) 1 atm CO, PdCl2(PPh3)2, iodobenzene, 
DMF, 60°C, 58%; d) allyl isothiocyanate, AcOH, EtOH, 70°C, 27%; e) propargyl bromide or 
139, Cs2CO3, 2-butanone, 70°C, 69-70%; f) TsCl, pyridine, 0-4°C, 24h, 72%. 
Diazirine probes 143-146 were synthesized via an analogous route beginning from aryl 
methyl ether 26c (Scheme 3.6). Demethylation and protection of the resulting phenol as a silyl 
ether resulted in 140, which could be employed in the synthesis of β-aminoester 141 in a manner 
similar to that for the benzophenone probes. In the course of our investigation, we found that 
cyclization with allyl isothiocyanate in the presence of cesium carbonate furnished the desired 2-
thioxopyrimidinone 142 with the concomitant loss of the silyl ether protecting group. Successive 
chemoselective alkylations at sulfur and oxygen were exploited to install the diazirine and alkyne 
linker moieties in four different arrangements, yielding probes 143-146. Diazirine-containing 
alkylating agent 149 was synthesized from 4-hydroxy-2-butanone (147) via diaziridination of the 
ketone with 7N methanolic ammonia and hydroxylamine O-sulfonic acid
100
 followed by 
oxidation and tosylation.
101
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Scheme 3.6. Synthesis of diazirine-functionalized tag-free probes 143-146.
a 
 
a
Reagents and conditions. a) BBr3, DCM, 0°C-RT, 16h; b) TBS-Cl, imidazole, DCM, 0°C-RT, 
16h, 96% over 2 steps; c) LDA, then ethyl 3,3-dimethyl acrylate, ZnI2, diglyme, -78°C-RT, 3h, 
63%; d) allyl isothiocyanate, Cs2CO3, EtOH, 70°C, 16h, 57%; e) 139, 149, or propargyl bromide, 
NaHCO3, 70°C, DMF, 3-6h, 45-71%; f) 139, 149, or propargyl bromide, Cs2CO3, 70°C, DMF, 
3h, 16-64%; g) 7N NH3:MeOH, hydroxylamine-O-sulfonic acid, 0°C-RT 16h; h) I2, Et3N, 0°C, 
MeOH, 30 min; i) Ts-Cl, pyridine, 0-4°C, 24h, 15% over 3 steps. 
Synthesis of the azide probe began with commercially available 2-cyano-3-methylaniline 
150 (Scheme 3.7). Masking the aniline functionality of 150 as a mono- or bis-Boc carbamate, 
diphenyl imine, or azide proved to be incompatible with the LDA/ZnI2 cyclization conditions. 
Finally, it was found that modified Sandmeyer conditions to transform the aniline to the aryl 
iodide
102
 permitted the formation of the β-aminoester 151 in modest yields. Gratifyingly, 
conversion to the corresponding aryl azide 152 via Cu(I)-mediated SNAr proceeded in excellent 
yields.
103
 Stepwise generation of the unsubstituted 2-thioxopyrimidinone with benzoyl 
isothiocyanate and potassium hydroxide afforded 153,
57
  which was then selectively S-alkylated  
with TBS-protected alkyne-containing unit 156.
104
 Alkyne protection was necessary to minimize 
cross-reactivity during the subsequent N-allylation under basic conditions to furnish 154. 
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Fluoride ion-promoted removal of the silyl group finally yielded the desired aryl azide probe 
155. 
Scheme 3.7. Synthesis of aryl azide-functionalized tag-free probe 155.
a
 
  
a
Reagents and conditions. a) NaNO2, HCl, then KI, H2O, 0°C, 70%; b) LDA, then ethyl 3,3-
dimethyl acrylate, ZnI2, diglyme, -78°C-RT, 3h, 23%; c) NaN3, CuI, N,N-dimethyl ethylene 
diamine, Na-ascorbate, DMSO:H2O (5:1), RT, 3h, 85%; d) benzoyl isothiocyanate, EtOH, 70°C, 
3h; e) KOH, EtOH:H2O, 2:1, 70°C, 3h, 54% over 2 steps; f) 156, NaHCO3, 70°C, DMF, 16h; g) 
NaOMe, allyl bromide, EtOH, 70°C, 3h, 44% over 2 steps; h) TBAF, THF, 0°C, 1h 65%; i) 
nBuLi, -78°C, THF, 2h, then TBS-OTf, -78°C-RT, 1h, 63%. 
 
SK Activity Assay 
The 7 tag-free affinity probes were assayed for their inhibitory effects on SK expression 
(described in Chapter 2) using our previously described chromogenic assay of plasmin activity.
45
 
Given the critical nature of retaining maximal potency to target identification, 50% SK 
expression inhibition at 5 µM was used as the cutoff value for further evaluating probe 
compounds. Compounds meeting this threshold were more completely characterized with full 
IC50 curve generation and were utilized in subsequent crosslinking trials. 
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SAR Analysis 
Benzophenone 137, with its S-propargyloxyethyl click ligation sidechain, was found to 
be more potent than the corresponding S-propargyl analog 136. This trend was also observed 
between diazirine probes 143 and 144. Disappointingly, reversing the positioning of the alkyne 
and diazirine in probes 145 and 146 resulted in the complete loss of activity. Azide probe 155, on 
the other hand, possessed potency slightly greater than lead compound 32, the most potent 
compound identified from our prior SAR studies (Chapter 2). Although we were not able to 
identify active probes with reversed alkyne and photolabile groups, we were gratified to 
demonstrate a sufficiently active probe containing each of the selected photolabile groups (137, 
144, and 155) for use in target identification studies. 
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Table 3.2. Activity data for tag-free photoprobes 136, 137, 143-146, and 155.   
 
Cmpd R
1
 R
2
 
T/C 
(5 μM)
a 
Growth T/C 
(50 μM)
b IC50
c 
136 propargyl 8-Bz 0.77 ± 0.34 1.09 ± 0.04  
137 
 
8-Bz 0.51 ± 0.07 0.94 ± 0.18 3.8 ± 0.6 
143 propargyl 
 
1.07 ± 0.16 0.96 ± 0.09  
144 
  
0.49 ± 0.34 1.07 ± 0.02 0.33 ± 0.70 
145 
  
0.71 ± 0.40 1.01 ± 0.09  
146 
 
8-O-propargyl 0.89 ± 0.16 1.02 ± 0.01  
155 
 
9-N3 0.30 ± 0.08 0.98 ± 0.04 0.19 ± 0.26 
32 Et 9-OMe 0.10 ± 0.06 0.73 ± 0.07 1.3 ± 0.6 
a
Amount of SK activity in GAS culture measured via colorimetric assay after incubation with 5 
µM test compound for 24 hours divided by SK activity measured in GAS culture 24 hours after 
treatment with DMSO +/- standard deviation derived from at least 3 individual experiments. 
b
Growth inhibition as measured by OD600 of GAS culture 24 hours after treatment with 50 µM 
test compound divided by OD600 of control GAS culture treated with DMSO after 24 hours +/- 
standard deviation derived from at least 3 individual experiments. 
c
Concentration at which 50% 
maximal inhibitory effect against SK expression was achieved +/- standard deviation. Each data 
point is derived from the statistical treatment of 3 replicates.  
 
Solvent Capture Study 
Representative probe 144 was subjected to crosslinking conditions in methanol to assess 
whether the core scaffold would exhibit undesired photo-induced reactivity (Scheme 3.8).  The 
methanolic solution of 144 was incubated under a 2.5A 365 nm UV lamp until the parent 
compound was completely consumed. Conversion of 144 to 2 new compounds (157 and 158, 
Scheme 3.8) was observed within 30 minutes.  NMR and ESI-MS analysis of these identified the 
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major product as 157, consistent with carbene insertion into the O-H bond of methanol (43% 
yield). The most prominent minor product consisted of a mixture of alkene isomers resulting 
from 1,2 hydride shifts
105
 (158, 27% combined yield). 
Scheme 3.8. UV-induced reactivity of probe compound 144 in methanol. 
 
Target Identification Assays 
With the identification of a number of active probes and successful photo-mediated 
solvent capture completed, our collaborators Colin Kretz and Autumn Holmes in David 
Ginsburg’s group initiated protein-probe crosslinking assays. Briefly, GAS cultures were 
incubated in the presence of probe compounds for 30 minutes, then exposed to long-wave UV 
radiation for 5 (144, 155) or 10 minutes (137) to promote crosslinking.  The cells were lysed and 
pelleted, and the resulting lysates were subjected to click chemistry conditions with azide-
functionalized Alexa Fluor 488 fluorescent dye.  Proteins were then precipitated via 
methanol/chloroform/water solution and separated via SDS-PAGE gel. Fluorescent imaging of 
the gel allowed for the identification of tagged protein, then total protein levels were visualized 
via staining with Sypro Ruby. Benzophenone probe 137 appeared to crosslink to a distinct 
population of proteins when separated on a polyacrylamide gel and imaged with Alexa Fluor 488 
(Figure 3.3). Tagging was found to be dose-dependent, based on reduced fluorescence with 
lower compound concentrations. Importantly, an identically treated control omitting the UV 
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crosslinking step did not fluorescently tag any proteins. Total protein staining of the gel with 
Sypro Ruby stain confirmed an abundance of protein in the sample, indicating that only a small 
subset of proteins were crosslinked with 137. Unfortunately, competition with soluble competitor 
17 did not reproducibly reduce the tagging of any protein band on the gel, which suggests a 
significant degree of nonspecific binding of 137 to protein. 
Figure 3.3. Crosslinking trials using benzophenone probe 137. 
 
Pane 1: Visualization of crosslinking and competition experiments with Alexa Fluor 488-
modified 137-protein adducts on PAGE gel. Pane 2: Total protein stain of gel with Sypro Ruby 
stain. Lane parameters: A: 100 μM 137; B: 100 μM 137 + 500 μM 17; C: 100 μM 137 + 1 mM 
17; D: 10 μM 137; E: 1 μM 137; F: 100 μM 137, no UV crosslinking. 
 
Crosslinking experiments undertaken with diazirine 144 and azide 155 (Figures 3.4 and 
3.5) showed similar trends to 137. In each case the intensity of Alexa Fluor 488-tagged proteins 
was dependent on both the concentration of the compound and the exposure to UV light. 
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Qualitative comparison of the fluorescent and total protein stains suggests that the fluorescent 
intensity was generally proportional to protein abundance. This phenomenon, along with the 
absence of any reduction of fluorescence observed in the presence of soluble competitor, 
indicates an even greater degree of nonspecific crosslinking with 144 and 155 than seen with 
137. Interestingly, the addition of 17 to test solutions containing 144 seemed to increase 
crosslinking efficiency, perhaps owing to increased solubility of the probe in solutions with 
greater DMSO content. 
Figure 3.4. Crosslinking trials using diazirine probe 144. 
 
Pane 1: Visualization of crosslinking and competition experiments with Alexa Fluor 488-
modified 144-protein adducts on PAGE gel. Pane 2: Total protein stain of gel with Sypro Ruby 
stain. Lane parameters: A: 100 μM 144; B: 10 μM 144; C: 10 μM 144 + 100 μM 17; D: 1 μM 
144; E: 1 μM 144 + 100 μM 17; F: 100 μM 144, no UV crosslinking; G: 100 μM 144, no click 
reaction. 
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Figure 3.5. Crosslinking trials using azide probe 155. 
 
Pane 1: Visualization of crosslinking and competition experiments with Alexa Fluor 488-
modified 155-protein adducts on PAGE gel. Pane 2: Total protein stain of gel with Sypro Ruby 
stain. Lane parameters: A: 100 μM 155; B: 10 μM 155; C: 10 μM 155 + 100 μM 17; D: 1 μM 
155.  
 
Conclusions 
Over the course of our efforts toward identifying the target(s) of the CCG-2979 
compound series in GAS, three biotinylated probes (1 noncovalent, 2 capable of UV 
crosslinking) and seven tag-free photoprobes were synthesized.  After disappointing results using 
the full-length noncovalent probe 113 and photolabile biotinylated probes 122 and 123, we were 
encouraged by the observation that 3 of the tag-free photoprobes (137, 144, 155), each with a 
different photolabile moiety, retained potency in the GAS-SK affinity assay. After confirming 
clean photoactivation of representative probe 144 without degradation of the scaffold, we 
performed preliminary target identification studies. Crosslinking in whole cells, followed by 
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protein isolation and the attachment of a fluorescent tag, led to relatively widespread fluorescent 
labeling that appears consistent with nonspecific labeling of GAS proteins.  
While biotin tagging and SDS-PAGE separation have been used successfully in the past 
for target identification, the nature of affinity chromatography and PAGE gel visualization 
confers a natural bias for highly potent interactions with high-abundance proteins.
106
 The 
possibility of the target being a bacterial transcription factor, which are among the least abundant 
proteins in the cellular milieu,
50
 along with the high propensity for nonspecific binding exhibited 
by these compounds, suggests that visual inspection of SDS-PAGE gels may not be sufficiently 
sensitive to identify the target with these probes. Future studies will employ proteomic 
techniques that offer far greater levels of sensitivity and data resolution, namely stable isotope 
labeling by amino acids in cell culture (SILAC)
106
 and GAS genome phage display library 
screening.
107
 These techniques are further discussed in Chapter 5. 
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Chapter 4: Biofilm Inhibition SAR Study 
Biofilms, Virulence, and Clinical Relevance 
The ability to form biofilms is an adaptation common to nearly all bacterial species 
dating back at least 3.5 billion years.
108
 In response to certain environmental stimuli (quorum 
sensing, colony density, nutrient levels, etc.), bacteria can begin to assemble biofilms on biotic or 
abiotic solid surfaces by secreting a sticky collection of sugar polymers known as 
exopolysaccharide (EPS) or glycocalyx, which allows for the permanent attachment of bacterial 
colonies to the substrate.
109
 Once attached, the secretion of additional EPS allows for the growth 
of the solid-supported colony as well as the recruitment of more planktonic bacteria.  By 
encasing themselves in a semi-permeable matrix, these bacterial cultures essentially trade 
unrestricted access to nutrients, and thus their capacity for exponential growth, for enhanced 
protection from environmental threats (e.g. host immune responses, other bacteria, viruses, 
extreme conditions).
109
 As biofilms mature, fluid channels begin to form between cell 
microcultures to alleviate issues of nutrient starvation and waste removal.
110
 Mature biofilms can 
also disseminate planktonic cells back into the aqueous environment, either through external 
forces or directly via genetic expression changes, and in this way serve as a reservoir for free-
floating colonies to establish biofilms on other solid substrates.
111
  These aspects both enhance 
bacterial colony survival and no doubt led to a strong evolutionary selection for bacteria able to 
efficiently construct robust biofilms. 
The ability for bacteria to form biofilms has important implications for human health. 
Many biological surfaces open to the environment, such as skin, tooth enamel, and the cornea, 
are hosts to persistent biofilm colonization of a more benign nature. However, biofilm-embedded 
colonies that access the bloodstream or internal organs, such as Pseudomonas aeruginosa 
colonization of the lungs in cystic fibrosis patients,
112
 streptococcal biofilm establishment on 
platelet aggregates and heart valves,
113
 and bacterial invasion of wounds
114
 represent a much 
more serious threat.  A number of characteristics of biofilm-mediated infections make them 
especially hard to clear with antibiotics. The EPS matrix surrounding biofilm-embedded bacteria 
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can act as a selectively permeable barrier, sequestering the population within from several 
aspects of the surrounding aqueous environment, including leukocytes and antibiotics. 
Depending on the nature of the biofilm and the antibiotic agent, up to 1000-fold greater effective 
resistance against some antibiotics has been observed.
115,116
 Sequestration from the surrounding 
environment has the added effect of restricting nutrient levels within the biofilm, slowing 
bacterial growth and inducing physiological stress responses that further decrease susceptibility 
to exogenous factors.
117,118
 Bacteria fixed within a biofilm, by virtue of greatly enhanced 
proximity between cells, also display enhanced lateral gene transfer, increasing the rate at which 
antibiotic resistance mechanisms are disseminated within the colony.
119
 The recalcitrant nature of 
biofilm-embedded bacterial colonies, combined with their ability to shed cells into the aqueous 
environment and maintain systemic infection, makes them particularly challenging to control.  It 
is estimated that up to 65% of serious nosocomial (hospital-acquired) infections are biofilm-
mediated,
120
 underscoring anti-biofilm agents as an area of unmet medical need. Biofilm 
formation is a particularly dire issue in the field of prosthetic implantation, prompting a regimen 
of very high doses of one or more antibiotics before and after the installation of internal 
prosthetics.
121
 
Early in the course of our investigation into GAS-SK inhibitors, a gene expression array 
suggested that our lead compounds reduced transcription levels of several key virulence factors, 
including those associated with host substrate colonization and the initiation of biofilm 
formation.
45
 Although GAS can form biofilms during systemic infection,
122
 we sought to assess 
the broad-spectrum utility of our compounds by assaying for biofilm inhibition in more clinically 
relevant bacterial species. Staphylococcus aureus and Staphylococcus epidermidis have been 
identified as two of the most important species involved in biofilm-mediated systemic 
infection.
123,124
  S. epidermidis is able to effectively colonize hydrophobic synthetic surfaces, and 
as a result is the most common pathogen associated with prosthetic-acquired systemic 
infections.
125,126
  Genome sequencing has shown that outside of exotoxin β-hemolysin, S. 
epidermidis relies almost exclusively on biofilm-associated mechanisms for virulence.
127
  S. 
aureus is recognized as one of the most serious threats to human health,
128
 with its multiple 
vectors of virulence and a propensity to quickly develop antibiotic resistance.
129
  S. aureus is also 
known to cause serious prosthesis-acquired infections, especially when introduced to the 
bloodstream via blood vessel catheters.
130
  We have chosen to focus our medicinal chemistry 
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study on developing biofilm inhibitors effective in these species based on the unmet medical 
need associated with prosthesis-acquired infection. 
Biofilm Inhibition Assay 
Assaying for biofilm inhibition is based on an established protocol with a straightforward 
readout of inhibitor effectiveness (OD).
131
  Briefly, bacterial colonies are grown in polystyrene 
96-well plates in the presence of various test compounds or DMSO (negative control).  The plate 
is incubated at 37°C for 16 hours, then an optical density measurement (OD600) is made to gauge 
the effect of test compounds on general bacterial growth.  Planktonic cells are removed by gentle 
washing, leaving only surface-associated bacteria behind.  The biofilm is stained with crystal 
violet, and excess dye is washed away before anchored colonies are re-solubilized with 
detergent.  Reading OD595 of the solubilized and stained biofilm colonies allows for the 
quantification of biofilm formation in test wells relative to controls treated only with DMSO.  In 
keeping with our focus on developing antibiotics that minimize the induction of evolved 
resistance, we were interested in identifying compounds that potently inhibit biofilm formation 
without significantly affecting colony growth.  The ease of testing compounds for anti-biofilm 
activity represents a significant improvement over the time consuming, inconsistent, and 
somewhat indirect nature of the GAS-SK activity assay. 
Scheme 4.1. Structure of 6 active compounds identified from the original 100 µM screen of 
GAS-SK inhibitors for anti-biofilm activity. 
†
Compound originally synthesized by W.G. Rajeswaran. 
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Initial Biofilm Inhibitor Screen 
An initial screen for inhibitors of Staphylococcus biofilm formation was performed using 
the 124 compound SAR set based on the structure of 1.  All compounds were originally tested at 
a concentration of 100 µM to speed up the identification of hits.  We were particularly interested 
in finding compounds potent in both Staphylococcus strains in order to maximize our chances of 
eventually developing a broadly active anti-biofilm compound. This initial screen revealed that 
21 compounds (17%) were able to inhibit biofilm in S. aureus >50% at this concentration, while 
8 (7%) were over 50% active in S. epidermidis. A total of 6 compounds overlapped between 
these data sets (Scheme 4.1): spiropiperidine analogs 159 and 160, n-propanol-substituted 
amides 161 and 162, and compound 43 identified during the metabolic attenuation study 
(Chapter 2). Although aminoethyl compound 13 also showed good activity in S. epidermidis, it 
was unacceptably toxic (35% growth inhib.) in S. aureus and was not followed up on in the 
biofilm study. We were gratified to see the activity of O-alkylated compound 160 in both strains, 
given the increased metabolic competence of this substitution pattern.  This subset of active 
compounds is considerably more narrow than what is observed in the GAS-SK study, in which 
68 compounds (55%) were capable of inhibition greater than 50% at the highest concentration 
tested (50 µM). We hypothesized that this smaller subset of active compounds should allow us to 
make more informed decisions regarding the efficient expansion of the SAR effort.   
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Figure 4.1. Inhibition of S. aureus biofilm formation on silicone wafers in the presence of 
increasing concentrations of CCG-203592 (31), as reported by Ma, et al. PLoS One 2012, 
e47255. 
 
During the course of the biofilm activity re-screen, analog CCG-203592 (31) was 
identified as one of the most consistently potent compounds in S. aureus. A more in-depth study 
of 31’s effects in S. aureus performed by Hongmin Sun and coworkers demonstrated the ability 
of this compound to inhibit biofilm formation with an IC50 of 2.4 ± 0.1 µM in virulent lab strain 
RN6390.
132
  Other experiments performed during this study also indicated its ability to inhibit 
biofilm formation in clinically-important S. aureus strains, both in polystyrene test wells and on 
medical-grade silicone (Figure 4.1).  Furthermore, 31 was shown to induce the down-regulation 
of several genes important for S. aureus biofilm formation and virulence, including fibronectin-, 
laminin-, and collagen-binding proteins that assist in anchoring GAS to host tissues.  This 
finding reinforces the hypothesis that the target of these compounds is an upstream regulator of 
bacterial virulence. Although this compound exhibited no anti-biofilm effect in S. epidermidis, 
its structural features were taken into account during the SAR expansion study. 
The promising results of these initial efforts prompted both the undertaking of a new 
synthetic SAR effort and a push to refine the initial 100 µM screening data.  Although activity 
data at a single, high-concentration data point was helpful to suggest direction to the SAR 
campaign at first, knowledge of how the compounds behave at lower concentrations was critical 
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for determining their relative potencies.  The limited solubility of most compounds in this series 
certainly excludes the possibility of each attaining an effective aqueous concentration of 100 
µM, muddling the original dataset somewhat.  In light of the limitations of a single-point activity 
determination, it was decided that each compound that was able to inhibit biofilm formation in 
either bacterial strain by more than 30% at 100 µM would be retested at 5 and 50 µM 
concentrations to more accurately assess their relative activity levels.  Since this study was 
performed concurrently to SAR expansion, several key structural features of active compounds 
that have not yet been explored in new analogs.   
According to the activity cutoff, 46 compounds were submitted for lower-concentration 
retesting against S. aureus, with a 10-compound subset also retested for activity in S. 
epidermidis.  Of these, 19 were found to inhibit S. aureus biofilm by 50% or greater at a 
concentration of 50 µM, while only one, 31, achieved >50% inhibition at 5 µM.  None of the 
compounds tested were able to inhibit S. epidermidis biofilm >50% at 5 or 50 µM.  A summary 
of the more-potent S. aureus biofilm inhibitors is included in Table 4.1. The aryl methyl ether 
analogs 31-33, among the best compounds identified in the GAS-SK study, also showed good 
activity against S. aureus biofilms. Interestingly, analogs with polar pyrimidinone substitution 
(e.g. 20, 42, 159, 160, 163-165) or more polar appendages adorning the phenyl ring (166-169), 
displayed relatively good potency against biofilm despite low activity in GAS.  Compounds 159, 
160, and 43 identified as active in both species in the 100 µM screen retained activity at lower 
concentrations in S. aureus, while 13, 161, and 162 did not.  The moderate activity of 160 and 
164 bolstered our hopes of synthesizing potent and metabolically stable O-alkyl amides. 
Compound 51 stands out as a good inhibitor of S. aureus biofilm with somewhat increased 
metabolic stability. Interestingly, compound 30 appears to be only weakly active in this assay, 
despite differing from potent compound 31 by only one carbon (S-allyl vs. S-ethyl). 
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Table 4.1. Activity of GAS-SK inhibitor analogs found to be particularly potent against S. 
aureus biofilm formation. 
 
 
 
 
 
1
Synthesized by Meghan Breen. 
2
Synthesized by Roderick Sorenson. 
3
Synthesized by Dr. 
Walajapet Rajeswaran. 
4
Synthesized by Michael Wilson. 
a
Ratio of S. aureus biofilm formation 
by S. aureus cultures in the presence of the indicated concentration of test compound compared 
to DMSO control.  
b
Half-maximal inhibitory concentrations against biofilm formation in the 
presence of the indicated compound, calculated from 6-point dose-response curve from 0.15 µM 
to 50 µM. nd = not determined. 
 
# Scaffold R
1
 R
2
 R
3
 SA 5 µM
a 
SA 50 µM
a IC
50 
(µM)
b 
20
1 
A HOCH2CH2 Allyl H 0.97 ± 0.03 0.32 ± 0.07 >50 
21 A NCCH2 Allyl H 1.08 ± 0.00 0.69 ± 0.09 nd 
30
2 
A Allyl Allyl 8-MeO 0.72 ± 0.13 0.56 ± 0.15 >50 
31 A Et Allyl 8-MeO 0.37 ± 0.03 0.26 ± 0.03 1.4 ± 0.4 
32 A Et Allyl 9-MeO 0.72 ± 0.09 0.21 ± 0.08 5.2 ± 0.4 
33 A Et Allyl 7-MeO 0.61 ± 0.06 0.31 ± 0.01 2.7 ± 0.4 
41 A CH3OCH2CH2 Et H 0.99 ± 0.01 0.44 ± 0.22 nd 
42 A Et CH3OCH2CH2 H 0.84 ± 0.01 0.31 ± 0.08 8.7 ± 0.9 
43 A Et Me 9-MeO 0.81 ± 0.10 0.28 ± 0.14 4.3 ± 0.6 
51 A F3CCH2 Allyl 9-MeO 0.80 ± 0.04 0.33 ± 0.04 2.9 ± 0.4 
63  0.94 ± 0.00 0.39 ± 0.01 35.0 ± 7.4 
 
       
159
3 
A CH3OCH2CH2 HO(CH2)3 H 0.90 ± 0.00 0.49 ± 0.14 41.6 ± 4.5 
160
3
 B CH3OCH2CH2 HO(CH2)3 H 0.83 ± 0.05 0.18 ± 0.12 14.1± 2.5 
161
3 
C R = CONHBu 1.04 ± 0.13 0.74 ± 0.01 nd 
162
3
 C        R = H 0.99 ± 0.10 0.87 ± 0.07 nd 
163
3
 A CH3OCH2CH2 
 
H 0.85 ± 0.07 0.41 ± 0.09 42 ± 8.5 
164
3
 B CH3OCH2CH2 
 
H 0.76 ± 0.15 0.52 ± 0.11 nd 
165
3
 A CH3OCH2CH2 NC(CH2)3 H 0.92 ± 0.00 0.43 ± 0.04 >50 
166
2
 A Et Allyl 
8-  
0.75 ± 0.16 0.36 ± 0.06 9.2 ± 1.3 
167
2
 A Et Allyl 8-HO2CCH2O 1.04 ± 0.01 0.50 ± 0.01 43.7 ± 1.4 
168
4
 A CH3OCH2CH2 Allyl 8-MeO2C 0.64 ± 0.29 0.45 ± 0.13 7.4 ± 5.0 
169
4
 A CH3OCH2CH2 Allyl 
8-  
0.86 ± 0.09 0.39 ± 0.02 13.4 ± 5.3 
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Alternative Scaffold Screening 
 In addition to the scaffold based on compound 1, our collaborators in the Sun group also 
screened the compounds originally purchased for the Broad Institute HTS follow-up in the GAS-
SK study (Chapter 2).  Compounds were screened at 100 µM, and only compounds potently 
inhibiting both S. aureus and S. epidermidis were considered.  Of the 53 total compounds 
screened, 20 compounds inhibited biofilm by more than 30% in S. aureus, 4 of which by 50% or 
more.  In contrast, only chromenone 170 (Scheme 4.2) was active in S. epidermidis, inhibiting 
biofilm formation by 40%.  Luckily, this compound was also found to be active in S. aureus 
(46% inhibition at 50 µM).  With only one compound meeting our criteria from the alternative 
scaffold screen, we purchased 17 analogs of 170 from commercial sources conforming to the 
general methylpiperidine-chromenone scaffold 171.  Unfortunately, none of the compounds were 
found to be active at 5 and 50 uM concentrations, including 170 itself. The lack of strong activity 
at low concentrations led us to abandon the alternative scaffold development aspect of the anti-
biofilm study. 
Scheme 4.2. Structure of alternative scaffold hit 170 and 17 related analogs of general 
structure 171. 
 
SAR Logic 
The failure of the alternative scaffold screen led us to propose a number of new analogs 
of 1 optimized for anti-biofilm activity.  We envisioned combining the salient features of several 
of the active compounds in the hope of generating compounds with synergistic gains in activity 
and/or pharmacokinetic competence.  Specifically, we planned the incorporation of more polar 
substitution at the pyrimidinone (n-propanol, acetonitrile) and phenyl positions (larger aryl 
ethers), and installing a spiropiperidine ring in place of the gem-dimethyl group on the central 
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ring. Although 161 and 162 (Table 4.1) did not show particularly potent activity at less than 100 
µM, the amine functionality of piperidine was incorporated to add an easily derivatized polar 
group in an otherwise lipophilic and difficult to functionalize region of the scaffold, allowing us 
to survey a wider range of substitutions and chemical space with our analogs.  
Synthesis 
 Compared to the SAR effort in the GAS-SK project, the chemistry involved to generate 
analogs for the biofilm study was more streamlined.  N-Boc-protected spiropiperidine analogs 
177-189 were accessed through Scheme 4.3. Synthesis began with the Horner-Wadsworth-
Emmons method of forming the α,β unsaturated ester 173 from 4-oxo-N-Boc piperidine 172.  
This ester was employed as the Michael acceptor for the LDA and zinc iodide-mediated 
cyclization reaction with the methoxytolunitrile 26c, generating β-aminoesters 174.55  Stepwise 
cyclization with benzoyl isothiocyanate followed by KOH afforded the unsubstituted 2-
thioxopyrimidinone 175.
57
  Finally, stepwise chemoselective alkylation of sulfur followed by the 
N- or O- position of the amide was accomplished to generate Boc-substituted final compounds 
177-189.   
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Scheme 4.3. Synthesis of N-Boc spiropiperidine analogs 177-189.
a 
 
a
Reagents and conditions: a) NaH, trimethyl phosphonoacetate, DMF, 0°C, 30 min; then 172, 
0°C-RT, 3h, 99%; b) LDA, 26c, -78°C, diglyme, 1h, then 173, ZnI2, -78°C-RT, 2h, 74%; c) 
benzoyl isothiocyanate, EtOH, reflux, 6h, 65%; d) KOH, EtOH:H2O (2:1), 70°C, 2h, 83%; e) R
1
-
X, NaHCO3, DMF, 50-70°C, 16h, 63-81%; f) R
2
-X, base, DMF, 50-70°C, 3-16h, 11-51%. 
 
Derivatization of the piperidine portion of the molecule was originally attempted with 
compounds 177, 181, and 184 (Scheme 4.4).  Boc deprotection was effected using 4M HCl in 
dioxane, which led to the near-instant precipitation of crystalline products 190-192 from the 
organic solution. To mimic the structure of active compound 161, functionalization of the 
secondary amines with valeryl chloride yielded tertiary amides 193-195.  All of these compounds 
were submitted for biological testing with the exception of 192, which rapidly decomposed in 
polar solvents via loss of allyl substitution at the O-position. The preparation of this compound 
as a hydrochloride salt may have allowed the chloride ion to nucleophilically cleave the O-allyl 
group under sufficiently polar conditions.  However, the general instability of several similar 
compounds in this series bearing basic amines, even when prepared in the absence of other 
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nucleophiles or acid catalysis, may suggest the innate instability of these compounds mediated 
by the amine itself.  This hypothesis is supported by the observation that the amidation of 192 
without isolation proceeded smoothly, and resulting compound 195 showed no signs of 
instability. 
Scheme 4.4. Synthesis of free amines 190-192 and pentanoyl amide derivatives 193-195.
a 
 
a
Reagents and conditions: a) 4M HCl-dioxane, 0°C-RT, 2h, 78-100%; b) valeryl chloride, 
DIPEA, DCM, 0°C-RT, 3h, 63-74%. 
 
Free amine 190 was further derivatized into several other nitrogen-containing functional 
groups using one of three one-step procedures (Scheme 4.5).  Tertiary amines 196 and 197 were 
synthesized by reductive amination using sodium cyanoborohydride and the corresponding 
aldehyde.
133,134
  Urea-containing compounds 198-200 were obtained via treatment with the 
corresponding carbamates under basic conditions.  Finally, chiral amides 201-202 were 
synthesized using amide coupling conditions (HOBt, EDC, tertiary amine base).  
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Scheme 4.5. Synthesis of spiropiperidine derivatives 196-202. 
a 
a
Reagents and conditions: a) HCHO or PhCHO, AcOH, NaBH(OAc)3, DCE, 16h, RT, 57-63%; 
b) R-NCO or R-NHCO-OSu, DIPEA, DCM, RT, 6h, 65-83%; c) (R)- or (S)-2-phenyl propanoic 
acid, DIPEA, HOBt, EDC, DCM, RT, 16h, 67-78%. 
 
Based on the successful derivatization of 190, we sought to generate the secondary amine 
analogs of the remaining 10 N-Boc final compounds.  4M HCl-dioxane was used to generate the 
original free amines 190-192 as easily handled, crystalline HCl salts, but stability issues were 
encountered under these conditions with a number of other compounds. We theorized this 
instability could be attributed to the acid-sensitivity of the nitrile group and formation of imino 
chlorides.  In these cases, a switch to 15-33% TFA:DCM solutions for deprotection conferred 
greater stability due to the non-nucleophilic nature of the TFA conjugate base. In the cases where 
TFA deprotection failed, a mildly basic method employing TMS-OTf and triethylamine offered 
an alternative mechanism of deprotection
135
 at the cost of necessitating purification by flash 
chromatography.  Even so, only five of the 10 possible free NH compounds (203-207, Scheme 
4.6) were sufficiently stable for characterization and use in the biofilm assay. 
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Scheme 4.6. Synthesis of free secondary amines 203-207.
a
 
a
Reagents and conditions: a) DCM:TFA (2-4:1), 0°C-RT, 4h, 63-90%; b) TMS-OTf, 2,6-lutidine, 
DCM, 0°C, 30 min, 56-100%.  
 
The ongoing collection and refinement of SAR data prompted us to revisit the synthesis 
of several new gem-dimethyl analogs as well (Scheme 4.7).  These compounds were synthesized 
in the same manner as the N- and O- alkylated amides 46-50 discussed in Chapter 2, beginning 
from unsubstituted 2-thioxopyrimidinone 44b. 
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Scheme 4.7. Synthesis of additional gem-dimethyl analogs with decreased lipophilicity 209-
215.
a 
 
a
Reagents and conditions: a) R
1
-X, NaHCO3, DMF, 50-70°C, 16h, 73-93%; b) R
2
-X, base, DMF, 
50-70°C, 3-16h, 22-57%. 
 
A synthetic effort to access chirally-substituted compounds was undertaken in order to 
assess the extent of chiral bias evident in the target-analog interaction. Spiropyrrolidine 
compounds 221-224 were originally synthesized as racemates to assess their activity before 
progressing to synthesis of enantiomerically enriched derivatives. The racemic synthesis 
proceeded adequately as described in Scheme 4.8, using chemistry already established in the 
generation of spiropiperidines 177-189.  Ultimately, Boc-protected analogs 221 and 222, as well 
as their deprotected secondary amine counterparts 223 and 224, were submitted for biological 
testing. 
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Scheme 4.8. Synthesis of racemic spiropyrrolidine compounds 221-224.
a 
 
a
Reagents and conditions: a) NaH, trimethyl phosphonoacetate, DMF, 0°C; then 216, 0°C-RT, 
3h, 82%; b) LDA, 217, diglyme, -78°C, 1h; then 15 or 26c, ZnI2, -78°C-RT, 2h, 20-25%; c) 
benzoyl isothiocyanate, EtOH, reflux, 6h; d) KOH, EtOH:H2O (2:1), reflux, 2h, 49-68% over 2 
steps; e) MeOCH2CH2OTs, NaHCO3, DMF, 70°C, 16h, 50-91%; f) allyl bromide, NaOMe, 
EtOH, 70°C, 16h, 32-42%; g) 4M HCl-dioxane, 0°C-RT, 2h, 77-94%. 
 
The synthesis of the corresponding enantiopure pyrrolidines 231 met with much more 
synthetic adversity (Scheme 4.9).  Since the LDA cyclization is not likely to induce asymmetry 
at the quaternary carbon, we pursued the functionalization of the pyrrolidine nitrogen with a 
chiral auxiliary.  This chiral auxiliary would have ideally allowed for the separation of 
diastereomers at some stage of the synthesis, either by flash chromatography or HPLC, then be 
selectively removed to allow derivatization of the enantiopure compounds.  We decided that 
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chiral α-methylbenzyl amine derivatives could function in this role since they can be removed 
via treatment with chloroformates.
136
 Chiral succinimide 226 was successfully synthesized from 
DL-malic acid and α-methylbenzylamine, mediated by stepwise additions of acetyl chloride.137  
Pan-reduction of the acetyl group and the succinimide with LAH generated the pyrollidinol, 
which was oxidized to the ketone under Swern conditions.
138
  Horner-Emmons olefination 
furnished the targeted chiral Michael acceptor.  The LDA/ZnI2 cyclization successfully afforded 
β-aminoester intermediate 229 as a 3:2 mixture of diastereomers, albeit in low yields.  
Unfortunately, the diastereomers were not separable at this stage, and it was found that no set of 
conditions led to the successful installation of the pyrimidinone ring.  The synthesis of this class 
of compounds was shelved at this point to explore more easily accessible chiral analogs. 
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Scheme 4.9. Attempted synthesis of chiral spiropyrrolidine analogs 231 via diasteromeric 
functionalization.
a 
 
a
Reagents and conditions: a) AcCl, reflux, 3h; b) (S)-α-methylbenzylamine, THF, RT, 4h; c) 
AcCl, reflux, 12h, 90% over 3 steps; d) LAH (6.5 eq), THF, 0°C-RT, 6h, 93%; e) oxalyl 
chloride, DMSO, DCM, -78°C, 10 min; then Et3N, -78°C, 1h, 55%; f) NaH, trimethyl 
phosphonoacetate, 0°C; then 227, 0°C-RT, 3h, 100%; g) LDA, 228, diglyme, -78°C, 1h; then 
26c, ZnI2, -78°C-RT, 2h, 25%. 
 
Due to the failure of the chiral pyrrolidine series, new chiral analogs were proposed that 
take advantage of later-stage chiral derivatization and routes that did not rely on diasteromeric 
separation for stereoenrichment.  The chiral amides (201 and 202) were easily accessed by 
coupling enantiomerically pure 2-phenyl-1-propionic acids to free amine 190 under standard 
EDC-mediated conditions, as shown in Scheme 4.5. 
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Scheme 4.10. Synthesis of pentacyclic enantiomer pairs 234-237.
a 
 
a
Reagents and conditions: a) thiophosgene, NaHCO3, DCM:H2O (1.4:1) RT, 3.5h 79%; b) (R)- 
or (S)-2-amino-1-propanol, Et2O, RT, 1h, 91%; c) NaOMe, MeOH, RT, 30 min 92%; d) TFA, 
DCM, 0°C-RT, 4h, 72-96%; e) Ph-CHO, AcOH, NaBH(OAc)3, DCE, RT, 16h, 48-62%. 
 
The generation of chiral pentacyclic analogs 234-237 (Scheme 4.10) required one 
significant alteration to the standard scheme.  The amine functionality of 174 (Scheme 4.3) was 
efficiently converted to the isothiocyanate under the action of thiophosgene in DCM, with a layer 
of aqueous sodium carbonate used as an HCl sink.
139
  The resulting β-isothiocyanato ester 232 
was found to readily react with amines under neutral conditions.  This reactivity was exploited 
using L- and D-alaninol to form chiral acyclic thiourea adducts that could be isolated via vacuum 
filtration and cyclized under basic conditions to intermediate 233a or 233b in the presence of 
sodium methoxide.  An acid-mediated intramolecular SN2 reaction assembled the fifth ring with 
concomitant removal of the Boc group, yielding chiral compounds 234 and 235.
140
  Further 
derivatization of the piperidine via reductive amination afforded tertiary benzylamine analogs 
236 and 237 as well. 
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The drastically improved efficiency of synthesizing 2-thioxopyrimidinone rings 
beginning from the β-isothiocyanato ester led us to alter the synthetic strategy used to access 
chiral diversity at the phenyl ring (Scheme 4.11).  Previously synthesized intermediates 140 and 
173 were coupled together under standard LDA/ZnI2 conditions, then the resultant amine 238 
was converted to isothiocyanate 239.  Treatment with allylamine followed by sodium methoxide 
in methanol cleanly afforded the N-allyl 2-thioxo-pyrimidinone 240 in excellent yields, and 
subsequent sulfur alkylation with 2-methoxyethyl tosylate yielded 241. This intermediate was 
treated with TBAF to reveal the phenol, which could be chirally substituted via Mitsunobu 
reaction with 1-phenylethanol in the presence of PPh3 and DIAD, yielding enantiomer pair 242 
and 243.
141
  Unfortunately, removal of the Boc group with TFA caused the concomitant loss of 
the chiral ether.  We suspect that other methods of Boc removal (HCl-dioxane, TMS-OTF + 
base) would also result in loss of the ether.  The resulting phenol 244 was submitted for activity 
assay nonetheless. 
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Scheme 4.11. Synthesis of aryl ether enantiomer pair 242 and 243, as well as phenol 244.
a
 
 
a
Reagents and conditions: a) LDA, 140, diglyme, -78°C, 1h; then 173, ZnI2, -78°C-RT, 2h, 40%; 
b) thiophosgene, NaHCO3, DCM:H2O (1.4:1), RT, 3.5h, 77%; c) allylamine, Et2O, RT, 1h; then 
NaOMe, MeOH, RT, 3h, 96%; d) MeOCH2CH2OTs, Cs2CO3, DMF, 70°C, 16h, 49%; e) TBAF, 
THF, 0°C-RT, 4h, 87%; f) PPh3, DIAD, (R)- or (S)-α-methylbenzyl alcohol, 0°C, 2h; then RT, 
16h, 43-52%; g) TFA (4 eq.) DCM, 0°C-RT, 3h, 96%. 
 
SAR Discussion 
 All new analogs for the SAR study were first assessed for their ability to inhibit biofilm 
in S. aureus and S. epidermidis relative to control at concentrations of 5 and 50 µM.  Compounds 
that showed satisfactory anti-biofilm activity (>50% inhibition at 50 µM) were selected for full 
dose-response curve and IC50 determination.  It is important to note that IC50 data was collected 
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after the completion of the entire 2-point concentration data set, and was thus not available to 
make SAR decisions until after nearly all of the analogs were synthesized.  Therefore, the 
following section discusses the SAR study in the context of the 2-point concentration data, with 
interpretation of the IC50 data discussed more thoroughly in a later section of this chapter. 
The feasibility of incorporating a spiropiperidine into the scaffold was explored with the 
first set of compounds synthesized, which drew inspiration from aryl ether 31 and 
spiropiperidines 161 and 162.  The activity data from this set of compounds (Table 4.2) 
identified several seemingly small changes that had significant effects on their ability to inhibit 
biofilm. Compounds based on 161 with pentanamide substitution (193-195) showed low or no 
activity in both bacterial strains. Interestingly, Boc-substituted compounds 177 and 181 possess 
similar and potent activity in S. aureus, but only weak activity in S. epidermidis.  In contrast, 
piperidine HCl salt 190 was found to be active in both strains at 50 µM, while 191 was acutely 
bacteriotoxic (>90% growth inhibition at 50 µM). 162 possessed low activity. Considering that 
these three compounds essentially differ only in the positioning of one or two methoxy groups, 
this wide variation in activity was quite surprising. O-alkylated amides 184 and 195 exhibited 
little to no activity in either strain. Based on this dataset, we concluded that the pursuit of 
additional spiropiperidine compounds (both free NH and Boc-substituted) was warranted.  Aryl 
methyl ether substitution was also included in most new analogs given the potency increase 
observed for 190 vs. 162. 
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Table 4.2. Activity of spiropiperidine analogs with varied substitution patterns. 
 
# Scaffold R
1
 R
2
 
SA 
5 µM
a 
SA 
50 µM
a 
SA 
IC50 (µM)
b 
SE 
5 µM
c 
SE 
50 µM
c 
177 A CH3OCH2CH2 Boc 0.44 ± 0.06 0.72 ± 0.14 >50 0.75 ± 0.05 0.82 ± 0.16 
181 A Et Boc 0.58 ± 0.07 0.58 ± 0.09 1.8 ± 0.7
3
 0.70 ± 0.04 0.78 ± 0.02 
184 B CH3OCH2CH2 Boc 0.91 ± 0.21 1.03 ± 0.31  0.98 ± 0.10 0.90 ± 0.19 
190 A CH3OCH2CH2 H 0.94 ± 0.06 0.41 ± 0.20 >50 1.01 ± 0.05 0.17 ± 0.05 
191
1
 A Et H 0.97 ± 0.12 0.04 ± 0.01  0.87 ± 0.01 0.07 ± 0.04 
193 A CH3OCH2CH2 COnBu 0.94 ± 0.15 1.24 ± 0.34  0.95 ± 0.13 1.07 ± 0.09 
194 A Et COnBu 0.98 ± 0.02 1.04 ± 0.15  0.91 ± 0.02 1.12 ± 0.10 
195 B CH3OCH2CH2 COnBu 0.85 ± 0.22 0.78 ± 0.16  1.01 ± 0.18 0.93 ± 0.20 
161
2 C CH3OCH2CH2 COnBu 1.04 ± 0.13 0.74 ± 0.01  0.78 ± 0.01 0.87 ± 0.01 
162
2 C CH3OCH2CH2 H 0.99 ± 0.10 0.87 ± 0.07  0.81 ± 0.08 0.62 ± 0.42 
a 
Ratio of S. aureus biofilm formation by S. aureus cultures in the presence of the indicated 
concentration of test compound compared to DMSO control.  
b 
Half-maximal inhibitory 
concentrations against biofilm formation in the presence of the indicated compound, calculated 
from 6-point dose-response curve from 0.15 µM to 50 µM. 
c 
Ratio of S. epidermidis biofilm 
formation by S. aureus cultures in the presence of the indicated concentration of test compound 
compared to DMSO control. 
1
Compound 191 induced acute bacteriotoxicity in both strains 
(>90% growth inhibition at 50 µM). 
2
Synthesized by W.G. Rajeswaran. 
3
IC50 curve indicates 
high potency but low efficacy (~35% max biofilm inhibition) for 181. 
 
Based on structural insights gleaned from the first set of biofilm analogs, we assessed 
diversity at the piperidine nitrogen using 190 as our reference compound (Table 4.3). Tertiary 
benzylamine 197 was equipotent to 190 against S. aureus, but significant variability in S. 
epidermidis implied that a considerable amount of activity had been lost.  In response to the loss 
of activity exhibited by amide compounds (193-195), we generated three ureas of varying bulk 
and polarity.  While the methyl (198) and phenyl (199) ureas were both found to be only weakly 
active, ethyl ester compound 200 was able to demonstrate modest activity against S. aureus 
biofilm.  Compound 244, an analog of 190 with an unmasked phenol, showed moderate but 
variable activity against S. aureus.  
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Table 4.3. Activity data for compounds with varied piperidine N-substitutions and phenol 
compound 244. 
 
# R
1
 R
2
 
SA 
5 µM
a 
SA 
50 µM
a 
SA IC
50
 
(µM)
b 
SE 
5 µM
c 
SE 
50 µM
c 
196 Me Me 0.95 ± 0.13 0.83 ± 0.32 >50 0.93 ± 0.11 0.86 ± 0.15 
197 Bn Me 0.92 ± 0.27 0.37 ± 0.11 >50 0.96 ± 0.16 0.57 ± 0.29 
198 CONHMe Me 1.16 ± 0.05 0.68 ± 0.06 
 
1.14 ± 0.23 1.02 ± 0.23 
199 CONHPh Me 1.11 ± 0.07 0.92 ± 0.07 
 
0.93 ± 0.08 0.83 ± 0.10 
200 CONHCH2CO2Et Me 1.06 ± 0.09 0.48 ± 0.13  
0.98 ± 0.14 0.81 ± 0.18 
244 H H 0.99 ± 0.03 0.59 ± 0.20 
 
nd nd 
190 H Me 0.94 ± 0.06 0.41 ± 0.20 >50 1.01 ± 0.05 0.17 ± 0.05 
a 
Ratio of S. aureus biofilm formation by S. aureus cultures in the presence of the indicated 
concentration of test compound compared to DMSO control.  
b 
Half-maximal inhibitory 
concentrations against biofilm formation in the presence of the indicated compound, calculated 
from 6-point dose-response curve from 0.15 µM to 50 µM. 
c 
Ratio of S. epidermidis biofilm 
formation by S. aureus cultures in the presence of the indicated concentration of test compound 
compared to DMSO control. 
 
Although 190 showed good activity in both test strains at 50 µM, the diversity of sulfur 
and amide substitutions in active compounds from the GAS-SK series suggested we may be able 
to install more polar functionality at these positions while retaining or improving activity.  
Higher polarity (lower cLogP) should enhance the aqueous solubility of this otherwise highly 
hydrophobic series and potentially decrease the scaffold’s susceptibility to oxidation by P450s.  
Furthermore, as previously observed in the GAS-SK study, compounds alkylated at the O-
position of the pyrimidinone amide were generally 4-15x more stable to metabolism when 
compared to their N-alkylated counterparts.  Therefore, the identification of a reasonably active, 
more polar compound with an O-alkylated pyrimidinone amide was considered highly desirable. 
We focused on the replacement of the lipophilic allyl group with smaller methyl or more polar 
acetonitrile and n-propanol functionalities, while either retaining methoxyethyl substitution of 
the sulfur or again substituting with acetonitrile.  A summary of the N-Boc substituted analogs is 
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presented in Table 4.4. Unfortunately, nearly all the compounds in this series displayed 
disappointingly low activity in both strains at 50 µM, with the exception of 180 in S. aureus. 
Although somewhat active at 50 µM, we had hoped that by combining the features of several 
distinct active compounds (N/O n-propanol, N-Boc or NH-piperidine, S-methoxyethyl) would 
result in drastic, synergistic gains in potency, but this was unfortunately not realized. Similarly, 
the five successfully synthesized and stable unsubstituted piperidines from this series (203-207) 
showed weak, highly variable, or no activity up to 50 µM (Table 4.5).   
 
Table 4.4. Activity data for Boc-substituted spiropiperidines compounds with varied 
substitution on the pyrimidinone ring. 
 
# Scaffold R
1
 R
2
 
SA 
5 µM
a 
SA 
50 µM
a 
SA 
IC
50
 (µM)
b 
SE 
5 µM
c 
SE 
50 µM
c 
178 A CH3OCH2CH2 NCCH2 0.74 ± 0.18 0.88 ± 0.15  1.00 ± 0.11 0.90 ± 0.06 
179 A CH3OCH2CH2 Me 0.92 ± 0.01 1.01 ± 0.13  0.98 ± 0.14 0.92 ± 0.03 
180 A CH3OCH2CH2 HO(CH2)3 0.81 ± 0.13 0.40 ± 0.10 16.7 ± 9.9 nd nd 
182 A NCCH2 Me 0.68 ± 0.02 0.70 ± 0.06  
1.00 ± 0.16 0.95 ± 0.14 
183 A NCCH2 NCCH2 0.79 ± 0.18 0.80 ± 0.03  
0.97 ± 0.09 0.95 ± 0.08 
185 B CH3OCH2CH2 NCCH2 0.82 ± 0.03 0.80 ± 0.02  
0.88 ± 0.09 0.87 ± 0.02 
186 B CH3OCH2CH2 Me 0.72 ± 0.09 1.03 ± 0.18  0.94 ± 0.09 0.85 ± 0.04 
187 B CH3OCH2CH2 HO(CH2)3 0.81 ± 0.04 0.67 ± 0.25  nd nd 
188 B NCCH2 Me 0.68 ± 0.22 0.75 ± 0.12  0.98 ± 0.13 0.88 ± 0.05 
189 B NCCH2 NCCH2 0.75 ± 0.11 0.75 ± 0.11  0.94 ± 0.15 0.87 ± 0.08 
a 
Ratio of S. aureus biofilm formation by S. aureus cultures in the presence of the indicated 
concentration of test compound compared to DMSO control.  
b 
Half-maximal inhibitory 
concentrations against biofilm formation in the presence of the indicated compound, calculated 
from 6-point dose-response curve from 0.15 µM to 50 µM. 
c 
Ratio of S. epidermidis biofilm 
formation by S. aureus cultures in the presence of the indicated concentration of test compound 
compared to DMSO control. 
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Table 4.5. Activity data for unsubstituted spiropiperidines compounds with varied 
substitution on the pyrimidinone ring. 
 
 
# Scaffold R
1
 R
2
 
SA 
5 µM
a 
SA 
50 µM
a 
SA 
IC
50
 (µM)
b 
SE 
5 µM
c 
SE 
50 µM
c 
203 A CH3OCH2CH2 HO(CH2)3 0.97 ± 0.03 0.94 ± 0.02  nd nd 
204 A NCCH2 Me 1.01 ± 0.15 0.89 ± 0.11  
1.03 ± 0.11 0.96 ± 0.30 
205 B CH3OCH2CH2 HO(CH2)3 0.95 ± 0.01 0.61 ± 0.20  nd nd 
206 B NCCH2 Me 1.05 ± 0.34 0.82 ± 0.65  
1.13 ± 0.10 0.92 ± 0.26 
207 B NCCH2 NCCH2 1.02 ± 0.21 0.69 ± 0.48  
0.99 ± 0.91 0.91 ± 0.17 
190 A CH3OCH2CH2 Allyl 0.94 ± 0.06 0.41 ± 0.20 >50 1.01 ± 0.05 0.17 ± 0.05 
a 
Ratio of S. aureus biofilm formation by S. aureus cultures in the presence of the indicated 
concentration of test compound compared to DMSO control.  
b 
Half-maximal inhibitory 
concentrations against biofilm formation in the presence of the indicated compound, calculated 
from 6-point dose-response curve from 0.15 µM to 50 µM. 
c 
Ratio of S. epidermidis biofilm 
formation by S. aureus cultures in the presence of the indicated concentration of test compound 
compared to DMSO control. 
 
In light of the limited success garnered from optimizing the spiropiperidine-based 
compounds for activity, we postulated that it may be useful to synthesize additional gem-
dimethyl substituted compounds using the same guiding principles as above.  Activity data for 
these compounds is summarized in Table 4.6.  Although the majority of these compounds are not 
very active, 210 was observed to be equipotent to compound 31 in S. aureus.  In contrast to our 
efforts to optimize the spiropiperidine series, 210 represents the successful realization of 
synergistic gains by combining the features of moderately potent analogs 51 and 43.  The 
enhanced microsomal stability and lower cLogP of this compound compared to 31 may 
distinguish 210 as being better suited for in vivo administration.  O-methyl compound 213 
continues the trend of being less active than its N-methylated counterpart 43. 
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Table 4.6. Activity data for additional gem-dimethyl compounds 209-215 in comparison to 
compounds 43 and 51.  
  
# Scaffold R
1
 R
2
 
SA 
5 µM
a 
SA 
50 µM
a 
SA IC
50
 
(µM)
b 
SE 
5 µM
c 
SE 
50 µM
c 
209 A Et NCCH2 1.18 ± 0.09 1.12 ± 0.03  1.01 ± 0.23 0.94 ± 0.14 
210 A F3CCH2 Me 0.38 ± 0.05 0.33 ± 0.00 3.7 ± 0.9 0.94 ± 0.16 0.87 ± 0.06 
211 A NCCH2 NCCH2 1.13 ± 0.15 0.61 ± 0.02  1.03 ± 0.12 0.92 ± 0.22 
212 B Et NCCH2 1.09 ± 0.16 0.97 ± 0.07  0.88 ± 0.13 0.89 ± 0.15 
213 B Et Me 1.22 ± 0.35 0.72 ± 0.06 
 
0.94 ± 0.14 0.83 ± 0.02 
214 B NCCH2 NCCH2 1.03 ± 0.10 0.80 ± 0.00  
1.01 ± 0.19 0.91 ± 0.18 
215 B NCCH2 Allyl 0.84 ± 0.00 0.54 ± 0.09  0.92 ± 0.09 0.82 ± 0.12 
43 A Et Me 0.81 ± 0.10 0.28 ± 0.14 4.3  ± 0.6 0.90 ± 0.07 0.57 ± 0.45 
51 A F3CCH2 Allyl 0.80 ± 0.04 0.33 ± 0.04 2.9  ± 0.4 nd nd 
a 
Ratio of S. aureus biofilm formation by S. aureus cultures in the presence of the indicated 
concentration of test compound compared to DMSO control.  
b 
Half-maximal inhibitory 
concentrations against biofilm formation in the presence of the indicated compound, calculated 
from 6-point dose-response curve from 0.15 µM to 50 µM. 
c 
Ratio of S. epidermidis biofilm 
formation by S. aureus cultures in the presence of the indicated concentration of test compound 
compared to DMSO control. 
 
At this point in the SAR optimization process, we tentatively concluded that little 
progress had been made on the optimization of activity against Staphylococcus biofilms.  
Compounds 190 and 210, the most active compounds against S. aureus from this series, were 
merely equipotent to GAS-SK compound 31, albeit with potentially enhanced physicochemical 
properties.  The picture was considerably more dire for the S. epidermidis arm of the SAR study.  
While progress had indeed been made in terms of identifying analogs with enhanced activity 
against S. epidermidis compared to GAS-SK compounds, 190 had proven to be the only 
compound with reproducible, non-toxic biofilm inhibition >50% at 50 µM.  Based on this 
troubling data, we decided to focus our efforts more directly on optimization against S. aureus. 
The wider range of activities exhibited by our compounds in this strain gave us more data from 
which structural conclusions could be derived. 
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Chiral Derivative Discussion 
 The generation of several enantiomeric pairs of chiral analogs was undertaken as a 
complementary strategy to more traditional structural analog development for SAR optimization.  
Since macromolecules are chiral in nature, chiral ligands allow for potentially greater interaction 
with the macromolecular environment compared to achiral molecules. Furthermore, if a given 
chiral compound is effective in increasing activity, its enantiomer is unlikely to accommodate the 
same pose in the chiral protein environment, decreasing its binding affinity. This phenomenon 
can be very significant, and is generally proportional to the potency of the ligand.
142
  The ratio of 
the affinity of the more active enantiomer (“eutomer”) to that of the less active enantiomer 
(“distomer”) is defined as the eudismic ratio.  The phenomenon of chiral differentiation in 
binding affinity, on top of being an important tool for SAR optimization, can be a strong 
indicator that a given compound is making a specific interaction with one or a few target 
macromolecules rather than evoking its characteristic phenotype through nonspecific means 
(membrane effects, protein expression pan-inhibition, self-aggregation, etc.).  It should be noted 
that although a high eudismic ratio implies a specific target-ligand interaction,
143
 the opposite is 
not true when no significant eudismic ratio is observed.  If, for example, the chiral portion of the 
molecule is situated in a region of the binding site that it does not meaningfully interact with, 
such as a solvent-exposed area, a significant eudismic ratio will not be observed.  Therefore, 
when generating enantiomer pairs to assess chiral differentiation, it is important to vary the site 
of chiral substitution as much as possible.  In light of this, we identified three distinct portions of 
the scaffold amenable to chiral derivatization. 
A total of 12 compounds were synthesized for the chiral discrimination study.  
Spiropyrrolidine compounds 221-224 (Table 4.7) were originally synthesized as racemates to be 
compared with their chiral counterparts.  While synthetic issues hampered the synthesis of the 
chiral versions, the racemates were submitted for activity assessment on their own.  Similarly to 
spiropiperidine compounds 177 and 181, Boc-substituted compounds 221 and 222 were found to 
be active, with methoxy-substituted 22 achieving slightly higher potency at 5 µM. The analogous 
free NH analogs 223 and 224 were nearly inactive.    
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Table 4.7. Activity data for racemic spiropyrrolidine compounds 221-224. 
 
# R
1
 R
2
 
SA 
5 µM
a 
SA 
50 µM
a 
SA IC
50
 
(µM)
b 
SE 
5 µM
c 
SE 
50 µM
c 
221 Boc H 0.77 ± 0.12 0.48 ± 0.18 3.2 ± 0.7 0.98 ± 0.02 0.78 ± 0.05 
222 Boc MeO 0.58 ± 0.17 0.52 ± 0.06 1.4 ± 0.2 0.84 ± 0.06 0.75 ± 0.18 
223 H H 0.96 ± 0.14 1.03 ± 0.27  1.14 ± 0.07 1.13 ± 0.29 
224 H MeO 0.85 ± 0.11 0.72 ± 0.19 >50 0.99 ± 0.29 0.91 ± 0.29 
a 
Ratio of S. aureus biofilm formation by S. aureus cultures in the presence of the indicated 
concentration of test compound compared to DMSO control.  
b 
Half-maximal inhibitory 
concentrations against biofilm formation in the presence of the indicated compound, calculated 
from 6-point dose-response curve from 0.15 µM to 50 µM. 
c 
Ratio of S. epidermidis biofilm 
formation by S. aureus cultures in the presence of the indicated concentration of test compound 
compared to DMSO control. 
 
 
The first enantiomeric pairs synthesized for this study were the alaninol-derived 
pentacycles 234-237 (Table 4.8).  Based on previous results, both the free secondary amine and 
tertiary benzylamine analogs were prepared.  This decision would prove fortuitous, as secondary 
amines 234 and 235 showed very weak activity at 50 µM.  Interestingly, there appears to be a 
slight degree of chiral differentiation between tertiary benzylamines 236 and 237 at 50 µM, 
though an activity ratio of 1.5 is not particularly conclusive.  Furthermore, the calculation of the 
IC50 value for the more potent (S)-enantiomer 237 reveals a disappointingly low value of 46 µM.  
Since this value nearly reaches the functional concentration limit of the assay, the calculation of 
a true eudismic ratio between 236 and 237 would not be informative.   
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Table 4.8. Activity data for chiral alaninol-derived pentacycles 234-237. 
                   
# R1 R2 SA 5 µMa
 SA 
50 µM
a
 SA IC50 
(µM)
b
 SE 
5 µM
c
 SE 
50 µM
c
 
234 (R)-Me H 0.97 ± 0.23 0.65 ± 0.31 
 
nd nd 
235 (S)-Me H 0.96 ± 0.16 0.68 ± 0.35 
 
nd nd 
236 (R)-Me Bn 0.86 ± 0.17 0.75 ± 0.09 
 
nd nd 
237 (S)-Me Bn 0.89 ± 0.15 0.50 ± 0.00 46 ± 1 nd nd 
a 
Ratio of S. aureus biofilm formation by S. aureus cultures in the presence of the indicated 
concentration of test compound compared to DMSO control.  
b 
Half-maximal inhibitory 
concentrations against biofilm formation in the presence of the indicated compound, calculated 
from 6-point dose-response curve from 0.15 µM to 50 µM. 
c 
Ratio of S. epidermidis biofilm 
formation by S. aureus cultures in the presence of the indicated concentration of test compound 
compared to DMSO control. 
 
The final two enantiomeric pairs assessed the extent of chiral differentiation at two other 
points on the scaffold (Table 4.9).  Unfortunately, the somewhat bulky substitutions at both the 
piperidine nitrogen and 8-position of the phenyl ring led to precipitous drops in activity.  
Compound 201 appears somewhat active, but its inter-assay variability is too high to make any 
meaningful comparison with 202.  It has been previously observed in this SAR study that only a 
few compounds with large substituents appended to the phenyl have retained activity.  In its 
current state, the chiral differentiation study hints at possible dissimilarity between enantiomeric 
pairs, but not convincingly so based on this small number of analogs and their relatively low 
levels of biofilm activity. 
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Table 4.9. Activity data for chiral aryl ethers 242-243 and chiral amides 201 and 202. 
  
# R
1
 R
2
 
SA 
5 µM
a 
SA 
50 µM
a 
SE 
5 µM
b 
SE 
50 µM
b 
242 Boc 
 
0.88 ± 0.17 0.90 ± 0.14 nd nd 
243 Boc 
 
0.91 ± 0.14 0.83 ± 0.19 nd nd 
201 
 
Me 0.70 ± 0.23 0.68 ± 0.24 nd nd 
202 
 
Me 0.87 ± 0.06 0.88 ± 0.02 nd nd 
a 
Ratio of S. aureus biofilm formation by S. aureus cultures in the presence of the indicated 
concentration of test compound compared to DMSO control. 
b
Ratio of S. epidermidis biofilm 
formation by S. aureus cultures in the presence of the indicated concentration of test compound 
compared to DMSO control. 
 
IC50 Data  
 As previously mentioned, our group decided to first examine the activity of each 
compound at 5 and 50 µM concentrations before progressing to IC50 determination.  This 
decision delayed the determination of IC50 values for virtually all analogs produced in this series 
until the end of the campaign.  Disappointingly, we found the S. aureus IC50 data for several 
compounds incongruous with the existing 2-point activity data we used to design our SAR 
strategy. For example, Compounds 177, 190, and 197, identified as good performers in the 
original activity data, returned IC50 values greater than 50 µM, the highest concentration tested in 
our dose-response curves.  The decision to employ the S-methoxyethyl appendage in a majority 
of later compounds, as well as our focus on preserving basic amine functionality, are counter to 
the conclusions one would draw from the IC50 data alone.  The IC50 values for the three most 
potent compounds in S. epidermidis, 190, 43, and 197, were all greater than 50 µM and highly 
variable, reinforcing our decision to focus more on S. aureus inhibition. 
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 Although at first puzzling, a key difference between the 2-point activity data and IC50 
data helps to partially explain the conflict.  While the activity data measures the ratio of activity 
compared to control from 0.00 to 1.00, IC50s by definition describe the point of half-maximal 
inhibitory concentration, calculated as the inflection point of a dose response curve.  None of the 
compounds in this series achieve 100% biofilm inhibition (i.e. a ratio of 0.00) at any 
concentration, but instead hit a ceiling of inhibition that could be due to either physicochemical 
or mechanistic reasons. This phenomenon led to lower than expected IC50 values for compounds 
that reach a maximal point at relatively high values. Compound 181 (Table 4.2) is an excellent 
example of this phenomenon. Likewise, higher than expected values are reported for compounds 
that do not reach an activity plateau over the concentration range tested (0.15 µM – 50 µM), like 
compounds 190 and 197.  Essentially, the two-point concentration data is a gauge of the efficacy 
of compounds in this series, while the IC50 values are measuring the concentration to achieve 
half of this maximal effect (potency).  It should also be noted that the most active compounds 
identified by the 2-point concentration data in SA, including 31, 51, and 210, have IC50 values 
that are highly consistent with the 2-point data, presumably because they are able to inhibit 
biofilm to a greater maximal degree than other compounds.  Thus, the IC50 values, when taken 
together with the original activity data, serve as an additional point of differentiation between 
compounds that allowed for the finer discrimination between our best analogs. 
In Vivo Efficacy Assays 
 Our collaborators in Hongmin Sun’s group have also performed whole-animal studies to 
complement the cell-based activity determination studies.  Catheters or silicone wafers 
inoculated with 10
7–108 CFU S. aureus or S. epidermidis were subcutaneously implanted into 
Balb/c mice, then treated IP with 100 µL of 2 mg/mL (8-10 mg/kg) test compound suspensions 
once a day for four days.  Test compounds included some of the most potent compounds 
identified in the series, including 31 and 51. The survival of test and control (PBS-treated) 
populations was compared over the course of seven days.  Data gleaned from this study suggests 
that although displaying potent activity in plate-based assays, compounds 31 and 51 are not able 
to achieve protection at statistically significant levels. This is likely due to the previously 
identified issues of metabolic stability and solubility observed with these compounds (Chapter 
2).  Compound 21 was also chosen for in vivo study based on its increased aqueous solubility 
(~35 µM) and metabolic stability (MLM t1/2 = 21 minutes). Interestingly, despite its fairly low 
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observed efficacy in plate-based assays (Table 4.1), 21 displays significant protective effects in 
mice (p = 0.004), underscoring the importance of solubility and stability to metabolism to in vivo 
efficacy. 
Figure 4.2. Survival data for Balb/c mice infected via subcutaneously-implanted silicone 
wafers inoculated with S. aureus in the presence of test compounds vs. negative control. 
 
Metabolic Stability 
 After the completion of the SAR dataset, we submitted potent compounds 210 and 222 to 
Duxin Sun’s group to assess their propensity for oxidation by mouse liver microsomal extract. 
Compound 222 (MLM t1/2 = 5.7 min, Table 4.10) was found to have mediocre metabolic 
stability, but was still greater than potent compounds 31 and 43.  We were pleased to find that 
compound 210, although slightly less potent than lead compound 31 (IC50 = 3.4 µM vs. 1.4 µM 
for 31), is nearly 25-fold more metabolically stable (MLM t1/2 = 19.7 min vs. 0.8 min for 31). 
This result was somewhat unexpected, given our previous observation that S-trifluoroethyl (51) 
or amide N-methyl substitution (43) alone was not sufficient to confer a significant increase in 
metabolic stability. Thus, 31 represents the first potent and potential metabolically competent 
compound developed for the S. aureus anti-biofilm SAR study. 
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Table 4.10. Microsomal stability and IC50 data for selected compounds potent against S. 
aureus biofilm production. 
# Structure 
SA IC
50 
(µM)
a 
MLM t
1/2 
(min)
b 
21 
 
nd
c 
20.6 
31 
 
1.4 ± 0.4 0.8 
32 
 
5.2 ± 0.4 2.3 
51 
 
2.9 ± 0.4 4.8 
43 
 
4.3 ± 0.6 1.7 
210 
 
3.7 ± 0.9 19.6 
222 
 
1.4 ± 0.2 5.7 
a
Half-maximal inhibitory concentrations against biofilm formation in the presence of the 
indicated compound, calculated from 6-point dose-response curve from 0.15 µM to 50 µM. 
b
Half-life of parent compound during incubation with mouse liver microsomes. 
c
Compound did 
not meet efficacy threshold to warrant IC50 determination. 21 achieved 31% biofilm inhibition 
vs. control at 50 µM in S. aureus. 
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Conclusions 
Despite our efforts to improve activity through carefully planned SAR expansion, none of 
the additional 47 compounds synthesized for this effort achieved a level of potency against S. 
aureus biofilm production greater than previously identified compound 31. The most active 
compounds in this series seem to inhabit a very narrow range of chemical space, characterized by 
small aryl methyl ethers and gem-dimethyl substitution on the central ring.  While this was 
difficult to predict based on the initial 100 µM compound screen, it became increasingly clear 
over the course of data refinement studies performed simultaneously to the SAR effort.  We were 
at first encouraged by several compounds which appeared efficacious (190, 180, 197, etc.) in 
both strains, but their weak and variable potencies observed during IC50 curve generation refuted 
the original 2-concentration activity data.  While unfortunate, these findings underscore the 
absolute importance of fully defining testing criteria, assay parameters, and generating robust 
initial data (in this case, the determination of IC50 values from several experiments with proper 
controls) before designing follow-up SAR.  While most of our compounds were weakly to 
moderately effective in inhibiting S. aureus biofilm production, no compounds possessing an 
IC50 less than 50 µM against S. epidermidis were identified.  Nonetheless, we were able to 
demonstrate the potent inhibition of biofilm formation in S. aureus with compounds 210, 221, 
and 222, which should serve as a starting point for the next round of SAR optimization.  The 
unexpected efficacy of 21 in mouse trials serves to further reinforce the necessity of good 
aqueous solubility and metabolic stability in achieving adequate protection in vivo. The enhanced 
metabolic stability of 210, combined with potency on par with 31, implies it may be particularly 
well suited to achieving antibacterial efficacy in mouse models.  
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Chapter 5: Future Directions 
GAS-SK SAR Studies 
Chapter 2, as well as our publication in Bioorganic Medicinal Chemistry,
144
 delineated 
our efforts toward optimizing the scaffold of 1 for activity against GAS-SK expression.  
Although we realized a 35-fold increase in the potency of the scaffold with analog 32 and 
identified amide alkylation at the O-position as protective against metabolic oxidation 
(compounds 48-50), we were never able to combine these desirable traits into a single 
compound.  By the time we discovered metabolically stable derivatives of 1, we had already 
been discussing the feasibility of repurposing these compounds for other virulence targets, most 
notably biofilm formation.
132
  The apparent intractability of potency optimization with retention 
of metabolic stability, combined with the increasingly promising potential of these compounds as 
biofilm inhibitors, led to the indefinite suspension of the SAR effort against GAS.  It is unlikely 
that this project will be restarted unless major breakthroughs are made in the target identification 
effort. 
 If a target was indeed identified, this development would re-energize the GAS-SK SAR 
study.  A validated target could lead to the development of a target-based biochemical assay, 
which would be an excellent supplement to the existing cell-based GAS-SK assay.  A 
biochemical assay would represent a drastic simplification of the test system with far fewer 
sources of variability. Decreased variability would in turn increase data resolution between 
compounds and provide much clearer SAR guidance.  Combining this enzymatic data with 
periodic cell assays to ensure we are retaining adequate cell permeability for activity would 
essentially give us the advantages of both phenotypic and target-based compound optimization.  
A third high-throughput screening effort, this time using the target in the primary screen and the 
cell-based GAS-SK assay as a means of hit validation, would have the potential to locate 
additional chemical matter useful against GAS virulence.  
Going forward, if a co-crystal structure of the target protein with an analog of 1 could be 
obtained, this would be of great importance to designing new analogs using the power of 
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structure-based drug design (SBDD).  Structural data derived from x-ray crystallography would 
allow us to identify which portions of the molecule are most important for interacting with the 
target, which would in turn guide the SAR effort and lead to analogs with potentially enhanced 
affinity.  In light of the as yet unresolved issues of solubility and metabolic stability with this 
compound series, other target-based technologies could be used to identify new leads, such as 
fragment-based virtual screening or molecular docking.  
Target Identification Studies 
 Chapter 3’s discussion of the target identification effort ends on a rather unfinished note, 
with all three generations of probe molecules failing to specifically identify any potential target 
and displaying a significant degree of apparent nonspecific binding in the cellular milieu.  As 
mentioned in the chapter, target identification with chemical probes using traditional affinity 
chromatography or fluorescence-based approaches is quite difficult, and only has a high chance 
of success in situations where the target is abundant and/or the target-ligand interaction is 
especially potent.  Given that bacterial transcription factors are among the lowest-abundance 
proteins in cells, it is likely that the target of our compounds is also relatively low-copy.  
Furthermore, the high lipophilicity and corresponding low aqueous solubility of our probe 
molecules and competitors works against our target identification efforts, both by encouraging a 
higher level of nonspecific association and crosslinking with lipophilic proteins, and also by 
limiting the effective concentration of soluble competitor compounds.  For example, in the 
benzophenone study, competitor concentrations were intended to be 500 µM and 1 mM, when in 
reality the effective concentration had to be far lower, given the aqueous solubility of compound 
17 is around 15 µM.  Essentially, to competitively block protein tagging at a level discernible by 
visual inspection of an SDS-PAGE gel, our assays should have had effective probe:competitor 
ratios of 1:100, instead of the level we more likely achieved, which is far from ideal for 
visualizing any strong competitive effect. 
 Although the issues with the probe compounds are not trivial, they are also not 
insurmountable.  In recent years, several new strategies for target identification using chemical 
probes have arisen.  Our collaborators in the Ginsburg group have proposed using genomic 
phage display libraries to screen for proteins interacting with probe molecules, a strategy that has 
previously been employed successfully to identify the targets of natural products (Figure 5.1).
107
  
Briefly, this technique is built around bacteriophages that are genetically altered to present 
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proteins or fragments of proteins on their outer protein coat.  Bacterial DNA is inserted into the 
phage genome and transfected into bacteria, inducing the production of fully-constructed phages 
with bacterial protein fragments on the outer portion of the viral capsid. Depending on the 
conditions used to generate phage-bacteria hybrid genomes (“phagemids”), these phages may 
represent one, many, or all the proteins coded by the bacterial genome.  The resulting phages are 
subjected to affinity chromatography using an immobilized photoprobe, UV-crosslinking, and 
subsequent washing away of non-bound phages. Similar to previous studies, complementary 
competition assays would assist in identifying hits attributable to nonspecific binding. The 
retained bacteriophage capsids are eluted from the matrix, then used to reinfect a new bacterial 
colony to amplify the enriched phage population.  These phages can then be lysed and submitted 
for gene sequencing, or be cycled through the affinity matrix process again to further enrich 
based on target-ligand interaction.  The ability to amplify and re-purify binding partners 
represents a significant advantage over traditional affinity screening methods.  Identifying targets 
using this methodology also carries the major advantage of having every protein represented in 
relatively equal amounts, so identification is not biased against proteins with low cellular 
abundance. 
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Figure 5.1. Using phage display libraries and affinity chromatography to identify specific 
target-probe interactions.  Adapted from Sche, Austin, et al., Chemistry and Biology 1999, 6, 
707-716. 
 
Members of the Ginsburg lab are developing a “shotgun” phage display library145 for S. 
aureus that demonstrates fully redundant coverage of the S. aureus genome, with GAS soon to 
follow.  However, the nature of the shotgun method of phage display library generation, in which 
bacterial genomic DNA is broken in random locations through the use of sonication before 
insertion into the phage genome, generates phage coding sequences with no regard for 
preservation of full proteins, correct reading frames, or the orientation of the gene insertion.  
Thus, a majority of the protein sequences presented by these phages are not informative, and a 
still smaller proportion of them will represent full proteins.  Although this will likely muddle 
target data that arises from this study, the skillful employment of competition assays and affinity 
chromatography-phage amplification cycling should enhance our chances of finding a target 
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using this methodology. If the main issue with successful target ID to this point has been the low 
relative abundance of the target protein, this method should work to alleviate this problem. 
A more quantitative approach to target identification was pioneered by the Schreiber 
group in a 2009 publication,
106
 borne out of a desire to more easily resolve weak binding 
interactions between small molecules and proteins, and to give a more informative view of a 
given small compound’s interaction with the entire proteome.  This proteomic approach to target 
identification relies on stable isotopic labeling of amino acids in cell culture (SILAC)
146
 to 
produce two nearly identical copies of the cellular proteome, differentiated by heavy carbon and 
nitrogen isotopes included in the growth medium of one of the populations.  By purposing these 
two proteomes into a test and control population, one can employ highly sensitive mass 
spectrometry techniques for quantification and identification of proteins.  Under optimal 
conditions, SILAC proteomic studies can detect differences in protein levels between the two 
populations as small as 1.3-fold.   
Figure 5.2. Example of a successful competition-based target ID assay using SILAC.  
 
Panel A: Summary of of cell culture and affinity chromatography conditions used to generate 
“heavy” proteins enriched via specific interaction with immobilized probe. Panel B: Tandem 
mass spectrometry fingerprinting signatures consistent with specific and nonspecific protein-
ligand interactions. Figure adapted from Ong, Carr, et al.¸ PNAS 2009, 106 (12), 4617-4622. 
 
SILAC methodology is easily adapted to target identification studies (Figure 5.2).  In the 
case of our study, both bacteria populations would be treated with an active photoprobe, and one 
of the populations would be simultaneously treated with a soluble competitor (e.g. 17, 21, 32).  
UV-induced crosslinking would proceed as normal, then the cells would be lysed and both 
populations combined. Click chemistry to azido-biotin would be performed, then protein 
purification and enrichment via streptavidin affinity column would leave a crude mixture of 
“light” and “heavy” proteins for mass spectrometry analysis.  Identifying the relative ratio of 
light and heavy proteins would rely on mass fingerprinting using tandem mass spectrometry.  For 
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light/heavy pairs with a ratio around 1, this would imply that affinity for the probe molecule was 
unaffected by soluble competitor, and is thus a nonspecific interaction.  A decrease in the protein 
population corresponding to the culture treated with soluble competitor, and thus a ratio 
significantly greater or less than 1, would imply a specific interaction and a potential target.  The 
vastly increased sensitivity, differentiation of specific and nonspecific binding events, and 
automatic identification of the sequence of each protein via MS/MS analysis inherent to SILAC 
target ID would represent powerful enhancements to the methodology we initially employed for 
target identification. 
The major caveat associated with SILAC is its reliance on near-quantitative replacement 
of targeted 
12
C/
14
N amino acids, normally lysine (K) and arginine (R), with their 
13
C/
15
N 
counterparts.  Given the sensitivity of the mass spectrometric assays involved, a situation where 
even 10% of R and K positions are wild-type in the heavy population would lead to extra peaks 
on the mass spectrum, muddling the interpretation of protein ratios.  In mammalian cell culture 
this is not an issue, as mammalian cells are completely unable to produce R and K de novo.  The 
mammalian reliance on outside sources of these amino acids, known as auxotrophy, was central 
to the development of SILAC as a proteomic technique.  Unfortunately, most bacteria possess 
the cellular machinery to produce all 20 natural amino acids, significantly complicating the use 
of SILAC in bacteria.  In cases where auxotrophy cannot be relied on, raising cell colonies in 
tagged media is the most viable strategy.  Unfortunately, this requires that a chemically defined 
medium for growth be established, rather than a medium based on biological extracts.  
Furthermore, even when defined media conditions are established, the 
13
C/
15
N-tagged versions of 
the reagents needed are often extremely expensive.   Several important lab strains, such as E. 
coli
147
 and S. aureus,
148
 have established chemically defined medium conditions; GAS does not.   
In light of these issues, we attempted to modify our GAS-SK assay conditions to be 
compatible with E. coli. The Sun group screened the active tag-free photoprobes for activity in 
an E. coli strain transfected with the ska-kan plasmid used during the high throughput screening 
effort.  Unfortunately, no kanamycin sensitization was observed with the diazirine or azide 
probes. This result suggests our probes either lack permeability across the Gram-negative cell 
membrane architecture, or that E. coli lacks virulence machinery sufficiently similar to GAS-SK 
to allow our probes to function as intended.   
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Given the challenges outlined above for SILAC-based target identification in GAS, the 
most promising way forward for the target ID portion of this study is to characterize probes built 
specifically for potency in S. aureus.  Although several active compounds have been identified 
with anti-biofilm activity in S. aureus, few have been as potent as the best compounds from the 
GAS-SK series.  In order to maximize the chances of a successful target ID, probe development 
for S. aureus will be postponed until the SAR effort identifies more potent (IC50 < 1 µM) 
compounds to use as templates for future probe molecules. 
Biofilm Inhibitor Studies 
Although initially showing promise, the optimization of this compound series in S. 
aureus and S. epidermidis strains has been difficult.  The initial screen identified several 
compounds that showed acceptable inhibitory percentages at 100 µM, but this activity was found 
not to extend to lower concentrations, especially in S. epidermidis.  The 47 compounds 
synthesized with the knowledge gained from screening the original 124 analogs developed 
against GAS-SK, while retaining modest potency in some cases, were not able to increase 
potency beyond that of 31 (IC50 = 1.4 µM).  Compounds 180, 187, 203, and 205, designed to 
incorporate features from active compounds 159-161, 43, 177, and 190, generally showed poor 
activity.   
Even though significant potency gains have yet to be realized against biofilm formation, 
compounds 210 and 222 possess a similar level of potency to 31, while also exhibiting 7- to 25-
fold increased stability in the presence of microsomal extract.  Since Hongmin Sun’s group was 
able to demonstrate in vivo efficacy with a metabolically stable and soluble, but weakly potent 
compound (21, Figure 4.2 and Table 4.10), 210 is a logical candidate for further murine trials.  
The observation of a significant protective effect in blocking biofilm formation (similar to 21) 
would merit a follow-up study assaying the ability of 210 to reduce existing biofilm cultures, at 
first in vitro, then on prosthetic implants in mice.  A compound able to destroy mature biofilms, 
rather than simply prevent initial attachment and nascent biofilm production, would have 
increased potential as an agent to be used in response to an established infection.  In contrast, 
compounds that simply block initial biofilm establishment might only be useful as protective 
agents during prosthesis installation. 
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Scheme 5.1. General structure of potential SAR expansion compounds for the biofilm 
study. 
 
Based on the dearth of analogs displaying potency in S. epidermidis, we have decided to 
de-prioritize the requirement for activity in both strains when assessing the desirability of new 
compounds. When viewed solely in the context of compound efficacy in S. aureus, one can see a 
marked preference for gem-dimethyl and spiropyrrolidine compounds vs. the spiropiperidine 
series.  Additionally, the increased activity of S-trifluoroethyl compounds 51 and 210 suggests 
the synthesis of more analogs with this substitution pattern.  A reasonable follow-up to these 
findings would be the synthesis of additional S-trifluoroethyl compounds with varied substitution 
at the N and O positions, and either gem-dimethyl or spiropyrrolidine substitution of the central 
ring (Scheme 5.1).  The substitution at the N- position of the pyrrolidine also warrants further 
investigation.  To this point, Boc substitution has been the most consistently efficacious 
substitution, suggesting that more carbamates should be investigated.  Carbamates are easily 
accessed through the reaction of the amine with chloroformates or dicarbonates. 
 
 
 
 
 
 
 
 
 
 
104 
 
Figure 5.3. Comparison of (S)- and (R)-enantiomers of model spiropyrrolidine analogs and 
the orientation of pyrrolidine N-substitution (green) as 2-D schematics and 3-D energy-
minimized
a
 structures. 
 
a
Energy-minimized 3-D structures generated using MMFF94 algorithm, ChemBio3D Ultra 
version 12.0. 
 
The synthesis of additional spiropyrrolidines warrants a re-examination of methods to 
synthesize enantiopure versions.  The orientation of the spiropyrrolidine ring would allow each 
enantiomer to project its N-substitutuent (green) in opposite directions relative to the plane of the 
molecule (Figure 5.3), increasing the likelihood of differential potency.  The failure of the 
original chiral spiropyrrolidine synthesis came during the installation of the thioxopyrimidinone 
ring.  Since the original attempt was abandoned, we made great strides in achieving the mild 
construction of this ring by first converting the β-aminoester intermediate into the corresponding 
β-isothiocyanate.  If this chemistry can be successfully applied to the previously synthesized 
aminoester, the following cyclization with a primary amine should be straightforward, leaving 
only an S-alkylation step to generate final compounds (Scheme 5.2). Each intermediate produced 
would be explored as a possible point for separating diastereomers and the pure enantiomers 
would be produced at the end through pyrrolidine deprotection with ethyl chloroformate. The 
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only drawback to this scheme is its current inability to produce O-alkylated amides, since the 
alkyl group at R
2 
is already attached to nitrogen.  One could potentially synthesize the 
unsubstituted amide using ammonia or a protected ammonia surrogate such as tosylamide, but no 
prior work in our group has explored this possibility to date. 
 
Scheme 5.2. Proposed synthesis of chiral spiropyrrolidine analogs of general structure (R)- 
and (S)-250.
a 
 
a
Reagents and conditions: a) thiophosgene, NaHCO3, DCM:H2O (1:1), RT, 6h; b) R
1
-NH2, Et2O, 
RT, 2h; c) NaOMe, MeOH, RT, 2h; d) R
2
-X, Cs2CO3, DMF, 50-70°C, 16h; e) separation of 
diastereomers*; f) ethyl chloroformate, then KOH, EtOH, H2O, RT; g) R
3
-CHO, (R
3
)2O, R
3
-Cl, 
etc. *separation may take place at any point after step c. 
 
In addition to continuing efforts to generate chiral spiropyrrolidine analogs, the expansion 
of the enantiomer-pair study described in Chapter 4 is also warranted.  The previous poor track 
record observed with bulky aryl substitution was continued with analogs 242 and 243, and 
should not be further pursued.  The inactivity of chiral piperidine amides 201 and 202 was more 
unexpected, given that several analogs with relatively bulky Boc groups were moderately active.  
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Furthermore, pentacycles 236 and 237 suggest a small amount of differentiation between 
enantiomers, even with variation in the configuration of only a methyl group; one would expect 
larger substitutions to make a bigger difference.  Based on the limited number of compounds 
tested from these two classes, we propose the synthesis of additional analogs of each (Scheme 
5.3).  Both of these compound classes are amenable to the rapid generation of enantiomer pairs 
thanks to the readily availability of natural and unnatural amino acids.  Chiral piperidine amides 
simply require a standard EDC-promoted coupling to any number of N-acetylated D- and L- 
amino acids, while further pentacycles of general structure 253 are derived from amino acids 
reduced to the corresponding amino alcohols. 
 
Scheme 5.3. Proposed synthesis of chiral analogs 251 and 252 using previously established 
methodology.
a
 
 
a
Reagents and conditions: a) N-acetyl D- or L-amino acid, EDC, HOBt, DIPEA, DCM, RT; b) 
D- or L-amino alcohol, Et2O, RT, 2h; c) NaOMe, MeOH, RT, 2h; d) TFA, DCM, 0°C-RT, 6h. 
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Chapter 6: Experimental Section 
General information: Chemical names follow CAS nomenclature. Starting materials were 
purchased from Fisher, Sigma–Aldrich Lancaster, Fluka or TCI-America and were used as 
supplied unless otherwise indicated. All reaction solvents were purchased from Fisher and used 
as received. Reactions were monitored by TLC using precoated silica gel 60 F254 plates. All 
anhydrous reactions were run under an atmosphere of dry nitrogen. Silica gel chromatography 
was performed with silica gel (220–240 mesh) obtained from Silicycle. Solvent abbreviations 
used: CDCl3, deutero-chloroform; DCM, dichloromethane; DMF, N,N-dimethylformamide; 
DMSO, dimethyl sulfoxide; EtOH, ethanol; EtOAc, ethyl acetate; hex, hexanes; MEK, methyl 
ethyl ketone; THF, tetrahydrofuran. Reagent abbreviations used: Cs2CO3, cesium carbonate; 
Na2SO4, sodium sulfate; MgSO4, magnesium sulfate; mCPBA, meta-chloro peroxybenzoic acid; 
KOH, potassium hydroxide; LDA, lithium diisopropylamide; NaHCO3, sodium bicarbonate; 
NaOMe, sodium methoxide; TMS, trimethylsilyl; HOBt 1-hydroxybenzotriazole; EDC, 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide; ZnI2, zinc iodide. 
NMR spectra were recorded on a Bruker 400 MHz, Bruker 500 MHz, Varian 400 MHz, 
or Varian 500 MHz spectrometer. Chemical shifts are reported in d (parts per million), by 
reference to the hydrogen residues of deuterated solvent as internal standard CDCl3: d = 7.28 
(1H NMR), or in reference to the hydrogen peaks of tetramethylsilane, d = 0.00 (1H NMR). 
Mass spectra were recorded on a Micromass LCT time-of-flight instrument utilizing electrospray 
ionization operating in positive-ion (ESI+) or negative-ion (ESI) modes where indicated. Melting 
points were measured on a MEL-TEMP melting point apparatus and are uncorrected. The purity 
of the compounds was assessed via analytical rpHPLC with one of three gradient methods. 
‘Method A’: 10% B to 90% B over 6 min, hold at 90% B for 7 additional minutes; ‘Method B’: 
50% B to 90% B, hold at 90% B for 7 additional minutes; ‘Method C’: 90% B over 12 min 
(solvent A = H2O, solvent B = acetonitrile, C18 column, 3.5 µm, 4.6 100 mm, 254 nm l). 
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 Compounds synthesized by other Vahlteich Medicinal Chemistry Core chemists that have 
appeared in our previous publications are cited where appropriate.  All compounds synthesized 
by Bryan Yestrepsky appear here in full detail. 
 
General Method A for generating methoxy-substituted o-tolunitriles: 
To anhydrous THF (6.4 mL) in a dry round-bottom flask was added nickel(II) bromide (279 mg, 
1.28 mmol), zinc powder (250 mg, 3.83 mmol), and triphenylphosphine (1.68 g, 6.39 mmol).  
The mixture was heated to 50°C and stirred for 30 minutes.  The selected o-chlorotoluene (25a 
or 25b, 12.78 mmol) was added, the temperature raised to 60°C, and the reaction was tightly 
capped and allowed to stir 30 minutes, then potassium cyanide (1.66g, 25.5 mmol) was added 
over the course of 5 hours in 2 equal portions.  The mixture was allowed to stir an additional 16 
hours.  Water was added to quench the reaction, and the suspension extracted 3x with ether.  The 
resulting organic layer was washed with H2O and brine, dried over MgSO4, filtered, and 
concentrated to a heterogeneous mixture of white crystals and clear oil.  The residue was diluted 
with 10 mL of toluene, then methyl iodide (997 mg, 7.02 mmol) was added and allowed to stir 
16 hours at room temperature.  The resulting white crystals were removed via vacuum filtration.  
The filtrate was concentrated in vacuo to a clear oil.  Flash chromatography with 2% EtOAc:hex 
delivered the pure product in 68-90% yield. 
 
General Method B for generating β-aminoesters from o-tolunitriles:  
A dry round bottom flask was charged with anhydrous diglyme (24 mL) and diisopropylamine 
(2.91 mL, 20.4 mmol), then cooled to -78°C in a dry ice/acetone bath.  To this solution was 
added n-butyllithium (2.5M in hexanes, 8.15 mL, 20.4 mmol).  The reaction was removed from 
the dry ice/acetone bath for 10 minutes, then re-cooled to -78°C. The desired o-tolunitrile (6.79 
mmol), dissolved in anhydrous diglyme (2 mL), was then added slowly dropwise then allowed to 
stir at -78°C for 45 minutes.   
A separate dry flask was charged with anhydrous diglyme (8.0 mL) and zinc powder (1.11 g, 
17.0 mmol).  Molecular iodine (3.45 g, 13.6 mmol) was added portionwise over the course of 10 
minutes.  The suspension was subsequently heated via heat gun in 30-second intervals until a 
silver precipitate of ZnI2 had formed and all iodine color had disappeared (caution: exothermic). 
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The selected acrylate ester (1-2.5 eq) was added to the first flask dropwise over 10 minutes.  The 
flask containing the ZnI2 suspension was then added to the reaction vessel and the resulting 
suspension allowed to stir for an additional 2 hours, slowly warming to room temperature. The 
reaction was quenched by the addition of saturated ammonium chloride solution and the 
resulting biphasic suspension was extracted with diethyl ether (3 x 30 mL), then washed with 
water (4 x 50 mL) and brine (1 x 50 mL). The organic extract was dried over MgSO4, vacuum 
filtered, and concentrated in vacuo. Further purification via flash chromatography (silica gel, 5% 
EtOAc:hex) delivered the desired products in 33-59% yields. 
 
General Method C for synthesizing 2-thioxopyrimidinones: 
Glacial acetic acid (147 μL, 2.56 mmol) and an alkyl isothiocyanate (2.56 mmol) were combined 
with the selected aminoester intermediate (1.28 mmol) in absolute ethanol (1.7 mL).  The 
solution was allowed to stir at reflux under nitrogen atmosphere for 1 hour. Additional allyl 
isothiocyanate (373 μL, 3.84 mmol) was added in equal portions over the course of 3 hours.  The 
reaction was allowed to stir at reflux 16 additional hours, then diluted with ethyl acetate. The 
organic mixture was washed with water and brine, dried over MgSO4, filtered, and concentrated 
in vacuo.   Trituration or flash chromatography delivered 2-thioxopyrimidinones in 21-59% 
yield. 
 
General Method D for S-alkylating N-substituted 2-thioxopyrimidinones: 
The selected 2-thioxopyrimidinone intermediate (0.101 mmol) was dissolved in MEK (0.591 
mL), to which Cs2CO3 (66 mg, 0.201 mmol) and alkylating agent (0.151 mmol) were added.  
The reaction was heated to 70°C and allowed to stir 16 hours.  The reaction mixture was diluted 
with H2O and extracted 2x with EtOAc.  The combined organic layers were washed with water 
and brine, then isolated, dried over MgSO4, vacuum filtered, and concentrated in vacuo.  Further 
purification via flash chromatography in an appropriate solvent system delivered the desired S-
alkylated compounds in 24-88% yield. 
 
General Method E for preparation of phenols from aryl methyl ethers. Boron tribromide 
solution (1M in dichloromethane, 4.42 mL) was added gradually to a stirred solution of the 
selected aryl ether intermediate (2.1 mmol) in dichloromethane (14 mL) at room temperature 
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under N2. The mixture was heated to reflux for 6 hours, then cooled to room temperature. Water 
(10 mL) was then added dropwise and the mixture was partitioned between DCM and water. The 
layers were separated and the organic layer washed with water, saturated aqueous NaHCO3, and 
saturated brine, then dried over MgSO4. The solvent was removed under reduced pressure and 
the residue was triturated in ethyl acetate, filtered, and dried under high vacuum.  The resulting 
crystalline phenols 16a-c (43-62% isolated yield) were used without further purification. 
General Method F to generate aryl ether compounds from phenols: 
The selected phenol intermediate 34-36 (0.622 mmol) was dissolved in DMF (3.66 mL), to 
which Cs2CO3 (304 mg, 0.933 mmol) and an alkylating agent (0.716 mmol) were added.  The 
resulting suspension was stirred at 70°C for 16 hours until the completion of the reaction.  
Compounds were purified as indicated in 35-92% yield. 
 
 
3-Allyl-2-thioxo-2,3-dihydro-1H-spiro[benzo[h]quinazoline-5,1′-cyclohexan]-4(6H)-one (6) 
Synthesized by J. Ryu in 4 steps from cyclohexanone as previously reported._ENREF_145  TLC Rf 
= 0.25 (10% EtOAc:hex). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 9.28 (s, 1H), 7.50 – 7.35 (m, 
3H), 7.32 (d, J = 7.4 Hz, 1H), 6.00 (ddt, J = 16.2, 11.3, 5.8 Hz, 1H), 5.37 (dd, 1H), 5.27 (dd, 1H), 
5.06 (d, J = 5.8 Hz, 2H), 3.03 (s, 2H), 2.48 (td, J = 13.3, 4.4 Hz, 2H), 1.72 (d, J = 13.3 Hz, 1H), 
1.62 – 1.44 (m, 4H), 1.33 (d, J = 14.3 Hz, 3H). 
 
 
3-Allyl-2-(methylthio)-3H-spiro[benzo[h]quinazoline-5,1'-cyclohexan]-4(6H)-one (11) 
(CCG-102620). Compound 6 (150 mg, 0.443 mmol) was dissolved in absolute EtOH at 0°C 
(2.61 mL) to which KOH (37 mg, 0.665 mmol) and methyl iodide (33 μL, 0.532 mmol) were 
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added.  The solution was allowed to stir for 10 minutes, resulting in the precipitation of white 
crystals.   The suspension was diluted with H2O and vacuum filtered to collect the precipitate.  
The precipitate was washed with water and dried in vacuo.  Recovered 150 mg (95% yield).  
1
H 
NMR (500 MHz, CDCl3) δ (ppm) 8.14 (d, J = 7.4 Hz, 1H), 7.35 (t, J = 7.3 Hz, 1H), 7.31 (t, J = 
6.8 Hz, 1H), 7.21 (d, J = 7.1 Hz, 1H), 5.94 (ddt, J = 15.9, 10.8, 5.6 Hz, 1H), 5.32 – 5.24 (m, 2H), 
4.68 (d, J = 5.6 Hz, 2H), 3.04 (s, 2H), 2.68 (s, 3H), 2.64 – 2.54 (m, 2H), 1.71 (d, J = 12.8 Hz, 
1H), 1.60 – 1.51 (m, 4H), 1.42 – 1.33 (m, 3H). ESI+MS m/z = 353.2 (M + H+), 375.2 (M + Na+).  
HPLC (Method C, tR = 4.19 min), purity >95%. 
 
 
3-Allyl-2-(methylsulfonyl)-3H-spiro[benzo[h]quinazoline-5,1'-cyclohexan]-4(6H)-one 
(intermediate in synthesis of 13).  Compound 11 (451 mg, 1.28 mmol) was dissolved in DCM 
(19.3 mL), then mCPBA (70 wt%, 787 mg, 3.19 mmol) was added and  the reaction mixture 
allowed to stir over the course of 16 hours at room temperature.  At this time the reaction 
mixture was diluted with DCM, washed with saturated aqueous NaHCO3 solution, water, and 
brine.  The organic layer was dried over MgSO4, vacuum filtered, and concentrated in vacuo.  
Purification via flash chromatography isolated the sulfone intermediate (385 mg, 78% yield). 
1
H 
NMR (500 MHz, Chloroform-d) δ 7.93 – 7.87 (m, 1H), 7.45 – 7.31 (m, 2H), 7.29 – 7.23 (m, 
1H), 6.11 – 5.99 (m, 1H), 5.45 – 5.30 (m, 2H), 5.04 – 4.99 (m, 2H), 3.57 (s, 3H), 3.09 (s, 2H), 
2.62 – 2.53 (m, 2H), 1.75 (d, J = 10.8 Hz, 1H), 1.67 – 1.51 (m, 5H), 1.41 (d, J = 12.6 Hz, 2H). 
 
 
3-Allyl-2-(ethylamino)-3H-spiro[benzo[h]quinazoline-5,1'-cyclohexan]-4(6H)-one (13) 
(CCG-203043).  The sulfone intermediate (385 mg, 1.00 mmol) was dissolved in a 1:1 mixture 
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of THF:DMF (2 mL).  Potassium carbonate (165 mg, 1.19 mmol) and 2M ethylamine solution in 
THF (1.00 mL, 2.00 mmol) were added, then the reaction vessel was tightly capped and allowed 
to stir 5 hours at RT.  The reaction mixture was diluted with diethyl ether, then washed with 3 
portions of H2O followed by brine.  The organic layer was isolated, dried over MgSO4, vacuum 
filtered, and concentrated in vacuo.  The residue was further purified by flash chromatography 
(10-33% EtOAc:hex) and isolated as a white crystalline solid (237 mg, 53% yield over 2 steps). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 8.13 (d, J = 7.4 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.18 (d, J = 
6.6 Hz, 1H), 5.92 (ddt, J = 17.3, 10.5, 5.3 Hz, 1H), 5.36 – 5.26 (m, 2H), 4.66 (d, J = 5.2 Hz, 2H), 
4.56 (d, J = 5.0 Hz, 1H), 3.57 (qd, J = 7.2, 5.0 Hz, 2H), 3.01 (s, 2H), 2.64 – 2.54 (m, 2H), 1.70 
(d, J = 12.6 Hz, 1H), 1.62 – 1.48 (m, 5H), 1.38 (d, J = 12.8 Hz, 3H), 1.28 (t, J = 7.2 Hz, 3H). 
ESI+MS m/z = 350.2 (M + H
+
), 372.2 (M + Na
+
).  HPLC (Method B, tR = 7.18 min), purity = 
94%. 
 
 
Ethyl 1-amino-3,3-dimethyl-3,4-dihydronaphthalene-2-carboxylate (15). Prepared according 
to General Method B from o-tolunitrile (14) and ethyl 3,3-dimethyl acrylate.  Isolated as a pale 
yellow oil (860 mg, 41% yield). TLC Rf = 0.30 (10% EtOAc:hex). 
1
H NMR (500 MHz, CDCl3) 
δ (ppm) 7.42 (d, J = 8.6 Hz, 1H), 7.36 – 7.29 (m, 2H), 7.20 (d, J = 7.3 Hz, 1H), 6.35 (s, 1H), 4.28 
(q, J = 7.1 Hz, 2H), 2.68 (s, 2H), 1.37 (t, J = 7.1 Hz, 3H), 1.22 (s, 6H). 
 
 
3-Allyl-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one (16). 
Prepared according to General Method C from 15 and allyl isothiocyanate.  Purified via 
trituration of the crude organic isolate with hexanes and diethyl ether; recovered in 24% yield 
(356 mg) as a white solid. Rf = 0.34 (10% EtOAc:hex). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 
9.28 (s, 1H), 7.50 – 7.37 (m, 3H), 7.29 (d, J = 7.4 Hz, 1H), 6.00 (ddt, J = 17.1, 10.3, 5.8 Hz, 1H), 
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5.37 (d, J = 17.1 Hz, 1H), 5.27 (d, J = 10.3 Hz, 1H), 5.07 (d, J = 5.8 Hz, 2H), 2.79 (s, 2H), 1.34 
(s, 6H). 
 
 
2-((3-Allyl-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl)thio)acetonitrile 
(21) (CCG-205390). Prepared according to General Method D from intermediate 16, using α-
chloroacetonitrile as the alkylating agent.  Isolated via flash chromatography (5% EtOAc:hex) as 
a white crystalline solid (92 mg, 81% yield). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 8.16 (d, J = 
7.0 Hz, 1H), 7.41 – 7.32 (m, 2H), 7.19 (d, J = 6.3 Hz, 1H), 5.91 (ddt, J = 16.1, 10.6, 5.6 Hz, 1H), 
5.34 – 5.26 (m, 2H), 4.65 (d, J = 5.6 Hz, 2H), 4.06 (s, 2H), 2.80 (s, 2H), 1.39 (s, 6H). ESI+MS 
m/z = 338.1 (M + H
+
), 360.1 (M + Na
+
).  HPLC (Method B, tR = 5.57 min), purity >95%. 
 
 
3-Allyl-5,5-dimethyl-2-(methylthio)-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (22). 
Intermediate 16 (116 mg, 0.39 mmol) was dissolved in EtOH (2.3 mL), to which KOH (38 mg, 
0.58 mmol) and methyl iodide (27 μL, 0.43 mmol) were added.  The solution was stirred for 30 
minutes, precipitating a crystalline white solid.  The solution was diluted with ethyl acetate and 
water.  The aqueous layer was extracted with additional EtOAc, then the combined organic 
layers were washed with water and brine.  The organic layer was isolated, dried over MgSO4, 
vacuum filtered, and concentrated in vacuo. The recovered crystalline material (116 mg, 96% 
yield) was found to be pure by NMR and used without further purification. 
1
H NMR (400 MHz, 
CDCl3) δ 8.15 (d, J = 7.3, 1H), 7.38-7.28 (m, 2H), 7.18 (d, J = 6.9, 1H), 6.01-5.75 (m, 1H), 5.33 
– 5.23 (m, 2H), 4.69 (d, J = 5.5, 2H), 2.79 (s, 2H), 2.69 (s, 3H), 1.39 (s, 6H). HPLC (Method B, 
tR = 7.57 min), purity >95%.  
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3-Allyl-2-ethoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (23) (CCG-
203803). Metallic sodium was added to absolute ethanol and allowed to stir at room temperature 
for 30 minutes.  Intermediate 22 was added, then the reaction was heated to 40°C and allowed to 
stir for 48 hours.  The reaction was then diluted with water and extracted with ethyl acetate.  The 
organic layer was dried over MgSO4, filtered, and concentrated.  Further purification via flash 
chromatography (15% EtOAc:hex) isolated 23 as a light yellow solid (22 mg, 69% yield). 
1
H 
NMR (500 MHz, CDCl3) δ (ppm) 8.09 (d, J = 7.3 Hz, 1H), 7.37 – 7.27 (m, 2H), 7.18 (d, J = 7.5 
Hz, 1H), 5.92 (ddt, J = 16.0, 10.3, 5.8 Hz, 1H), 5.25 – 5.16 (m, 2H), 4.62 (d, J = 5.8 Hz, 2H), 
4.57 (q, J = 7.1 Hz, 2H), 2.78 (s, 2H), 1.45 (t, J = 7.1 Hz, 3H), 1.37 (s, 6H). ESI+MS m/z = 311.1 
(M + H
+
), 333.1 (M + Na
+
).  HPLC (Method B, tR = 7.94 min), purity >95%. 
 
 
3-Allyl-5,5-dimethyl-2-(methylsulfonyl)-5,6-dihydrobenzo[h]quinazolin-4(3H)-one 
(intermediate in the synthesis of 24). The methyl sulfide intermediate 22 (116 mg, 0.371 
mmol) and mCPBA (70 wt%, 229 mg, 0.928 mmol) were combined in DCM (5.6 mL) at 0°C.  
The reaction mixture was maintained at 0°C for 1 hour, then allowed to warm to RT over 16 
hours.  The reaction mixture was diluted with DCM and washed with saturated aqueous sodium 
bicarbonate solution, water, and brine, then isolated, dried over MgSO4, filtered, and 
concentrated in vacuo.  Purification of the crude material by FC (10g column, 5% -> 10% 
EtOAc:hex) afforded the desired product, confirmed by NMR, as a yellowish solid (70 mg, 55% 
yield). 
1
H NMR (500 MHz, Chloroform-d) δ 7.92 (d, J = 7.6 Hz, 1H), 7.42 (t, J = 7.3 Hz, 1H), 
7.35 (t, J = 7.3 Hz, 1H), 7.24 (d, J = 7.3 Hz, 1H), 6.10 – 6.00 (m, 1H), 5.42 (d, J = 17.2 Hz, 1H), 
5.33 (d, J = 8.3 Hz, 1H), 5.03 (d, J = 5.8 Hz, 2H), 3.58 (s, 3H), 2.85 (s, 2H), 1.42 (s, 6H). 
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3-Allyl-2-(ethylamino)-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (24) (CCG-
203804). Prepared in a manner similar to 13 from the sulfone intermediate above (70 mg, 0.203 
mmol). Isolated the desired compound as a white solid (48 mg, 77% yield; 41% overall yield 
from 22). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 8.15 (d, J = 7.3 Hz, 1H), 7.36 – 7.26 (m, 2H), 
7.16 (d, J = 7.4 Hz, 1H), 5.92 (ddt, J = 17.3, 10.5, 5.3 Hz, 1H), 5.36 – 5.26 (m, 2H), 4.68 (d, J = 
5.2 Hz, 2H), 4.58 (t, J = 4.9 Hz, 1H), 3.57 (qd, J = 7.2, 5.2 Hz, 2H), 2.77 (s, 2H), 1.37 (s, 6H), 
1.28 (t, 3H). ESI+MS m/z = 310.1 (M + H
+
), 332.1 (M + Na
+
).  HPLC (Method B, tR = 5.47 
min), purity >95%. 
 
 
5-Methoxy-2-methylbenzonitrile (26a). Synthesized from 25a according to General Method A. 
Isolated in 90% yield. 
1
H NMR (400 MHz, CDCl3) δ (ppm) 7.21 (d, J = 8.5 Hz, 1H), 7.08 (d, J = 
2.8 Hz, 1H), 7.03 (dd, J = 8.5, 2.8 Hz, 1H), 3.81 (s, 3H), 2.47 (s, 3H). 
 
 
3-Methoxy-2-methylbenzonitrile (26b). Synthesized from 25b according to General Method A.  
Isolated as a clear oil, 68% yield. 
1
H NMR (500 MHz, CDCl3) δ (ppm) 7.24 (t, J = 7.9 Hz, 1H), 
7.19 (d, J = 7.7 Hz, 1H), 7.03 (d, J = 8.1 Hz, 1H), 3.86 (s, 3H), 2.42 (s, 3H). 
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Ethyl 1-amino-7-methoxy-3,3-dimethyl-3,4-dihydronaphthalene-2-carboxylate (27a). 
Prepared according to General Method B from 26a and ethyl 3,3-dimethyl acrylate.  Isolated as a 
pale yellow oil (623 mg, 33% yield). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 7.11 (d, J = 8.1 Hz, 
1H), 6.96 (s, 1H), 6.88 (d, J = 8.1 Hz, 1H), 6.27 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 3.85 (s, 3H), 
2.60 (s, 2H), 1.37 (t, J = 7.1 Hz, 3H), 1.20 (s, 6H). 
 
 
Ethyl 1-amino-5-methoxy-3,3-dimethyl-3,4-dihydronaphthalene-2-carboxylate (27b). 
Prepared according to General Method B from 26b and ethyl 3,3-dimethyl acrylate. Isolated as a 
yellow oily solid (636 mg, 35% yield). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 7.24 (t, J = 8.1 Hz, 
2H), 7.04 (d, J = 8.1 Hz, 1H), 6.92 (d, J = 8.1 Hz, 1H), 6.31 (s, 2H), 4.25 (q, J = 7.1 Hz, 2H), 
3.85 (s, 3H), 2.66 (s, 2H), 1.34 (t, J = 7.1 Hz, 3H), 1.20 (s, 6H). 
 
 
Ethyl 1-amino-6-methoxy-3,3-dimethyl-3,4-dihydronaphthalene-2-carboxylate (27c).  
Prepared according to General Method B from 26c and ethyl 3,3-dimethyl acrylate. Isolated as 
pale yellow crystals (1.108 g, 59% yield). TLC Rf = 0.14 (10% EtOAc:hex). 
1
H NMR (500 
MHz, CDCl3) δ (ppm) 7.35 (d, J = 8.5 Hz, 1H), 6.81 (dd, J = 8.5, 2.4 Hz, 1H), 6.73 (d, J = 2.4 
Hz, 1H), 6.37 (s, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.86 (s, 3H), 2.64 (s, 2H), 1.36 (t, J = 7.1 Hz, 
3H), 1.22 (s, 6H). 
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3-Allyl-9-methoxy-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one 
(28a). Prepared according to General Method C from 27a and allyl isothiocyanate.  Purified via 
trituration with hexanes and diethyl ether (125 mg, 21% yield).  
1
H NMR (400 MHz, CDCl3) δ 
(ppm) 9.29 (s, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 8.0 Hz, 1H), 7.00 (s, 1H), 6.08 (ddt, J = 
15.8, 10.9, 5.5 Hz, 1H), 5.45 – 5.30 (m, 2H), 5.18 (d, J = 5.5 Hz, 2H), 3.85 (s, 3H), 2.73 (s, 2H), 
1.34 (s, 6H). 
 
 
3-Allyl-7-methoxy-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one 
(28b). Prepared according to General Method C from 27b and allyl isothiocyanate.  Purified via 
trituration of the crude organic isolate with hexanes and diethyl ether (133 mg, 24% yield). 
1
H 
NMR (500 MHz, CDCl3) δ (ppm) 9.29 (s, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.08 – 7.01 (m, 2H), 
6.00 (ddt, J = 16.8, 10.8, 5.8 Hz, 1H), 5.37 (d, J = 16.8 Hz, 1H), 5.27 (d, J = 10.8 Hz, 1H), 5.06 
(d, J = 5.8 Hz, 2H), 3.89 (s, 3H), 2.79 (s, 2H), 1.34 (s, 6H). 
 
 
3-Allyl-8-methoxy-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one 
(28c). Prepared according to General Method C from 27c and allyl isothiocyanate.  Purified via 
trituration of the crude organic isolate with hexanes and diethyl ether; isolated as tan crystals 
(252 mg, 59% yield). TLC Rf = 0.11 (10% EtOAc:hex).  
1
H NMR (400 MHz, CDCl3) δ (ppm) 
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9.27 (s, 1H), 7.38 (d, J = 8.6 Hz, 1H), 6.88 (dd, J = 8.6, 2.5 Hz, 1H), 6.80 (d, J = 2.5 Hz, 1H), 
5.99 (ddt, J = 16.6, 10.4, 5.7 Hz, 1H), 5.36 (dd, J = 16.6, 1.3 Hz, 2H), 5.26 (dd, J = 10.4, 1.3 Hz, 
1H), 5.06 (d, J = 5.7 Hz, 2H), 3.87 (s, 3H), 2.74 (s, 2H), 1.33 (s, 6H). ESI-MS m/z = 327 (M-H
+
). 
 
 
3-Allyl-8-methoxy-2-((2-methoxyethyl)thio)-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-
4(3H)-one (29) (CCG-203576). Prepared according to General Method D from intermediate 
28c, using 2-methoxyethyl p-toluenesulfonate as the alkylating agent.  Isolated as a crystalline 
white solid after flash chromatography (67 mg, 76% yield). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 
8.01 (d, J = 8.6 Hz, 1H), 6.83 (d, J = 8.6 Hz, 1H), 6.71 (s, 1H), 5.92 (ddt, J = 16.1, 10.6, 5.5 Hz, 
1H), 5.31 – 5.23 (m, 2H), 4.69 (d, J = 5.5 Hz, 2H), 3.86 (s, 3H), 3.75 (t, J = 6.3 Hz, 2H), 3.52 (t, 
J = 6.3 Hz, 2H), 3.42 (s, 3H), 2.75 (s, 2H), 1.38 (s, 6H). ESI+MS m/z = 387.2 (M + H
+
), 409.2 
(M + Na
+
).  HPLC (Method B, tR = 7.05 min), purity >95%. 
 
 
3-Allyl-2-(ethylthio)-8-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one 
(31) (CCG-203592). Prepared according to General Method D from intermediate 28c, using 
iodoethane as the alkylating agent.  Isolated as white crystals via flash chromatography (105 mg, 
88% yield). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 8.05 (d, J = 8.6 Hz, 1H), 6.84 (dd, J = 8.6, 2.4 
Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 5.93 (ddt, J = 15.8, 10.8, 5.5 Hz, 1H), 5.30 – 5.22 (m, 2H), 
4.67 (d, J = 5.4 Hz, 2H), 3.86 (s, 3H), 3.30 (q, J = 7.3 Hz, 2H), 2.75 (s, 2H), 1.47 (t, J = 7.3 Hz, 
3H), 1.38 (s, 6H). ESI+MS m/z = 357.2 (M + H
+
), 379.2 (M + Na
+
).  HPLC (Method B, tR = 8.26 
min), purity >95%. 
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3-Allyl-2-(ethylthio)-9-methoxy-5,5-dimethyl-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-
one (32) (CCG-203625). Prepared according to General Method D from intermediate 28a, using 
iodoethane as the alkylating agent.  Isolated via flash chromatography as a white solid (74 mg, 
71% yield). 
1
H NMR (400 MHz, CDCl3) δ (ppm) 7.70 (s, 1H), 7.10 (d, J = 8.2 Hz, 1H), 6.91 (d, 
J = 8.2 Hz, 1H), 5.93 (ddt, J = 15.8, 10.9, 5.5 Hz, 1H), 5.33 – 5.21 (m, 2H), 4.68 (d, J = 5.5 Hz, 
2H), 3.85 (s, 3H), 3.31 (q, J = 7.3 Hz, 2H), 2.72 (s, 2H), 1.49 (t, J = 7.3 Hz, 3H), 1.37 (s, 6H). 
ESI+MS m/z = 357.2 (M + H
+
), 379.2 (M + Na
+
).  HPLC (Method B, tR = 8.53 min) purity 
>95%. 
 
 
3-Allyl-2-(ethylthio)-7-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one 
(33) (CCG-203629). Prepared according to General Method D from intermediate 28b, using 
iodoethane as the alkylating agent.  Isolated via flash chromatography (75 mg, 69% yield).  
1
H 
NMR (500 MHz, CDCl3) δ (ppm) 7.80 (d, J = 7.8 Hz, 1H), 7.30 (t, J = 8.0 Hz, 1H), 6.97 (d, J = 
8.1 Hz, 1H), 5.95 (ddt, J = 16.0, 10.6, 5.6 Hz, 1H), 5.34 – 5.25 (m, 2H), 4.70 (d, J = 5.5 Hz, 2H), 
3.90 (s, 3H), 3.33 (q, J = 7.3 Hz, 2H), 2.82 (s, 2H), 1.49 (t, J = 7.3 Hz, 3H), 1.41 (s, 6H). 
ESI+MS m/z = 357.2 (M + H
+
), 379.1 (M + Na
+
).  HPLC (Method B, tR = 8.52 min), purity 
>95%. 
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3-Allyl-2-(ethylthio)-8-hydroxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (34) 
(CCG-203594). Prepared according to General Method E from compound 31. Isolated as tan 
crystals (310 mg, 43% yield). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 7.62 (d, J = 8.2 Hz, 1H), 
6.85 – 6.79 (m, 2H), 5.88 (ddt, J = 16.3, 10.8, 5.9 Hz, 1H), 5.48 – 5.40 (m, 2H), 4.86 (d, J = 5.9 
Hz, 2H), 4.22 (q, J = 7.3 Hz, 2H), 2.74 (s, 2H), 1.59 (t, J = 7.3 Hz, 3H), 1.31 (s, 6H). 
 
 
3-Allyl-2-(ethylthio)-7-hydroxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (35) 
(CCG-203631). Prepared according to General Method E from compound 33. Isolated as a tan 
solid (43 mg, 45% yield).  
1
H NMR (500 MHz, CDCl3) δ (ppm) 7.76 (d, J = 7.8 Hz, 1H), 7.18 (t, 
J = 7.8 Hz, 1H), 6.89 (d, J = 7.8 Hz, 1H), 5.99 – 5.87 (m, 1H), 5.31 – 5.24 (m, 2H), 5.18 (s, 1H), 
4.68 (d, J = 5.5 Hz, 2H), 3.31 (q, J = 7.4 Hz, 2H), 2.78 (s, 2H), 1.47 (t, J = 7.4 Hz, 3H), 1.41 (s, 
6H). 
 
 
3-Allyl-2-(ethylthio)-9-hydroxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one 
(36). Prepared according to General Method E from compound 32.  Isolated as a tan solid (60 
mg, 62% yield). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 7.91 (s, 1H), 7.05 (d, J = 8.2 Hz, 1H), 6.98 
(d, J = 8.2 Hz, 1H), 5.90 (ddt, J = 16.3, 10.7, 5.6 Hz, 1H), 5.44 – 5.36 (m, 2H), 4.83 (d, J = 5.6 
Hz, 2H), 3.95 (q, J = 6.8 Hz, 2H), 2.75 (s, 2H), 1.52 (t, J = 6.8 Hz, 3H), 1.36 (s, 6H). 
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3-Allyl-2-(ethylthio)-8-(2-methoxyethoxy)-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-
4(3H)-one (37) (CCG-203596). Prepared using General Method F from phenol intermediate 34 
and 2-methoxyethyl p-toluenesulfonic ester, heated to 70°C for 16 hours.  Reaction mixture was 
partitioned between ethyl acetate and water, then the organic layer washed with water and brine.  
The organic layer was isolated, dried over MgSO4, vacuum filtered, and concentrated in vacuo. 
Further purification via flash chromatography (0-10% EtOAc:hex) delivered the desired product 
(39 mg, 71% yield). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 8.04 (d, J = 8.6 Hz, 1H), 6.86 (dd, J = 
8.6, 2.4 Hz, 1H), 6.74 (d, J = 2.2 Hz, 1H), 5.92 (ddt, J = 15.9, 10.6, 5.4 Hz, 1H), 5.30 – 5.22 (m, 
2H), 4.67 (d, J = 5.5 Hz, 2H), 4.18 (t, J = 5.0 Hz, 2H), 3.78 (t, J = 5.0 Hz, 2H), 3.47 (s, 3H), 3.30 
(q, J = 7.4 Hz, 2H), 2.74 (s, 2H), 1.47 (t, J = 7.3 Hz, 3H), 1.37 (s, 6H). ESI+MS m/z = 401.1 (M 
+ H
+
), 423.1 (M + Na
+
).  HPLC (Method B, tR = 7.56 min), purity >95%. 
 
 
3-Allyl-2-(ethylthio)-9-(2-methoxyethoxy)-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-
4(3H)-one (38) (CCG-203627). Prepared using General Method F from 36 and 2-methoxyethyl 
p-toluenesulfonic ester, heated to 70°C for 16 hours.  Reaction mixture was partitioned between 
ethyl acetate and water, then the organic layer washed with water and brine.  The organic layer 
was isolated, dried over MgSO4, vacuum filtered, and concentrated in vacuo. Further purification 
via flash chromatography (0-10% EtOAc:hex) delivered the desired product (38 mg, 65% yield).  
1
H NMR (500 MHz, CDCl3) δ (ppm) 7.71 (s, 1H), 7.09 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 8.2 Hz, 
1H), 5.93 (ddt, J = 16.0, 10.7, 5.6 Hz, 1H), 5.31 – 5.23 (m, 2H), 4.68 (d, J = 5.5 Hz, 2H), 3.81 – 
3.75 (m, 2H), 3.61 – 3.55 (m, 2H), 3.47 (s, 3H), 3.31 (q, J = 7.3 Hz, 2H), 2.72 (s, 2H), 1.48 (t, J 
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= 7.3 Hz, 3H), 1.37 (s, 6H). ESI+MS m/z = 401.2 (M + H
+
), 423.2 (M + Na
+
).  HPLC (Method 
B, tR = 7.83 min), purity >95%. 
 
 
3-Allyl-2-(ethylthio)-7-(2-methoxyethoxy)-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-
4(3H)-one (39) (CCG-203633). Prepared using General Method F from phenol intermediate 35 
and 2-methoxyethyl p-toluenesulfonic ester, heated to 70°C for 16 hours.  Reaction mixture was 
partitioned between ethyl acetate and water, then the organic layer washed with water and brine.  
The organic layer was isolated, dried over MgSO4, vacuum filtered, and concentrated in vacuo. 
Further purification via flash chromatography (0-10% EtOAc:hex) delivered the desired product 
(36 mg, 68% yield). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 7.78 (d, J = 7.8 Hz, 1H), 7.25 (t, J = 
8.0 Hz, 1H), 6.96 (d, J = 8.1 Hz, 1H), 5.99 – 5.87 (m, 1H), 5.31 – 5.23 (m, 2H), 4.68 (d, J = 5.5 
Hz, 2H), 4.17 (dd, J = 5.5, 4.2 Hz, 2H), 3.80 (dd, J = 5.5, 4.2 Hz, 2H), 3.48 (s, 3H), 3.30 (q, J = 
7.4 Hz, 2H), 2.83 (s, 2H), 1.47 (t, J = 7.4 Hz, 3H), 1.39 (s, 6H). ESI+MS m/z = 401.2 (M + H
+
), 
423.2 (M + Na
+
).  HPLC (Method B, tR = 7.91 min), purity >95%. 
 
 
3-Ethyl-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one (40a). 
Prepared according to General Method C from 15 and ethyl isothiocyanate.  Purified via flash 
chromatography (0 to 10% EtOAc:hex); recovered in 31% yield. TLC Rf = 0.20 (10% 
EtOAc:hex). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 9.24 (s, 1H), 7.49 – 7.35 (m, 3H), 7.29 (d, J = 
7.4 Hz, 1H), 4.49 (q, J = 7.0 Hz, 2H), 2.79 (s, 2H), 1.35 (t, J = 7.0 Hz, 3H), 1.34 (s, 6H). 
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3-(2-Methoxyethyl)-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one 
(40b). Prepared according to General Method C from 15 and 2-methoxyethyl isothiocyanate.  
Evaporation of the solvent, followed by trituration with ethyl acetate returned the desired product 
as a white crystalline solid (40 mg, 27% yield). 
1
H NMR (300 MHz, CDCl3) δ (ppm) 9.40 (s, 
1H), 7.50-7-31 (m, 4H), 4.70 (t, J = 6.2 Hz, 2H), 3.80 (t, J = 6.2 Hz, 2H), 3.43 (s, 3H), 2.80 (s, 
2H), 1.35 (s, 6H). 
 
 
9-Methoxy-3,5,5-trimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one (40c). 
Prepared according to General Method C from 27a and methyl isothiocyanate.  Purified via flash 
chromatography (0-10% EtOAc:hex) and recovered in 27% yield.   
1
H NMR (400 MHz, CDCl3) 
δ (ppm) 9.35 (s, 1H), 7.20 (d, J = 8.3 Hz, 1H), 6.99 (dd, J = 8.3, 2.3 Hz, 1H), 6.94 (d, J = 2.3 Hz, 
1H), 3.87 (s, 3H), 3.74 (s, 3H), 2.71 (s, 2H), 1.33 (s, 6H). 
 
 
3-Ethyl-2-((2-methoxyethyl)thio)-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one 
(41) (CCG-203598). Prepared according to General Method D from intermediate 40a, using 2-
methoxyethyl p-toluenesulfonate as the alkylating agent.  Isolated as a clear oil after flash 
chromatography (66 mg, 71% yield). 
1
H NMR (500 MHz, CDCl3) δ (ppm) 8.09 (dd, J = 7.5, 1.3 
Hz, 1H), 7.37 (td, J = 7.3, 1.6 Hz, 1H), 7.33 (td, J = 7.5, 1.4 Hz, 1H), 7.21 (d, J = 6.9 Hz, 1H), 
4.14 (q, J = 7.1 Hz, 2H), 3.80 (t, J = 6.2 Hz, 2H), 3.57 (t, J = 6.2 Hz, 2H), 3.46 (s, 3H), 2.81 (s, 
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2H), 1.43 – 1.36 (m, 9H). ESI+MS m/z = 345.2 (M + H+), 367.2 (M + Na+).  HPLC (Method B, 
tR = 7.53 min), purity >95%. 
 
 
2-(Ethylthio)-3-(2-methoxyethyl)-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one 
(42) (CCG-203802). Prepared according to General Method D from intermediate 40b, using 
iodoethane as the alkylating agent.  Isolated as a clear oil after flash chromatography. 
1
H NMR 
(500 MHz, cdcl3) δ 8.11 (dd, J = 7.5, 1.5, 1H), 7.38 – 7.33 (td, J = 7.5, 1.5, 1H), 7.31 (td, J = 7.5, 
1.5, 1H), 7.18 (d, J = 6.9, 1H), 4.26 (t, J = 6.4, 2H), 3.71 (t, J = 6.4, 2H), 3.40 (s, 3H), 3.32 (q, J 
= 7.4, 2H), 2.79 (s, 2H), 1.48 (t, J = 7.4, 3H), 1.38 (s, 6H). ESI+MS m/z = 345.2 (M + H
+
), 367.2 
(M + Na
+
).  HPLC (Method B, tR = 7.95 min), purity >95%. 
 
 
2-(Ethylthio)-9-methoxy-3,5,5-trimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (43) 
(CCG-206353). Prepared according to General Method D from intermediate 40c, using 
iodoethane as the alkylating agent.  Isolated as a colorless oil (20 mg, 55% yield) after flash 
chromatography.  
1
H NMR (400 MHz, CDCl3)  δ (ppm) 7.70 (s, 1H), 7.10 (d, J = 8.2 Hz, 1H), 
6.90 (d, J = 8.2 Hz, 1H), 3.85 (s, 3H), 3.50 (s, 3H), 3.32 (q, J = 7.3 Hz, 2H), 2.72 (s, 2H), 1.50 (t, 
J = 7.3 Hz, 3H), 1.38 (s, 6H). ESI+MS m/z = 331.2 (M + H
+
), 353.2 (M + Na
+
).  HPLC (Method 
A, tR = 9.25 min), purity >95%. 
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Ethyl 1-(3-benzoylthioureido)-7-methoxy-3,3-dimethyl-3,4-dihydronaphthalene-2-
carboxylate (intermediate leading to 44b). To a solution of β-aminoester intermediate 27a 
(3.47 g, 12.64 mmol) in absolute EtOH (15 mL) was added benzoyl isothiocyanate (1.7 mL, 
12.64 mmol), and the reaction mixture was warmed to reflux for 30 minutes. Additional benzoyl 
isothiocyanate (400 μL, 2.7 mmol) was added in two equal portions over the course of 1 hour, 
then the reaction was allowed to cool. The thiourea adduct can be purified via crystallization 
from ethanol, but was generally used as a crude mixture in the next step with assumed 100% 
conversion.
 1
H NMR (400 MHz, Chloroform-d) δ 11.70 (s, 1H), 9.17 (s, 1H), 7.91 (d, J = 7.4 Hz, 
2H), 7.71 – 7.62 (m, 1H), 7.55 (t, J = 7.8 Hz, 2H), 7.10 (d, J = 8.2 Hz, 1H), 6.85 (d, J = 2.6 Hz, 
1H), 6.80 (dd, J = 8.3, 2.3 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 2.76 (s, 2H), 1.29 (t, J 
= 7.1 Hz, 3H), 1.25 (s, 6H). 
 
 
9-Methoxy-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one (44b). 
The crude benzoyl thiourea adduct (12.64 mmol) was added to a solution of KOH (1.21 g, 21.57 
mmol) in ethanol:water (2:1, 30 mL).  The reaction mixture was warmed to reflux and allowed to 
stir for 1.5 hours.  The reaction mixture was cooled, then acidified to pH 5-6 with 1N HCl.  The 
resulting precipitate was isolated via vacuum filtration, washed with EtOH and water and dried 
under high vacuum.  Isolated in 62% yield (2.26 g) over 2 steps as a white crystalline solid.
 1
H 
NMR (400 MHz, CDCl3) δ (ppm) 9.32 (s, 2H), 7.20 (d, J = 8.2 Hz, 1H), 7.00 (dd, J = 8.2, 2.4 
Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 3.87 (s, 3H), 2.71 (s, 2H), 1.32 (s, 6H). 
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2-(Ethylthio)-9-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (45b). 
The 2-thioxo intermediate 44b (118 mg, 0.409 mmol) was dissolved in EtOH (2.4 mL), to which 
KOH (23 mg, 0.409 mmol) and iodoethane (64 mg, 0.409 mmol) were added.  The reaction was 
warmed to 75°C and allowed to stir for 3 hours.  The reaction mixture was diluted with 1N HCl 
and the resulting precipitate was collected via sintered glass funnel, washed with water, and dried 
under high vacuum. Isolated the desired product as a white powder (91 mg, 71% yield).  
1
H 
NMR (400 MHz, DMSO-d6) δ 12.53 (s, 1H), 7.61 (d, J = 2.3 Hz, 1H), 7.17 (d, J = 8.2 Hz, 1H), 
6.96 (dd, J = 8.3, 2.7 Hz, 1H), 3.78 (s, 3H), 3.22 (q, J = 7.3 Hz, 2H), 2.68 (s, 2H), 1.39 (t, J = 7.3 
Hz, 3H), 1.27 (s, 6H). 
 
  
2-(Ethylthio)-9-methoxy-5,5-dimethyl-3-(2,2,2-trifluoroethyl)-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (47) (CCG-206357) and 2-(Ethylthio)-9-methoxy-5,5-
dimethyl-4-(2,2,2-trifluoroethoxy)-5,6-dihydrobenzo[h]quinazoline (49) (CCG-206356). A 
portion of the S-alkylated adduct (27 mg, 0.085 mmol) was combined with 1,1,1-trifluoro-2-
iodoethane (27 mg, 0.128 mmol) and Cs2CO3 (33 mg, 0.102 mmol) in DMF (500 μL).  The 
reaction was tightly capped and heated to 70°C for 16 hours.  The reaction mixture was 
partitioned between ethyl acetate and water, then the organic layer was washed with water and 
brine.  The organic layer was concentrated in vacuo and purified via flash chromatography (0-
3% EtOAc:hex) to yield compounds 47 (6 mg, 13% yield over 2 steps) and 49 (17 mg, 36% yield 
over 2 steps) as crystalline white solids.  
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2-(Ethylthio)-9-methoxy-5,5-dimethyl-3-(2,2,2-trifluoroethyl)-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (47) (CCG-206357). 
1
H NMR (400 MHz, CDCl3) δ 
(ppm) 7.68 (d, J = 2.8 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 6.93 (dd, J = 8.2, 2.8 Hz, 1H), 4.78 (q, J 
= 8.0 Hz, 2H), 3.85 (s, 3H), 3.35 (q, J = 7.3 Hz, 2H), 2.74 (s, 2H), 1.50 (t, J = 7.3 Hz, 3H), 1.36 
(s, 6H). ESI+MS m/z = 399.2 (M + H
+
), 421.2 (M + Na
+
).  HPLC (Method B, tR = 8.49 min), 
purity >95%.  
2-(Ethylthio)-9-methoxy-5,5-dimethyl-4-(2,2,2-trifluoroethoxy)-5,6-
dihydrobenzo[h]quinazoline (49) (CCG-206356). 
1
H NMR (400 MHz, CDCl3) δ (ppm) 7.81 
(d, J = 2.7 Hz, 1H), 7.10 (d, J = 8.2 Hz, 1H), 6.94 (dd, J = 8.2, 2.7 Hz, 1H), 4.80 (q, J = 8.5 Hz, 
2H), 3.87 (s, 3H), 3.21 (q, J = 7.3 Hz, 2H), 2.76 (s, 2H), 1.47 (t, J = 7.3 Hz, 3H), 1.33 (s, 6H). 
ESI+MS m/z = 399.2 (M + H
+
).  HPLC (Method A, tR = 9.84 min), purity >95%. 
 
 
4-(Allyloxy)-2-(ethylthio)-9-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazoline (50) 
(CCG-206358). A portion of the S-alkylated adduct (30 mg, 0.095 mmol) was combined with 
Cs2CO3 (37 mg, 0.114 mmol) and allyl bromide (17 mg, 0.142 mmol) in DMF (558 μL).  The 
reaction mixture was tightly capped and warmed to 75°C, and allowed to stir for 16 hours.  The 
reaction mixture was partitioned between ethyl acetate and water, then the organic layer was 
washed with water and brine.  The organic layer was concentrated in vacuo, and the residue was 
purified via flash chromatography (0-5% EtOAc:hex) to yield 50 (14 mg, 30% yield over 2 
steps). 
1
H NMR (400 MHz, CDCl3) δ (ppm) 7.81 (d, J = 2.5 Hz, 1H), 7.08 (d, J = 8.2 Hz, 1H), 
6.91 (dd, J = 8.2, 2.5 Hz, 1H), 6.09 (ddt, J = 16.4, 10.6, 5.5 Hz, 1H), 5.40 (d, J = 16.4 Hz, 1H), 
5.27 (d, J = 10.6 Hz, 1H), 4.94 (d, J = 5.5 Hz, 2H), 3.87 (s, 3H), 3.19 (q, J = 7.3 Hz, 2H), 2.74 (s, 
2H), 1.47 (t, J = 7.3 Hz, 3H), 1.33 (s, 6H). ESI+MS m/z = 357.2 (M + H
+
), 379.2 (M + Na
+
).  
HPLC (Method B, tR = 10.41 min), purity >95%.  N-allyl compound 32 was also isolated (10 
mg, 21% yield over 2 steps). 
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3-Allyl-9-methoxy-5,5-dimethyl-2-((2,2,2-trifluoroethyl)thio)-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (51) (CCG-206352). Prepared according to General 
Method D from intermediate 28a, using 2,2,2-trifluoro-1-iodoethane as the alkylating agent.  
Reaction was heated to 50°C to avoid evaporation of the alkylating agent.  Flash chromatography 
(5-10% EtOAc:hex) delivered the product (7 mg, 24% yield).
 1
H NMR (400 MHz, CDCl3)  δ 
(ppm) 7.61 (s, 1H), 7.10 (d, J = 8.1 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 5.93 (ddt, J = 16.5, 11.1, 
5.6 Hz, 1H), 5.34 – 5.23 (m, 2H), 4.71 (d, J = 5.6 Hz, 2H), 4.16 (q, J = 9.7 Hz, 2H), 3.84 (s, 3H), 
2.73 (s, 2H), 1.37 (s, 6H). ESI+MS m/z = 411.2 (M + H
+
), HPLC (Method B, tR = 7.98 min), 
purity = >95%. 
 
 
3-Allyl-2-(ethylsulfonyl)-9-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one 
(52) (CCG-206354). Compound 32 (28 mg, 0.79 mmol) and mCPBA (70 wt%, 48 mg, 0.196 
mmol) were combined in DCM (1.2mL) at 0°C.  The reaction mixture was kept at 0°C for 1 
hour, then allowed to warm to RT over the course of 16 hours.  The reaction mixture was then 
diluted with more DCM and washed with saturated sodium bicarbonate solution, water, and 
brine.  The organic layer was isolated, dried over MgSO4, vacuum filtered, and concentrated in 
vacuo.  Further purification via flash chromatography (5-10% EtOAc:hex) delivered the desired 
product as a light yellow solid (19 mg, 62% yield). 
 1
H NMR (400 MHz, CDCl3) δ (ppm) 7.43 (s, 
1H), 7.14 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 6.04 (ddt, J = 16.8, 10.3, 5.5 Hz, 1H), 
5.40 (d, J = 16.8 Hz, 1H), 5.30 (d, J = 10.3 Hz, 1H), 5.02 (d, J = 5.5 Hz, 2H), 3.84 (s, 3H), 3.81 
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(q, J = 7.3 Hz, 2H), 2.75 (s, 2H), 1.62 (t, J = 7.3 Hz, 3H), 1.38 (s, 6H). ESI+MS m/z = 389.2 (M 
+ H
+
), 411.2 (M + Na
+
).  HPLC (Method A, tR = 8.64 min), purity >95%. 
 
 
3-Allyl-2-(ethylsulfinyl)-9-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one 
(53) (CCG-206355). Compound 32 (20 mg, 0.056 mmol) was added to a 3.5:1 THF:water 
mixture (0.617 mL), and the reaction then cooled to 0°C.  A solution of Oxone (34 mg, 0.056 
mmol) in water (0.411 mL) was added slowly dropwise, and the reaction was allowed to stir 3.5 
hours at 0°C, then allowed to warm to room temperature over 16 hours.   At this point the 
reaction was partitioned between EtOAc and water.  The organic layer was washed with water 
and brine, then isolated, dried over MgSO4, vacuum filtered, and concentrated under reduced 
pressure.  The resulting residue was purified via flash chromatography (10-33% EtOAc:hex) to 
deliver the product as light yellow crystals (13 mg, 62% yield).  
1
H NMR (400 MHz, CDCl3) δ 
(ppm) 7.66 (d, J = 2.7 Hz, 1H), 7.12 (d, J = 8.2 Hz, 1H), 6.93 (dd, J = 8.2, 2.7 Hz, 1H), 6.56 – 
5.61 (m, 1H), 5.30 (d, J = 10.3 Hz, 1H), 5.24 (d, J = 17.2 Hz, 1H), 5.13 (ab with 5.00; ddt, J = 
1.6, 5.0, 15.8 Hz, 1H), 5.00 (ab with 5.13; dd, J = 5.0, 15.8 Hz, 1H), 3.86 (s, 3H), 3.46 – 3.27 (m, 
2H), 2.75 (s, 2H), 1.43 (t, J = 7.5 Hz, 3H), 1.39 (s, 3H), 1.38 (s, 3H). ESI+MS m/z = 395.2 (M + 
H
+
).  HPLC (Method A, tR = 7.39 min), purity >95%. 
 
 
Methyl 1,1-dimethyl-3-oxo-2,3-dihydro-1H-indene-2-carboxylate (55).   Sodium hydride (80 
wt%, 280 mg, 9.36 mmol) was added to a dry flask containing anhydrous dimethyl carbonate 
(2.62 mL, 31.2 mmol).  The resulting metallic suspension was heated to 80°C, then 3,3-dimethyl 
1-indanone (54, 500 mg, 3.12 mmol) in anhydrous THF (4 mL) was added over 1 hour via 
syringe pump.  The reaction was allowed to stir at 80°C for 3 additional hours, then halted by the 
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addition of water (~10 mL).  The suspension was extracted into diethyl ether 2x, then the pooled 
organic extract was washed with water and brine, then dried over MgSO4, vacuum filtered, and 
concentrated in vacuo to a reddish oil (664 mg, 97% yield), used without further purification. 
NMR indicates the compound is isolated as a 2:1 mixture of keto and enol tautomers (664 mg, 
97% yield). 
1
H NMR (keto form): (500 MHz, Chloroform-d) δ 7.79 (d, J = 7.8 Hz, 1H ), 7.68 (t, 
J = 7.6 Hz, 1H), 7.52 (d, J  = 7.8 Hz, 1H), 7.43 (t, J  = 7.6 Hz, 1H), 3.77 (s, 3H), 3.51 (s, 1H), 
1.58 (s, 3H), 1.38 (s, 3H). 
 
 
Methyl 3-amino-1,1-dimethyl-1H-indene-2-carboxylate (56).  A solution of 55 (664 mg, 3.04 
mmol) in methanol (9.2 mL) was warmed to reflux, then ammonium acetate (5.85 g, 76  mmol) 
was added.  The solution was allowed to stir at reflux for 18 hours, at which point additional 
ammonium acetate (5.85 g, 76 mmol) was added.  After an additional 5 hours at reflux, the 
solution was evaporated to dryness and the resulting residue was partitioned between ethyl 
acetate and saturated sodium bicarbonate solution.  The organic layer was washed with water and 
brine, then isolated, dried over MgSO4, vacuum filtered, and concentrated in vacuo.  Further 
purification via column chromatography (10% ethyl acetate: hexanes) isolated 365 mg of a light 
tan crystalline solid found to be product by NMR (yield = 55%). 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.40 (m, 4H), 3.85 (s, 3H), 1.46 (s, 6H). 
 
 
3-Allyl-5,5-dimethyl-2-thioxo-2,3-dihydro-1H-indeno[1,2-d]pyrimidin-4(5H)-one (57).  
Intermediate 56 (125 mg, 0.575 mmol) and allyl isothiocyanate (56 µL, 0.575 mmol) were 
combined in a high pressure reaction vessel with anhydrous pyridine (0.75 mL) and heated to 
reflux.  Additional allyl isothiocyanate (168 µL, 1.73 mmol) was added in 3 equal portions over 
the next 5 hours, and the reaction was allowed to stir at reflux an additional 12 hours.  At this 
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time, the reaction was allowed to cool to room temperature, then was diluted with aqueous 1N 
HCl and extracted with ethyl acetate.  The organic layer was washed with additional aqueous 1N 
HCl, water, and brine, then isolated, dried over MgSO4, vacuum filtered, and concentrated to a 
brown oil.  Further purification via flash chromatography (0-10% EtOAc:hex) isolated the 
desired product as a white crystalline solid (46 mg, 23% yield).
 1
H NMR (500 MHz, 
Chloroform-d) δ 11.33 (s, 1H), 7.97 – 7.81 (m, 1H), 7.64 – 7.50 (m, 2H), 7.46 (t, J = 7.3 Hz, 
1H), 6.14 – 5.98 (m, 1H), 5.42 (dd, J = 17.2, 1.7 Hz, 1H), 5.30 (d, J = 10.2 Hz, 1H), 5.20 (d, J = 
5.9 Hz, 2H), 1.56 (s, 6H). 
 
 
3-Allyl-2-((2-methoxyethyl)thio)-5,5-dimethyl-3H-indeno[1,2-d]pyrimidin-4(5H)-one (58) 
(CCG-203572). Intermediate 57 (37 mg, 0.130 mmol) was dissolved in 2-butanone (0.75 mL), to 
which cesium carbonate (63.5 mg, 0.195 mmol) and 2-methoxyethyl p-toluenesulfonic ester (60 
mg, 0.260 mmol) were added.  The solution was warmed to 80°C and allowed to stir for 16 
hours, at which point the reaction was diluted with ethyl acetate and washed with water and 
brine.  The organic layer was isolated, dried over MgSO4, vacuum filtered, and concentrated in 
vacuo.  Purification via flash chromatography (0-10 % ethyl acetate:hexane) yielded the desired 
compound as white crystals (27.5 mg, 62% yield).
 1
H NMR (500 MHz, Chloroform-d) δ 7.85 (d, 
J = 7.5 Hz, 1H), 7.54 – 7.46 (m, 2H), 7.42 (t, J = 7.0 Hz, 1H), 5.97 (ddt, J = 16.3, 10.8, 5.4 Hz, 
1H), 5.36 – 5.27 (m, 2H), 4.81 (d, J = 5.4 Hz, 2H), 3.81 (t, J = 6.2 Hz, 2H), 3.60 (t, J = 6.2 Hz, 
2H), 3.47 (s, 3H), 1.57 (s, 6H). ESI+MS m/z = 343.1 (M + H
+
).  HPLC (Method B, tR = 6.22 
min), purity >95%. 
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Ethyl 2-cyano-4-phenylpentanoate (60). Diisopropylazodicarboxylate (358 mg, 1.77 mmol) 
and triphenylphosphine (464 mg, 1.77 mmol) were combined in anhydrous THF (2.5 mL) and 
cooled to -20°C.  The reaction mixture was allowed to stir at this temperature for 20 minutes, 
then 2-phenyl-1-propanol (200 mg, 1.47 mmol) and ethyl cyanoacetate (249 mg, 2.20 mmol) in 
THF (2.5 mL) were slowly added and the reaction was allowed to stir at -20°C for an additional 
3 hours.  The reaction vessel was transferred to a 4°C refrigerator to stand overnight (20h), then 
was subsequently concentrated to a crude brown oil in vacuo.  Purification via FC (0 to 10% 
EA:hex) yielded the desired cyanoester product as a brown oil (280 mg, 82% yield).  NMR 
indicates the product is a nearly 1:1 mixture of diastereomers.  
1
H NMR (500 MHz, Chloroform-
d) δ 7.41 – 7.32 (m, 2H), 7.32 – 7.20 (m, 3H), 4.23 (q, J = 7.1 Hz, 1H), 4.17 (qd, J = 7.1, 3.3 Hz, 
1H), 3.41 (t, J = 7.3 Hz, 0.5H), 3.12 (dd, J = 9.7, 6.5 Hz, 0.5H), 3.09 – 2.95 (m, 1H), 2.33 – 2.18 
(m, 2H), 1.37 (dd, J = 14.5, 6.9 Hz, 3H), 1.31 (td, J = 7.1, 2.5 Hz, 3H). 
 
 
Ethyl 1-amino-4-methyl-3,4-dihydronaphthalene-2-carboxylate (61). Intermediate 60 (166 
mg, 0.718 mmol) was dissolved in DCM (7 mL) under N2, to which trifluoromethanesulfonic 
acid (1 mL) was added slowly dropwise.  The reaction mixture was allowed to stir 24 hours at 
room temperature.  The reaction was judged complete by TLC, and the mixture neutralized by 
the slow addition of saturated sodium bicarbonate to ~pH 7.  The mixture was then extracted 2x 
with ethyl acetate, and the organic layer washed with water and brine.  Organic layer dried over 
MgSO4, vacuum filtered, and concentrated in vacuo to a white powder, confirmed to be the 
desired β-aminoester compound 61 (153 mg, 92% yield). 1H NMR (500 MHz, Chloroform-d) δ 
7.50 (d, J = 7.6 Hz, 1H), 7.39 (t, J = 7.4 Hz, 1H), 7.35 – 7.29 (m, 2H), 6.88 – 6.14 (m, 2H), 4.24 
(q, J = 7.1 Hz, 2H), 2.96 – 2.85 (m, 1H), 2.67 (dd, J = 15.4, 5.2 Hz, 1H), 2.39 (dd, J = 15.4, 8.0 
Hz, 1H), 1.35 (t, J = 7.1 Hz, 3H), 1.29 (d, J = 7.0 Hz, 3H). 
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3-Allyl-6-methyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one (62). Compound 
61 (310 mg, 1.34 mmol) was dissolved in absolute ethanol (1.8 mL) under N2, to which allyl 
isothiocyanate (268 μL, 2.68 mmol) and acetic acid (158 μL, 2.68 mmol) were added.  The 
reaction was warmed to reflux and allowed to stir for 4h; over this time, additional allyl 
isothiocyanate (402 μL, 4.01mmol) was added in 3 portions.  After complete addition of the allyl 
isothiocyanate, reaction allowed to stir at reflux an additional 12 hours.  The reaction was diluted 
with ethyl acetate, washed with water and brine, then dried over MgSO4 and concentrated in 
vacuo.  The resulting orange oil was purified via flash chromatography (5-10% EA:hex), 
delivering the desired cyclic thiourea 62 as a white crystalline solid (135 mg, 35% yield). 
1
H 
NMR (500 MHz, Chloroform-d) δ 9.35 (s, 1H), 7.53 – 7.44 (m, 2H), 7.39 (t, J = 8.1 Hz, 2H), 
6.07 – 5.95 (m, 1H), 5.39 (d, J = 17.0 Hz, 1H), 5.28 (d, J = 10.2 Hz, 1H), 5.11 (d, J = 6.0 Hz, 
2H), 3.09 (q, J = 6.9 Hz, 1H), 2.80 (dd, J = 16.6, 6.7 Hz, 1H), 2.59 (dd, J = 16.6, 6.7 Hz, 1H), 
1.28 (d, J = 6.9 Hz, 3H). 
 
 
3-Allyl-2-((2-methoxyethyl)thio)-6-methyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (63) 
(CCG-203574).  Compound 62 (30 mg, 0.105 mmol), cesium carbonate (52 mg, 0.158 mmol), 
and p-toluenesulfonic acid 2-methoxyethyl ester (27 mg, 0.116 mmol) were combined in 2-
butanone (618 μL) and warmed to 75°C.  The reaction mixture was allowed to stir 16h, at which 
point the reaction was judged complete by TLC. The reaction mixture was diluted with ethyl 
acetate and the organic layer washed with water and brine.  The organic layer was dried over 
MgSO4, vacuum filtered, and concentrated in vacuo.  The resulting crude oil was purified via 
flash chromatography (0-8% EA:hex) to deliver the desired compound as a clear brown oil (27 
mg, 75% yield).  
1
H NMR (500 MHz, cdcl3) δ 8.13 (dd, J = 7.4, 1.4, 1H), 7.39 (td, J = 7.4, 1.4, 
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1H), 7.33 (td, J = 7.4, 1.4, 1H), 7.28 (d, J = 7.4, 1H), 5.94 (ddt, J = 17.1, 10.3, 5.7, 1H), 5.36 – 
5.23 (m, 2H), 4.75 (qdt, J = 15.9, 5.7, 1.5, 2H), 3.78 (t, J = 6.3, 2H), 3.56 (t, J = 6.3, 2H), 3.43 (s, 
3H), 3.09 (h, J = 6.7, 1H), 2.91 (dd, J = 16.6, 6.7, 1H), 2.70 (dd, J = 16.6, 6.7, 1H), 1.27 (d, J = 
6.7, 3H). TOF ES+ MS: 343.1 (M+H), 365.1 (M+Na). HPLC (Method B, tR = 5.81 min), purity 
>95%. 
 
 
Ethyl 1-amino-3,4-dimethyl-3,4-dihydronaphthalene-2-carboxylate (65).  Prepared according 
to General Method B from 2-ethylbenzonitrile 64 and ethyl 3-methyl acrylate. Isolated in 36% 
yield. 
1
H NMR (400 MHz, Chloroform-d) δ 7.45 (d, J = 7.6, 1.3H), 7.39 (td, J = 7.5, 1.3 Hz, 
0.3H), 7.33 (td, J = 7.4, 1.4 Hz, 1.0H), 7.30 – 7.24 (m, 1.6H), 7.19 (dd, J = 7.3, 1.5 Hz, 1H), 6.50 
(bs, 2.6H), 4.30– 4.15 (m, 2.6H), 3.11 – 3.01 (m, 0.3H), 2.93 – 2.81 (m, 1.3H), 2.69 (qd, J = 7.1, 
1.4 Hz, 1H), 1.38 (d, J = 7.0 Hz, 0.9H), 1.32 (td, J = 7.1, 1.1 Hz, 3.9H), 1.15 (d, J = 7.1 Hz, 3H), 
0.90 (d, J = 6.9 Hz, 3H), 0.66 (d, J = 6.8 Hz, 0.9H). 
 
 
3-Allyl-5,6-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one (66). 
Prepared according to General Method C from Ethyl 1-amino-3,4-dimethyl-3,4-
dihydronaphthalene-2-carboxylate (65) and allyl isothiocyanate. Purified via flash 
chromatography (0-15% ethyl acetate:hexanes) to yield the product as a mixture of the cyclized 
2-thioxopyrimidinone and the uncyclized thiourea-ester adduct, used together without further 
purification (36 mg, 30% yield).  
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3-Allyl-2-((2-methoxyethyl)thio)-5,6-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one 
(67) (CCG-206601). Prepared according to General Method D from intermediate 66 (36 mg, 
0.121 mmol), using 2-methoxyethyl p-toluenesulfonic ester (56 mg, 0.241 mmol) as the 
alkylating agent.  Flash chromatography (5-10% EtOAc:hex) delivered the product as a clear oil 
(10:3 mixture of diastereomers, 29 mg, 67% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.16 – 
8.06 (m, 1.3H), 7.46 – 7.28 (m, 2.9H), 7.22 (d, J = 7.3 Hz, 1.0H), 5.94 (ddt, J = 16.5, 10.9, 5.7 
Hz, 1.3H), 5.35 – 5.24 (m, 2.6H), 4.84 – 4.66 (m, 2.6H), 3.78 (q, J = 5.4, 4.7 Hz, 2.6H), 3.63 – 
3.50 (m, 2.6H), 3.43 (s, 3.9H), 3.22 – 3.09 (m, 1.6H), 2.85 (q, J = 7.0 Hz, 1.0H), 1.45 (d, J = 6.1 
Hz, 0.9H), 1.12 (d, J = 7.0 Hz, 3.0H), 1.03 (d, J = 7.0 Hz, 3.0H), 0.82 (d, J = 6.1 Hz, 0.9H). 
ESI+MS m/z = 357.1 (M + H
+
), 379.1 (M + Na
+
).  HPLC (Method B, tR = 6.44 and 6.89 min), 
purity >95%. 
 
 
2-Bromobenzyl acetate (69). Anhydrous DMF (12 mL) was added to a dry reaction vessel 
under N2, followed by 2-bromomethyl bromobenzene (68, 1.50 g, 6.00 mmol) and sodium 
acetate (1.48 g, 18.01 mmol).  The reaction mixture was heated to 70°C and allowed to stir 16 
hours.  After this time, the reaction was diluted with water (100 mL) and extracted 3x with 
diethyl ether. The organic extract was washed 3x with water and 1x with brine, then isolated, 
dried over MgSO4, vacuum filtered, and concentrated, leaving a very pale yellow oil (1.28 g, 
93% yield) that was used without further purification. 
1
H NMR (400 MHz, Chloroform-d) δ 7.58 
(d, J = 7.8 Hz, 1H), 7.41 (d, J = 7.5 Hz, 1H), 7.32 (t, J = 7.5 Hz, 1H), 7.19 (t, J = 7.8 Hz, 1H), 
5.20 (s, 2H), 2.14 (s, 3H). 
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(2-Bromophenyl)methanol (70). The brominated benzyl acetate 69 (1.28 g, 5.59 mmol) was 
dissolved in methanol (11.2 mL), followed by potassium carbonate (927 mg, 6.71 mmol).  The 
resulting suspension was allowed to stir 60 minutes at room temperature under N2, then diluted 
with saturated aqueous sodium chloride solution and extracted three times with ethyl acetate. The 
combined organic extract was washed with brine, then dried over MgSO4, vacuum filtered, and 
concentrated to a clear oil that eventually crystallized.  The white crystalline product (1.01 g, 
96% yield) was used without further purification. 
1
H NMR (400 MHz, Chloroform-d) δ 7.55 (d, 
J = 8.0 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 7.17 (t, J = 7.7 Hz, 1H), 4.76 
(s, 2H), 2.00 (s, 1H). 
 
 
1-Bromo-2-(methoxymethyl)benzene (71) . 2-bromophenyl methanol 70 (880 mg, 4.71 mmol) 
and potassium hydroxide (1.30 g, 19.8 mmol) were dissolved in DMSO (11.2 mL), then the 
reaction mixture was allowed to stir at room temperature for 10 minutes. Methyl iodide (647 µL, 
10.35 mmol) was added dropwise, then the reaction was stirred for an additional 90 minutes. The 
reaction was halted by the addition of water (~40 mL), then was extracted with diethyl ether 3 
times.  The combined organic extract was washed with saturated aqueous sodium bicarbonate 
solution (1x), water (3x), and brine (1x), then dried over MgSO4, vacuum filtered, and 
concentrated to a clear oil (910 mg, 96% yield) that was used without further purification. 
1
H 
NMR (400 MHz, Chloroform-d) δ 7.54 (d, J = 7.9 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.32 (t, J = 
7.5 Hz, 1H), 7.15 (t, J = 7.5 Hz, 1H), 4.53 (s, 2H), 3.47 (s, 3H). 
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2-(Methoxymethyl)benzonitrile (72). Aryl bromide intermediate 71 (400 mg, 1.99 mmol) was 
dissolved in anhydrous DMF (15.3 mL) in a dry reaction vessel.  Copper (I) cyanide (356 mg, 
3.98 mmol) was added, then the solution was warmed to 120°C and allowed to stir for 16 h.  The 
reaction was quenched via the addition of saturated aqueous sodium bicarbonate solution (80 
mL), then the resulting suspension was extracted with diethyl ether (3x).  The combined organic 
extract was combined and washed 3x with water and 1x with brine, then was isolated, dried over 
MgSO4, vacuum filtered and concentrated to a light yellow oil (237 mg, 81% yield) that was 
used without further purification.
 1
H NMR (400 MHz, Chloroform-d) δ 7.66 (d, J = 7.6 Hz, 1H), 
7.63 – 7.54 (m, 2H), 7.40 (t, J = 7.2 Hz, 1H), 4.65 (s, 2H), 3.48 (s, 3H). 
 
 
Ethyl 1-amino-4-methoxy-3,3-dimethyl-3,4-dihydronaphthalene-2-carboxylate (73). 
Prepared according to General Method B from 2-(methoxyethyl)benzonitrile (72) and ethyl 3,3-
dimethyl acrylate.  Isolated via flash chromatography (5-15% EtOAc:hex) as a yellow oil (238 
mg, 54% yield) 
1
H NMR (400 MHz, Chloroform-d) δ 7.57 – 7.28 (m, 4H), 6.32 (s, 2H), 4.32 – 
4.18 (m, 2H), 3.67 (s, 1H), 3.35 (s, 3H), 1.34 (t, J = 7.0 Hz, 3H), 1.28 (s, 3H), 1.11 (s, 3H). 
 
 
3-Allyl-6-methoxy-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one 
(74). To a dry vessel containing absolute ethanol (1 mL), acetic acid (94 µL, 1.63 mmol), and 
intermediate 73 (225 mg, 0.817 mmol) was added allyl isothiocyanate (159 µL, 1.64 mmol).  
This reaction was securely capped and warmed to 75°C.  Additional allyl isothiocyanate (238 
µL, 2.45 mmol) was added in 3 equal portions over 3 hours, then the reaction was allowed to stir 
an additional 16 hours at 75°C. The reaction mixture was then diluted with ethyl acetate and 
washed with water and brine in a separatory funnel. The organic layer was isolated, dried over 
MgSO4, vacuum filtered, and concentrated to an orange oil. This crude material was redissolved 
138 
 
in sodium ethoxide solution in ethanol (1.0 M, 1.5 mL) and allowed to stir for 30 minutes. The 
reaction was halted via the addition of water (20 mL) and extracted 3x with ethyl acetate.  The 
pooled organic extract was washed with water and brine, then dried over MgSO4, vacuum 
filtered, and concentrated.  Flash chromatography (0->10% EtOAc:hex) isolated the desired 
product as a white crystalline solid (142 mg, 53% yield).
1
H NMR (400 MHz, Chloroform-d) δ 
9.67 (s, 1H), 7.61 (d, J = 7.2 Hz, 1H), 7.58 – 7.48 (m, 2H), 7.42 (d, J = 7.0 Hz, 1H), 6.04 – 5.90 
(m, 1H), 5.37 (d, J = 17.2 Hz, 1H), 5.25 (d, J = 10.3 Hz, 1H), 5.14 – 4.94 (m, 2H), 3.70 (s, 1H), 
3.27 (s, 3H), 1.56 (s, 3H), 1.11 (s, 3H). 
 
 
3-Allyl-2-(ethylthio)-6-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one 
(75) (CCG-206602).  Compound synthesized according to General Method D from intermediate 
74 (100 mg, 0.304 mmol) using iodoethane (95 mg, 0.609 mmol) as the alkylating agent.  
Isolated after chromatography (5% EtOAc:hex) as a white crystalline solid (60 mg, 55% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.19 (dd, J = 7.4, 1.6 Hz, 1H), 7.50 – 7.38 (m, 2H), 7.35 – 
7.28 (m, 1H), 5.99 – 5.84 (m, 1H), 5.35 – 5.22 (m, 2H), 4.73 – 4.57 (m, 2H), 3.69 (s, 1H), 3.37 – 
3.27 (m, 2H), 3.25 (s, 3H), 1.65 (s, 3H), 1.47 (t, J = 7.4 Hz, 3H), 1.13 (s, 3H). ESI-MS+ m/z = 
357.0 (M + H
+
), 379.0 (M + Na
+
). HPLC (Method B, tR = 7.59 min), purity >95%. 
 
 
17-Hydroxy-3,6,9,12,15-pentaoxaheptadecyl methanesulfonate (106). PEG-6 (105, 1.00 g, 
3.54 mmol) was dissolved in DCM (8 mL), to which silver oxide (862 mg, 3.72 mmol) was 
added.  A solution of mesyl chloride (345 µL, 4.43 mmol) in DCM (1.4 mL) was added 
dropwise, then the reaction was allowed to stir for 48 hours.  The reaction was diluted with 
additional DCM (20 mL), filtered through celite, then concentrated in vacuo. Further purification 
via flash chromatography (10% MeOH:EtOAc) furnished the desired product as a clear oil (330 
mg, 26% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 4.43 – 4.38 (m, 2H), 3.81 – 3.77 (m, 2H), 
3.77 – 3.72 (m, 2H), 3.71 – 3.65 (m, 16H), 3.65 – 3.61 (m, 2H), 3.11 (s, 3H), 2.71 (s, 1H). 
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17-Azido-3,6,9,12,15-pentaoxaheptadecan-1-ol (107). Mesylated intermediate 106 (330 mg, 
0.569 mmol) was dissolved in anhydrous DMF (1.3 mL).  Sodium azide (119 mg, 1.83 mmol) 
was added and the solution heated to 90°C for 6 hours.  The reaction was cooled and partitioned 
between brine and ethyl acetate.  The organic layer was separated, dried over MgSO4, filtered, 
and concentrated to a colorless oil (189 mg, 67% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 
3.78 – 3.56 (m, 22H), 3.41 (td, J = 5.1, 2.0 Hz, 2H), 2.75 (s, 1H). 
 
 
17-Amino-3,6,9,12,15-pentaoxaheptadecan-1-ol (108). Azide intermediate 107 was dissolved 
in THF (1.1 mL) and cooled to 0°C. Triphenylphosphine (126 mg, 0.480 mmol) was added and 
the solution was stirred for 12 hours while warming to room temperature.  Water (50 µL, 2.78 
mmol) was added and the reaction allowed to stir for 12 hours at room temperature.  Volatiles 
were removed in vacuo, then the resulting crude oil was dissolved in water and washed 3 times 
with toluene.  The aqueous layer was evaporated under reduced pressure to yield the desired 
product as a colorless oil (115 mg, 94% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 3.76 – 3.71 
(m, 2H), 3.71 – 3.63 (m, 16H), 3.63 – 3.58 (m, 2H), 3.56 – 3.51 (m, 2H), 2.88 (t, J = 5.1 Hz, 
2H), 2.44 (s, 3H). 
 
 
tert-Butyl (17-hydroxy-3,6,9,12,15-pentaoxaheptadecyl)carbamate (109).
 
Monoamine 108 
(115 mg, 0.409 mmol) was dissolved in 0.6 mL of 2:1 H2O:dioxane solution and cooled to 0°C.  
Potassium hydroxide (25 mg, 0.450 mmol) was added and the mixture allowed to stir for 15 
minutes, then di-tert-butyl dicarbamate (98 mg, 0.450 mmol) was added.  The reaction was 
allowed to stir and warm to room temperature over 5 hours, then the reaction halted by the 
addition of dichloromethane and brine.  The organic layer was washed with additional brine, 
isolated, dried over MgSO4, and concentrated in vacuo to a clear oil (129 mg, 83% yield), used 
without further purification. (
1
H NMR (500 MHz, Chloroform-d) δ 3.80 – 3.60 (m, 20H), 3.56 (t, 
J = 5.3 Hz, 2H), 3.34 (d, J = 5.2 Hz, 2H), 2.80 (s, 1H), 2.06 (s, 1H), 1.46 (s, 9H). 
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2,2-Dimethyl-4-oxo-3,8,11,14,17,20-hexaoxa-5-azadocosan-22-yl methanesulfonate (110). 
Boc-protected intermediate 109 (129 mg, 0.338 mmol) was dissolved in DCM (1.7 mL) and 
cooled to 0°C.  Triethylamine (52 µL, 0.372 mmol) and mesyl chloride (29 µL, 0.372 mmol) 
were added, and the solution was allowed to stir at 16 h while warming to room temperature.  
The solvent was removed in vacuo and purified via flash chromatography (30-100% EtOAc:hex) 
to a clear oil (107 mg, 69% yield).  (
1
H NMR (500 MHz, Chloroform-d) δ 5.05 (s, 1H), 4.41 – 
4.36 (m, 2H), 3.80 – 3.74 (m, 2H), 3.69 – 3.60 (m, 16H), 3.54 (t, J = 5.2 Hz, 2H), 3.32 (d, J = 5.5 
Hz, 2H), 3.09 (s, 3H), 1.44 (s, 9H). 
 
 
tert-Butyl (17-((3-allyl-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl)thio)-
3,6,9,12,15-pentaoxaheptadecyl)carbamate (111). Synthesized according to General Method D 
from 2-thioxo intermediate 16 and alkylating agent 110. Isolated in 62% yield. 
1
H NMR (500 
MHz, Chloroform-d) δ 8.09 (d, J = 7.5 Hz, 1H), 7.40 – 7.30 (m, 2H), 7.20 (d, J = 7.2 Hz, 1H), 
5.95 (ddt, J = 16.2, 10.6, 5.6 Hz, 1H), 5.34 – 5.25 (m, 2H), 5.06 (s, 1H), 4.71 (d, J = 5.6 Hz, 2H), 
3.87 (t, J = 6.4 Hz, 2H), 3.75 – 3.59 (m, 16H), 3.59 – 3.49 (m, 4H), 3.33 (d, J = 5.2 Hz, 2H), 2.81 
(s, 2H), 1.46 (s, 9H), 1.40 (s, 6H). 
 
 
3-Allyl-2-((17-amino-3,6,9,12,15-pentaoxaheptadecyl)thio)-5,5-dimethyl-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (112). The Boc-protected intermediate 111 was 
dissolved in a 2:1 solution of DCM:TFA and allowed to stir at room temperature for 3 hours.  
The reaction mixture was neutralized via the slow addition of aqueous sodium carbonate solution 
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until bubbling stopped.  The organic layer was isolated and the aqueous layer was washed 3 
times with additional DCM.  The combined organic layers were concentrated in vacuo to a sticky 
oil that was used without further purification, isolated in 81% yield. 
1
H NMR (500 MHz, 
Chloroform-d) δ 9.47 (s, 2H), 8.01 (d, J = 7.7 Hz, 1H), 7.39 (t, J = 7.3 Hz, 1H), 7.35 – 7.11 (m, 
2H), 5.89 (ddt, J = 17.2, 10.8, 5.5 Hz, 1H), 5.33 – 5.19 (m, 2H), 4.81 – 4.65 (m, 2H), 3.88 (t, J = 
6.3 Hz, 2H), 3.81 – 3.58 (m, 18H), 3.55 (t, J = 6.3 Hz, 2H), 3.19 (d, J = 5.0 Hz, 2H), 2.81 (s, 
2H), 1.36 (s, 6H). 
 
 
N-(17-((3-Allyl-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl)thio)-
3,6,9,12,15-pentaoxaheptadecyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (113) (CCG-203618). The PEG-6 functionalized intermediate 
112 was dissolved in DCM, to which DIPEA and biotin-O-succinimide were added.  The 
reaction was allowed to stir for 24 hours, then volatiles were removed in vacuo. Further 
purification via flash chromatography (0-10% MeOH:DCM) isolated the desired product (51% 
yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.07 (d, J = 7.5 Hz, 1H), 7.38 – 7.27 (m, 2H), 7.18 
(d, J = 6.4 Hz, 1H), 6.56 (s, 1H), 5.99 – 5.86 (m, 2H), 5.32 – 5.23 (m, 2H), 5.04 (s, 1H), 4.74 – 
4.62 (m, 2H), 4.53 – 4.46 (m, 1H), 4.35 – 4.28 (m, 1H), 3.84 (td, J = 6.7, 3.0 Hz, 2H), 3.72 – 
3.58 (m, 16H), 3.59 – 3.49 (m, 4H), 3.48 – 3.36 (m, 2H), 3.14 (td, J = 7.3, 3.9 Hz, 1H), 2.94 – 
2.86 (m, 1H), 2.79 (s, 2H), 2.73 (d, J = 12.7 Hz, 1H), 2.28 – 2.17 (m, 2H), 1.79 – 1.61 (m, 4H), 
1.48 – 1.41 (m, 2H), 1.38 (s, 6H). 
 
 
2,2-Dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl methanesulfonate (115). Compound 
supplied by Jessica Bell, used without further purification. 
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tert-Butyl (2-(2-(2-((3-allyl-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-
yl)thio)ethoxy)ethoxy)ethyl)carbamate (116). The thiourea intermediate (85 mg, 0.284 mmol) 
and Boc protected PEG-3 mesylate (115) (111 mg, 0.340 mmol) were dissolved in DMF (1.7 
mL), and cesium carbonate (139 mg, 0.425 mmol) was then added.  The solution was heated to 
75°C and allowed to stir for 3 hours, then quenched by the addition of water.  The resulting 
suspension was extracted with ethyl acetate twice.  The pooled organic extract was washed with 
water 2x and brine, then isolated, dried over MgSO4, vacuum filtered, and concentrated.  Isolated 
156 mg (104% crude yield) as the desired product with a trace amount of the alkylating agent 
present.  Used without further purification. 
1
H NMR (500 MHz, Chloroform-d) δ 8.09 (d, J = 7.5 
Hz, 1H), 7.37 (td, J = 7.3, 1.5 Hz, 1H), 7.32 (t, J = 7.5 Hz, 1H), 7.21 (d, J = 7.3 Hz, 1H), 6.01 – 
5.89 (m, 1H), 5.34 – 5.26 (m, 2H), 5.01 (s, 1H), 4.71 (d, J = 5.6 Hz, 2H), 3.87 (t, J = 6.4 Hz, 
2H), 3.72 – 3.63 (m, 4H), 3.60 – 3.54 (m, 4H), 3.38 – 3.28 (m, 2H), 2.81 (s, 2H), 1.45 (s, 9H), 
1.40 (s, 6H). 
 
 
3-Allyl-2-((2-(2-(2-aminoethoxy)ethoxy)ethyl)thio)-5,5-dimethyl-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (117). Boc-protected intermediate 116 (156 mg, 0.295 
mmol) was dissolved in DCM (2.0 mL), then TFA (1.0 mL) was added slowly.  The reaction 
mixture was allowed to stir under N2 for 1 hour and 45 minutes, then concentrated in vacuo, and 
treated with saturated sodium bicarbonate solution.  The aqueous mixture was extracted with 
ethyl acetate 3x, then the pooled organic extract was isolated, dried over MgSO4, vacuum 
filtered, concentrated in vacuo to a clear oil (163 mg, 130% crude yield) and used directly in the 
next step. 
1
H NMR (500 MHz, Chloroform-d) δ 10.29 (s, 3H), 7.92 (d, J = 7.8 Hz, 1H), 7.43 (td, 
J = 7.4, 1.3 Hz, 1H), 7.34 (td, J = 7.6, 1.3 Hz, 1H), 7.25 (d, J = 7.5 Hz, 1H), 5.94 – 5.82 (m, 1H), 
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5.36 – 5.25 (m, 2H), 4.76 (d, J = 5.7 Hz, 2H), 4.00 (t, J = 5.8 Hz, 2H), 3.77 – 3.66 (m, 6H), 3.61 
(t, J = 5.8 Hz, 2H), 3.32 – 3.25 (m, 2H), 2.82 (s, 2H), 1.36 (s, 6H). 
 
 
(9H-fluoren-9-yl)methyl tert-butyl (6-((2-(2-(2-((3-allyl-5,5-dimethyl-4-oxo-3,4,5,6-
tetrahydrobenzo[h]quinazolin-2-yl)thio)ethoxy)ethoxy)ethyl)amino)-6-oxohexane-1,5-
diyl)dicarbamate (118). Primary amine 117 (163 mg, 0.379 mmol) was combined with HOBT 
(87 mg, 0.569 mmol), EDC (109 mg, 0.569 mmol), DIPEA (166 µL, 0.949 mmol), and 
orthogonally protected DL-lysine (267 mg, 0.569 mmol) in DCM (3.8 mL) under N2.  The 
reaction mixture was allowed to stir at room temperature for 24 hours.  The reaction mixture was 
diluted with additional DCM (20 mL) and washed with saturated aqueous sodium bicarbonate, 
sat. aq. ammonium chloride solution, water, and brine.  The organic layer was then dried over 
MgSO4, vacuum filtered, and concentrated in vacuo.  The resulting residue was further purified 
via column chromatography (5% MeOH:DCM) to yield 194 mg of the desired amide as a 
gelatinous solid (145 mg, 58% yield over 3 steps). 10% MeOH:DCM rf = .35. 
 
 
tert-Butyl (1-((2-(2-(2-((3-allyl-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-
yl)thio)ethoxy)ethoxy)ethyl)amino)-6-amino-1-oxohexan-2-yl)carbamate (119). 
Orthogonally protected Lys intermediate 118 (194 mg, 0.220 mmol) was dissolved in DMF (1.7 
mL), to which piperidine was added (440 mg, 5.17 mmol).  This mixture was stirred at RT for 1 
hour, then the solvent was removed under reduced pressure. Flash chromatography (10% 
MeOH:DCM, then 10% 7N NH3-MeOH:DCM) was used to isolate the product. The fractions 
containing the desired product were evaporated under reduced pressure, then redissolved in 
dichloromethane, filtered via vacuum filtration, and concentrated, resulting in the isolation of the 
desired product as a yellow oil (109 mg, 75% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.07 
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(d, J = 7.5 Hz, 1H), 7.39 – 7.30 (m, 2H), 7.20 (d, J = 7.3 Hz, 1H), 6.01 – 5.89 (m, 1H), 5.53 – 
5.42 (m, 1H), 5.33 – 5.25 (m, 2H), 4.71 (d, J = 5.9 Hz, 2H), 4.21 (s, 1H), 3.87 (t, J = 6.3 Hz, 
2H), 3.68 (d, J = 11.3 Hz, 4H), 3.62 (t, J = 5.5 Hz, 2H), 3.57 (t, J = 6.5 Hz, 2H), 3.51 (s, 2H), 
3.47 – 3.38 (m, 1H), 3.20 – 3.14 (m, 2H), 3.10 – 3.02 (m, 2H), 2.80 (s, 2H), 1.99 – 1.88 (m, 4H), 
1.73 – 1.65 (m, 2H), 1.43 (s, 9H), 1.39 (s, 6H). 
 
 
tert-Butyl (1-((3-allyl-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl)thio)-
10,17-dioxo-21-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6-dioxa-9,16-
diazahenicosan-11-yl)carbamate (120). Free amine intermediate 119 (112 mg, 0.170 mmol) 
was combined with biotin-O-succinimide (58 mg, 0.170 mmol) and DIPEA in DCM under N2.  
The reaction was allowed to stir at RT for 16h, then the reaction mixture was diluted with 
additional DCM and washed with H2O and brine.  The organic layer was isolated, dried over 
MgSO4, vacuum filtered, and concentrated.  Column chromatography (10% MeOH:DCM) was 
used to further purify the product; isolated as a gelatinous solid (118 mg, 79% yield). 
1
H NMR 
(500 MHz, Chloroform-d) δ 8.09 (d, J = 7.5 Hz, 1H), 7.41 – 7.31 (m, 2H), 7.21 (d, J = 7.2 Hz, 
1H), 6.19 (s, 1H), 6.05 (s, 1H), 5.95 (ddd, J = 16.1, 10.6, 5.4 Hz, 1H), 5.73 (s, 1H), 5.45 (s, 1H), 
5.40 – 5.26 (m, 3H), 5.04 (s, 1H), 4.72 (d, J = 5.5 Hz, 2H), 4.56 – 4.49 (m, 1H), 4.37 – 4.30 (m, 
1H), 4.14 (s, 1H), 3.88 (t, J = 6.3 Hz, 2H), 3.72 – 3.64 (m, 4H), 3.63 – 3.54 (m, 4H), 3.52 – 3.44 
(m, 2H), 3.33 – 3.21 (m, 2H), 3.17 (s, 1H), 2.81 (s, 2H), 2.29 – 2.16 (m, 2H), 1.69 (d, J = 31.2 
Hz, 8H), 1.56 (d, J = 7.5 Hz, 2H), 1.53 – 1.30 (m, 18H). 
 
 
N-(2-(2-(2-((3-Allyl-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-
yl)thio)ethoxy)ethoxy)ethyl)-2-amino-6-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)hexanamide (121). Reaction was performed in a manner similar to that 
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employed for 112 using 120 (50 mg, 0.057 mmol) as the substrate.  After neutralization with 
saturated aqueous sodium bicarbonate, extraction into dichloromethane, drying over MgSO4, 
filtering, and concentration under reduced pressure, the desired amine product was isolated as a 
light brown oil (44 mg, 99% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.08 (d, J = 6.9 Hz, 
1H), 7.39 – 7.26 (m, 2H), 7.19 (d, J = 7.2 Hz, 1H), 5.94 (ddt, J = 17.3, 10.6, 5.6 Hz, 1H), 5.33 – 
5.24 (m, 2H), 4.70 (d, J = 5.5 Hz, 2H), 4.51 (q, J = 5.6 Hz, 1H), 4.35 – 4.28 (m, 1H), 3.90 – 3.83 
(m, 2H), 3.71 – 3.63 (m, 4H), 3.61 – 3.52 (m, 4H), 3.51 – 3.41 (m, 2H), 3.28 – 3.12 (m, 3H), 
2.80 (s, 2H), 2.78 – 2.71 (m, 1H), 2.26 – 2.12 (m, 7H), 1.79 – 1.64 (m, 5H), 1.61 – 1.21 (m, 
16H). 
 
 
N-(1-((3-Allyl-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl)thio)-10,17-
dioxo-21-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6-dioxa-9,16-diazahenicosan-
11-yl)-4-benzoylbenzamide (122) (CCG-203924).  Free amine 121 (50 mg, 0.064 mmol) was 
dissolved in DCM (0.64 mL), then DIPEA (56 µL, 0.319 mmol), HOBT (15 mg, 0.096 mmol), 
EDC (18 mg, 0.096 mmol) and 4-benzoyl benzoic acid (22 mg, 0.096) were added. The reaction 
was allowed to stir for 24 hours at room temperature, then the reaction was quenched by the 
addition of H2O and additional DCM.  The organic layer was washed with saturated aqueous 
sodium carbonate (10 mL), aqueous ammonium hydroxide (10 mL), water (20 mL), and brine 
(10 mL), then isolated, dried over MgSO4, filtered, and concentrated in vacuo. Purification by 
flash chromatography (5% MeOH:DCM) furnished the product as a sticky light brown solid (26 
mg, 41% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.08 (d, J = 7.6 Hz, 1H), 8.02 (dd, J = 8.3, 
3.4 Hz, 2H), 7.91 – 7.82 (m, 2H), 7.82 – 7.77 (m, 2H), 7.63 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.7 
Hz, 2H), 7.47 – 7.30 (m, 2H), 7.20 (d, J = 7.0 Hz, 1H), 6.50 – 6.42 (m, 1H), 6.37 (t, J = 5.6 Hz, 
0.5H), 6.19 (s, 0.5H), 5.99 – 5.87 (m, 1H), 5.67 (s, 0.5H), 5.40 (s, 0.5H), 5.35 – 5.24 (m, 2H), 
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4.78 – 4.64 (m, 3H), 4.50 (t, J = 6.3 Hz, 1H), 4.36 – 4.26 (m, 1H), 3.85 (t, J = 6.4 Hz, 2H), 3.66 
(d, J = 4.8 Hz, 4H), 3.64 – 3.58 (m, 2H), 3.58 – 3.52 (m, 2H), 3.52 – 3.44 (m, 2H), 3.37 – 3.18 
(m, 2H), 3.18 – 3.09 (m, 1H), 2.89 (dt, J = 12.8, 4.4 Hz, 1H), 2.80 (s, 2H), 2.72 (dd, J = 20.1, 
12.8 Hz, 1H), 2.24 – 2.14 (m, 2H), 1.97 – 1.78 (m, 2H), 1.77 – 1.52 (m, 6H), 1.50 – 1.41 (m, 
3H), 1.39 (s, 6H), 1.28 (m, 3H). ESI-MS+ m/z = 1014.2 (M + Na
+
). 
 
 
N-(1-((3-allyl-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl)thio)-10,17-
dioxo-21-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6-dioxa-9,16-diazahenicosan-
11-yl)-4-azido-2,3,5,6-tetrafluorobenzamide (123). The free amine starting material 121 (27 
mg, 0.034 mmol) was dissolved in DCM (140 µL), to which the NHS-
azidotetrafluorophenylazide ester (14 mg, 0.041 mg) and DIPEA (9 µL, 0.052 mmol) were 
added.  The reaction vessel was covered in tinfoil and the solution was allowed to stir for 48 
hours at room temperature, then the solvent was removed at reduced pressure.  Flash 
chromatography (5% MeOH:EtOAc) delivered the final product as a light brown oil (12.5 mg, 
36% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.05 (d, J = 7.7 Hz, 1H), 7.38 – 7.28 (m, 2H), 
7.18 (d, J = 7.3 Hz, 1H), 6.50 (s, 0.5H), 6.36 (s, 0.5H), 6.16 (s, 0.5H), 6.07 (s, 0.5H), 5.99 – 5.86 
(m, 1H), 5.35 – 5.21 (m, 2H), 4.74 – 4.66 (m, 2H), 4.65 – 4.55 (m, 1H), 4.52 – 4.42 (m, 1H), 
4.34 – 4.23 (m, 1H), 3.85 (t, J = 6.3 Hz, 2H), 3.71 – 3.62 (m, 4H), 3.59 (q, J = 4.8 Hz, 2H), 3.54 
(t, J = 6.5 Hz, 2H), 3.51 – 3.36 (m, 3H), 3.18 – 3.04 (m, 1H), 2.92 – 2.82 (m, 1H), 2.78 (s, 2H), 
2.69 (dd, J = 31.6, 12.8 Hz, 1H), 2.21 – 2.15 (m, 1H), 1.86 (s, 5H), 1.68 – 1.62 (m, 2H), 1.54 (s, 
2H), 1.44 (s, 2H), 1.37 (s, 6H), 1.30 – 1.23 (m, 4H). 
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(9H-Fluoren-9-yl)methyl tert-butyl (6-((2-(benzyloxy)ethyl)amino)-6-oxohexane-1,5-
diyl)dicarbamate (125). Boc-Fmoc-DL-lysine (200 mg, 0.427 mmol) was dissolved in 
anhydrous DMF (2.2 mL), to which HATU (195 mg, 0.512 mmol) and DIPEA (112 µL, 0.640 
mmol) were added.  After 10 minutes, 2-(benzyloxy)ethanamine (124, 77 mg, 0.512 mmol) was 
added.  This mixture was allowed to stir at RT for 1.5 hours, then the reaction was diluted with 
water. The resulting suspension was extracted into ethyl acetate 2x, then the organic layer 
washed with saturated aqueous NaHCO3, sat. aq. NH4Cl, water, and brine.  The organic layer 
was isolated, dried over MgSO4, vacuum filtered, and concentrated.  The crude product (257 mg, 
quant. yield) was carried on to the next reaction without further purification. 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.79 (d, J = 7.5 Hz, 2H), 7.62 (d, J = 7.5 Hz, 2H), 7.42 (t, J = 7.4 Hz, 2H), 7.39 
– 7.30 (m, 7H), 6.52 – 6.44 (m, 1H), 5.16 (d, J = 8.1 Hz, 1H), 5.00 – 4.90 (m, 1H), 4.52 (s, 2H), 
4.47 – 4.37 (m, 2H), 4.23 (t, J = 6.8 Hz, 1H), 4.14 – 4.03 (m, 1H), 3.55 (t, J = 5.3 Hz, 2H), 3.50 
(q, J = 5.4 Hz, 2H), 3.23 – 3.12 (m, 2H), 1.82 (d, J = 7.0 Hz, 2H), 1.57 – 1.49 (m, 2H), 1.44 (s, 
9H), 1.41 – 1.34 (m, 2H). 
 
 
tert-Butyl (6-amino-1-((2-(benzyloxy)ethyl)amino)-1-oxohexan-2-yl)carbamate (126). Boc 
(Fmoc) protected, amide functionalized lysine 125 (266 mg, 0.442 mmol) was dissolved in DCM 
(3.5 mL).  Piperidine (0.9 mL) was added and the reaction was allowed to stir for 1 hour under 
N2.  The reaction mixture was concentrated in vacuo on a rotary evaporator, then under high 
vacuum.  The resulting residue was purified by flash chromatography (1%MeOH:DCM to 10%  
methanolic ammonia:DCM)  Compound successfully isolated and confirmed to be the desired 
material by NMR (167 mg, 100% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 7.42 – 7.30 (m, 
5H), 6.71 (s, 1H), 5.17 (s, 1H), 4.53 (s, 2H), 4.18 – 4.02 (m, 1H), 3.57 (t, J = 5.2 Hz, 2H), 3.53 – 
3.42 (m, 2H), 2.70 (t, J = 6.8 Hz, 2H), 2.01 (s, 3H), 1.88 – 1.78 (m, 1H), 1.69 – 1.55 (m, 2H), 
1.55 – 1.32 (m, 12H). 
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tert-Butyl (1-((2-(benzyloxy)ethyl)amino)-1-oxo-6-(5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)hexan-2-yl)carbamate (127). The free amine intermediate 126 
(152 mg, 0.401 mmol) was combined with biotin-O-succinimide (137 mg, 0.401 mmol) and 
DIPEA (105 µL, 0.602 mmol) in DCM (2 mL) under N2.  The reaction was allowed to stir at RT 
for 16h, then was diluted with additional DCM and washed 1x with H2O and brine.  The organic 
layer was isolated, dried over MgSO4, vacuum filtered, and concentrated.  Column 
chromatography (10% MeOH:DCM) was used to further purify the product, isolated as a 
gelatinous solid in 76% yield (184 mg). 
1
H NMR (500 MHz, Chloroform-d) δ 7.39 – 7.29 (m, 
5H), 6.56 – 6.49 (m, 1H), 6.42 (s, 0.5H), 6.28 (s, 0.5H), 5.94 (s, 0.5H), 5.78 (s, 0.5H), 5.47 – 
5.38 (m, 1H), 4.53 (s, 2H), 4.45 (dd, J = 7.8, 4.8 Hz, 0.5H), 4.33 – 4.26 (m, 1H), 4.15 – 4.08 (m, 
1H), 3.64 – 3.58 (m, 2H), 3.56 – 3.45 (m, 2H), 3.35 – 3.23 (m, 1H), 3.19 – 3.12 (m, 2H), 2.90 – 
2.79 (m, 1H), 2.75 – 2.67 (m, 2H), 2.61 (d, J = 12.8 Hz, 0.5H), 2.26 – 2.19 (m, 2H), 1.83 – 1.64 
(m, 6H), 1.58 – 1.50 (m, 2H), 1.48 – 1.36 (m, 13H). 
 
 
2-Amino-N-(2-(benzyloxy)ethyl)-6-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)hexanamide (128). Boc-protected dummy probe intermediate 127 (51 mg, 
0.084 mmol) was dissolved in a 2:1 mixture of DCM and TFA (850 µL) and allowed to stir for 2 
hours.  The solution was concentrated under reduced pressure, and the crude material was 
redissolved in water.  The aqueous phase was washed with DCM, then isolated and evaporated 
under reduced pressure to afford the desired product (48 mg, 113% yield due to water 
contaminant), used without further purification. 
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4-Azido-N-(1-((2-(benzyloxy)ethyl)amino)-1-oxo-6-(5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)hexan-2-yl)-2,3,5,6-tetrafluorobenzamide (129) (CCG-
204000). The free amine starting material 128 (43 mg, 0.085 mmol) was dissolved in DMF (1 
mL), to which the NHS-azidotetrafluorophenylazide ester (34 mg, 0.102 mmol) and DIPEA (22 
µL, 0.128 mmol) were added.  The reaction vessel was covered in tin foil and was allowed to stir 
for 24 hours at room temperature.  The reaction was diluted with H2O then extracted 2x with 
EtOAc.  Organic layer washed with sat. aq. NaHCO3, 2x with water, and once with brine.  The 
organic layer was isolated, dried over MgSO4, filtered, and concentrated, leaving a brownish 
crude residue.  Further purification via flash chromatography (0-10% MeOH:DCM) recovered 
the product as a sticky brown oil (22 mg, 36% yield). 
 
 
2,5-Dioxopyrrolidin-1-yl 4-azido-2,3,5,6-tetrafluorobenzoate (131). 4-azido 
tetrafluorobenzoic acid (130, 25 mg, 0.106 mmol), N-hydroxy succinimide (15 mg, 0.128 mmol), 
and EDC (24 mg, 0.128 mmol) were added to DCM (0.4 mL). The reaction vessel was covered 
in tinfoil and warmed to 35°C.  Mixture allowed to stir for 16h.  Additional EDC (12 mg, 0.064 
mmol) was added and the reaction stirred for a further 3 hours. The reaction was quenched with 
H2O and extracted 2x with DCM.  The pooled organic layers were washed 2x with water and 1x 
with brine, isolated, dried over MgSO4, vacuum filtered, and concentrated.  The 
1
H-NMR 
spectrum of the resulting white crystalline material was consistent with that of literature 
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precedent and was used without further purification.  Isolated 28 mg (78% yield). 
1
H NMR (500 
MHz, Chloroform-d) δ 2.92 (s, 4H). 
 
 
Ethyl 1-amino-6-bromo-3,3-dimethyl-3,4-dihydronaphthalene-2-carboxylate (133). To a dry 
flask containing anhydrous diglyme (18 mL) was added diisopropylamine (1.45 mL, 10.2 mmol).  
The solution was cooled to -78°C in a dry ice bath, then n-butyllithium (2.5 M in hexane, 4.1 
mL, 10.2 mmol) was added slowly.  A solution of 4-bromo-2-methylbenzonitrile (132, 1.00 g, 
5.1 mmol) in anhydrous diglyme (~3 mL) was added slowly dropwise, then the solution allowed 
to stir for 45 minutes before the dropwise addition of ethyl-3,3-dimethyl acrylate (1.06 mL, 7.65 
mmol) was added dropwise. The solution was allowed to stir for 1 hour at -78°C before addition 
of a freshly prepared solution of zinc iodide (3.26 g, 10.2 mmol) in anhydrous diglyme (6 mL) 
was added.  The suspension was allowed slowly warm to room temperature and stir an additional 
2 hours.  Reaction was quenched with sat. aq. NH4Cl, then extracted 3x with diethyl ether.  
Organic layer was washed 3x with H2O, 1x with brine, then isolated, dried, filtered, and 
concentrated.  Purification by FC (100% hex -> 5% EtOAc:hex) isolated the desired product as 
867 mg of a  yellow oil, 50.4% yield.
1
H NMR (500 MHz, Chloroform-d) δ 7.41 (dd, J = 8.3, 2.1 
Hz, 1H), 7.33 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 8.3 Hz, 1H), 6.23 (s, 2H), 4.25 (q, J = 7.1 Hz, 2H), 
2.62 (s, 2H), 1.34 (t, J = 7.1 Hz, 3H), 1.19 (s, 6H). 
 
 
Ethyl 1-amino-3,3-dimethyl-6-(tributylstannyl)-3,4-dihydronaphthalene-2-carboxylate 
(intermediate in synthesis of 134). Brominated aminoester 133 (890 mg, 2.75 mmol) was added 
to dry toluene (27.5 mL) under N2, followed by bis(tributyltin) (2.39 g, 4.12 mmol) and 
tetrakis(triphenylphosphine) palladium (0) (317 mg, 0.275 mmol).  The flask was fitted with a 
reflux condenser and an N2 needle and warmed to reflux for 16 hours. The reaction was cooled 
151 
 
and the solvent removed in vacuo.  The crude isolate was purified via flash chromatography (0-
5% ethyl acetate: hexanes) to yield the stannylated product as a clear oil (547 mg, 37% yield).  
1
H NMR (500 MHz, Chloroform-d) δ 7.37 (d, J = 7.5 Hz, 1H), 7.31 (d, J = 7.5 Hz, 1H), 7.25 (d, 
J = 7.5 Hz, 1H), 6.33 (s, 2H), 4.25 (q, J = 7.1 Hz, 2H), 2.63 (s, 2H), 1.60 – 1.49 (m, 6H), 1.39 – 
1.28 (m, 9H), 1.20 (s, 6H), 1.10 – 1.03 (m, 6H), 0.89 (t, J = 7.3 Hz, 9H). 
 
 
Ethyl 1-amino-6-benzoyl-3,3-dimethyl-3,4-dihydronaphthalene-2-carboxylate (134). The 
stannylated aminoester (553 mg, 1.035 mmol) was combined with anhydrous DMF (4.2 mL) in a 
dry round bottom flask.  Iodobenzene (128 µL, 1.14 mmol) and bis-(triphenylphosphine) 
palladium (II) dichloride (73 mg, 0.103 mmol) were then added. Gaseous carbon monoxide was 
bubbled into the solution via needle for 5 minutes. The reaction securely capped and affixed with 
a CO-filled balloon.  The reaction warmed to 90°C and allowed to stir for 4 hours. The reaction 
vessel was allowed to cool, then excess CO was purged via nitrogen for 15 minutes.  Water was 
added to the reaction mixture, and the resulting suspension was extracted 2x with diethyl ether.  
The pooled organic extract was washed with water and saturated NaCl solution, then isolated, 
dried over MgSO4, vacuum filtered, and concentrated, leaving a bright yellow residue.  Flash 
chromatography (5% EtOAc:hex) isolated 210 mg of the product as a bright yellow solid (58% 
yield).  
1
H NMR (400 MHz, Chloroform-d) δ 7.81 (d, J = 8.2 Hz, 2H), 7.74 – 7.56 (m, 3H), 7.50 
(t, J = 8.2 Hz, 3H), 6.26 (s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 2.72 (s, 2H), 1.36 (t, J = 7.1 Hz, 3H), 
1.22 (s, 6H). 
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3-Allyl-8-benzoyl-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one 
(135). Allyl isothiocyanate (117 µL, 1.2 mmol) was added to a solution of aminoester 134 (210 
mg, 0.60 mmol) and acetic acid (69 µL, 1.20 mmol) in absolute ethanol (0.8 mL).  The solution 
was warmed to 78°C and allowed to stir in a capped vial.  Additional allyl isothiocyanate (175 
µL, 1.80 mmol) was added in equal portions over 3 hours, then allowed to stir for an additional 
12h at 78°C.  The solution was diluted with ethyl acetate and the organic layer washed with 
saturated sodium bicarbonate solution, water, and brine. The organic extract was then dried over 
MgSO4, vacuum filtered, and concentrated in vacuo.  Trituration of the crude extract with 
hexanes caused the precipitation of a light yellow solid, confirmed to be the desired product by 
NMR.  Recovered 64 mg (27% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 9.36 (s, 1H), 7.84 – 
7.80 (m, 2H), 7.78 – 7.72 (m, 2H), 7.66 – 7.62 (m, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.53 (t, J = 7.7 
Hz, 2H), 6.00 (ddt, J = 17.0, 10.7, 5.8 Hz, 1H), 5.39 (d, J = 17.0 Hz, 1H), 5.28 (d, J = 10.7 Hz, 
1H), 5.07 (d, J = 5.8 Hz, 2H), 2.87 (s, 2H), 1.37 (s, 6H). 
 
 
3-Allyl-8-benzoyl-5,5-dimethyl-2-(prop-2-yn-1-ylthio)-5,6-dihydrobenzo[h]quinazolin-
4(3H)-one (136) (CCG-204080). Thiourea 135 (30 mg, 0.075 mmol) was dissolved in 2-
butanone (0.44 mL), to which cesium carbonate (27 mg, 0.082 mmol) and propargyl bromide (10 
mg, 0.082 mmol) were added.  The reaction was warmed to 75°C and allowed to stir for 16 
hours.  The reaction was quenched via the addition of water, and the suspension was extracted 
with ethyl acetate.  The organic layer was washed with water 2x and brine 1x, isolated, dried 
over MgSO4, vacuum filtered, and concentrated in vacuo. Flash chromatography isolated the 
desired product as white crystals (23 mg, 70% yield).
 1
H NMR (500 MHz, Chloroform-d) δ 8.27 
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(d, J = 8.0 Hz, 1H), 7.83 (d, J = 7.6 Hz, 2H), 7.73 (d, J = 8.0 Hz, 1H), 7.66 (s, 1H), 7.61 (t, J = 
7.6 Hz, 1H), 7.51 (t, J = 7.6 Hz, 2H), 5.97 – 5.87 (m, 1H), 5.35 – 5.27 (m, 2H), 4.68 (d, J = 5.5 
Hz, 2H), 4.07 (d, J = 2.6 Hz, 2H), 2.87 (s, 2H), 2.27 (t, J = 2.6 Hz, 1H), 1.41 (s, 6H). ESI-MS+ 
m/z = 441.2 (M + H
+
), 463.2 (M + Na
+
). 
 
 
3-Allyl-8-benzoyl-5,5-dimethyl-2-((2-(prop-2-yn-1-yloxy)ethyl)thio)-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (137) (CCG-205365).  Prepared in the same manner as 
136, using 2-(prop-2-yn-1-yloxy)ethyl 4-methylbenzenesulfonate (139) as the alkylating agent.  
Product isolated after column chromatography (0-10% ethyl acetate: hexanes) as a white solid 
(53 mg, 69% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 8.18 (d, J = 8.1 Hz, 1H), 7.84 (d, J = 
75.0 Hz, 2H), 7.73 (d, J = 8.1 Hz, 1H), 7.66 (s, 1H), 7.62 (t, J = 7.5 Hz, 1H), 7.51 (t, J = 7.5 Hz, 
2H), 5.94 (ddt, J = 16.6, 10.7, 5.7 Hz, 1H), 5.35 – 5.26 (m, 2H), 4.71 (d, J = 5.7 Hz, 2H), 4.23 (d, 
J = 2.4 Hz, 2H), 3.91 (t, J = 6.4 Hz, 2H), 3.57 (t, J = 6.4 Hz, 2H), 2.86 (s, 2H), 2.44 (t, J = 2.4 
Hz, 1H), 1.41 (s, 6H). ESI-MS+ m/z = 485.0 (M + H
+
), 507.0 (M + Na
+
). HPLC (Method B, TR = 
8.15 min), 86% purity. 
 
 
2-(Prop-2-yn-1-yloxy)ethyl 4-methylbenzenesulfonate (139).  Prepared in a manner similar to 
compound 149 from propynol ethoxylate (138, 500 mg, 4.99 mmol).  Isolated the desired 
compound as a light yellow oil (914 mg, 72% yield).
1
H NMR (400 MHz, Chloroform-d) δ 7.81 
(d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 4.23 – 4.16 (m, 2H), 4.12 (d, J = 2.4 Hz, 2H), 3.75 
– 3.71 (m, 2H), 2.45 (s, 3H), 2.42 (t, J = 2.4 Hz, 1H). 
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4-Hydroxy-2-methylbenzonitrile (intermediate in synthesis of 140). To a dry flask of 
dichloromethane (34 mL) was added 4-methoxy-2-methylbenzonitrile 26c (1.5 g, 10.2 mmol).  
Boron trifluoride dimethyl sulfide complex (10.7 mL, 102 mmol) was then added slowly to the 
reaction mixture over 5 minutes. The reaction was allowed to stir 16 hours at room temperature. 
The reaction was quenched by the addition of water, and was allowed to stir for 15 minutes until 
fuming stopped.  The reaction was diluted with ethyl acetate (~100 mL) and partitioned via 
separatory funnel. The aqueous layer was extracted 2 more times with EtOAc, then the combined 
organic extract was washed with water 2x and brine.  The organic layer was isolated, dried over 
MgSO4, vacuum filtered and concentrated in vacuo to a light pink solid (1.31 g, 96% yield), used 
without further purification 
1
H NMR (500 MHz, DMSO-d6) δ 10.49 (s, 1H), 7.56 (d, J = 8.5 Hz, 
1H), 6.79 (d, J = 2.4 Hz, 1H), 6.72 (dd, J = 8.5, 2.4 Hz, 1H), 2.38 (s, 3H). 
 
 
4-((tert-Butyldimethylsilyl)oxy)-2-methylbenzonitrile (140). The phenol intermediate (1.305 g, 
9.80 mmol) was combined with dry DMF (1.7 mL) in a flask at room temperature.  Imidazole 
(1.67 g, 24.5 mmol) and TBS-Cl (1.77 g, 11.8 mmol) were added and the reaction was allowed 
to stir for 16h.  The reaction became biphasic over the course of reaction.  After 16h, the reaction 
mixture was poured into diethyl ether and washed 3x with water and 1x with brine.  The organic 
layer was isolated, dried over MgSO4, vacuum filtered, and concentrated in vacuo to a 
transparent red oil.  After further solvent removal via vacuum pump, the resulting oil (2.41 g, 
quant) was carried on without further purification. 
1
H NMR (500 MHz, Chloroform-d) δ 7.47 (d, 
J = 8.4 Hz, 1H), 6.74 (d, J = 2.3 Hz, 1H), 6.70 (dd, J = 8.4, 2.3 Hz, 1H), 2.48 (s, 3H), 0.98 (s, 
9H), 0.22 (s, 6H). 
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Ethyl 1-amino-6-((tert-butyldimethylsilyl)oxy)-3,3-dimethyl-3,4-dihydronaphthalene-2-
carboxylate (141). To a dry flask under N2 atmosphere was added anhydrous diglyme (46 mL) 
and diisopropylamine (5.5 mL, 38.8 mmol). The solution was cooled to -78°C in a dry ice bath, 
then n-butyllithium (2.5M in hexanes, 5.53 mL) was added slowly.  Benzonitrile intermediate 
140 (2.4 g, 9.7 mmol) was dissolved in ~3mL dry diglyme and added slowly dropwise to the 
reaction and was allowed to stir at -78°C for 60 minutes. Ethyl-3,3-dimethyl acrylate (4.05 mL, 
29.1 mmol) was added dropwise and allowed to stir an additional 1 hour at -78°C.  Concurrently, 
ZnI2 was generated in situ in a separate flame-dried flask containing dry diglyme (15 mL).  After 
addition of zinc powder (1.59 g, 24.3 mmol) to the flask, iodine (4.92 g, 19.4 mmol) was added 
portionwise over 20 minutes to the reaction (warning: exothermic). The reaction vessel was 
warmed in 30 second bursts with a heat gun until the color of iodine was replaced with a metallic 
silver color.  The suspension was allowed to cool to room temperature, then added to the first 
reaction mixture after its 2nd hour of stirring at -78°C, and then allowed to slowly warm to room 
temperature over the course of 2 hours.  The reaction was quenched with sat. aq. NH4Cl solution 
then extracted 3x with diethyl ether.  The combined organic extract was washed 3x with water 
and 1x with brine, then isolated, dried over MgSO4, vacuum filtered, and concentrated in vacuo.  
Purification via FC (0-15% EtOAc:hex) isolated 1.9 g of the desired product; a second FC 
purification of impure fractions resulted in an additional 400 mg to combine for 2.3 g of a light 
yellow solid (63% yield).
1
H NMR (500 MHz, Chloroform-d) δ 7.28 (d, J = 8.4 Hz, 1H), 6.74 
(dd, J = 8.4, 2.5 Hz, 1H), 6.67 (d, J = 2.4 Hz, 1H), 6.35 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 2.60 (s, 
2H), 1.36 (t, J = 7.1 Hz, 3H), 1.21 (s, 6H), 1.01 (s, 9H), 0.24 (s, 6H). 
 
 
3-Allyl-8-hydroxy-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one 
(142). TBS-protected aminoester 141 (1.9 g, 5.06 mmol) was dissolved in absolute ethanol (7 
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mL). Cesium carbonate (3.30 g, 10.12 mmol) was added, along with allyl isothiocyanate (983 
µL, 10.1 mmol).  The reaction mixture was warmed to 75°C and tightly capped.  Additional allyl 
isothiocyanate (1.48 mL, 15.2 mmol) was added in equal portions over the course of the next 3 
hours, then the reaction mixture was allowed to stir 12 additional hours at 75°C.  Reaction 
diluted with water and extracted into EtOAc 3x.  The pooled organic layers were washed with 
water and brine, then concentrated in vacuo.  Trituration of the resulting orange residue caused 
the precipitation of white crystals.  The crystals were collected via vacuum filtration and washed 
with cold hexanes and diethyl ether.  The desired product was recovered as a white powder (900 
mg, 57% yield).  Used without further purification. 
1
H NMR (400 MHz, DMSO-d6) δ 12.16 (s, 
1H), 10.15 (s, 1H), 7.78 (d, J = 8.3 Hz, 1H), 6.73 – 6.66 (m, 2H), 5.89 (ddd, J = 23.0, 10.6, 5.4 
Hz, 1H), 5.20 – 5.11 (m, 2H), 4.96 (d, J = 5.4 Hz, 2H), 2.65 (s, 2H), 1.21 (s, 6H). 
 
 
3-Allyl-8-hydroxy-5,5-dimethyl-2-(prop-2-yn-1-ylthio)-5,6-dihydrobenzo[h]quinazolin-
4(3H)-one (intermediate leading to 143). Deprotected thiourea 142 (50 mg, 0.159 mmol) was 
dissolved in dry DMF (1.0 mL) and cooled to 0°C in an ice bath.  Sodium bicarbonate (27 mg, 
0.318 mmol) was added, followed by propargyl bromide (21 µL, 0.239 mmol).  The reaction was 
allowed to stir for 16 hours while warming to room temperature.  The reaction was diluted with 
sat. aq. ammonium chloride solution. The resulting suspension was extracted 3x with ethyl 
acetate, then the combined organic layers were washed 3x with water and 1x with brine.  The 
organic layer was dried over MgSO4, vacuum filtered, and concentrated in vacuo. Further 
purification via column chromatography (100 hex -> 10% EtOAc:hex -> 20% EtOAc:hex) 
isolated the compound as a yellow solid  (40 mg, 71% yield). 
1
H NMR (500 MHz, DMSO-d6) δ 
9.91 (s, 1H), 8.02 (d, J = 8.5 Hz, 1H), 6.76 – 6.61 (m, 2H), 5.95 – 5.80 (m, 1H), 5.28 – 5.13 (m, 
2H), 4.57 (d, J = 5.2 Hz, 2H), 4.14 (s, 2H), 3.23 (s, 1H), 2.69 (s, 2H), 1.28 (s, 6H). 
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3-Allyl-5,5-dimethyl-8-(2-(3-methyl-3H-diazirin-3-yl)ethoxy)-2-(prop-2-yn-1-ylthio)-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (143) (CCG-205457). The S-propargyl phenol 
intermediate (30 mg, 0.085 mmol), alkylating agent 149 (16 mg, 0.063 mmol), and cesium 
carbonate (37 mg, 0.113 mmol) were combined in dry DMF (0.3 mL).  The reaction was capped 
and heated to 70°C for 1 hour.  The reaction mixture was diluted with water, and extracted 2x 
with diethyl ether.  The organic layer was then washed with water and brine, dried over MgSO4, 
vacuum filtered, and concentrated.  The resulting residue was purified via FC (0-10% 
EtOAc:hex) to furnish the product as a white solid (4 mg, 16% yield). 
1
H NMR (400 MHz, 
Chloroform-d) δ 8.08 (d, J = 8.6 Hz, 1H), 6.83 (dd, J = 8.6, 2.4 Hz, 1H), 6.75 – 6.64 (m, 2H), 
5.92 (ddt, J = 15.9, 10.7, 5.5 Hz, 1H), 5.37 – 5.22 (m, 2H), 5.16 (d, J = 6.5 Hz, 2H), 4.65 (d, J = 
5.5 Hz, 2H), 3.93 (t, J = 6.3 Hz, 2H), 2.74 (s, 2H), 1.84 (t, J = 6.3 Hz, 2H), 1.37 (s, 6H), 1.14 (s, 
3H). ESI+MS m/z = 435.2 (M + H
+
), 457.2 (M + Na
+
).   
 
 
3-Allyl-8-hydroxy-5,5-dimethyl-2-((2-(prop-2-yn-1-yloxy)ethyl)thio)-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (intermediate leading to 144).  Thiourea 142 (300 mg, 
0.954 mmol) was dissolved in DMF (5.6 mL), to which sodium bicarbonate (120 mg, 1.43 
mmol) and propargyloxyethyl tosylate 139 (291 mg, 1.145 mmol) were added.  The reaction was 
warmed to 75°C, capped, and allowed to stir for 16 h. Water was added to quench the reaction, 
and the resulting suspension was extracted 2x with ethyl acetate.  The organic layer washed with 
water 2x and brine 1x, then dried over MgSO4, vacuum filtered, and concentrated. The partially 
crystalline residue was further purified via flash chromatography (5-25% EtOAc:hex) to deliver 
248 mg of the desired product (66% yield).  
1
H NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 7.90 
(d, J = 8.5 Hz, 1H), 6.72 (d, J = 8.5 Hz, 1H), 6.64 (s, 1H), 5.91 – 5.79 (m, 1H), 5.21 (d, J = 10.4 
158 
 
Hz, 1H), 5.12 (d, J = 17.3 Hz, 1H), 4.59 (d, J = 5.2 Hz, 2H), 4.20 (d, J = 2.3 Hz, 2H), 3.78 (t, J = 
6.2 Hz, 2H), 3.50 (t, J = 6.2 Hz, 2H), 3.46 (t, J = 2.3 Hz, 1H), 2.67 (s, 2H), 1.27 (s, 6H).  
 
 
3-Allyl-5,5-dimethyl-8-(2-(3-methyl-3H-diazirin-3-yl)ethoxy)-2-((2-(prop-2-yn-1-
yloxy)ethyl)thio)-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (144) (CCG-205458). The S-
ethyloxypropargyl phenol intermediate (248 mg, 0.622 mmol) was dissolved in DMF (3.7 mL), 
to which cesium carbonate (304 mg, 0.933 mmol) and alkylating agent 149 (182 g, 0.716 mmol) 
were added.  The reaction was warmed to 75°C and tightly capped.   The reaction was allowed to 
stir for 4 hours, at which point water was added to quench the reaction, and the suspension was 
extracted with ethyl acetate.  The resulting organic layer was washed with water 2x and brine 1x, 
then isolated, dried over MgSO4, filtered, and concentrated. Further purification via flash 
chromatography (0-15% EtOAc:hex) isolated the desired product as 190 mg of a white 
crystalline solid (64% yield).   
1
H NMR (400 MHz, Chloroform-d) δ 8.00 (d, J = 8.5 Hz, 1H), 
6.81 (d, J = 8.5 Hz, 1H), 6.70 (s, 1H), 5.91 (ddt, J = 16.1, 10.5, 5.6 Hz, 1H), 5.31 – 5.21 (m, 2H), 
4.67 (d, J = 5.6 Hz, 2H), 4.21 (d, J = 2.4 Hz, 2H), 3.95 – 3.84 (m, 4H), 3.53 (t, J = 6.4 Hz, 2H), 
2.73 (s, 2H), 2.43 (t, J = 2.4 Hz, 1H), 1.83 (t, J = 6.4 Hz, 2H), 1.36 (s, 6H), 1.13 (s, 3H). 
ESI+MS m/z = 479.2 (M + H
+
), 501.2 (M + Na
+
). HPLC (Method B, TR = 8.17 min), >95% 
purity. 
 
 
3-Allyl-8-hydroxy-5,5-dimethyl-2-((2-(3-methyl-3H-diazirin-3-yl)ethyl)thio)-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (intermediate leading to 145 and 146). Thiourea 142 
(100 mg, 0.318 mmol) was dissolved in dry DMF (1.9 mL) and heated to 50°C.  Sodium 
bicarbonate (53 mg, 0.636 mmol) was added, followed by alkylating agent 149 (121 mg, 0.477 
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mmol).  Reaction was allowed to stir for 16h at 50°C.  Reaction mixture was diluted with sat. aq. 
NH4Cl, causing a white precipitate to form.  The suspension was extracted with EtOAc 3x, then 
the organic layer was washed 2x with water and 1x with brine.  The organic extract was dried 
over MgSO4, vacuum filtered, and concentrated, leaving an impure white solid. Trituration with 
diethyl ether furnished the desired product as 57 mg of a white solid (45% yield). 
1
H NMR (400 
MHz, DMSO-d6) δ 9.93 (s, 1H), 7.85 (d, J = 8.5 Hz, 1H), 6.72 (dd, J = 8.5, 2.4 Hz, 1H), 6.64 (d, 
J = 2.4 Hz, 1H), 5.86 (ddt, J = 16.6, 10.4, 5.1 Hz, 1H), 5.21 (d, J = 10.4 Hz, 1H), 5.11 (d, J = 
16.6 Hz, 2H), 4.57 (d, J = 5.1 Hz, 2H), 3.21 (t, J = 7.6 Hz, 2H), 2.67 (s, 2H), 1.80 (t, J = 7.6 Hz, 
2H), 1.26 (s, 6H), 1.09 (s, 3H). 
 
 
3-Allyl-5,5-dimethyl-2-((2-(3-methyl-3H-diazirin-3-yl)ethyl)thio)-8-(2-(prop-2-yn-1-
yloxy)ethoxy)-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (145) (CCG-205459). The S-2,2-
diazirinylbutane phenol (37 mg, 0.093 mmol) and alkylating agent 139 (36 mg, 0.140 mmol) 
were combined in dry DMF (549 µL)  along with of cesium carbonate (61 mg, 0.187 mmol).  
The reaction heated to 70°C and stirred for 16h.  The reaction was quenched via dilution with 
water, causing a white suspension to form.  The solution was extracted with ether 3x, then the 
organic layer was washed 2x with water and 1x with brine.  The organic layer was isolated, dried 
over MgSO4, vacuum filtered, and concentrated. Very conservative flash chromatography 
conditions (0-5% ethyl acetate:hexanes) was required to separate unreacted alkylating agent from 
the desired product, which was eventually isolated as a clear oil (18 mg, 41% yield). 
1
H NMR 
(400 MHz, Chloroform-d) δ 7.98 (d, J = 8.6 Hz, 1H), 6.88 (dd, J = 8.6, 2.2 Hz, 1H), 6.75 (d, J = 
2.2 Hz, 1H), 5.91 (ddt, J = 15.7, 10.3, 5.5 Hz, 1H), 5.33 – 5.18 (m, 2H), 4.65 (d, J = 5.5 Hz, 2H), 
4.29 (d, J = 2.3 Hz, 2H), 4.25 – 4.18 (m, 2H), 3.95 – 3.87 (m, 2H), 3.23 – 3.08 (m, 2H), 2.73 (s, 
2H), 2.48 (t, J = 2.3 Hz, 1H), 1.96 – 1.81 (m, 2H), 1.37 (s, 6H), 1.12 (s, 3H). ESI+MS m/z = 
479.2 (M + H
+
), 501.2 (M + Na
+
).   
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3-Allyl-5,5-dimethyl-2-((2-(3-methyl-3H-diazirin-3-yl)ethyl)thio)-8-(prop-2-yn-1-yloxy)-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (146) (CCG-205460): The S-2,2-diazirinylbutane 
phenol intermediate (30 mg, 0.076 mmol)and propargyl bromide (14 mg, 0.113 mmol) were 
combined in dry DMF (0.5 mL) with cesium carbonate (49 mg, 0.151 mmol).  The reaction 
heated to 70°C for 16 hours.  The reaction was diluted with water, causing a white suspension to 
form.  The solution was extracted with ether 3x, then the organic layer washed 2x with water and 
1x with brine.  The organic layer was isolated, dried over MgSO4, filtered, and concentrated.  
Flash purification (100% hex to 5% EtOAc:hex) isolated the compound as a white crystalline 
solid (8 mg, 24% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.01 (d, J = 8.6 Hz, 1H), 6.94 (dd, 
J = 8.6, 2.4 Hz, 1H), 6.79 (d, J = 2.4 Hz, 1H), 5.91 (ddt, J = 15.6, 10.7, 5.5 Hz, 1H), 5.35 – 5.18 
(m, 2H), 4.75 (d, J = 2.3 Hz, 2H), 4.66 (d, J = 5.5 Hz, 2H), 3.24 – 3.08 (m, 2H), 2.76 (s, 2H), 
2.56 (t, J = 2.3 Hz, 1H), 1.96 – 1.80 (m, 2H), 1.37 (s, 6H), 1.12 (s, 3H). ESI+MS m/z = 435.2 (M 
+ H
+
), 457.2 (M + Na
+
).   
 
 
2-(3-Methyl-3H-diazirin-3-yl)ethan-1-ol (148). 4-hydroxy-2-butanone (147, 1.00 grams, 11.35 
mmol) was pipetted into a dry RBF and cooled down to 0°C under N2.  7N methanolic ammonia 
was added via syringe (11.2 mL, 79 mmol), and the solution was allowed to stir at 0°C for 3 
hours.  A solution of hydroxylamine-O-sulfonic acid (1.476 g, 13.05 mmol) in methanol (9.7 
mL)was added dropwise, then was allowed to stir for an additional 16 hours while slowly 
warming to room temperature. The reaction was filtered through a sintered glass funnel, then 
transferred to a reaction vessel and re-cooled to 0°C. Triethylamine (1.58 mL, 11.35 mmol) was 
added, then molecular iodine (2.88 g, 11.35 mmol) was added slowly in 10 equal portions until 
the purple/brown color of iodine persisted in the reaction vessel.  The solvent was removed under 
reduced pressure.  Purification of the crude isolate via Kugelrohr distillation (60°C, 1-3 torr) 
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delivered the desired product as a clear oil (304 mg, 27% yield).
1
H NMR (500 MHz, 
Chloroform-d) δ 3.55 (t, J = 6.3 Hz, 2H), 1.65 (t, J = 6.3 Hz, 2H), 1.50 (bs, 1H), 1.08 (s, 3H). 
 
 
2-(3-Methyl-3H-diazirin-3-yl)ethyl 4-methylbenzenesulfonate (149). 3,3-diazirinyl butan-1-ol 
148 (300 mg, 3.00 mmol) was dissolved in dry pyridine (6 mL) and cooled to 0°C in an ice bath.   
To this solution was added p-toluenesulfonyl chloride (628 mg, 3.30 mmol).  The reaction 
mixture was allowed to stir for 24 hours at 0-4°C, then was poured into a mixture of 37% w/v 
HCl (15 mL) and ice (80 mL).  The resulting suspension was extracted 3x with ether, then the 
pooled organic layers were washed with 1N HCl solution, 1N NaOH solution, water, and brine.  
The organic extract was dried over MgSO4, vacuum filtered, and concentrated to a clear oil (428 
mg, 56.2% yield) used without further purification. TLC Rf (2:1 hex:EtOAc) = 0.6.
1
H NMR 
(500 MHz, Chloroform-d) δ 7.82 (d, J = 7.9 Hz, 2H), 7.37 (d, J = 7.9 Hz, 2H), 3.96 (t, J = 6.4 
Hz, 2H), 2.46 (s, 3H), 1.68 (t, J = 6.4 Hz, 2H), 1.01 (s, 2H). 
 
 
5-Iodo-2-methylbenzonitrile (intermediate used in synthesizing 151). Water (30 mL) and 
concentrated hydrogen chloride solution (37% w/v, 9 mL) were cooled to 0°C in an ice bath.  
Aniline intermediate 150 (3.00 g, 22.7 mmol) was added, followed by a solution of sodium 
nitrite (1.72 g, 25.0 mmol) in water (7.5 mL). The solution was allowed to stir at 0°C until all of 
the starting material dissolved (30 minutes).  A solution of potassium iodide (5.65 g, 34.0 mmol) 
in water (7.5 mL) was added and allowed to stir for an additional 30 minutes at 0°C. Diethyl 
ether (20 mL) was added before stirring an additional 30 min.  The reaction mixture was loaded 
into a separatory funnel, and the organic layer was isolated.  The aqueous layer was extracted 
with additional diethyl ether, then the pooled organic extracts were washed with saturated 
aqueous sodium thiosulfate solution, saturated NaHCO3, water, and brine.  The organic layer was 
dried over MgSO4, filtered, and concentrated, leaving an orange crystalline residue. Flash 
purification via 3-5% EtOAc:hex delivered the title compound as a white solid (3.86 g, 70% 
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yield). TLC Rf (10% EtOAc:hex) = 0.7, 
1
H NMR (400 MHz, Chloroform-d) δ 7.90 (d, J = 1.9 
Hz, 1H), 7.79 (dd, J = 8.2, 1.9 Hz, 1H), 7.07 (d, J = 8.2 Hz, 1H), 2.50 (s, 3H). 
 
 
Ethyl 1-amino-7-iodo-3,3-dimethyl-3,4-dihydronaphthalene-2-carboxylate (151).  Prepared 
according to General Method B from the previously described iodotolunitrile (3.5 g, 14.4 mmol).  
Recovered the desired product as light yellow crystals (1.23 g, 23% yield).  
1
H NMR (400 MHz, 
Chloroform-d) δ 7.70 (d, J = 1.6 Hz, 1H), 7.61 (dd, J = 7.8, 1.6 Hz, 1H), 6.92 (d, J = 7.9 Hz, 
1H), 6.18 (s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 2.58 (s, 2H), 1.34 (t, J = 7.1 Hz, 3H), 1.18 (s, 6H). 
 
 
Ethyl 1-amino-7-azido-3,3-dimethyl-3,4-dihydronaphthalene-2-carboxylate (152). Iodo-
aminoester 151 (1.00 g, 2.69 mmol) was added to a 5:1 DMSO:water solution (5.4 mL) under 
argon atmosphere. Sodium ascorbate (107 mg, 0.539 mmol), N,N-dimethyl-ethylenediamine (43 
µL, 0.404 mmol) and sodium azide (350 mg, 5.39 mmol) were added and allowed to fully 
dissolve. The mixture was purged with argon via immersion of an argon needle below the 
surface for 2 minutes, then copper(I)iodide (51 mg, 0.269 mmol) was added and the reaction 
vessel sealed under argon atmosphere.  The reaction vessel was lightly heated with a heat gun to 
promote reaction components to fully dissolve.  The reaction vessel was covered in tin foil and 
allowed to stir at RT for 30 minutes.  Reaction quenched via addition of more water, then was 
extracted with diethyl ether.  The organic layer was washed 2x with water and 1x with brine, 
then dried over MgSO4, vacuum filtered and concentrated in vacuo, delivering the title 
compound as a light brown oil (658 mg, 85% yield).
1
H NMR (400 MHz, Chloroform-d) δ 7.17 
(d, J = 7.8 Hz, 1H), 7.04 – 6.94 (m, 2H), 6.19 (s, 2H), 4.26 (q, J = 7.0 Hz, 2H), 2.62 (s, 2H), 1.35 
(t, J = 7.0 Hz, 3H), 1.19 (s, 6H). 
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9-Azido-5,5-dimethyl-2-thioxo-2,3,5,6-tetrahydrobenzo[h]quinazolin-4(1H)-one (153).  
Aminoester intermediate 152 (658 mg, 2.30 mmol) was combined with benzoyl isothiocyanate 
(488 mg, 2.99 mmol) in absolute ethanol (2.7 mL).  The reaction was warmed to 75°C and 
allowed to stir 3 hours.  Additional benzoyl isothiocyanate (244 mg, 1.50 mmol) was added, and 
the reaction was allowed to stir at 75°C for an additional 12 hours.  At this point the reaction 
mixture was dissolved in DCM, and the organic layer washed with water and brine. The organic 
layer was isolated, dried over MgSO4, filtered, and concentrated, resulting in a yellow-orange oil.  
Column chromatography isolated the uncyclized N-benzoyl thiourea (690 mg) as a white solid. 
This intermediate was dissolved in EtOH (3 mL) and warmed to 75°C.  A solution of KOH (172 
mg, 3.07 mmol) in water (1.5 mL) was added to the flask allowed to stir for 1.5 hours. Reaction 
was quenched via the addition of ~5mL 1N HCl, causing the precipitation of a white solid. Solid 
was collected via vacuum filtration and washed with saturated aqueous sodium bicarbonate and 
water.  Drying under high vacuum yielded the desired product as a white powder (372 mg, 54% 
yield over 2 steps). 
1
H NMR (400 MHz, DMSO-d6) δ 12.43 (s, 1H), 12.28 (s, 1H), 7.78 (d, J = 
2.1 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.13 (dd, J = 8.0, 2.1 Hz, 1H), 2.71 (s, 2H), 1.21 (s, 6H). 
 
 
9-Azido-2-((2-((3-(tert-butyldimethylsilyl)prop-2-yn-1-yl)oxy)ethyl)thio)-5,5-dimethyl-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (intermediate used in synthesis of 154). Azido 2-
thioxopyrimidinone intermediate 153 (320 mg, 1.07 mmol) was dissolved in DMF (6.3 mL), to 
which the TBS-protected alkyne alkylating agent 156 (414 mg, 1.12 mmol) was added.  Sodium 
bicarbonate (135 mg, 1.60 mmol) was added and the mixture was stirred at 50°C for 6 hours.  
The reaction was quenched by the addition of water, causing the precipitation of a white solid 
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from the aqueous layer.  Vacuum filtration isolated 530 mg of solid (92% crude yield) found to 
be the title compound with a minor (~10%) impurity of alkylating agent.  Carried on without 
further purification. 
1
H NMR (400 MHz, Chloroform-d) δ 12.14 (s, 1H), 7.82 (d, J = 2.4 Hz, 
1H), 7.17 (d, J = 8.0 Hz, 1H), 7.00 (dd, J = 8.0, 2.4 Hz, 1H), 4.26 (s, 2H), 3.92 (t, J = 6.1 Hz, 
2H), 3.50 (t, J = 6.1 Hz, 2H), 2.76 (s, 2H), 1.41 (s, 6H), 0.88 (s, 9H), 0.06 (s, 6H). 
 
 
3-Allyl-9-azido-2-((2-((3-(tert-butyldimethylsilyl)prop-2-yn-1-yl)oxy)ethyl)thio)-5,5-
dimethyl-5,6-dihydrobenzo[h]quinazolin-4(3H)-one (154). The S-alkylated intermediate 
described above (490 mg, 0.988 mmol) was dissolved in absolute EtOH (5.8 mL), to which 
sodium methoxide (107 mg, 1.98 mmol) was added.  The mixture was allowed to stir for 20 
minutes, then allyl bromide (598 mg, 4.94 mmol) was added.  Reaction was heated to 75°C and 
allowed to stir for 16 hours.  The reaction was halted by the addition of H2O.  The aqueous 
mixture was extracted into ethyl acetate 3 times, then the pooled organic extracts were washed 
twice with water and once with brine. The organic layer was isolated, dried over MgSO4, 
filtered, and concentrated in vacuo.  Further purification via FC (5% EtOAc:hex) returned the 
compound as a clear oil (254 mg, 48% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.78 (d, J = 
2.4 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 6.99 (dd, J = 8.0, 2.4 Hz, 1H), 5.92 (ddt, J = 15.9, 10.9, 5.6 
Hz, 1H), 5.34 – 5.23 (m, 2H), 4.69 (d, J = 5.6 Hz, 2H), 4.24 (s, 2H), 3.92 (t, J = 6.0 Hz, 2H), 
3.54 (t, J = 6.0 Hz, 2H), 2.76 (s, 2H), 1.38 (s, 6H), 0.87 (s, 9H), 0.05 (s, 6H). 
 
 
3-Allyl-9-azido-5,5-dimethyl-2-((2-(prop-2-yn-1-yloxy)ethyl)thio)-5,6-
dihydrobenzo[h]quinazolin-4(3H)-one (155) (CCG-206603). The TBS-protected intermediate 
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154 (254 mg, 0.474 mmol) was dissolved in anhydrous THF (4 mL) and cooled to 0°C.  TBAF 
(1M solution in THF, 1.00 mL) was then added dropwise to the reaction and monitored for 3 
hours.  After 3 hours, the spot corresponding to starting material had completely disappeared, 
being replaced by a more polar spot that still turned brown upon UV exposure. The reaction was 
quenched with water and diluted with diethyl ether.  The organic layer was washed with water 
and brine, then dried, filtered, and concentrated.  Further purification by FC (0-15% EtOAc:hex) 
delivered the desired product as a white crystalline solid (130 mg, 65% yield).
1
H NMR (400 
MHz, Chloroform-d) δ 7.77 (d, J = 2.2 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 7.00 (dd, J = 8.0, 2.2 
Hz, 1H), 5.93 (ddt, J = 16.3, 10.8, 5.6 Hz, 1H), 5.34 – 5.24 (m, 2H), 4.70 (d, J = 5.6 Hz, 2H), 
4.23 (d, J = 2.1 Hz, 2H), 3.92 (t, J = 6.2 Hz, 2H), 3.55 (t, J = 6.2 Hz, 2H), 2.76 (s, 2H), 2.43 (t, J 
= 2.1 Hz, 1H), 1.38 (s, 6H). ESI+MS m/z = 444.1 (M + Na
+
). HPLC (Method B, tR = 8.74 min), 
purity >95%. 
 
 
2-((3-(tert-Butyldimethylsilyl)prop-2-yn-1-yl)oxy)ethyl 4-methylbenzenesulfonate (156). A 
dry flask was charged with anhydrous THF (5.2 mL) and tosylated alkyne 139 (200 mg, 0.786 
mmol) was cooled to -78°C.  A hexane solution of n-butyllithium (2.5 M, 0.5 mL) was added 
slowly dropwise, and the mixture was allowed to stir for 2 hours before the dropwise addition of 
TBS-OTf (271 µL, 1.18 mmol).  The reaction was stirred for an additional 30 minutes, then 
quenched via the addition of saturated aqueous NH4Cl solution.  The resulting suspension was 
extracted 3x into ether, then washed with saturated aqueous NaHCO3 and brine, isolated, dried 
over MgSO4, vacuum filtered, and concentrated. Flash chromatography (5% EtOAc:hex) isolated 
the title compound as a clear oil (182 mg, 63% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.80 
(d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 4.23 – 4.15 (m, 2H), 4.13 (s, 2H), 3.76 – 3.69 (m, 
2H), 2.45 (s, 3H), 0.92 (s, 9H), 0.10 (s, 6H). 
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tert-Butyl 4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate (173). Sodium hydride (60 
wt%, 1.31 g, 32.6 mmol) was added to a dry reaction vessel and triturated 2x with hexanes. 
Anhydrous DMF (50 mL) was added to the reaction flask and the resulting suspension was 
cooled to 0°C.  Trimethyl phosphonoacetate (5.71 g, 31.4 mmol) was added slowly over the 
course of 15 minutes, causing the evolution of hydrogen gas bubbles.  The reaction was allowed 
to stir for an additional 15 minutes, then a solution of tert-butyl 4-oxopiperidine-1-carboxylate 
(172, 5.00 g, 25.1 mmol) in anhydrous DMF (10 mL) was added over the course of 10 minutes.  
The reaction was allowed to slowly warm to room temperature over 3 hours with stirring.  The 
reaction was quenched via the addition of water (200 mL), and the resulting aqueous suspension 
was extracted 3x with diethyl ether.  The pooled organic fractions were washed with water (3x) 
and brine, then dried over MgSO4, vacuum filtered, and concentrated in vacuo.  The resulting 
white crystalline solid (6.36g, 99% yield) was used without further purification. 
1
H NMR (400 
MHz, Chloroform-d) δ 5.70 (s, 1H), 3.68 (s, 3H), 3.53 – 3.42 (m, 4H), 2.92 (t, J = 5.8 Hz, 2H), 
2.27 (t, J = 5.8 Hz, 2H), 1.46 (s, 9H). 
 
 
1'-tert-Butyl 3-methyl 4-amino-7-methoxy-1H-spiro[naphthalene-2,4'-piperidine]-1',3-
dicarboxylate (174). Reaction performed according to General Method B from tolunitrile 26c 
(2.31 g, 15.67 mmol) and Michael acceptor 173 (4.00 g, 15.67 mmol).  Purification of the 
concentrated organic extract via flash chromatography (5-25% EtOAc:hex), followed by 
trituration of the resulting residue with cold diethyl ether furnished the desired product as a white 
powder (4.25 g, 74% yield).
 1
H NMR (400 MHz, Chloroform-d) δ 7.33 (d, J = 8.6 Hz, 1H), 6.80 
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(dd, J = 8.6, 2.6 Hz, 1H), 6.73 (d, J = 2.6 Hz, 1H), 6.30 (s, 2H), 3.98 – 3.77 (m, 5H), 3.74 (s, 
3H), 3.06 – 2.89 (m, 2H), 2.87 (s, 2H), 2.39 – 2.23 (m, 2H), 1.46 (s, 9H), 1.26 – 1.17 (m, 2H). 
 
 
1'-tert-Butyl 3-methyl 4-(3-benzoylthioureido)-7-methoxy-1H-spiro[naphthalene-2,4'-
piperidine]-1',3-dicarboxylate (intermediate in synthesis of 175).  To a stirred solution of β-
aminoester 174 (4.25 g, 10.6 mmol) in absolute ethanol (21.2 mL) was added benzoyl 
isothiocyanate (1.80 mL, 12.7 mmol).  The reaction was warmed to reflux and allowed to stir for 
2 hours.  Additional benzoyl isothiocyanate (900 µL, 6.35 mmol) was added and the reaction 
was stirred at reflux for an additional 4 hours.  The reaction was quenched via the addition of 
water (80 mL), and the resulting aqueous solution was extracted 3x with ethyl acetate.  The 
organic extract was washed with water and brine, then dried over MgSO4, vacuum filtered, and 
concentrated to an orange oil.  Further purification via flash chromatography (10-40% 
EtOAc:hex) furnished the desired product as a pale yellow solid (3.88 g, 65% yield). 
1
H NMR 
(400 MHz, Chloroform-d) δ 11.74 (s, 1H), 9.15 (s, 1H), 7.91 (d, J = 7.9 Hz, 2H), 7.67 (t, J = 7.4 
Hz, 1H), 7.55 (t, J = 7.6 Hz, 2H), 7.22 (d, J = 8.4 Hz, 1H), 6.79 – 6.71 (m, 2H), 4.02 – 3.76 (m, 
8H), 3.12 – 2.94 (m, 4H), 1.96 (td, J = 13.1, 4.8 Hz, 2H), 1.46 (d, J = 1.8 Hz, 11H). 
 
 
tert-Butyl 8-methoxy-4-oxo-2-thioxo-2,3,4,6-tetrahydro-1H-spiro[benzo[h]quinazoline-5,4'-
piperidine]-1'-carboxylate (175). The N-benzoyl thiourea intermediate (3.88 g, 6.86 mmol) was 
dissolved in absolute ethanol (18 mL) and warmed to 70°C.  A solution of potassium hydroxide 
(85 wt%, 905 mg, 13.72 mmol) in water (9.2 mL) was added, and the resulting suspension was 
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stirred at 70°C for 2 hours.  At this time the reaction was diluted with water (50 mL) and 
carefully acidified to pH ~7 with 1M HCl and cooled to 4°C.  The resulting white precipitate was 
collected via vacuum filtration, washed with water and cold diethyl ether, and dried under high 
vacuum to yield the desired product (2.44 g, 83% yield) as an off-white solid used without 
further purification. 
1
H NMR (400 MHz, DMSO-d6) δ 12.12 (s, 2H), 7.83 (d, J = 8.7 Hz, 1H), 
6.96 (d, J = 2.6 Hz, 1H), 6.90 – 6.82 (m, 1H), 3.82 – 3.69 (m, 5H), 3.11 – 2.84 (m, 4H), 2.59 – 
2.30 (m, 2H), 1.37 (s, 9H), 1.11 (d, J = 12.8 Hz, 2H). 
 
 
tert-Butyl 8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (176a).  Cyclic thiourea 
intermediate 175 (500 mg, 1.16 mmol) was added to anhydrous DMF (6.8 mL), followed by 
sodium bicarbonate (108 mg, 1.28 mmol) and 2-methoxyethyl p-toluenesulfonic ester (281 mg, 
1.22 mmol).  The suspension was warmed to 70°C and allowed to stir for 16 hours.  At this point 
the reaction was diluted with water (50 mL) and the resulting precipitate was collected via 
vacuum filtration.  The precipitate was washed with water, followed by cold hexane:diethyl ether 
(1:1) and dried further under high vacuum to isolate the desired product as a white powder (360 
mg, 63% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 12.52 (s, 1H), 7.94 (d, J = 8.7 Hz, 1H), 6.94 – 
6.83 (m, 2H), 3.81 – 3.69 (m, 5H), 3.60 (t, J = 6.3 Hz, 2H), 3.38 (t, J = 6.3 Hz, 2H), 3.26 (s, 3H), 
3.02 (s, 4H), 2.67 – 2.38 (m, 2H), 1.38 (s, 9H), 1.19 (d, J = 13.3 Hz, 2H). 
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tert-Butyl 2-(ethylthio)-8-methoxy-4-oxo-4,6-dihydro-3H-spiro[benzo[h]quinazoline-5,4'-
piperidine]-1'-carboxylate (176b). The 2-thioxo pyrimidinone intermediate 175 (79 mg, 0.184 
mmol) was dissolved in DMF (1.1 mL), to which sodium bicarbonate (23 mg, 0.276 mmol) and 
iodoethane (16 µL, 0.202 mmol) were added.  The reaction was capped and heated to 50°C for 
16 hours.  The reaction was quenched via the addition of water, followed by extraction into ethyl 
acetate (3x).  The pooled organic layers were then washed 3x with water and brine.  The organic 
layer was isolated, dried over MgSO4, vacuum filtered, and concentrated to a crystalline residue 
(68 mg, 81% yield), used without further purification. 
1
H NMR (400 MHz, Chloroform-d) δ 
10.59 (s, 1H), 8.06 (d, J = 8.6 Hz, 1H), 6.84 (dd, J = 8.6, 2.5 Hz, 1H), 6.72 (d, J = 2.5 Hz, 1H), 
4.06 – 3.87 (m, 2H), 3.84 (s, 3H), 3.27 (q, J = 7.4 Hz, 2H), 3.15 – 2.92 (m, 4H), 2.90 – 2.77 (m, 
1H), 2.71 – 2.56 (m, 1H), 1.45 (s, 12H), 1.42 – 1.34 (m, 2H). 
 
 
tert-Butyl 2-((cyanomethyl)thio)-8-methoxy-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (176c). Synthesis performed in a 
manner similar to 176a from 175 (250 mg, 0.582 mmol) using α-chloroacetonitrile (48 mg, 0.640 
mmol) as the alkylating agent.  The washed organic extract concentrated under high vacuum 
yielded a light yellow powder that was used without further purification (220 mg, 81% yield). 
1
H 
NMR (400 MHz, DMSO-d6) δ 12.79 (s, 1H), 8.13 (d, J = 8.8 Hz, 1H), 6.98 – 6.87 (m, 2H), 4.31 
(s, 2H), 3.93 – 3.68 (m, 5H), 3.25 – 2.92 (m, 4H), 2.69 – 2.36 (m, 2H), 1.41 (s, 9H), 1.25 (d, J = 
11.9 Hz, 2H). 
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tert-Butyl 3-allyl-8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (177) (CCG-206660) and tert-
Butyl 4-(allyloxy)-8-methoxy-2-((2-methoxyethyl)thio)-6H-spiro[benzo[h]quinazoline-5,4'-
piperidine]-1'-carboxylate (184) (CCG-208862). The S-alkylated intermediate (790 mg, 1.62 
mmol) was dissolved in absolute EtOH (9.5 mL), to which allyl bromide (210 µL, 2.43 mmol) 
and sodium methoxide (175 mg, 3.24 mmol) were added.  Reaction was heated to 75°C and 
capped, allowed to stir for 2 hours. Additional allyl bromide (210 µL, 2.43 mmol) was added in 3 
equal portions over the course of 3 hours, and the reaction mixture was then allowed to stir a 
further 12 hours. The reaction was cooled, then diluted with H2O and extracted 3x with EtOAc.  
The organic extract was washed with water and brine, then isolated, dried over MgSO4, vacuum 
filtered, and concentrated.  Further purification via FC (5% EtOAc:hex) returned the pure N-
alkylated 177 (210 mg, 25% yield) and O-alkylated 184 (94 mg, 11% yield). 
tert-Butyl 3-allyl-8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (177) (CCG-206660): 
1
H NMR 
(400 MHz, Chloroform-d) δ 8.02 (d, J = 8.6 Hz, 1H), 6.85 (dd, J = 8.6, 2.5 Hz, 1H), 6.74 (d, J = 
2.4 Hz, 1H), 5.91 (ddt, J = 15.9, 10.4, 5.6 Hz, 1H), 5.29 – 5.23 (m, 2H), 4.67 (d, J = 4.9 Hz, 2H), 
4.09 – 3.89 (m, 2H), 3.86 (s, 3H), 3.75 (t, J = 6.2 Hz, 2H), 3.52 (t, J = 6.2 Hz, 2H), 3.42 (s, 3H), 
3.17 – 2.86 (m, 5H), 2.70 – 2.50 (m, 1H), 1.46 (s, 9H), 1.37 (d, J = 10.6 Hz, 2H). ESI+MS m/z = 
528.2 (M + H
+
), 550.2 (M + Na
+
). HPLC (Method B, tR = 8.14 min), purity >95%. 
tert-Butyl 4-(allyloxy)-8-methoxy-2-((2-methoxyethyl)thio)-6H-spiro[benzo[h]quinazoline-
5,4'-piperidine]-1'-carboxylate (184) (CCG-208862). 
1
H NMR (400 MHz, Chloroform-d) δ 
8.13 (d, J = 8.6 Hz, 1H), 6.84 (dd, J = 8.6, 2.5 Hz, 1H), 6.70 (d, J = 2.5 Hz, 1H), 6.11 – 5.96 (m, 
1H), 5.35 (d, J = 17.3 Hz, 1H), 5.24 (d, J = 10.5 Hz, 1H), 4.90 (d, J = 5.4 Hz, 2H), 4.05 – 3.86 
(m, 2H), 3.84 (s, 3H), 3.70 (t, J = 6.9 Hz, 2H), 3.40 (s, 3H), 3.36 (t, J = 6.9 Hz, 2H), 3.16 – 2.94 
(m, 4H), 2.48 (td, J = 13.1, 4.9 Hz, 2H), 1.48 – 1.38 (m, 11H). ESI+MS m/z = 528.2 (M + H+), 
550.2 (M + Na
+
).  HPLC (Method B, tR = 9.07 min), purity 95%. 
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tert-Butyl 4-(cyanomethoxy)-8-methoxy-2-((2-methoxyethyl)thio)-6H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (185) (CCG-211814) and tert-
Butyl 3-(cyanomethyl)-8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (178) (CCG-211815). Prepared in 
a manner similar to 183 and 189 from intermediate 176a (77 mg, 0.158 mmol) and alkylating 
agent α-chloroacetonitrile.  Isolated the products via column chromatography (5-25% 
EtOAc:hex). tert-Butyl 4-(cyanomethoxy)-8-methoxy-2-((2-methoxyethyl)thio)-6H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (185) (CCG-211814) 24 mg, 29% 
yield; 
1
H NMR (500 MHz, Chloroform-d) δ 8.17 (d, J = 8.7 Hz, 1H), 6.88 (dd, J = 8.7, 2.4 Hz, 
1H), 6.73 (d, J = 2.4 Hz, 1H), 5.21 – 4.93 (m, 2H), 4.08 – 3.88 (m, 2H), 3.87 (s, 3H), 3.75 (t, J = 
6.7 Hz, 2H), 3.46 – 3.38 (m, 5H), 3.16 – 2.99 (m, 4H), 2.44 – 2.29 (m, 2H), 1.55 – 1.43 (m, 
11H). ESI+MS m/z = 527.1 (M + H
+
) 549.0 (M + Na
+
). HPLC (Method B, tR = 6.51 min), purity 
84%.; tert-Butyl 3-(cyanomethyl)-8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-
3H-spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (178) (CCG-211815) 24 mg, 
29% yield; 
1
H NMR (500 MHz, Chloroform-d) δ 8.01 (d, J = 8.6 Hz, 1H), 6.87 (dd, J = 8.6, 2.5 
Hz, 1H), 6.75 (d, J = 2.5 Hz, 1H), 5.09 – 4.78 (m, 2H), 4.07 – 3.90 (m, 2H), 3.87 (s, 3H), 3.78 (t, 
J = 6.1 Hz, 2H), 3.61 (t, J = 6.1 Hz, 2H), 3.43 (s, 3H), 3.16 – 2.92 (m, 4H), 2.91 – 2.75 (m, 1H), 
2.69 – 2.46 (m, 1H), 1.47 (s, 9H), 1.44 – 1.32 (m, 2H). ESI+MS m/z = 527.1 (M + H+) 549.0 (M 
+ Na
+
). HPLC (Method B, tR = 6.53 min), purity >95%. 
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tert-Butyl 4,8-dimethoxy-2-((2-methoxyethyl)thio)-6H-spiro[benzo[h]quinazoline-5,4'-
piperidine]-1'-carboxylate (186) (CCG-211816) and tert-Butyl 8-methoxy-2-((2-
methoxyethyl)thio)-3-methyl-4-oxo-4,6-dihydro-3H-spiro[benzo[h]quinazoline-5,4'-
piperidine]-1'-carboxylate (179) (CCG-211817). Prepared in a manner similar to 182 and 188 
from intermediate 176a (150 mg, 0.308 mmol) and methyl tosylate.  Isolated the products via 
column chromatography (5-25% EtOAc:hex). tert-Butyl 4,8-dimethoxy-2-((2-
methoxyethyl)thio)-6H-spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (186) 
(CCG-211816) 30 mg, 20% yield; 
1
H NMR (500 MHz, Chloroform-d) δ 8.16 (d, J = 8.7 Hz, 
1H), 6.86 (dd, J = 8.7, 2.5 Hz, 1H), 6.74 – 6.70 (m, 1H), 3.97 (s, 3H), 3.94 – 3.89 (m, 2H), 3.86 
(s, 3H), 3.74 (t, J = 6.9 Hz, 2H), 3.47 – 3.36 (m, 5H), 3.14 – 3.05 (m, 2H), 3.04 (s, 2H), 2.54 – 
2.37 (m, 2H), 1.49 (s, 9H), 1.44 (d, J = 12.0 Hz, 2H). ESI+MS m/z = 502.1 (M + H
+
). HPLC 
(Method B, tR = 8.44 min), purity >95%. tert-Butyl 8-methoxy-2-((2-methoxyethyl)thio)-3-
methyl-4-oxo-4,6-dihydro-3H-spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate 
(179) (CCG-211817) 68 mg, 44% yield 
1
H NMR (500 MHz, Chloroform-d) δ 8.02 (d, J = 8.6 
Hz, 1H), 6.86 (dd, J = 8.6, 2.6 Hz, 1H), 6.74 (d, J = 2.6 Hz, 1H), 4.06 – 3.90 (m, 2H), 3.86 (s, 
3H), 3.77 (t, J = 6.2 Hz, 2H), 3.54 (t, J = 6.2 Hz, 2H), 3.50 (s, 3H), 3.43 (s, 3H), 3.17 – 2.84 (m, 
5H), 2.71 – 2.54 (m, 1H), 1.47 (s, 9H), 1.40 – 1.31 (m, 2H). ESI+MS m/z = 502.1 (M + H+) 
524.1 (M + Na
+
). HPLC (Method B, tR = 7.31 min), purity >95%. 
 
tert-Butyl 4-(3-hydroxypropoxy)-8-methoxy-2-((2-methoxyethyl)thio)-6H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (187) (CCG-212346) and tert-
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Butyl 3-(3-hydroxypropyl)-8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (180) (CCG-212347). Prepared in 
a manner similar to 182 and 188 from intermediate 176a (300 mg, 0.615 mmol) and 3-
bromopropan-1-ol (83 µL, 0.923 mmol).  Separation of the crude mixture (180 mg, 54% crude 
yield) required the use of prep-scale HPLC, yielding 35 mg 180 and 20 mg 187. tert-Butyl 4-(3-
hydroxypropoxy)-8-methoxy-2-((2-methoxyethyl)thio)-6H-spiro[benzo[h]quinazoline-5,4'-
piperidine]-1'-carboxylate (187) (CCG-212346)
 1
H NMR (400 MHz, Chloroform-d) δ 8.15 (d, 
J = 8.6 Hz, 1H), 6.86 (dd, J = 8.6, 2.5 Hz, 1H), 6.72 (d, J = 2.5 Hz, 1H), 4.57 (t, J = 6.0 Hz, 2H), 
4.13 – 3.89 (m, 2H), 3.86 (s, 3H), 3.81 – 3.62 (m, 4H), 3.42 (s, 3H), 3.39 (t, J = 7.0 Hz, 2H), 3.15 
– 2.97 (m, 4H), 2.62 – 2.34 (m, 2H), 2.29 – 2.23 (m, 1H), 2.02 (p, J = 6.0 Hz, 2H), 1.48 (s, 9H), 
1.44 (d, J = 13.6 Hz, 2H).  ESI+MS m/z = 546.3 (M + H
+
). HPLC (Method A, tR = 8.56 min), 
purity >95%. tert-Butyl 3-(3-hydroxypropyl)-8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-
dihydro-3H-spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (180) (CCG-212347). 
1
H NMR (400 MHz, Chloroform-d) δ 7.99 (d, J = 8.6 Hz, 1H), 6.84 (dd, J = 8.6, 2.5 Hz, 1H), 
6.73 (d, J = 2.5 Hz, 1H), 4.25 – 4.19 (m, 2H), 4.04 – 3.88 (m, 2H), 3.85 (s, 3H), 3.78 – 3.67 (m, 
3H), 3.56 – 3.47 (m, 4H), 3.41 (s, 3H), 3.01 (d, J = 23.4 Hz, 4H), 2.90 – 2.73 (m, 1H), 2.70 – 
2.50 (m, 1H), 1.97 (p, J = 5.9 Hz, 2H), 1.46 (s, 9H), 1.34 (d, J = 13.2 Hz, 2H). ESI+MS m/z = 
546.3 (M + H
+
) 568.3 (M + Na
+
). HPLC (Method A, tR = 8.24 min), purity 90%. 
 
 
tert-Butyl 3-allyl-2-(ethylthio)-8-methoxy-4-oxo-4,6-dihydro-3H-spiro[benzo[h]quinazoline-
5,4'-piperidine]-1'-carboxylate (181) (CCG-206663).  Compound synthesized in a manner 
similar to 177 beginning from S-ethyl intermediate 176b (68 mg, 0.149 mmol).  Isolated 38 mg 
of N-allyl product (51% yield) after column chromatography (5-15% EtOAc:hex). 
1
H NMR (400 
MHz, Chloroform-d) δ 8.05 (d, J = 8.6 Hz, 1H), 6.86 (dd, J = 8.6, 2.4 Hz, 1H), 6.74 (d, J = 2.4 
Hz, 1H), 5.92 (ddt, J = 15.9, 10.8, 5.5 Hz, 1H), 5.30 – 5.22 (m, 2H), 4.65 (d, J = 5.5 Hz, 2H), 
4.07 – 3.89 (m, 2H), 3.86 (s, 3H), 3.30 (q, J = 7.3 Hz, 2H), 3.19 – 2.86 (m, 5H), 2.69 – 2.52 (m, 
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1H), 1.51 – 1.42 (m, 12H), 1.42 – 1.32 (m, 2H). ESI+MS m/z = 520.2 (M + Na+). HPLC 
(Method B, tR = 9.16 min), purity >95%. 
 
 
tert-Butyl 2-((cyanomethyl)thio)-4,8-dimethoxy-6H-spiro[benzo[h]quinazoline-5,4'-
piperidine]-1'-carboxylate (188) (CCG-211810) and tert-Butyl 2-((cyanomethyl)thio)-8-
methoxy-3-methyl-4-oxo-4,6-dihydro-3H-spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-
carboxylate (182) (CCG-211811). S-alkylated intermediate 176c (170 mg, 0.363 mmol) was 
dissolved in DMF (2.1 mL), to which cesium carbonate (142 mg, 0.435 mmol) and methyl 
tosylate (74 mg, 0.399 mmol) were added.  Reaction was heated to 75°C and capped, allowed to 
stir for 16 hours.  After this time, TLC indicated that the consumption of starting material was 
complete, and 2 new, less polar spots were evident.  Reaction diluted with H2O and extracted 3x 
with EtOAc.  Organic layer washed with water and brine, then isolated, dried, filtered, and 
concentrated.  Further purification via flash chromatography (5-25% EtOAc:hex) delivered the 
two products each in pure form; tert-Butyl 2-((cyanomethyl)thio)-4,8-dimethoxy-6H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (188) (CCG-211810) 28 mg, 16% 
yield. 
1
H NMR (500 MHz, Chloroform-d) δ 8.19 (d, J = 8.6 Hz, 1H), 6.89 (dd, J = 8.6, 2.6 Hz, 
1H), 6.73 (d, J = 2.6 Hz, 1H), 4.03 (s, 3H), 4.07 – 3.82 (m, 2H), 3.92 (s, 2H), 3.86 (s, 3H), 3.13 – 
3.00 (m, 4H), 2.56 – 2.34 (m, 2H), 1.49 (s, 9H), 1.47 – 1.41 (m, 2H). ESI+MS m/z = 483.1 (M + 
H
+
) 505.0 (M + Na
+
). HPLC (Method B, tR = 7.23 min), purity 86%. 
 tert-Butyl 2-((cyanomethyl)thio)-8-methoxy-3-methyl-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (182) (CCG-211811) 26 mg, 15% 
yield 
1
H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J = 8.6 Hz, 1H), 6.89 (dd, J = 8.6, 2.5 Hz, 
1H), 6.74 (d, J = 2.5 Hz, 1H), 4.06 (s, 2H), 4.04 – 3.90 (m, 2H), 3.87 (s, 3H), 3.49 (s, 3H), 3.17 – 
2.93 (m, 4H), 2.93 – 2.75 (m, 1H), 2.72 – 2.52 (m, 1H), 1.47 (s, 9H), 1.43 – 1.33 (m, 2H). 
ESI+MS m/z = 483.1 (M + H
+
) 505.0 (M + Na
+
). HPLC (Method B, tR = 5.55 min), purity 84%. 
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tert-Butyl 4-(cyanomethoxy)-2-((cyanomethyl)thio)-8-methoxy-6H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (189) (CCG-211812) and tert-
Butyl 3-(cyanomethyl)-2-((cyanomethyl)thio)-8-methoxy-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (183) (CCG-211813). S-alkylated 
intermediate 176c (170 mg, 0.363 mmol) was dissolved in DMF (2.1 mL), to which cesium 
carbonate (142 mg, 0.435 mmol) and α-chloroacetonitrile (25 µL, 0.399 mmol)  were added.  
Reaction was heated to 50°C and capped, allowed to stir for 16 hours.  After this time, TLC 
indicated that the consumption of starting material was complete, and 2 new, less polar spots 
were evident.  Reaction diluted with H2O and extracted 3x with EtOAc.  Organic layer washed 
with water and brine, then isolated, dried, filtered, and concentrated.  Further purification via 
flash chromatography (5-25% EtOAc:hex) delivered the two products each in pure form: tert-
Butyl 4-(cyanomethoxy)-2-((cyanomethyl)thio)-8-methoxy-6H-spiro[benzo[h]quinazoline-
5,4'-piperidine]-1'-carboxylate (189) (CCG-211812) 49 mg, 27% yield; 
1
H NMR (500 MHz, 
Chloroform-d) δ 8.21 (d, J = 8.6 Hz, 1H), 6.90 (dd, J = 8.6, 2.5 Hz, 1H), 6.75 (d, J = 2.5 Hz, 
1H), 5.11 (s, 2H), 4.09 – 3.96 (m, 2H), 3.93 (s, 2H), 3.88 (s, 3H), 3.15 – 3.01 (m, 4H), 2.46 – 
2.27 (m, 2H), 1.56 – 1.45 (m, 11H). ESI+MS m/z = 508.0 (M + H+) 530.0 (M + Na+). HPLC 
(Method B, tR = 6.31 min), purity >95%.; tert-Butyl 3-(cyanomethyl)-2-((cyanomethyl)thio)-8-
methoxy-4-oxo-4,6-dihydro-3H-spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate 
(183) (CCG-211813) 27 mg, 14% yield; 
1
H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J = 8.6 
Hz, 1H), 6.91 (dd, J = 8.7, 2.5 Hz, 1H), 6.76 (d, J = 2.5 Hz, 1H), 5.07 – 4.75 (m, 2H), 4.12 (s, 
2H), 4.09 – 3.90 (m, 2H), 3.88 (s, 3H), 3.20 – 2.91 (m, 4H), 2.89 – 2.67 (m, 1H), 2.67 – 2.49 (m, 
1H), 1.48 (s, 9H), 1.40 (d, J = 13.0 Hz, 2H). ESI+MS m/z = 530.0 (M + Na
+
). HPLC (Method B, 
tR = 5.25 min), purity >95%. 
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3-Allyl-8-methoxy-2-((2-methoxyethyl)thio)-3H-spiro[benzo[h]quinazoline-5,4'-piperidin]-
4(6H)-one (190) (CCG-206661). 2-Thioxopyrimidinone intermediate 177 (1.071 g, 2.03 mmol) 
was suspended in DCM (10.2 mL) and cooled to 0°C. TFA (3.13 mL) was added dropwise and 
the suspension was allowed to stir 2 hours at 0°C, then an additional 2h at room temperature. 
Reaction was quenched via the slow addition of saturated aqueous sodium carbonate and then 
extraction of the aqueous layer with DCM (2x). The pooled organic layers were washed with 
water and brine, then isolated, dried over MgSO4, vacuum filtered, and concentrated. Vacuum 
filtration followed by washing with diethyl ether furnished the desired product as a free-flowing 
white solid, (680 mg, 78% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 9.97 (s, 1H), 8.74 (s, 
1H), 8.01 (d, J = 8.6 Hz, 1H), 6.87 (d, J = 8.6 Hz, 1H), 6.79 (s, 1H), 5.95 – 5.83 (m, 1H), 5.28 – 
5.19 (m, 2H), 4.68 (d, J = 4.2 Hz, 2H), 3.87 (s, 3H), 3.75 (t, J = 6.1 Hz, 2H), 3.53 (t, J = 6.1 Hz, 
2H), 3.50 – 3.43 (m, 2H), 3.42 (s, 3H), 3.36 – 3.21 (m, 2H), 3.02 (s, 2H), 2.99 – 2.84 (m, 2H), 
1.69 (d, J = 13.7 Hz, 2H). ESI+MS m/z = 428.2 (M + H
+
). HPLC (Method A, tR = 5.73 min), 
purity >95%. 
 
 
3-Allyl-2-(ethylthio)-8-methoxy-3H-spiro[benzo[h]quinazoline-5,4'-piperidin]-4(6H)-one 
(CCG-206664) (191).  Boc intermediate 181 (24 mg, 0.048 mmol) was dissolved in 4M HCl 
solution in dioxane (0.5 mL).  Reaction was allowed to stir at room temperature for 2 hours, then 
diluted with diethyl ether and the crystalline solid isolated via filtration and submitted without 
further purification.  Isolated 17 mg (89% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 9.98 (s, 
1H), 8.77 (s, 1H), 8.05 (d, J = 8.6 Hz, 1H), 6.87 (dd, J = 8.6, 1.9 Hz, 1H), 6.78 (s, 1H), 6.01 – 
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5.79 (m, 1H), 5.32 – 5.13 (m, 2H), 4.66 (d, J = 4.7 Hz, 2H), 3.87 (s, 3H), 3.55 – 3.41 (m, 2H), 
3.35 – 3.22 (m, 4H), 3.02 (s, 2H), 2.98 – 2.85 (m, 2H), 1.69 (d, J = 14.2 Hz, 2H), 1.47 (t, J = 7.3 
Hz, 3H). ESI+MS m/z = 398.2 (M + H
+
) 420.2 (M + Na
+
). HPLC (Method A, tR = 6.13 min), 
purity >95%. 
 
 
4-(Allyloxy)-8-methoxy-2-((2-methoxyethyl)thio)-6H-spiro[benzo[h]quinazoline-5,4'-
piperidine] (192). Boc-protected intermediate 184 (94 mg, 0.178 mmol) was dissolved into a 
solution of HCl (4M in dioxane, 1.0 mL) cooled to 0°C.  The reaction was allowed to stir for 2 
hours while slowly warming to room temperature. At this time, the reaction mixture was diluted 
with diethyl ether (5 mL), causing the precipitation of a white solid that was collected via 
vacuum filtration.  Drying under high vacuum delivers the desired product (82 mg, quant. yield) 
as a white solid that is unstable to dissolution in polar solvents. 
1
H NMR (400 MHz, DMSO-d6) 
δ 9.08 – 8.95 (m, 1H), 8.63 (s, 1H), 8.00 (d, J = 8.6 Hz, 1H), 6.98 (d, J = 2.5 Hz, 1H), 6.92 (dd, J 
= 8.5, 2.5 Hz, 1H), 6.14 (ddt, J = 16.1, 10.6, 5.3 Hz, 1H), 5.35 (dd, J = 17.4, 1.7 Hz, 1H), 5.25 
(dd, J = 10.6, 1.7 Hz, 1H), 4.94 (d, J = 5.3 Hz, 2H), 3.80 (s, 3H), 3.63 (s, 4H), 3.34 – 3.24 (m, 
5H), 3.15 (s, 4H), 2.59 (td, J = 13.4, 13.0, 6.4 Hz, 2H), 1.53 (d, J = 14.0 Hz, 2H). ESI-MS m/z = 
428.2 (M + H
+
). 
 
 
3-Allyl-8-methoxy-2-((2-methoxyethyl)thio)-1'-pentanoyl-3H-spiro[benzo[h]quinazoline-
5,4'-piperidin]-4(6H)-one (193) (CCG-206662). N-deprotected intermediate 190 (12 mg, 0.028 
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mmol) was added to DCM (140 µL) in a dry 1 dram vial.  N,N-diisopropylethylamine was added 
(9.8 µL, 0.056 mmol), then the mixture was cooled to 0°C.  Pentanoyl chloride (4.0 µL, 0.034 
mmol) was added, and the reaction allowed to stir while warming to RT over 3 hours.  Reaction 
quenched via the addition of saturated NH4Cl aqueous solution.  The biphasic solution was 
partitioned between DCM and NH4Cl, then the organic layer was washed with water and brine.  
The organic layer was isolated, dried over MgSO4, vacuum filtered, and concentrated, then 
further purified via flash chromatography (10-40% EtOAc:hex) to yield the desired compound as 
a white solid (10 mg, 70% yield).
 1
H NMR (400 MHz, Chloroform-d) δ 8.02 (d, J = 8.5 Hz, 1H), 
6.86 (dd, J = 8.5, 2.4 Hz, 1H), 6.74 (d, J = 2.4 Hz, 1H), 5.95 – 5.83 (m, 1H), 5.32 – 5.22 (m, 2H), 
4.66 (d, J = 5.6 Hz, 2H), 4.35 (d, J = 12.5 Hz, 1H), 3.86 (s, 3H), 3.84 – 3.71 (m, 3H), 3.52 (t, J = 
6.3 Hz, 2H), 3.42 (s, 3H), 3.41 – 3.31 (m, 1H), 3.16 – 2.87 (m, 4H), 2.47 (dt, J = 13.5, 6.7 Hz, 
1H), 2.38 – 2.29 (m, 2H), 1.68 – 1.53 (m, 2H), 1.49 – 1.31 (m, 4H), 0.93 (t, J = 7.3 Hz, 3H).  
ESI+MS m/z = 512.2 (M + H
+
) 534.2 (M + Na
+
). HPLC (Method B, tR = 6.51 min), purity >95%. 
 
 
3-Allyl-2-(ethylthio)-8-methoxy-1'-pentanoyl-3H-spiro[benzo[h]quinazoline-5,4'-piperidin]-
4(6H)-one (194) (CCG-206665). Compound was prepared in a manner similar to 193 from 191 
(10.5 mg, 0.026 mmol).  Isolated the desired compound after flash chromatography (10-40% 
EtOAc:hex) as a white powder (8 mg, 63% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.06 (d, 
J = 8.6 Hz, 1H), 6.87 (dd, J = 8.6, 2.5 Hz, 1H), 6.74 (d, J = 2.5 Hz, 1H), 5.98 – 5.84 (m, 1H), 
5.30 – 5.22 (m, 2H), 4.65 (d, J = 5.6 Hz, 2H), 4.36 (d, J = 13.7 Hz, 1H), 3.87 (s, 3H), 3.80 (d, J = 
13.7 Hz, 1H), 3.42 – 3.25 (m, 3H), 3.16 – 2.88 (m, 4H), 2.47 (td, J = 13.2, 4.8 Hz, 1H), 2.38 – 
2.29 (m, 2H), 1.68 – 1.56 (m, 2H), 1.51 – 1.32 (m, 7H), 0.93 (t, J = 7.3 Hz, 3H). ESI+MS m/z = 
482.2 (M + H
+
) 504.2 (M + Na
+
). HPLC (Method B, tR = 7.63 min), purity >95%. 
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1-(4-(Allyloxy)-8-methoxy-2-((2-methoxyethyl)thio)-6H-spiro[benzo[h]quinazoline-5,4'-
piperidin]-1'-yl)pentan-1-one (195) (CCG-208863). Reaction was performed in a manner 
similar to 193 beginning from intermediate 192 (30 mg, 0.070 mmol).  Isolated the desired 
compound after flash chromatography (10-40% EtOAc:hex) as a white powder (27 mg, 74% 
yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.16 (d, J = 8.6 Hz, 1H), 6.87 (dd, J = 8.6, 2.1 Hz, 
1H), 6.73 (d, J = 2.1 Hz, 1H), 6.04 (ddt, J = 16.9, 10.6, 5.6 Hz, 1H), 5.35 (d, J = 16.9 Hz, 1H), 
5.26 (d, J = 10.6 Hz, 1H), 4.91 (d, J = 5.6 Hz, 2H), 4.43 (d, J = 13.7 Hz, 1H), 3.86 (s, 3H), 3.72 
(t, J = 6.8 Hz, 2H), 3.44 – 3.34 (m, 6H), 3.15 – 3.00 (m, 2H), 2.96 (t, J = 12.0 Hz, 1H), 2.57 (td, 
J = 13.3, 4.7 Hz, 1H), 2.44 (td, J = 13.3, 4.7 Hz, 1H), 2.35 (td, J = 7.3, 3.4 Hz, 2H), 1.70 – 1.58 
(m, 3H), 1.58 – 1.46 (m, 2H), 1.46 – 1.33 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). ESI+MS m/z = 512.2 
(M + H
+
), 534.2 (M + Na
+
).  HPLC (Method B, tR = 7.44 min), purity >95%. 
 
 
3-Allyl-8-methoxy-2-((2-methoxyethyl)thio)-1'-methyl-3H-spiro[benzo[h]quinazoline-5,4'-
piperidin]-4(6H)-one (196) (CCG-208981).  Intermediate 190 (30 mg, 0.065 mmol) was 
dissolved in dry 1,2-dichloroethane (300 µL), followed by acetic acid (4.5 µL, 0.078 mmol), 
paraformaldehyde (9.7 mg, 0.323 mmol), and sodium triacetoxyborohydride (21 mg, 0.097 
mmol). The reaction was stirred at room temperature for 16 hours, then diluted with 
dichloromethane and washed with saturated aqueous sodium bicarbonate, water, and brine.  The 
organic extract was dried over MgSO4, vacuum filtered, and concentrated in vacuo.  Further 
purification via flash chromatography (0-20% MeOH:DCM) furnished the desired product (18 
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mg, 63% yield) as a sticky yellow oil. 
1
H NMR (400 MHz, Chloroform-d) δ 8.01 (d, J = 8.6 Hz, 
1H), 6.84 (dd, J = 8.6, 2.3 Hz, 1H), 6.74 (d, J = 2.3 Hz, 1H), 5.91 (ddt, J = 16.2, 11.0, 5.7 Hz, 
1H), 5.33 – 5.21 (m, 2H), 4.67 (d, J = 5.7 Hz, 2H), 3.86 (s, 3H), 3.75 (t, J = 6.3 Hz, 2H), 3.51 (t, 
J = 6.3 Hz, 2H), 3.42 (s, 3H), 3.00 (s, 2H), 2.98 – 2.89 (m, 2H), 2.74 (d, J = 11.6 Hz, 2H), 2.64 
(s, 2H), 2.34 (s, 3H), 1.36 (d, J = 13.5 Hz, 2H). ESI+MS m/z = 442.1 (M + H
+
). HPLC (Method 
A, tR = 5.83 min), purity = 90%. 
 
 
3-Allyl-1'-benzyl-8-methoxy-2-((2-methoxyethyl)thio)-3H-spiro[benzo[h]quinazoline-5,4'-
piperidin]-4(6H)-one (197) (CCG-208982). Synthesized in a manner similar to 196 from 190 
(36 mg, 0.078 mmol) and benzaldehyde (11 mg, 0.101 mmol).  Product recovered after flash 
chromatography (0-20% MeOH:DCM) as a clear oil (23 mg, 57% yield).
 1
H NMR (400 MHz, 
Chloroform-d) δ 7.99 (d, J = 8.8 Hz, 1H), 7.64 – 7.51 (m, 2H), 7.44 – 7.29 (m, 3H), 6.88 – 6.81 
(m, 2H), 5.98 – 5.85 (m, 1H), 5.34 – 5.24 (m, 2H), 4.71 (d, J = 5.0 Hz, 2H), 3.85 (s, 3H), 3.75 (t, 
J = 6.2 Hz, 2H), 3.53 (t, J = 6.2 Hz, 2H), 3.42 (s, 3H), 3.31-3.04 (m, 4H), 3.06 – 2.93 (m, 3H), 
1.90 – 1.61 (m, 5H). ESI+MS m/z = 518.2 (M + H+) 540.2 (M + Na+). HPLC (Method A, tR = 
6.83 min), purity >95%. 
 
 
3-Allyl-8-methoxy-2-((2-methoxyethyl)thio)-N-methyl-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxamide (198) (CCG-211970). The free 
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amine intermediate (30 mg, 0.070 mmol) was combined with N,N-diisopropylethylamine (18 µL, 
0.105 mmol) and N-succinimidyl N-methylcarbamate (24 mg, 0.140 mmol) in DCM (350 µL).  
The reaction was stirred at room temperature for 6 hours, then partitioned between saturated 
aqueous sodium bicarbonate solution and additional DCM.  The organic layer was washed with 
water and brine, then dried over MgSO4 and concentrated in vacuo. The resulting crude residue 
was further purified via flash chromatography (0-10% MeOH:DCM) to yield the desired product 
as a white solid (22 mg, 65% yield).
 1
H NMR (500 MHz, Chloroform-d) δ 8.02 (d, J = 8.6 Hz, 
1H), 6.86 (dd, J = 8.6, 2.5 Hz, 1H), 6.74 (d, J = 2.5 Hz, 1H), 5.91 (ddt, J = 15.9, 10.7, 5.6 Hz, 
1H), 5.31 – 5.23 (m, 2H), 4.67 (d, J = 5.6 Hz, 2H), 4.42 (d, J = 4.6 Hz, 1H), 3.86 (s, 3H), 3.82 – 
3.72 (m, 4H), 3.52 (t, J = 6.3 Hz, 2H), 3.42 (s, 3H), 3.17 (td, J = 12.7, 3.0 Hz, 2H), 3.01 (s, 2H), 
2.81 (d, J = 4.6 Hz, 3H), 2.74 (td, J = 13.2, 4.9 Hz, 2H), 1.43 (d, J = 13.6 Hz, 2H). ESI+MS m/z 
= 485.1 (M + H
+
), 507.1 (M + Na
+
).  HPLC (Method B, tR = 5.64 min), purity >95%. 
 
 
3-Allyl-8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-N-phenyl-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxamide (199) (CCG-211971). Prepared 
in the same manner as 198 from 190 (30 mg, 0.070 mmol) and phenyl isocyanate (15 µL, 0.140 
mmol).  Recovered the desired product after flash chromatography as a white powder (32 mg, 
83% yield).
 1
H NMR (500 MHz, Chloroform-d) δ 8.04 (d, J = 8.6 Hz, 1H), 7.37 (d, J = 7.7 Hz, 
2H), 7.32 – 7.25 (m, 2H), 7.02 (t, J = 7.3 Hz, 1H), 6.88 (dd, J = 8.6, 2.5 Hz, 1H), 6.76 (d, J = 2.5 
Hz, 1H), 6.39 (s, 1H), 5.92 (ddt, J = 15.9, 10.8, 5.6 Hz, 1H), 5.33 – 5.25 (m, 2H), 4.69 (d, J = 5.6 
Hz, 2H), 3.94 (dt, J = 13.0, 4.1 Hz, 2H), 3.88 (s, 3H), 3.76 (t, J = 6.3 Hz, 2H), 3.54 (t, J = 6.3 Hz, 
2H), 3.43 (s, 3H), 3.31 (td, J = 12.8, 3.0 Hz, 2H), 3.04 (s, 2H), 2.78 (td, J = 13.6, 4.7 Hz, 2H), 
1.52 (d, J = 13.8 Hz, 2H). ESI+MS m/z = 547.1 (M + H
+
), 569.1 (M + Na
+
).  HPLC (Method B, 
tR = 5.83 min), purity >95%. 
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Ethyl 2-(3-allyl-8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidin]-1'-ylcarboxamido)acetate (200) (CCG-211972).  
Prepared in a manner similar to 196 from intermediate 190 (30 mg, 0.070 mmol) and ethyl 2-
isocyanatoacetate (16 µL, 0.140 mmol).  The desired product was isolated via flash 
chromatography as a white powder (26 mg, 67% yield).
 1
H NMR (500 MHz, Chloroform-d) δ 
8.02 (d, J = 8.6 Hz, 1H), 6.86 (dd, J = 8.6, 2.5 Hz, 1H), 6.74 (d, J = 2.5 Hz, 1H), 5.91 (ddt, J = 
15.9, 10.8, 5.6 Hz, 1H), 5.32 – 5.23 (m, 2H), 4.94 (t, J = 5.0 Hz, 1H), 4.67 (d, J = 5.6 Hz, 2H), 
4.22 (q, J = 7.1 Hz, 2H), 4.02 (d, J = 5.0 Hz, 2H), 3.87 (s, 3H), 3.82 (dt, J = 12.9, 4.0 Hz, 2H), 
3.75 (t, J = 6.3 Hz, 2H), 3.52 (t, J = 6.3 Hz, 2H), 3.42 (s, 3H), 3.23 (td, J = 12.7, 3.0 Hz, 2H), 
3.01 (s, 2H), 2.75 (td, J = 13.3, 4.8 Hz, 2H), 1.45 (d, J = 13.6 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). 
ESI+MS m/z = 557.1 (M + H
+
), 579.1 (M + Na
+
).  HPLC (Method B, tR = 4.12 min), purity 
>95%. 
 
 
(S)-3-Allyl-8-methoxy-2-((2-methoxyethyl)thio)-1'-(2-phenylpropanoyl)-3H-
spiro[benzo[h]quinazoline-5,4'-piperidin]-4(6H)-one (201) (CCG-212350). S-2-phenyl 
propanoic acid (26 mg, 0.175 mmol) was dissolved in DCM (1.2 mL), to which DIPEA (61 µL, 
0.351 mmol), HOBt hydrate (27 mg, 0.175 mmol), and EDC (34 mg, 0.175 mmol) were added.  
The reaction mixture was allowed to stir at room temperature for 15 minutes, then intermediate 
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190 (50 mg, 0.117 mmol) was added and the mixture allowed to stir an additional 16 hours at 
room temperature.  The reaction mixture was diluted with additional DCM (20 mL), then washed 
with saturated aqueous sodium carbonate and ammonium chloride solutions, followed by water 
and brine.  The organic extract was isolated, dried over MgSO4, vacuum filtered, and 
concentrated in vacuo. Further purification via flash chromatography (10-40% EtOAc:hex) 
furnished the product as a white solid (44 mg, 67% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 
7.98 (t, J = 8.2 Hz, 1H), 7.37 – 7.21 (m, 5H), 6.83 (dd, J = 8.6, 2.4 Hz, 1H), 6.62 (d, J = 2.7 Hz, 
1H), 5.97 – 5.82 (m, 1H), 5.32 – 5.20 (m, 2H), 4.69 – 4.60 (m, 2H), 4.40 – 4.28 (m, 1H), 3.94 – 
3.68 (m, 6H), 3.56 – 3.45 (m, 2H), 3.41 (s, 3H), 3.37 – 3.27 (m, 1H), 3.16 – 2.91 (m, 4H), 2.82 – 
2.73 (m, 1H), 2.55 – 2.44 (m, 1H), 2.10 – 2.00 (m, 1H), 1.49 – 1.35 (m, 3H), 1.26 (d, J = 11.2 
Hz, 1H). ESI+MS m/z = 560.4 (M + H
+
), 582.4 (M + Na
+
).  HPLC (Method B, tR = 7.17 min), 
purity >95%. 
 
 
(R)-3-Allyl-8-methoxy-2-((2-methoxyethyl)thio)-1'-(2-phenylpropanoyl)-3H-
spiro[benzo[h]quinazoline-5,4'-piperidin]-4(6H)-one (202) (CCG-212351).  Prepared in a 
manner similar to 201 from intermediate 190 (50 mg, 0.117 mmol) and (R)-2-phenyl propanoic 
acid (26 mg, 0.175 mmol).  Isolated after flash chromatography as a white solid (51 mg, 78% 
yield).
1
H NMR (400 MHz, Chloroform-d) δ 7.98 (t, J = 8.2 Hz, 1H), 7.37 – 7.15 (m, 5H), 6.83 
(dd, J = 8.6, 2.6 Hz, 1H), 6.62 (d, J = 2.5 Hz, 1H), 5.98 – 5.82 (m, 1H), 5.33 – 5.20 (m, 2H), 4.70 
– 4.60 (m, 2H), 4.40 – 4.30 (m, 1H), 3.95 – 3.59 (m, 6H), 3.55 – 3.45 (m, 2H), 3.41 (s, 3H),3.37 
– 3.26 (m, 1H), 3.18 – 2.89 (m, 4H), 2.78 (d, J = 15.8 Hz, 1H), 2.50 (td, J = 13.1, 4.9 Hz, 1H), 
2.05 (t, J = 10.3 Hz, 1H), 1.49 – 1.36 (m, 3H), 1.26 (d, J = 12.2 Hz, 1H). ESI+MS m/z = 560.4 
(M + H
+
), 582.4 (M + Na
+
).  HPLC (Method B, tR = 7.12 min), purity >95%. 
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3-(3-Hydroxypropyl)-8-methoxy-2-((2-methoxyethyl)thio)-3H-spiro[benzo[h]quinazoline-
5,4'-piperidin]-4(6H)-one (203) (CCG-212353). A 4:1 solution of DCM:TFA (0.55 mL) was 
cooled to 0°C in an ice bath to which compound 180 (30 mg, 0.055 mmol) was added. The 
reaction was stirred for 4 hours while gradually warming to room temperature.  The reaction was 
quenched with saturated aqueous sodium carbonate, then extracted 3x with DCM.  The organic 
layer was collected, dried over MgSO4, vacuum filtered and concentrated.  Resuspension of the 
crude organic extract in 3:2 diethyl ether:hexanes caused the precipitation of a white powder that 
was collected via vacuum filtration.  Isolated 22 mg (90% yield). 
1
H NMR (400 MHz, Methanol-
d4) δ 8.07 (d, J = 9.2 Hz, 1H), 6.96 – 6.89 (m, 2H), 4.21 – 4.13 (m, 2H), 3.86 (s, 3H), 3.75 (t, J = 
6.3 Hz, 2H), 3.64 (t, J = 6.1 Hz, 2H), 3.56 (t, J = 6.3 Hz, 2H), 3.39 (s, 3H), 3.37 – 3.22 (m, J = 
2.3, 1.9 Hz, 4H), 3.15 (s, 2H), 3.09 – 2.95 (m, 2H), 2.02 – 1.90 (m, 2H), 1.60 (d, J = 15.1 Hz, 
2H). ESI+MS m/z = 446.3 (M + H
+
), 468.3 (M + Na
+
).  HPLC (Method A, tR = 4.93 min), purity 
>95%. 
 
 
2-((8-Methoxy-3-methyl-4-oxo-4,6-dihydro-3H-spiro[benzo[h]quinazoline-5,4'-piperidin]-2-
yl)thio)acetonitrile (204) (CCG-212013). Prepared in the same manner as 206 from 
intermediate 182.  Precipitation from 1:1 CHCl3:diethyl ether and subsequent vacuum filtration 
yielded the product as a light yellow powder (10 mg, 63% yield).
 1
H NMR (400 MHz, Methanol-
d4) δ 8.24 (d, J = 8.5 Hz, 1H), 7.01 – 6.82 (m, 2H), 4.29 (s, 2H), 3.85 (s, 3H), 3.50 (s, 3H), 3.41 – 
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3.22 (m, 4H), 3.15 (s, 2H), 3.01 (td, J = 13.4, 12.4, 6.0 Hz, 2H), 1.60 (d, J = 14.2 Hz, 2H). ESI-
MS+ m/z = 383.0 (M + H
+
). HPLC (Method A, tR = 5.04 min), purity >95%. 
 
3-((8-Methoxy-2-((2-methoxyethyl)thio)-6H-spiro[benzo[h]quinazoline-5,4'-piperidin]-4-
yl)oxy)propan-1-ol (205) (CCG-212354). Intermediate 187 (15 mg, 0.027 mmol) was dissolved 
in a 4:1 mixture of DCM:TFA (270 µL) at 0°C and allowed to stir for 2 hours while warming to 
room temperature. Reaction was quenched by the addition of saturated sodium carbonate.  The 
organic layer was diluted with additional DCM, and the aqueous layer extracted 2x with 
additional DCM.  Organic layer was isolated, dried over MgSO4, filtered, and evaporated. 
Resuspension of the crude organic extract in 3:2 diethyl ether:hexanes caused the precipitation of 
a white powder that was collected via vacuum filtration.  Isolated 9 mg (74% yield). 
1
H NMR 
(400 MHz, Methanol-d4) δ 8.10 (d, J = 9.4 Hz, 1H), 6.95 – 6.89 (m, 2H), 4.59 (t, J = 6.3 Hz, 
2H), 3.86 (s, 3H), 3.74 (t, J = 6.3 Hz, 2H), 3.70 (t, J = 6.7 Hz, 2H), 3.41 – 3.38 (m, 3H), 3.38 – 
3.22 (m, 6H), 3.17 (s, 2H), 2.74 (td, J = 13.9, 4.9 Hz, 2H), 2.07 (p, J = 6.3 Hz, 2H), 1.69 (d, J = 
13.3 Hz, 2H).  ESI+MS m/z = 446.3 (M + H
+
), HPLC (Method A, tR = 5.19 min), purity >95%. 
 
 
2-((4,8-Dimethoxy-6H-spiro[benzo[h]quinazoline-5,4'-piperidin]-2-yl)thio)acetonitrile (206) 
(CCG-212014). Boc-protected intermediate 188 (20 mg, 0.041 mmol) was dissolved in DCM 
(0.7 mL) and cooled to 0°C.  2,6-lutidine (19 µL, 0.166 mmol) was added, then TMS-OTf  (22 
µL, 0.124 mmol) was added slowly dropwise.  The reaction was allowed to stir for 30 minutes at 
0°C. TLC indicated the completion of the reaction.  The reaction was quenched via the addition 
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of MeOH and allowed to stir 16h.  The solvent was removed in vacuo and the crude residue was 
treated with a 1:1 mixture of chloroform and diethyl ether, causing the precipitation of a white 
solid, collected by vacuum filtration. Recovered the desired product as a white powder (16 mg, 
100% yield). 
1
H NMR (400 MHz, Methanol-d4) δ 8.18 (d, J = 9.3 Hz, 1H), 6.98 – 6.91 (m, 2H), 
4.12 (s, 2H), 4.10 (s, 3H), 3.86 (s, 3H), 3.43 – 3.25 (m, 4H), 3.20 (s, 2H), 2.75 (td, J = 14.2, 5.0 
Hz, 2H), 1.72 (d, J = 15.2 Hz, 2H). ESI+MS m/z = 383.1 (M + H
+
). HPLC (Method A, tR = 5.32 
min), purity >95%. 
 
 
2-((4-(Cyanomethoxy)-8-methoxy-6H-spiro[benzo[h]quinazoline-5,4'-piperidin]-2-
yl)thio)acetonitrile (207) (CCG-212015). Prepared in the same manner as 206 from 
intermediate 189.  Precipitation from 1:1 CHCl3:diethyl ether and subsequent vacuum filtration 
yielded the product as a white powder (9 mg, 56% yield).
 1
H NMR (400 MHz, Methanol-d4) δ 
8.24 (d, J = 8.7 Hz, 1H), 7.02 – 6.89 (m, 2H), 5.28 (s, 2H), 4.16 (s, 2H), 3.87 (s, 3H), 3.43 – 3.33 
(m, 2H), 3.33 – 3.26 (m, 2H), 3.24 (s, 2H), 2.67 (td, J = 14.3, 13.8, 5.1 Hz, 2H), 1.80 (d, J = 15.1 
Hz, 2H). ESI+MS m/z = 408.1 (M + H
+
) 430.1 (M + Na
+
). HPLC (Method A, tR = 5.37 min), 
purity >95%. 
 
9-Methoxy-5,5-dimethyl-2-((2,2,2-trifluoroethyl)thio)-5,6-dihydrobenzo[h]quinazolin-
4(3H)-one (208a). Prepared in a manner similar to 208b from intermediate 44b (175 mg, 0.607 
mmol), using 1,1,1-trifluoro-2-iodoethane (150 µL, 1.517 mmol) as the alkylating agent.  
Concentration of the washed organic extract under high vacuum yielded a yellow solid that was 
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used without further purification (208 mg, 93% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 
11.68 (s, 1H), 7.65 (d, J = 2.7 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 6.94 (dd, J = 8.2, 2.7 Hz, 1H), 
4.10 (q, J = 9.6 Hz, 2H), 3.85 (s, 3H), 2.74 (s, 2H), 1.40 (s, 6H). 
 
 
2-((9-Methoxy-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-
yl)thio)acetonitrile (208b). Intermediate 44b (150 mg, 0.520 mmol) was combined with α-
chloroacetonitrile (36 µL, 0.572 mmol) and sodium bicarbonate (66 mg, 0.780 mmol) in DMF (3 
mL) and warmed to 50°C.  The reaction was allowed to stir for 6 hours at 50°C, then was diluted 
with water and extracted twice with ethyl acetate.  The organic extract was washed with water 
(3x) and brine (1x), then was dried over MgSO4, vacuum filtered, and concentrated in vacuo.  
Further purification via flash chromatography (10-40% EtOAc:hex) returned the product as a 
yellow powdery solid (125 mg, 73% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 12.85 (s, 1H), 
7.80 (d, J = 2.4 Hz, 1H), 7.18 (d, J = 8.2 Hz, 1H), 6.97 (dd, J = 8.2, 2.4 Hz, 1H), 4.31 (s, 2H), 
3.80 (s, 3H), 2.70 (s, 2H), 1.28 (s, 6H). 
 
 
2-((2-(Ethylthio)-9-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4-
yl)oxy)acetonitrile (212) (CCG-211791) and 2-(2-(Ethylthio)-9-methoxy-5,5-dimethyl-4-oxo-
5,6-dihydrobenzo[h]quinazolin-3(4H)-yl)acetonitrile (209) (CCG-211792). Prepared in a 
manner similar to 215 from intermediate 45b (60 mg, 0.190 mmol), using α-chloroacetonitrile 
(14 µL, 0.228 mmol) as the alkylating agent.  Flash chromatography furnished both isomers in 
pure form. 2-((2-(Ethylthio)-9-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-4-
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yl)oxy)acetonitrile (212) (CCG-211791): 15 mg, 22% yield. 
1
H NMR (400 MHz, Chloroform-
d) δ 7.79 (d, J = 2.8 Hz, 1H), 7.09 (d, J = 8.2 Hz, 1H), 6.94 (dd, J = 8.2, 2.8 Hz, 1H), 5.08 (s, 
2H), 3.86 (s, 3H), 3.22 (q, J = 7.3 Hz, 2H), 2.75 (s, 2H), 1.47 (t, J = 7.3 Hz, 3H), 1.31 (s, 6H). 
ESI+MS m/z = 356.1 (M + H
+
) 378.0 (M + Na
+
). HPLC (Method B, tR = 7.54 min), purity >95%. 
 2-(2-(Ethylthio)-9-methoxy-5,5-dimethyl-4-oxo-5,6-dihydrobenzo[h]quinazolin-3(4H)-
yl)acetonitrile (209) (CCG-211792): 31 mg, 46% yield. 
1
H NMR (400 MHz, Chloroform-d) δ 
7.66 (d, J = 2.7 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 6.93 (dd, J = 8.2, 2.7 Hz, 1H), 4.96 (s, 2H), 
3.84 (s, 3H), 3.38 (q, J = 7.3 Hz, 2H), 2.72 (s, 2H), 1.52 (t, J = 7.4 Hz, 3H), 1.36 (s, 6H). 
ESI+MS m/z = 356.1 (M + H
+
) 378.0 (M + Na
+
). HPLC (Method B, tR = 6.56 min), purity >95%. 
 
 
9-Methoxy-3,5,5-trimethyl-2-((2,2,2-trifluoroethyl)thio)-5,6-dihydrobenzo[h]quinazolin-
4(3H)-one (210) (CCG-211790). Prepared in a manner similar to 215 from 208a (54 mg, 0.146 
mmol), using methyl iodide (23 mg, 0.160 mmol) as the alkylating agent.  Flash chromatography 
isolated only the N-alkylated isomer (32 mg, 57% yield).
 1
H NMR (500 MHz, Chloroform-d) δ 
7.62 (d, J = 2.6 Hz, 1H), 7.10 (d, J = 8.2 Hz, 1H), 6.93 (dd, J = 8.2, 2.6 Hz, 1H), 4.18 (q, J = 9.7 
Hz, 2H), 3.85 (s, 3H), 3.56 (s, 3H), 2.73 (s, 2H), 1.37 (s, 6H). ESI+MS m/z = 385.0 (M + H
+
) 
407.0 (M + Na
+
). HPLC (Method B, tR = 7.01 min), purity >95%. 
 
 
2-((4-(Cyanomethoxy)-9-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-2-
yl)thio)acetonitrile (214) (CCG-202011) and 2-((3-(Cyanomethyl)-9-methoxy-5,5-dimethyl-
4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl)thio)acetonitrile (211) (CCG-212012).  
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Prepared in a manner similar to 215 from 208b (60 mg, 0.183 mmol) using α-chloroacetonitrile 
as the alkylating agent.  The crude mixture of N- and O-alkylated isomers was separated via flash 
chromatography (0-10% EtOAc:hex) to furnish 211 and 214.  
2-((4-(cyanomethoxy)-9-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-2-
yl)thio)acetonitrile (214) (CCG-212011) 26 mg, 39% yield. 
1
H NMR (400 MHz, Chloroform-
d) δ 7.84 (d, J = 2.7 Hz, 1H), 7.12 (d, J = 8.3 Hz, 1H), 6.98 (dd, J = 8.3, 2.7 Hz, 1H), 5.12 (s, 
2H), 3.92 (s, 2H), 3.89 (s, 3H), 2.78 (s, 2H), 1.34 (s, 6H). ESI+MS m/z = 367.1 (M + H
+
) 389.1 
(M + Na
+
). HPLC (Method B, TR = 5.85 min), purity >95%. 2-((3-(cyanomethyl)-9-methoxy-
5,5-dimethyl-4-oxo-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl)thio)acetonitrile (211) (CCG-
212012). 15 mg, 22% yield. 
1
H NMR (400 MHz, Chloroform-d) δ 7.76 (d, J = 2.6 Hz, 1H), 7.12 
(d, J = 8.2 Hz, 1H), 6.97 (dd, J = 8.2, 2.6 Hz, 1H), 4.96 (s, 2H), 4.10 (s, 2H), 3.88 (s, 3H), 2.75 
(s, 2H), 1.37 (s, 6H). ESI+MS m/z = 367.1 (M + H
+
) 389.1 (M + Na
+
). HPLC (Method B, tR = 
4.59 min), purity >95%. 
 
 
2-(Ethylthio)-4,9-dimethoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazoline (213) (CCG-
211793).  Prepared in a manner similar to 215 from intermediate 45b (55 mg, 0.174 mmol), 
using methyl p-toluenesulfonic ester (39 mg, 0.209 mmol) as the alkylating agent.  Flash 
chromatography (2-15% EtOAc:hex) isolates the desired compound as a white powder (18 mg, 
31% yield).  N-alkylated regioisomer (43, CCG-206353) was also isolated (32 mg, 56% yield).
 
1
H NMR (500 MHz, Chloroform-d) δ 7.81 (d, J = 2.7 Hz, 1H), 7.08 (d, J = 8.2 Hz, 1H), 6.91 
(dd, J = 8.2, 2.7 Hz, 1H), 4.00 (s, 3H), 3.87 (s, 3H), 3.21 (q, J = 7.3 Hz, 2H), 2.73 (s, 2H), 1.48 
(t, J = 7.3 Hz, 3H), 1.30 (s, 6H). ESI+MS m/z = 331.0 (M + H
+
) 353.0 (M + Na
+
). HPLC 
(Method B, tR = 9.35 min), purity 95%. 
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2-((4-(Allyloxy)-9-methoxy-5,5-dimethyl-5,6-dihydrobenzo[h]quinazolin-2-
yl)thio)acetonitrile (215) (CCG-212010). S-alkylated intermediate 208b (60 mg, 0.183 mmol) 
was dissolved in DMF (1 mL), to which allyl tosylate (43 mg, 0.202 mmol) and cesium 
carbonate (72 mg, 0.220 mmol) were added.  Reaction was heated to 50°C and allowed to stir for 
16 hours, then diluted with H2O and extracted 3x with EtOAc.  Organic layer washed with water 
and brine, then isolated, dried over MgSO4, vacuum filtered, and concentrated.  Further 
purification via FC (5% EtOAc:hex) returned the O-alkylated compound as a clear oil, (22 mg, 
33% yield). The N-alkylated isomer was recovered in trace amounts and found to be significantly 
impure and was thus not further pursued.
 1
H NMR (400 MHz, Chloroform-d) δ 7.83 (d, J = 2.7 
Hz, 1H), 7.08 (d, J = 8.2 Hz, 1H), 6.93 (dd, J = 8.2, 2.7 Hz, 1H), 6.08 (ddt, J = 16.7, 10.6, 5.6 
Hz, 1H), 5.41 (dd, J = 16.7, 1.4 Hz, 1H), 5.29 (dd, J = 10.6, 1.1 Hz, 1H), 4.96 (d, J = 5.6 Hz, 
2H), 3.90 – 3.85 (m, 5H), 2.74 (s, 2H), 1.34 (s, 6H). ESI+MS m/z = 368.1 (M + H+) 390.1 (M + 
Na
+
). HPLC (Method B, TR = 8.07 min) >95% purity. 
 
tert-Butyl 3-(2-methoxy-2-oxoethylidene)pyrrolidine-1-carboxylate (217).  Prepared in a 
manner similar to 173 beginning from tert-butyl 3-oxopyrrolidine-1-carboxylate (216, 2.00 g, 
10.8 mmol).  Isolated 2.14 g (82% yield) of a clear oil via flash chromatography (10-40% 
EtOAc:hex) as a separable mixture of E and Z isomers. 
1
H NMR (400 MHz, Chloroform-d) δ 
5.65 (isomer A, s, 1H), 5.61 (isomer B, s, 1H), 4.17 – 4.12 (isomer A, m, 4H), 4.12 – 4.08 
(isomer B, m, 4H), 3.72 (isomer A, s, 3H), 3.70 (isomer B, s, 3H), 3.16 (isomer A+B, s, 4H), 
1.48 (isomer A+B, d, J = 2.9 Hz, 18H). 
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1'-tert-Butyl 3-methyl 4-amino-1H-spiro[naphthalene-2,3'-pyrrolidine]-1',3-dicarboxylate 
(218a). Prepared in a manner similar to 174 from o-tolunitrile 15 (631 mg, 5.39 mmol) and 
Michael acceptor 217 (1.00 g, 4.14 mmol).  Isolated 297 mg (20% yield) after silica gel flash 
chromatography. 
1
H NMR (400 MHz, Chloroform-d) δ 7.39 (d, J = 7.1 Hz, 1H), 7.36 – 7.26 (m, 
2H), 7.18 (d, J = 6.5 Hz, 1H), 6.56 (s, 2H), 3.76 (s, 3H), 3.55 (d, J = 10.5 Hz, 1H), 3.51 – 3.30 
(m, 2H), 3.22 – 3.04 (m, 1H), 2.89 – 2.70 (m, 2H), 2.49 – 2.33 (m, 1H), 1.61 – 1.52 (m, 1H), 
1.44 (d, J = 18.5 Hz, 9H). 
 
 
tert-Butyl 3-allyl-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,3'-pyrrolidine]-1'-carboxylate (218b).  Prepared in a manner 
similar to 174 from Michael acceptor 217 (552 mg, 2.29 mmol) and tolunitrile 26c. Isolated the 
desired product as a yellow oil (219 mg, 25% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.37 
(d, J = 8.2 Hz, 1H), 6.82 (d, J = 6.4 Hz, 1H), 6.72 (s, 1H), 6.64 (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H), 
3.54 – 3.32 (m, 3H), 3.14 (dd, J = 36.6, 10.6 Hz, 1H), 2.88 – 2.68 (m, 2H), 2.52 – 2.33 (m, 1H), 
1.63 – 1.52 (m, 1H), 1.46 (d, J = 15.8 Hz, 9H). 
 
 
tert-Butyl 4-oxo-2-thioxo-2,3,4,6-tetrahydro-1H-spiro[benzo[h]quinazoline-5,3'-
pyrrolidine]-1'-carboxylate (219a). Aminoester intermediate 218a (190 mg, 0.530 mmol) was 
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combined with benzoyl isothiocyanate (112 mg, 0.689 mmol) in absolute ethanol (0.63 mL).  
The reaction was capped, warmed to 75°C and stirred 3 hours. Additional benzoyl isothiocyanate 
(43 mg, 0.265 mmol) was added, and the reaction mixture was allowed to stir overnight at 75°C. 
The reaction mixture was cooled and the solvent evaporated under reduced temperature.  The 
crude organic isolate was redissolved in a 2:1 ethanol:water solution (1.3 mL).  Potassium 
hydroxide (49 mg, 0.870 mmol) was added, and the solution warmed to 75°C for 1.5 hours.   The 
reaction was quenched via the addition of ~5mL saturated aqueous ammonium chloride, then 
extracted 3x into dichloromethane. The pooled organic layers were washed with sat. aq. NaHCO3 
and brine, then isolated, dried over MgSO4, vacuum filtered and concentrated.  Further 
purification via FC (10-30% EtOAc:hex) delivered the desired product as 114 mg of off-white 
crystals (68% yield). ESI-MS+ m/z = 408.0 (M + Na
+
). 
1
H NMR (400 MHz, Chloroform-d) δ 
9.48 (s, 1H), 9.35 (s, 1H), 7.58 – 7.29 (m, 4H), 3.96 (d, J = 10.7 Hz, 0.5H), 3.83 (d, J = 10.9 Hz, 
0.5H), 3.61 – 3.41 (m, 2H), 3.30 (d, J = 10.7 Hz, 0.5H), 3.19 (d, J = 10.7 Hz, 0.5H), 3.08 – 2.74 
(m, 4H), 1.47 (s, 4.5H), 1.44 (s, 4.5H). 
 
 
tert-Butyl 8-methoxy-4-oxo-2-thioxo-2,3,4,6-tetrahydro-1H-spiro[benzo[h]quinazoline-5,3'-
pyrrolidine]-1'-carboxylate (219b). Prepared in a manner similar to 175 from 218b (520 mg, 
1.34 mmol). Isolated the desired product as a crystalline white solid (275 mg, 49% yield over 2 
steps). 
1
H NMR (400 MHz, Chloroform-d) δ 9.41 (s, 2H), 7.46 (t, J = 7.7 Hz, 1H), 6.93 – 6.84 
(m, 1H), 6.80 (d, J = 2.4 Hz, 1H), 3.95 (d, J = 10.8 Hz, 0.5H), 3.87 (s, 3H), 3.83 – 3.73 (m, 
0.5H), 3.59 – 3.38 (m, 2.5H), 3.29 (d, J = 10.4 Hz, 0.5H), 3.17 (d, J = 10.4 Hz, 0.5H), 3.06 – 
2.74 (m, 3.5H), 1.46 (s, 4.5H), 1.43 (s, 4.5H). 
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tert-Butyl 2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-spiro[benzo[h]quinazoline-5,3'-
pyrrolidine]-1'-carboxylate (220a).  Prepared in a manner similar to 176a from 219a (111 mg, 
0.288 mmol). Isolated the desired product as a white solid after vacuum filtration (116 mg, 91% 
yield). 
 
 
tert-Butyl 8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,3'-pyrrolidine]-1'-carboxylate (220b). Prepared in a manner 
similar to 176a from 219b (275 mg, 0.728 mmol). Isolated the desired product after column 
chromatography (10-40% EtOAc:hex) as a white solid (155 mg, 50% yield). 
1
H NMR (400 
MHz, Chloroform-d) δ 10.85 (s, 1H), 8.05 (d, J = 8.4 Hz, 1H), 6.85 (d, J = 8.4 Hz, 1H), 6.70 (d, 
J = 2.5 Hz, 1H), 4.05 (d, J = 10.8 Hz, 0.5H), 3.94 (d, J = 10.6 Hz, 0H), 3.85 (s, 3H), 3.76 (t, J = 
6.0 Hz, 2H), 3.65 – 3.47 (m, 2H), 3.45 (s, 3H), 3.41 (t, J = 6.0 Hz, 2H), 3.34 (d, J = 10.8 Hz, 
0.5H), 3.22 (d, J = 10.6 Hz, 0.5H), 3.13 - 2.94 (m, 1H), 2.94 – 2.81 (m, 2H), 1.72 – 1.63 (m, 1H), 
1.47 (s, 4.5H), 1.43 (s, 4.5H). 
 
 
tert-Butyl 3-allyl-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,3'-pyrrolidine]-1'-carboxylate (221) (CCG-208860).  Prepared 
in a manner similar to 177 from 220a (116 mg, 0.262 mmol).  Isolated as a clear oil (40 mg, 32% 
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yield) after column chromatography. 
1
H NMR (400 MHz, Chloroform-d) δ 8.10 (t, J = 7.2 Hz, 
1H), 7.41 – 7.30 (m, 2H), 7.19 (d, J = 7.2 Hz, 1H), 5.92 (d, J = 5.6 Hz, 1H), 5.30 (d, J = 18.7 Hz, 
2H), 4.69 (d, J = 4.9 Hz, 2H), 3.99 (dd, J = 32.9, 10.8 Hz, 1H), 3.76 (t, J = 6.1 Hz, 2H), 3.63 – 
3.45 (m, 4H), 3.42 (s, 3H), 3.27 (dd, J = 39.4, 10.4 Hz, 1H), 2.96 (q, J = 15.9 Hz, 3H), 1.70 – 
1.62 (m, 1H), 1.45 (d, J = 15.7 Hz, 9H). ESI+MS m/z = 506.1 (M + Na
+
).  HPLC (Method B, tR 
= 7.81 min), purity >95%. 
 
 
tert-Butyl 3-allyl-8-methoxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,3'-pyrrolidine]-1'-carboxylate (222) (CCG-208864). Prepared in 
a manner similar to 177 from intermediate 220b (150 mg, 0.317 mmol). Isolated the desired 
product as a clear oil (68 mg, 42% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.03 (d, J = 8.4 
Hz, 1H), 6.85 (d, J = 8.7 Hz, 1H), 6.70 (s, 1H), 5.89 (s, 1H), 5.28 (d, J = 19.5 Hz, 2H), 4.67 (d, J 
= 4.9 Hz, 2H), 3.97 (dd, J = 41.9, 10.2 Hz, 1H), 3.85 (s, 3H), 3.74 (t, J = 6.1 Hz, 2H), 3.62 – 3.43 
(m, 4H), 3.41 (s, 3H), 3.25 (dd, J = 41.9, 10.6 Hz, 1H), 3.15 – 2.83 (m, 3H), 1.70 – 1.59 (m, 1H), 
1.44 (d, J = 14.0 Hz, 9H). ESI+MS m/z = 536.1 (M + Na
+
).  HPLC (Method B, tR = 7.61 min), 
purity >95%. 
 
 
3-Allyl-2-((2-methoxyethyl)thio)-3H-spiro[benzo[h]quinazoline-5,3'-pyrrolidin]-4(6H)-one 
(223) (CCG-208861).  Prepared in a manner similar to 190 from 221 (33 mg, 0.068 mmol).  
Isolated the desired product as a white powder after filtration (27 mg, 94% yield). 
1
H NMR (400 
MHz, Chloroform-d) δ 11.37 (s, 1H), 8.32 (s, 1H), 8.10 (d, J = 7.4 Hz, 1H), 7.48 – 7.36 (m, 2H), 
7.31 (d, J = 7.0 Hz, 1H), 5.96 – 5.84 (m, 1H), 5.35 – 5.26 (m, 2H), 4.72 (d, J = 4.7 Hz, 2H), 4.00 
– 3.86 (m, 1H), 3.76 (t, J = 6.0 Hz, 2H), 3.68 – 3.47 (m, 4H), 3.42 (s, 3H), 3.30 (d, J = 14.6 Hz, 
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2H), 2.96 (d, J = 14.8 Hz, 1H), 2.22 – 2.10 (m, 2H). ESI+MS m/z = 384.1 (M + H+). HPLC 
(Method B, tR = 1.25 min), purity 90%. 
 
 
3-Allyl-8-methoxy-2-((2-methoxyethyl)thio)-3H-spiro[benzo[h]quinazoline-5,3'-pyrrolidin]-
4(6H)-one (224) (CCG-208865). Prepared in a manner similar to 190 from 222 (30 mg, 0.058 
mmol). Isolated the desired product as a white powder (20 mg, 77% yield). 
1
H NMR (400 MHz, 
Chloroform-d) δ 11.62 (s, 1H), 8.16 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 
6.81 (s, 1H), 5.97 – 5.80 (m, 1H), 5.38 – 5.20 (m, 2H), 4.78 – 4.59 (m, 2H), 4.05 – 3.92 (m, 1H), 
3.88 (s, 3H), 3.75 (t, J = 6.0 Hz, 3H), 3.65 – 3.51 (m, 3H), 3.42 (s, 3H), 3.38 – 3.16 (m, 2H), 2.98 
– 2.78 (m, 1H), 2.26 – 1.99 (m, 2H). ESI+MS m/z = 414.1 (M + H+), 436.1 (M + Na+).  HPLC 
(Method B, tR = 1.53 min), purity >95%. 
 
 
2,5-Dioxo-1-((S)-1-phenylethyl)pyrrolidin-3-yl acetate (226): DL-malic acid (1.00 g, 7.46 
mmol) was dissolved in acetyl chloride (4 mL). The reaction vessel was affixed with a reflux 
condenser and warmed to reflux under N2 atmosphere for 3 hours.  The reaction was cooled and 
concentrated in vacuo, then under high vacuum.  The resulting crude residue was dissolved in 
anhydrous THF (5 mL), then (S)-α-methylbenzylamine (961 µL, 7.46 mmol) was added.  The 
reaction was allowed to stir at room temperature for 4 hours.  The solvent was removed in vacuo, 
then additional acetyl chloride (4 mL) was added and the solution allowed to reflux for 12 hours.  
The reaction mixture was again concentrated in vacuo, and the crude organic residue was 
purified via flash chromatography (0-20% EtOAc:hex) to yield the desired product as a white 
solid (1.75 g, 90% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.45 (d, J = 7.4 Hz, 2H), 7.38 – 
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7.27 (m, 3H), 5.50 – 5.31 (m, 2H), 3.10 (ddd, J = 18.3, 8.8, 4.5 Hz, 1H), 2.63 (dt, J = 18.3, 5.2 
Hz, 1H), 2.15 (d, J = 3.6 Hz, 3H), 1.83 (dd, J = 7.3, 3.3 Hz, 3H). 
 
 
1-((S)-1-Phenylethyl)pyrrolidin-3-ol (intermediate in synthesis of 227). A suspension of 
lithium aluminum hydride (3.04 g, 80 mmol) was prepared at 0°C in anhydrous THF (24 mL).  A 
solution of succinimide 226 (3.22 g, 12.32 mmol) was added slowly dropwise, then allowed to 
stir while coming to room temperature for 6 hours.  Reaction was quenched by the dropwise, 
successive addition of 3 mL of water, 3 mL of 15% NaOH solution, and finally 9 mL of water.  
The resulting suspension was diluted with diethyl ether (40 mL) and filtered through Celite.  The 
organic layer was dried over MgSO4 and vacuum filtered, then concentrated under reduced 
pressure to a crude oil (2.20 g, 93% crude yield).  Used in the next step without further 
purification. 
1
H NMR (400 MHz, Chloroform-d) δ 7.36 – 7.20 (m, 5H), 4.38 – 4.24 (m, 1H), 
3.25 (qd, J = 6.6, 4.1 Hz, 1H), 3.01 (td, J = 8.4, 7.6, 4.3 Hz, 0.5H), 2.81 (d, J = 9.9 Hz, 0.5H), 
2.66 (td, J = 8.7, 5.1 Hz, 0.5H), 2.55 – 2.40 (m, 1.5H), 2.33 – 2.07 (m, 3H), 1.39 (dd, J = 6.6, 3.9 
Hz, 3H). 
 
 
(S)-1-(1-Phenylethyl)pyrrolidin-3-one (227). A solution of oxalyl chloride (2.01 mL, 23.00 
mmol) in dichloromethane (40 mL) was cooled to -78°C in a dry ice/acetone bath.  Anhydrous 
DMSO (2.04 mL, 28.8 mmol) was added and the solution was allowed to stir for 10 minutes.  A 
solution of the pyrrolidinol intermediate (2.2 g, 11.5 mmol) in DCM (3 mL) was added slowly 
dropwise, followed by the dropwise addition of triethylamine (8.02 mL, 57.5 mmol).  The 
reaction was allowed to stir at -78°C for 1 hour.  The reaction was quenched via the addition of 
saturated aqueous sodium bicarbonate solution and diethyl ether.  The water layer was extracted 
2x with ether, then the pooled organic fractions were washed with water and brine.  The organic 
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layer was concentrated in vacuo and further purified by flash chromatography (10-33% 
EtOAc:hex) to furnish the product as a clear oil (1.20 g, 55% yield).
 1
H NMR (400 MHz, 
Chloroform-d) δ 7.37 – 7.22 (m, 5H), 3.36 (q, J = 6.6 Hz, 1H), 3.02 (d, J = 17.1 Hz, 1H), 2.96 – 
2.72 (m, 3H), 2.38 (t, J = 7.0 Hz, 2H), 1.42 (d, J = 6.6 Hz, 3H). 
 
 
(S)-Methyl 2-(1-(1-phenylethyl)pyrrolidin-3-ylidene)acetate (228).  Prepared in a manner 
similar to 217 from intermediate 227 (1.3 g, 8.93 mmol).  Isolated the desired compound as a 
crude mixture of Z- and E-isomers, (1.7 g, 100% crude yield) which could be separated by 
column chromatography. E-isomer: 
1
H NMR (400 MHz, Chloroform-d) δ 7.37 – 7.19 (m, 5H), 
5.77 – 5.71 (m, 1H), 3.86 (d, J = 18.0 Hz, 1H), 3.66 (s, 3H), 3.49 (d, J = 18.0 Hz, 1H), 3.32 (q, J 
= 6.6 Hz, 1H), 2.66 – 2.50 (m, 4H), 1.43 (d, J = 6.6 Hz, 3H). Z-isomer: 1H NMR (400 MHz, 
Chloroform-d) δ 7.35 – 7.29 (m, 4H), 7.28 – 7.23 (m, 1H), 5.76 – 5.70 (m, 1H), 3.68 (s, 3H), 
3.32 – 3.13 (m, 3H), 2.94 (t, J = 6.4 Hz, 2H), 2.86 – 2.76 (m, 1H), 2.59 – 2.48 (m, 1H), 1.41 (d, J 
= 6.6 Hz, 3H). 
 
 
Methyl 4-amino-7-methoxy-1'-((S)-1-phenylethyl)-1H-spiro[naphthalene-2,3'-pyrrolidine]-
3-carboxylate (229). Prepared in a manner similar to 218a from tolunitrile 26c and pyrollidine 
ester 228 (1.76 g, 7.17 mmol).  Column chromatography resulted in the isolation of 754 mg of 
the desired product as a sticky brown oil (3:2 mixture of diastereomers, 25% yield). 
1
H NMR 
(400 MHz, Chloroform-d) δ 7.40 – 7.06 (diastereomer a + b, m, 16H), 6.88 – 6.76 (diastereomer 
a+b, m, 2H), 6.73 – 6.67 (diastereomer a + b, m, 2H), 6.50 (diastereomer a, s, 2H), 6.45 
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(diastereomer b, s, 3H), 3.85 (diastereomer a, s, 3H), 3.80 (diastereomer b, s, 4.5H), 3.74 – 3.68 
(diastereomer a+b, m, 7.5H), 3.68-3.52 (diastereomer a + b, m, 2.5H), 3.30 – 3.14 (diastereomer 
a + b, m, 4H), 3.11 – 2.98 (diastereomer a + b, m, 2H), 2.83 – 2.60 (diastereomer a + b, m, 4H), 
2.49 – 2.18 (diastereomer a + b, m, 7H), 2.10 – 2.01 (diastereomer a + b, m, 2H), 1.75 – 1.61 
(diastereomer b, m, 2H), 1.59 – 1.46 (diastereomer a, m, 1H), 1.34 (diastereomer b, d, J = 6.5 
Hz, 4.5H), 1.24 (diastereomer a, d, J = 6.0 Hz, 3H). 
 
 
1'-tert-Butyl 3-methyl 4-isothiocyanato-7-methoxy-1H-spiro[naphthalene-2,4'-piperidine]-
1',3-dicarboxylate (232). Thiophosgene (411 µL, 4.40 mmol) was dissolved in DCM (2.5 mL) 
and saturated aqueous sodium bicarbonate (2.5 mL) was added.  β-aminoester 174 (1.18 g, 2.93 
mmol) was dissolved in DCM (1 mL) with gentle heating and added dropwise to the biphasic 
thiophosgene mixture, causing a light refluxing of the organic layer. Allowed to stir for 1.5 
hours, then additional thiophosgene (137 µL, 1.47 mmol) and sat. aq. NaHCO3 (2 mL) was 
added and allowed to stir another 2 hours.  The reaction mixture was diluted with additional 
DCM and partitioned. The aqueous layer was extracted twice with DCM, then the combined 
organic fractions were washed with sodium carbonate, water and brine.  Organic layer dried over 
MgSO4 and concentrated in vacuo.  Further purification via column chromatography (15% 
EtOAc:hex) isolates the desired product as a sticky pale yellow solid (1.029g, 79% yield). 
1
H 
NMR (400 MHz, Chloroform-d) δ 7.41 (d, J = 8.5 Hz, 1H), 6.81 (dd, J = 8.5, 2.6 Hz, 1H), 6.71 
(d, J = 2.5 Hz, 1H), 4.00 – 3.85 (m, 5H), 3.82 (s, 3H), 3.05 – 2.83 (m, 4H), 1.89 (td, J = 13.0, 4.9 
Hz, 2H), 1.52 – 1.39 (m, 11H). 
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1'-tert-Butyl 3-methyl 4-(3-(1-hydroxypropan-2-yl)thioureido)-7-methoxy-1H-
spiro[naphthalene-2,4'-piperidine]-1',3-dicarboxylate (intermediate in the synthesis of 
233a, 233b). The isothiocyanate intermediate (200 mg, 0.450 mmol) was dissolved in anhydrous 
diethyl ether (1.6 mL).  Enantiopure 2-amino-1-propanol (39 µL, 0.495 mmol) was added 
dropwise, then the reaction allowed to stir at room temperature for 1 hour, over which time a 
white precipitate accumulated.  The reaction mixture was diluted with additional ether and the 
solid was collected via vacuum filtration.  Isolated 220 mg (91% yield) as a white powder, used 
without further purification. 
1
H NMR (500 MHz, Chloroform-d) δ 7.28 (d, J = 8.3 Hz, 1H), 6.91 
(s, 1H), 6.81 – 6.74 (m, 2H), 5.96 (d, J = 8.4 Hz, 1H), 4.57 (s, 1H), 4.05 – 3.70 (m, 9H), 3.52 – 
3.44 (m, 1H), 3.09 – 2.89 (m, 4H), 1.86 – 1.74 (m, 2H), 1.64 – 1.53 (m, 3H), 1.46 (s, 9H), 1.19 – 
1.03 (m, 3H). 
 
 
tert-Butyl 3-(1-hydroxypropan-2-yl)-8-methoxy-4-oxo-2-thioxo-2,3,4,6-tetrahydro-1H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (233a and 233b). The chiral 
amine-isothiocyanate adduct (234 mg, 0.450 mmol) was added to anhydrous methanol (1.60 
mL), then sodium methoxide (49 mg, 0.901 mmol) was added and the solution allowed to stir for 
30 minutes.  Over this time the product slowly dissolves to leave a clear solution.  Reaction 
quenched by the addition of sat. aq. NH4Cl. The resulting aqueous suspension was extracted 2x 
with DCM, then the organic layers combined and washed with water and brine.  The organic 
layer was dried over MgSO4, vacuum filtered, and concentrated in vacuo to render the desired 
product as white crystals (203 mg, 92% yield). 
1
H NMR (500 MHz, Chloroform-d) δ 9.31 (s, 
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1H), 7.39 (d, J = 8.6 Hz, 1H), 6.91 (dd, J = 8.6, 2.6 Hz, 1H), 6.83 (d, J = 2.5 Hz, 1H), 6.10 – 5.95 
(m, 1H), 4.17 – 4.04 (m, 1H), 4.04 – 3.90 (m, 3H), 3.88 (s, 3H), 3.46 – 3.31 (m, 1H), 3.21 – 2.77 
(m, 4H), 2.74 – 2.55 (m, 1H), 2.52 – 2.35 (m, 1H), 1.51 (d, J = 7.0 Hz, 3H), 1.48 (s, 9H), 1.30 (d, 
J = 13.5 Hz, 2H). 
 
 
(R)-3-Methoxy-9-methyl-9,10-dihydrospiro[benzo[h]thiazolo[2,3-b]quinazoline-6,4'-
piperidin]-7(5H)-one (234) (CCG-212230). The 2-thioxopyrimidinone intermediate 233a (191 
mg, 0.392 mmol) was suspended in DCM (2 mL) and cooled to 0°C. TFA (600 µL, 7.83 mmol) 
was added dropwise, then the solution allowed to stir for 4 hours, warming slowly to room 
temperature over this time. The reaction was quenched via the slow addition of saturated 
aqueous sodium carbonate, then the mixture was extracted with DCM.  The pooled organic 
layers were washed with water and brine, then isolated, dried, filtered, and concentrated.  Further 
purification via FC (0-20% MeOH-NH3: DCM) furnished the desired product (139 mg) in 96% 
yield. 
1
H NMR (500 MHz, Methanol-d4) δ 7.97 (d, J = 9.0 Hz, 1H), 6.92 – 6.86 (m, 2H), 5.15 (p, 
J = 6.5 Hz, 1H), 3.85 (s, 3H), 3.81 (dd, J = 11.4, 7.8 Hz, 1H), 3.25 – 2.98 (m, 8H), 2.72 (td, J = 
13.6, 5.2 Hz, 1H), 1.54 – 1.46 (m, 5H). ESI+MS m/z = 370.2 (M + H+). HPLC (Method A, TR = 
5.22 min) >95% purity. 
 
 
(S)-3-Methoxy-9-methyl-9,10-dihydrospiro[benzo[h]thiazolo[2,3-b]quinazoline-6,4'-
piperidin]-7(5H)-one (235) (CCG-212231). Compound synthesized in a manner similar to that 
for 234 from intermediate 233b (48 mg, 0.098 mmol).  Isolated after column chromatography as 
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a white powder (26 mg, 72% yield). 
1
H NMR (500 MHz, Methanol-d4) δ 8.00 (d, J = 9.2 Hz, 
1H), 6.95 – 6.89 (m, 2H), 5.21 – 5.12 (m, 1H), 3.86 (s, 3H), 3.83 (dd, J = 11.4, 7.8 Hz, 1H), 3.36 
– 3.26 (m, 4H), 3.25 – 3.00 (m, 4H), 2.88 – 2.77 (m, 1H), 1.60 (d, J = 14.7 Hz, 2H), 1.52 (d, J = 
6.4 Hz, 3H). ESI+MS m/z = 370.2 (M + H
+
). HPLC (Method A, tR = 5.15 min), purity >95%. 
 
 
(R)-1'-Benzyl-3-methoxy-9-methyl-9,10-dihydrospiro[benzo[h]thiazolo[2,3-b]quinazoline-
6,4'-piperidin]-7(5H)-one (CCG-212232) (236). Spiropiperidine intermediate 234 (40 mg, 
0.108 mmol) was dissolved in DCE (0.55 mL). Benzaldehyde (14 µL, 0.141 mmol) and acetic 
acid (7.5 µL, 0.130 mmol) were added and the reaction allowed to stir for 30 minutes at room 
temperature.  Sodium triacetoxyborohydride (34 mg, 0.162 mmol) was then added and the 
reaction mixture was allowed to stir at room temperature an additional 16 hours.  At this time the 
reaction was quenched via the addition of sat. aq. sodium bicarbonate (5 mL).  The biphasic 
mixture was extracted with diethyl ether (2x 10 mL), and the combined organic layers were 
pooled and washed with water and brine.  The organic layer was dried over MgSO4, vacuum 
filtered and concentrated in vacuo, then the solvent was removed under reduced pressure. Further 
purification via flash chromatography (0-10%) DCM:MeOH furnished the product as a white 
solid (31 mg, 62% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.01 (d, J = 8.6 Hz, 1H), 7.39 (s, 
2H), 7.31 (t, J = 7.4 Hz, 2H), 7.27 – 7.20 (m, 1H), 6.82 (dd, J = 8.6, 2.6 Hz, 1H), 6.72 (d, J = 2.5 
Hz, 1H), 5.18 (p, J = 6.7 Hz, 1H), 3.85 (s, 3H), 3.74 (dd, J = 11.2, 7.8 Hz, 1H), 3.67 – 3.48 (m, 
2H), 3.19 – 3.05 (m, 2H), 2.97 (d, J = 11.1 Hz, 1H), 2.89 (d, J = 15.5 Hz, 1H), 2.83 – 2.68 (m, 
2H), 2.45 – 2.20 (m, 2H), 1.87 – 1.69 (m, 2H), 1.57 (d, J = 6.4 Hz, 3H), 1.43 – 1.28 (m, 2H). 
ESI+MS m/z = 460.3 (M + H
+
). HPLC (Method A, tR = 5.98 min), purity >95%. 
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(S)-1'-Benzyl-3-methoxy-9-methyl-9,10-dihydrospiro[benzo[h]thiazolo[2,3-b]quinazoline-
6,4'-piperidin]-7(5H)-one (CCG-212233) (237). Prepared in a manner similar to 236 from 
intermediate 235 (40 mg, 0.108 mmol). Isolated the desired product after chromatography as a 
white powder (24 mg, 48% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 8.00 (d, J = 8.6 Hz, 
1H), 7.42 – 7.33 (m, 2H), 7.29 (t, J = 7.1 Hz, 2H), 7.25 – 7.20 (m, 1H), 6.81 (dd, J = 8.6, 2.2 Hz, 
1H), 6.71 (d, J = 2.2 Hz, 1H), 5.16 (p, J = 6.9 Hz, 1H), 3.84 (s, 3H), 3.72 (dd, J = 11.2, 7.9 Hz, 
1H), 3.63 – 3.48 (m, 2H), 3.17 – 3.04 (m, 2H), 2.95 (d, J = 11.1 Hz, 1H), 2.88 (d, J = 15.6 Hz, 
1H), 2.80 – 2.65 (m, 2H), 2.40 – 2.21 (m, 2H), 1.80 – 1.66 (m, 2H), 1.55 (d, J = 6.4 Hz, 3H), 
1.38 – 1.27 (m, 2H). ESI+MS m/z = 460.3 (M + H+). HPLC (Method A, tR = 6.02 min), purity 
>95%. 
 
 
1'-tert-Butyl 3-methyl 4-amino-7-((tert-butyldimethylsilyl)oxy)-1H-spiro[naphthalene-2,4'-
piperidine]-1',3-dicarboxylate (238). Prepared in a manner similar to compound xxx from 
tolunitrile 140 (1.94 g, 7.83 mmol) and α,β-unsaturated piperidine ester 173 (2.00 g, 7.83 mmol).  
After isolation of the crude organic extract, dissolution in a 3:2 mixture of diethyl ether:hexanes 
caused the precipitation of the desired product as a light yellow solid that was collected via 
vacuum filtration and used without further purification.  Isolated 1.43 g (40% yield). 
1
H NMR 
(400 MHz, Chloroform-d) δ 7.26 (d, J = 8.4 Hz, 1H), 6.73 (dd, J = 8.4, 2.5 Hz, 1H), 6.67 (d, J = 
2.5 Hz, 1H), 6.29 (s, 2H), 3.98 – 3.76 (m, 2H), 3.74 (s, 3H), 3.05 – 2.86 (m, 2H), 2.83 (s, 2H), 
2.40 – 2.22 (m, 2H), 1.46 (s, 9H), 1.26 – 1.16 (m, 2H), 0.98 (s, 9H), 0.21 (s, 6H). 
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1'-tert-butyl 3-methyl 7-((tert-butyldimethylsilyl)oxy)-4-isothiocyanato-1H-
spiro[naphthalene-2,4'-piperidine]-1',3-dicarboxylate (239). Prepared in a manner similar to 
232 from intermediate 238 (1.42 g, 2.82 mmol).  Isolated 1.18 g after chromatography of a 
yellow solid (77% yield), used without further purification. 
1
H NMR (400 MHz, Chloroform-d) 
δ 7.35 (d, J = 8.4 Hz, 1H), 6.75 (dd, J = 8.4, 2.4 Hz, 1H), 6.65 (d, J = 2.4 Hz, 1H), 4.04 – 3.75 
(m, 5H), 3.04 – 2.84 (m, 4H), 1.89 (td, J = 13.0, 4.9 Hz, 2H), 1.51 – 1.42 (m, 11H), 0.97 (s, 9H), 
0.21 (s, 6H). 
 
 
tert-Butyl 3-allyl-8-((tert-butyldimethylsilyl)oxy)-4-oxo-2-thioxo-2,3,4,6-tetrahydro-1H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (240). The β-isothiocyanato ester 
239(1.17 g, 2.15 mmol) was suspended in diethyl ether (3.8 mL), then allylamine (177 µL, 2.36 
mmol) was added.  The reaction mixture was allowed to stir 1 hour until a white precipitate 
formed.  Anhydrous methanol (7 mL) was added, followed by sodium methoxide (174 mg, 3.22 
mmol).  The reaction was stirred for an additional 3 hours.  At this time the hazy solution was 
diluted with saturated aqueous ammonium chloride solution (30 mL) and extracted 3x into 
diethyl ether.  The organic layer was washed with water and brine, then concentrated in vacuo to 
the desired product as a white solid (1.18 g, 96% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 
9.19 (s, 1H), 7.33 (d, J = 8.5 Hz, 1H), 6.83 (dd, J = 8.5, 2.4 Hz, 1H), 6.76 (d, J = 2.4 Hz, 1H), 
5.97 (ddd, J = 17.3, 10.5, 5.6 Hz, 1H), 5.35 (dd, J = 17.3, 1.5 Hz, 1H), 5.25 (dd, J = 10.5, 1.4 Hz, 
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1H), 5.03 (d, J = 5.6 Hz, 2H), 4.07 – 3.87 (m, 2H), 3.12 – 2.86 (m, 4H), 2.84 – 2.70 (m, 1H), 
2.63 – 2.43 (m, 1H), 1.45 (s, 9H), 1.29 (d, J = 12.9 Hz, 2H), 0.99 (s, 9H), 0.24 (s, 6H). 
 
 
tert-Butyl 3-allyl-8-((tert-butyldimethylsilyl)oxy)-2-((2-methoxyethyl)thio)-4-oxo-4,6-
dihydro-3H-spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (241). Intermediate 
240 (1.17 g, 2.05 mmol) was combined with sodium bicarbonate (259 mg, 3.08 mmol) and 2-
methoxyethyl tosylate (496 mg, 2.16 mmol) in anhydrous DMF (12 mL), and heated to 75°C.  
The reaction was allowed to stir for 16 hours, at which time the reaction was quenched by the 
addition of water.  The aqueous suspension was extracted 3x into ethyl acetate, then the pooled 
organic extract was washed 2x with water and 1x with brine.  The organic layer was dried over 
MgSO4, vacuum filtered, and concentrated, then further purified via flash chromatography (0-
20% EtOAc:hexanes) to furnish the product as a white solid (626 mg, 49% yield). 
1
H NMR (500 
MHz, Chloroform-d) δ 7.95 (d, J = 8.4 Hz, 1H), 6.79 (dd, J = 8.4, 2.4 Hz, 1H), 6.69 (d, J = 2.4 
Hz, 1H), 5.91 (ddt, J = 16.2, 10.7, 5.6 Hz, 1H), 5.32 – 5.24 (m, 2H), 4.67 (d, J = 5.6 Hz, 2H), 
4.06 – 3.87 (m, 2H), 3.76 (t, J = 6.2 Hz, 2H), 3.52 (t, J = 6.2 Hz, 2H), 3.43 (s, 3H), 3.16 – 2.84 
(m, 5H), 2.67 – 2.52 (m, 1H), 1.46 (s, 9H), 1.41 – 1.32 (m, 2H), 1.00 (s, 9H), 0.24 (s, 6H). 
 
 
tert-Butyl 3-allyl-8-hydroxy-2-((2-methoxyethyl)thio)-4-oxo-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (intermediate in synthesis of 242, 
243). Silyl ether intermediate 241 (550 mg, 0.876 mmol) was dissolved in anhydrous THF (9 
mL) and cooled to 0°C.  TBAF (1M solution in THF, 1.05 mL) was added slowly dropwise.  The 
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reaction was allowed to stir for 4 hours while slowly warming to room temperature.  The 
reaction was quenched by the addition of water, and the resulting biphasic solution was extracted 
into ethyl acetate.  The organic layer was washed 2x with water and 1x with brine, then isolated, 
dried over MgSO4, filtered, and concentrated to a light yellow oil.  Further purification by flash 
chromatography (5-25% EtOAc:hex) furnished the product as a white solid (390 mg, 87% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.95 (d, J = 8.5 Hz, 1H), 6.79 (dd, J = 8.5, 2.5 Hz, 1H), 
6.69 (d, J = 2.5 Hz, 1H), 6.59 (s, 1H), 5.91 (ddt, J = 17.3, 10.7, 5.6 Hz, 1H), 5.32 – 5.22 (m, 2H), 
4.67 (d, J = 4.9 Hz, 2H), 3.98 (d, J = 12.8 Hz, 2H), 3.75 (t, J = 6.2 Hz, 2H), 3.52 (t, J = 6.2 Hz, 
2H), 3.42 (s, 3H), 3.23 – 2.82 (m, 5H), 2.51 – 2.35 (m, 1H), 1.47 (s, 9H), 1.37 (d, J = 12.8 Hz, 
2H). 
 
 
(S)-tert-Butyl 3-allyl-2-((2-methoxyethyl)thio)-4-oxo-8-(1-phenylethoxy)-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (242) (CCG-212348).  Anhydrous 
THF (0.3 mL) was cooled to 0°C in an ice bath, then triphenylphosphine (28 mg, 0.107 mmol) 
and DIAD (22 mg, 0.107 mmol) were added.  The solution was allowed to stir for 30 minutes, 
then (R)-α-methylbenzyl alcohol (13 µL, 0.107 mmol) was added and stirred for an additional 15 
minutes.  The deprotected phenol intermediate (50 mg, 0.097 mmol) was added and the reaction 
allowed to stir at 0°C for 2 hours, then an additional 16 hours at room temperature overnight.  
The reaction mixture was diluted with water and extracted into ethyl acetate 2x.  The organic 
layer was washed with saturated aqueous ammonium chloride, water, and brine, then dried over 
MgSO4, vacuum filtered, and concentrated under reduced pressure.  The crude organic extract 
was purified via flash chromatography (5-40% EtOAc:hex) to furnish the desired product as a 
crystalline white solid (26 mg, 43% yield).
 1
H NMR (400 MHz, Chloroform-d) δ 7.90 (d, J = 8.6 
Hz, 1H), 7.42 – 7.31 (m, 4H), 7.31 – 7.21 (m, 1H), 6.78 (d, J = 8.6 Hz, 1H), 6.71 (s, 1H), 5.89 
(ddt, J = 16.0, 10.7, 5.6 Hz, 1H), 5.37 (q, J = 6.4 Hz, 1H), 5.30 – 5.21 (m, 2H), 4.65 (d, J = 5.0 
Hz, 2H), 4.05 – 3.81 (m, 2H), 3.71 (t, J = 6.2 Hz, 2H), 3.48 (t, J = 6.2 Hz, 2H), 3.39 (s, 3H), 3.13 
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– 2.79 (m, 5H), 2.66 – 2.43 (m, 1H), 1.66 (d, J = 6.4 Hz, 3H), 1.45 (s, 9H), 1.40 – 1.23 (m, 2H).  
ESI+MS m/z = 618.3 (M + H
+
), 640.3 (M + Na
+
).  HPLC (Method B, tR = 10.03 min), purity 
>95%. 
 
 
(R)-tert-Butyl 3-allyl-2-((2-methoxyethyl)thio)-4-oxo-8-(1-phenylethoxy)-4,6-dihydro-3H-
spiro[benzo[h]quinazoline-5,4'-piperidine]-1'-carboxylate (243) (CCG-212349). Prepared in 
a manner similar to 242 from the deprotected phenol (50 mg, 0.097 mmol) and (S)-α-
methylbenzyl alcohol (25 µL, 0.127 mmol).  Isolated after column chromatography as a white 
powder (31 mg, 52% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.90 (d, J = 8.6 Hz, 1H), 7.42 
– 7.30 (m, 4H), 7.31 – 7.23 (m, 1H), 6.78 (d, J = 8.7 Hz, 1H), 6.71 (s, 1H), 5.94 – 5.82 (m, 1H), 
5.37 (q, J = 6.4 Hz, 1H), 5.30 – 5.21 (m, 2H), 4.65 (d, J = 5.3 Hz, 2H), 4.04 – 3.85 (m, 2H), 3.71 
(t, J = 6.2 Hz, 2H), 3.48 (t, J = 6.2 Hz, 2H), 3.39 (s, 3H), 3.15 – 2.78 (m, 5H), 2.64 – 2.46 (m, 
1H), 1.66 (d, J = 6.4 Hz, 3H), 1.45 (s, 9H), 1.39 – 1.22 (m, 2H).. ESI+MS m/z = 618.4 (M + H+), 
640.3 (M + Na
+
).  HPLC (Method B, tR = 10.06 min), purity >95%. 
 
 
3-Allyl-8-hydroxy-2-((2-methoxyethyl)thio)-3H-spiro[benzo[h]quinazoline-5,4'-piperidin]-
4(6H)-one (244) (CCG-212352).  Chiral ether 242 (26 mg, 0.043 mmol) was dissolved in DCM 
(400 µL) and cooled to 0°C.  TFA (14 µL, 0.171 mmol) was added and the reaction was allowed 
to stir and warm to room temperature over 3 hours.  The reaction was quenched by the dropwise 
addition of saturated aqueous sodium carbonate, and the suspension extracted with additional 
DCM.  The organic layer was washed with water and brine, then dried over MgSO4, filtered, and 
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concentrated.  Treatment of the organic extract with diethyl ether induced the precipitation of a 
white solid, found to be 244, which was isolated by vacuum filtration (17 mg, 96% yield).
 1
H 
NMR (400 MHz, Methanol-d4) δ 7.96 (d, J = 8.4 Hz, 1H), 6.78 – 6.68 (m, 2H), 5.90 (ddd, J = 
17.1, 10.5, 5.3 Hz, 1H), 5.27 – 5.15 (m, 2H), 4.69 (d, J = 5.4 Hz, 2H), 3.73 (t, J = 6.3 Hz, 2H), 
3.53 (t, J = 6.3 Hz, 2H), 3.39 (s, 3H), 3.23 – 3.10 (m, 4H), 3.08 (s, 2H), 2.91 (td, J = 13.3, 5.8 
Hz, 2H), 1.52 (d, J = 14.1 Hz, 2H). ESI-MS+ m/z = 414.0 (M + H
+
).  HPLC (Method A, tR = 
5.05 min), purity >95%. 
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